"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems, Inc. First Quarter or 2016 Earnings Release Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I will now turn the conference over to your host, Spencer Sias,",59,"Greetings, and welcome to the Varian Medical Systems, Inc. First Quarter or 2016 Earnings Release Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I will now turn the conference over to your host, Spencer Sias, Vice President of Investor Relations and Corporate Communications for Varian Medical Systems. Thank you, Mr. Sias, you may now begin."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Good afternoon, and welcome to Varian Medical Systems conference call for the first quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will",272,"Thank you. Good afternoon, and welcome to Varian Medical Systems conference call for the first quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. To simplify our discussion, unless otherwise stated, all references to the quarter or year are fiscal quarters and fiscal years. Quarterly comparisons are for the first quarter of fiscal year 2016 versus the first quarter of fiscal year 2015. References to financial results for orders are to gross orders unless otherwise indicated. This discussion includes non-GAAP financial measures in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. A reconciliation to the most comparable GAAP measure is included in our earnings release, which can be accessed on our website. Please advise that this discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, should, will, slated and scheduled and similar expressions are intended to identify those statements, which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks related to our business are described in our first quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise. 
And now, here's Dow."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Varian is reporting revenues and earnings above our expectations for the first quarter of fiscal 2016, while managing through some challenging conditions in our markets, and we're raising our earnings guidance for the year. In",912,"Good afternoon, and welcome. Varian is reporting revenues and earnings above our expectations for the first quarter of fiscal 2016, while managing through some challenging conditions in our markets, and we're raising our earnings guidance for the year. In summary, we are reporting non-GAAP net earnings of $0.99 per diluted share and $0.91 per diluted share on a GAAP basis. Revenues of $757 million, up 3% in dollars and 7% in constant currency. Soft orders in our Oncology Systems business the expected declines in Imaging Components orders and revenues and good news on the tax fronts with a permanent R&D tax credit and the suspension of the medical device excise tax. 
Focusing on operational highlights. In our Oncology business, gross orders totaled $533 million for the quarter, down 5% in dollars and down 1% in constant currency. Gross orders in the Americas for the quarter increased by 3% in both dollars and constant currency with the fastest growth in Latin America. Gross orders in North America rose by 2% in dollars and constant currency. In EMEA, gross orders declined by 14% in dollars and 5% in constant currency. Gross orders in APAC declined by 12% in dollars and 7% in constant currency with continued market contraction in Japan and a modest decline in China. 
Global markets have been weakened by ongoing political unrest, weak oil prices and economic uncertainty. In EMEA, for example, Russia announced further delays in its cancer plan. Germany scaled back investments, and the Middle East was negatively impacted by political unrest and falling oil prices. 
On a positive note, in EMEA we received an order from the U.K.'s National Health Service for our further 10 TrueBeam Systems during the quarter. The National Health System has now ordered more than 50 TrueBeams in the last few years for its cancer programs. Economic uncertainty was also a prime cause of weakness in Japan, which led to an overall orders decline in APAC. 
In China, gross orders declined slightly. As of the end of the first quarter, we continue to see hospitals in China aiming to invest in advanced radiotherapy and radiosurgery systems for their cancer patients. We booked several orders for EDGE radiosurgery systems in China during the quarter. 
In the Americas, the multimillion-dollar Siemens replacement project in Argentina and a key Ministry of Health win in Chile drove the growth in Latin America, while North America continue to move forward with investments in our new product platforms to replace aging systems. 
We're focused on global market development through our access to care initiative, an educational program that seeks to bridge the gap between the growing need for modern radiotherapy treatment machines in developing countries and the lack of trained personnel to operate them. This program is already working in Africa and Vietnam, and we took steps during the quarter to initiate this program in India to an educational partnership with Apollo Hospitals Group. This program will train radiation technologists in India. 
We made good progress with our software business during the quarter. Licenses for RapidPlan, our tool for enhancing efficiency and quality and treatment planning, have tripled since the end of the fiscal year and are now installed at over 50 sites. Clinical networks, including a health care system in Victoria, Australia that took 4 licenses during the quarter, are rebuilding treatment capabilities around RapidPlan. 
Turning to our Oncology service business. Orders were up 1% in dollars, but up 6% in constant currency compared with a strong year-ago quarter. 
Let me turn now Imaging Components, where orders shrank by 22% to $127 million for the quarter, and revenues fell by 15% to $141 million. Beginning in the second half of last fiscal year, this business has been confronted with currency-related pricing pressures, weak market conditions for Security and Inspection Products and an in-sourcing at a major panel customer. These challenges, together with excess TrueBeam inventory at a key customer, contributed to the declines in this business during the quarter. Volumes for tubes were down in the quarter, while demand for our higher-margin dynamic fluoroscopic panels increased and led to a sequential improvement in the growth margin for Imaging Components. 
A recent acquisitions, MeVis and Claymount, gained momentum in the quarter and are performing well. As a reminder, we're aiming for about $50 million in revenue from these newly acquired businesses this fiscal year. 
Moving to protons. We made good progress with installations. During the quarter, we turned over the first room of the Maryland Proton Therapy Center for clinical commissioning, and first treatments are slated to begin next month. We have successfully extracted beams from the cyclotron at Cincinnati Children's Hospital, where a patient treatments are scheduled to begin before the end of the year. Installation is also underway at the Paul Institute in Switzerland, and we are scheduled to begin installations at sites in Holland, Russia and Saudi Arabia later this year. 
Proton order activity was quiet in the quarter, but our prospects for booking several more systems this year continue to look good. 
Before I hand it over to Elisha, I'd like to say how proud I am that Varian has been honored for its commitment to sustainability by being included for the second year in a row on the Corporate Knights Global 100 Most Sustainable Corporations list, which compares to sustainability performance of some 4,600 companies globally. This was announced last week at the World Economic Forum in Dow's. 
Now I'll turn it over to Elisha."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 7% from the year-ago period. Backlog adjustments during the quarter totaled $55 million, bringing net orders fo",536,"Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 7% from the year-ago period. Backlog adjustments during the quarter totaled $55 million, bringing net orders for the company to $617 million. 
Now let me walk you through the P&L. First quarter revenues for the total company increased 3% in dollars and 7% in constant currency. Oncology posted a 5% gain in revenues during the quarter with a 9% gain in constant currency. There was a significant geographic mix shift towards international revenues, which grew 21% in dollars and 31% in constant currency versus a year-ago quarter, while North American revenues declined by about 10%. 
International business constituted 55% of total Oncology revenues in the quarter. Imaging Components posted a first quarter revenue decline of 15% with decreases in tubes, panels and Security and Inspection Products. 
Our Particle Therapy business posted revenues of $27 million, up $18 million from the year-ago quarter as we continued to make progress on projects in backlog. 
The total company gross margin for the quarter was 41.1%, down as expected by a little more than 3 points. Oncology Systems gross margin also fell by about 3 points to 42.4% due to geographic and product mix shifts as well as minor currency effects. Imaging Components gross margin for the quarter fell by about 1.5 points to 40.7% due largely to lower pricing and volumes. 
First quarter SG&A expenses were $124 million or 16% of revenue, an improvement of about 1 point as a percentage of revenue with the year-ago quarter. First quarter R&D expenses were $60 million or 8% of revenues, equal to the year-ago quarter as a percentage of revenue. First quarter operating earnings totaled $128 million or 17% of revenue, down about 2 points as a percentage of revenue from the year-ago quarter and in line with our expectation for the quarter. 
Depreciation and amortization totaled $19 million for the quarter. The effective tax rate was 24.8%, down almost 4 points from the year-ago quarter due largely to the geographic mix of profits and the R&D tax credit that was reinstated in late December. We now expect that the tax rate will be about 26% to 27% for the year. 
Fully diluted shares outstanding decreased almost 4 million from the year-ago quarter to 97.8 million due to our ongoing share repurchase program. Diluted EPS was $0.99 for the quarter.
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $953 million, debt of $728 million and stockholders equity of $1.6 billion. DSO at 99 days was up significantly from the year-ago quarter due to a lower mix of Imaging Components business, a higher mix of proton business and the timing of collections in Oncology. 
First quarter cash flow from operations fell slightly from the year-ago period to $77 million. Primary uses of cash were $27 million for CapEx and $192 million for the repurchase of 2.4 million shares of stock. At the end of the quarter, we had 7 million shares remaining under the existing repurchase authorization that extends through calendar year 2016. 
Now back to Dow for the outlook."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. Including the effects of the R&D tax credit reenactment and the suspension of the medical device excise tax in the U.S., we now believe that for fiscal year 2016, total company non-GAAP earnings will be in the range of $4.55 to $4.65 per d",122,"Thanks, Elisha. Including the effects of the R&D tax credit reenactment and the suspension of the medical device excise tax in the U.S., we now believe that for fiscal year 2016, total company non-GAAP earnings will be in the range of $4.55 to $4.65 per diluted share. We continue to expect that revenues for fiscal year 2016 will increase by about 4% to 5% over fiscal year 2015. For the second quarter of fiscal year 2016, we expect revenues to be up 1% to 2% from the year-ago quarter in dollars. We expect non-GAAP earnings for the second quarter of fiscal year 2016 to be in the range of $1.06 to $1.10 per diluted share. 
We are now ready for your questions."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] Our first question comes from Jeff Johnson from Robert Baird.",12,"[Operator Instructions] Our first question comes from Jeff Johnson from Robert Baird."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So Dow, one question for you and one question for Elisha, and let me start with a question for you Dow. So you sound a little bit may be more cautious on some of the European and given that the Middle East is in your European number on the Oncology side a",143,"So Dow, one question for you and one question for Elisha, and let me start with a question for you Dow. So you sound a little bit may be more cautious on some of the European and given that the Middle East is in your European number on the Oncology side a little more cautious on Europe and APAC. Is that the right read here? And I guess, as I look back over the last several quarters, we've seen Oncology orders in both those markets in negative territory. I think 3 out of the last 4 quarters. Is that kind of where we should level set? I know you don't guide to orders, but just given your comments and kind of the last several quarter trendline, is that kind of where we should be still hanging out with our thoughts for the year?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me say that maybe just kind of cast it in a broader view for a second, Jeff, and then kind of some of the regional data. When you look at the last 12 months in Oncology in dollars, it's down 2%. In constant currency, it's up 4%. I mean, this first qua",330,"Let me say that maybe just kind of cast it in a broader view for a second, Jeff, and then kind of some of the regional data. When you look at the last 12 months in Oncology in dollars, it's down 2%. In constant currency, it's up 4%. I mean, this first quarter is not the greatest growth that we've ever had. Our funnel remains very good, so we like what we see. The fourth quarter was huge for us in Europe. The constant currency and dollar growth in Europe was outstanding in Q4. So our Q4 was 12.5% constant currency growth last quarter. So maybe there was a little bit of quarter-over-quarter balancing going on. So I think the 12-month trailing is kind of what we're feeling right now. Clearly, we're reading the papers like everybody and some of the macroeconomic weakness in Europe is real. I mean, we did have a light Q1. But I think we're -- we still see markets growing in that low to mid-single-digit range at this point. We haven't seen anything that would pull us off that. Japan has been kind of the ongoing structural change in Japan. In China, we did have a win in the quarter that was protested. So I mean, we're very close to flat in China. Our funnel remains very good in China. So I think Japan is probably going to be kind of more of same. That's been a pretty consistent story the last few quarters. But I do think China will come back that order that was protested was a fairly large order. So is that within our numbers, then China would have been great. But anyway, I mean, those are the kinds of things that happen around the quarter. I'd say over the long haul, looking at the last 12 months, we haven't seen anything that would, at this point, pull us off a market growth number in that kind of 3 to 5 range."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And yes, the 4% you cited is a trailing 12 months you're referring kind of worldwide. So kind of mix-wise, we think North America little bit stronger maybe than others going forward is that fair?",38,"Okay. That's helpful. And yes, the 4% you cited is a trailing 12 months you're referring kind of worldwide. So kind of mix-wise, we think North America little bit stronger maybe than others going forward is that fair?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Last -- when you look at it in pure dollars, America's last 12 months is at 4.5%. And international is down 6.5% in dollars constant currency adjustment the whole thing it's 4% up. So that's kind of -- I think last 12 months is -- and that's kind of",58,"Yes. Last -- when you look at it in pure dollars, America's last 12 months is at 4.5%. And international is down 6.5% in dollars constant currency adjustment the whole thing it's 4% up. So that's kind of -- I think last 12 months is -- and that's kind of the market that, I think, we're still feeling."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And then, Elisha, the question for you just around EPS guidance. Since you guided back in October, the euro's kind of worked a little bit more against you, I think a little bit to a stronger dollar against the euro since you guided s",141,"Okay. That's helpful. And then, Elisha, the question for you just around EPS guidance. Since you guided back in October, the euro's kind of worked a little bit more against you, I think a little bit to a stronger dollar against the euro since you guided some of the emerging market currency is still going the wrong way. So as I look at the dime raised to guidance here, how much was med tech tax in R&D driving that dime raise? How much kind of in the guidance number is coming from those 2 things? How much of an incremental currency headwind with there, if any, included in your guidance? And then maybe how are you think about the core underlying business? So just trying to bucket kind of those 3 areas on what contributed to the dime change in guidance."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. So it's just the simple answer is if I take the R&D tax credit and the medical device excise tax together, it's a dime for the year. So -- and that splitter for even at about $0.05 each year. So we got a benefit of $0.04 in Q1 for those 2 impacts. A",94,"Sure. So it's just the simple answer is if I take the R&D tax credit and the medical device excise tax together, it's a dime for the year. So -- and that splitter for even at about $0.05 each year. So we got a benefit of $0.04 in Q1 for those 2 impacts. And what we're saying is the additional $0.06 is going to come from Q2 to Q4. So essentially, we took the benefit from those 2 things, packed it on to the prior guidance and got us to the 4 60 midpoint."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then underlying kind of the core business, Are you -- I'm trying to figure out if currency I thought was an incremental headwind since you last guided Does that imply that your core expectations have improved a little bit?",41,"Okay. And then underlying kind of the core business, Are you -- I'm trying to figure out if currency I thought was an incremental headwind since you last guided Does that imply that your core expectations have improved a little bit?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I mean, certainly Q1, we feel good about. And in terms of what I would refer to as an operational, if you take out the $0.04 related to the tax impact, we had about a nickel deep and that was due to higher Oncology revenue and frankly, very good cos",229,"Well, I mean, certainly Q1, we feel good about. And in terms of what I would refer to as an operational, if you take out the $0.04 related to the tax impact, we had about a nickel deep and that was due to higher Oncology revenue and frankly, very good cost controls on SG&A. Little bit on share repurchase was a little bit more than we historically done, but in line with that 1 million to 2 million shares per quarter. I think your next question's going to be why aren't you giving me that nickel? And I'm still a little bit of after Q4, frankly. And when we missed on that revenue number, it's very early in the year. And I think this just has to do with some timing. And I think Oncology did a fantastic job and probably pulled a little bit revenue forward from Q2 and Q3 to make sure we didn't have a repeat performance. But for the year, we -- it still looks good with the revenue guidance and the EPS from where we stand today. Currency from when I last guided has been relatively stable. I mean, you may have heard us, I don't know, I think I was at 1 12 versus 1 09. But again, we built some of that into the range for the guidance when we gave it."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Amit Hazan from Citi.",9,"Our next question comes from Amit Hazan from Citi."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So start on the gross margin line just may be a question on Oncology gross margin. So I was looking back just kind of taking a little bit several quarter view. And if I strip out service, which is kind of look at your gross margin on the Oncology side, it",148,"So start on the gross margin line just may be a question on Oncology gross margin. So I was looking back just kind of taking a little bit several quarter view. And if I strip out service, which is kind of look at your gross margin on the Oncology side, it kind of implies this pretty big decline over the past year. I don't know it is about 36% in fiscal '14 down to 31% in fiscal '15. And obviously just the product side. So I'm wondering if you can share with us whether that trend continued this quarter, first of all, and what the drivers share might be outside of FX because you've kind of actually had a nice mix shift in revenue towards the U.S. up until this quarter. And so I'm wondering why product margins in Oncology would be down as much as they were."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. So Amit, the biggest impact on Q1 was just the geographic mix shift. We had a 7-point [ph] shift international particularly the Middle East and Eastern Europe, which are our lower-margin countries. And that was just based on scheduled delivery date.",164,"Yes. So Amit, the biggest impact on Q1 was just the geographic mix shift. We had a 7-point [ph] shift international particularly the Middle East and Eastern Europe, which are our lower-margin countries. And that was just based on scheduled delivery date. So we fully anticipated we were going to have margin declines in Oncology and for the total company. And I think that was reflected in the guidance that we gave last quarter. So for the year, I still expect, even with the -- we still have some currency impact in Q1. We'll have a little bit in Q2 and then it should anniversary. For the year, we still think Oncology is right in that 43% range. So holding in line with our long-term expectations. I would point out service was a bigger proportion in the year-ago quarter, and that is one of our highest-margin product lines. So that impacted it as well. But I think Oncology is performing well at this point."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And just to reiterate, nothing outside anything that's outside of FX is hurting the product side of gross margins in Oncology. That's what seems to have been down over the course of the year.",34,"And just to reiterate, nothing outside anything that's outside of FX is hurting the product side of gross margins in Oncology. That's what seems to have been down over the course of the year."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Region mix.",2,"Region mix."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Region. Of the region mix of the geographic mix, yes. So international went from 48% of total revenue in the year-ago period to 55%. It's just a very big geographic mix shift. But on an apples-to-apples basis, it's really just the geography that was impac",56,"Region. Of the region mix of the geographic mix, yes. So international went from 48% of total revenue in the year-ago period to 55%. It's just a very big geographic mix shift. But on an apples-to-apples basis, it's really just the geography that was impacting it. And again, the service as a percentage of the total."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Let me jump to imaging, just a couple questions on that. Number one, I'm wondering if you're reiterating kind of the guidance you laid out for fiscal year, which I think was about flat or so on imaging revenues. And then secondly, specifically, has",70,"Okay. Let me jump to imaging, just a couple questions on that. Number one, I'm wondering if you're reiterating kind of the guidance you laid out for fiscal year, which I think was about flat or so on imaging revenues. And then secondly, specifically, has had your assessment of the risk around losing more business in flat panel and in tubes changed at all since the earnings call last quarter?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think maybe the one difference we'd have here is Toshiba announced during the quarter that they're selling their medical unit. Otherwise, I think it's very much consistent with what we guided a quarter ago. The challenges continue. The Security and Insp",216,"I think maybe the one difference we'd have here is Toshiba announced during the quarter that they're selling their medical unit. Otherwise, I think it's very much consistent with what we guided a quarter ago. The challenges continue. The Security and Inspection business is stabilized -- stabilizing theory at the lower revenue levels. The panel pricing declines should anniversary in the second half, and we're still absorbing the loss of major -- of a major customer that went in-sourcing on flat panel that's -- probably not that's happening every quarter to us and probably doesn't anniversary until Q4-ish. Toshiba's volume -- the good news is most of that business is a service business. So that is going to continue to need to be replaced, but their ongoing forward production with the uncertainty around their sale and kind of who picks it up, et cetera. We might see a little bit of a volume adjustment there. As I did say in the script, they do have some inventory that they're working through as they kind of manage through this whole thing. The good news is the MeVis and Claymount acquisitions seem to be performing for us. So we're looking for a return to growth, I think consistent with what we said before in 2017 and 2018."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Anthony Petrone from Jeffrey's.",10,"Our next question comes from Anthony Petrone from Jeffrey's."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Couple questions, maybe on proton. Couple questions on proton. I'll begin with proton and then we can follow up with some of the geographies as well in Oncology. But maybe just an update on the potential to hit the $0.15 swing factor in proton specificall",97,"Couple questions, maybe on proton. Couple questions on proton. I'll begin with proton and then we can follow up with some of the geographies as well in Oncology. But maybe just an update on the potential to hit the $0.15 swing factor in proton specifically. So I think it hinged on the Emory deal. And then in your prepared comments, Dow, you mentioned potentially an installation in Russia. But you also touched upon some dislocations in an marketplace. So maybe just proton overall the potential to the $0.15 where Emory is and how Russia plays into that."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. The cites a name for all in our guidance so there orders that we have and no mystery around those. We have not guided the Emory. It is not a booked order yet. Until the financing is complete, we won't put it into guidance. If that were to happen, it",57,"Sure. The cites a name for all in our guidance so there orders that we have and no mystery around those. We have not guided the Emory. It is not a booked order yet. Until the financing is complete, we won't put it into guidance. If that were to happen, it'd be a nice upside for us."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. We problem. We're not doing that. And it's just -- it's our customer with securing the financing. We are working with them, but it really is somewhat outside of Varian's control and we're monitoring it closely.",37,"Yes. We problem. We're not doing that. And it's just -- it's our customer with securing the financing. We are working with them, but it really is somewhat outside of Varian's control and we're monitoring it closely."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Great. And then just on geographies. You touched on China a bit, but Brazil is also sort of in the headlines out there with struggles. And so maybe just an update on that specific tender. I think if you go back, it was 50 Linacs, several of which had alre",65,"Great. And then just on geographies. You touched on China a bit, but Brazil is also sort of in the headlines out there with struggles. And so maybe just an update on that specific tender. I think if you go back, it was 50 Linacs, several of which had already been sort of shipped and installed. So maybe just an update on that specific tender."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We're seeing the Ministry of Health is continuing their program. I mean, obviously that order was placed with us a year ago, but we are completing first installations this year and it is going as expected. So from a backlog point of view, we haven't seen",68,"We're seeing the Ministry of Health is continuing their program. I mean, obviously that order was placed with us a year ago, but we are completing first installations this year and it is going as expected. So from a backlog point of view, we haven't seen a change in their approach on these. So that's good. Market's a little bit quiet there, but it hasn't been bad."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then just a last one for me would just be on software specifically. So last year, that really seemed to be a driver, particularly on share gains. I think both on information management and even treatment planning. So maybe do you see that as still a s",75,"And then just a last one for me would just be on software specifically. So last year, that really seemed to be a driver, particularly on share gains. I think both on information management and even treatment planning. So maybe do you see that as still a share gain story for 2016? And may be just an update on how many RapidPlans sort of how many Eclipse users have migrated to RapidPlan at this point?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean, first of all, for the overall software business, it continues to do very well. We just got news a couple of weeks ago that both Eclipse and ARIA got top ranking from class -- classes the Gartner of our industry, independent organization that",153,"Yes. I mean, first of all, for the overall software business, it continues to do very well. We just got news a couple of weeks ago that both Eclipse and ARIA got top ranking from class -- classes the Gartner of our industry, independent organization that evaluates products for customers. So we were very thrilled by that external validation. The -- and then in terms of RapidPlan, as I said in the script, it's now installed over 50 sites. I have to get you the exact number of orders, but it's well over 300 now. So the momentum continues there. I think from a overall differentiation point of view, our treatment planning position is terrific. I think we're way ahead with our knowledge-based tools. And then in ARIA, our workflow tools and our informatics are very good differentiators for us, and we continue to see very strong competitive takeout with both those products."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from David Roman from Goldman Sachs.",10,"Our next question comes from David Roman from Goldman Sachs."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","I wanted just to start with a clarification on the proton. I understand that Emory is not in the guidance and with the it's sort of a context for why you did that. But are Russia and Saudi Arabia that you talked about are to what extent are those reflecte",54,"I wanted just to start with a clarification on the proton. I understand that Emory is not in the guidance and with the it's sort of a context for why you did that. But are Russia and Saudi Arabia that you talked about are to what extent are those reflected in the forward guidance?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","They're very small amounts. They are in the guidance.",10,"They're very small amounts. They are in the guidance."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","All of them were -- under the percentage of completion all of our projects where we have actually identified material specific to our customer we are taking revenue on those projects. So Saudi and Russia would be included in that number.",41,"All of them were -- under the percentage of completion all of our projects where we have actually identified material specific to our customer we are taking revenue on those projects. So Saudi and Russia would be included in that number."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Saudi, for example, I know we already took a fair amount last year.",13,"Saudi, for example, I know we already took a fair amount last year."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We've taken about $43 million in total and in Russia about $25 million in total.",16,"We've taken about $43 million in total and in Russia about $25 million in total."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then maybe a more strategic question, I mean, Dow, obviously, we focused a lot on the quarter-to-quarter order trends and how you're doing by region. But as you kind of take a step back and think about your growth rate, how things have progresse",90,"Okay. And then maybe a more strategic question, I mean, Dow, obviously, we focused a lot on the quarter-to-quarter order trends and how you're doing by region. But as you kind of take a step back and think about your growth rate, how things have progressed the past several quarters versus where you kind of want them to be, how much of the forward outlook depends on factors over which you have control and can invest to drive growth versus being dependent on macro factors sort of end market conditions?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, for the whole company, I think that cancer business remains a terrific business for us. Constant currency growth last year was 5%, 6% in Oncology, very strong fourth quarter. A little weak this quarter, but our funnel still looks good. And we thin",333,"I mean, for the whole company, I think that cancer business remains a terrific business for us. Constant currency growth last year was 5%, 6% in Oncology, very strong fourth quarter. A little weak this quarter, but our funnel still looks good. And we think that the cancer business, unfortunately, weathers economic downturns. I mean, people get cancer regardless of economics. And now if you look back when economic times were bad, we weathered those storms pretty well. It's not to say that we might see something in our orders if the economy really turns out. But there was this nice external validation of that last quarter with the global task force on the utilization of radiation Oncology published in the Lancet journal that called for [ph] thousands more machines. Basically, 2.5x the installed base that we have today and really asking international organizations to help countries develop cancer plans. So especially outside of U.S., a huge focus on utilizing radiation therapy for cancer. I think one of our big challenges I mentioned in the script there is making sure the people side of that comes along with it because we've got to have the people to be able to do the work. But I think as you look at the long-term health of the Oncology business, the franchise is in as good a product position as we've ever had. And I think the market remains in the long term, very, very solid. Now on the imaging business, we're clearly going through a big storm right now. And we still like the fundamentals of the business. We do think it's an industry that has some consolidation opportunity. And we've got figure out how to play that hand a little bit. But the -- as we get through the in-sourcing of this one customer, this kind of short-term Toshiba probations and look to the long term, the digitization of especially the radiographic market remains a huge opportunity. And we like the long-term fundamentals there."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And maybe just a last one may be sort of a follow-up to that. As you think about the opportunities that sit in front of you, what was sort of the thought process around what to do with the medical device tax? I know in dollars it's not all that material f",96,"And maybe just a last one may be sort of a follow-up to that. As you think about the opportunities that sit in front of you, what was sort of the thought process around what to do with the medical device tax? I know in dollars it's not all that material for you compared to some of the other companies in the group. But why not tell some of those savings back into the business? And how should we sort of think about your spending patterns on a go-forward basis just some of that growth."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","On a high-level, let me take first crack at this and I'll have Elisha walk you through some of the detail but at a high level, we have actually taken up our R&D spend as a percent of sales over the last couple of years. So we're investing a lot in the bus",154,"On a high-level, let me take first crack at this and I'll have Elisha walk you through some of the detail but at a high level, we have actually taken up our R&D spend as a percent of sales over the last couple of years. So we're investing a lot in the business. We want to make sure we get popped for that growth. So we're challenging the spend as we do it because we want to see the growth kind of linking it to your previous question. But we have taken up the R&D investment as a percent of the total over the last couple years. So we were never kind of making the R&D decision as a result of our tax impact. I mean, clearly it would've been a little easier if we didn't have to pay that. But we were making that independent making that decision independent of the tax."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And I would just add I mean, our road map is kind of set for the year. We've got the people, the projects. It may be more disruptive to try and even accelerate some of it at this point. And the last point is when we increased R&D, it comes from people. An",72,"And I would just add I mean, our road map is kind of set for the year. We've got the people, the projects. It may be more disruptive to try and even accelerate some of it at this point. And the last point is when we increased R&D, it comes from people. And that tends to be permanent in nature, whereas this is only a reprieve for 2 years at this point."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Jason Wittes from Brean Capital.",10,"Our next question comes from Jason Wittes from Brean Capital."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So I just wanted to ask first off, in terms of Security business, I think you said about $25 million of the revenues related to security are service-related is that right? And is that mostly revenues we should expect this year or should we also expect som",52,"So I just wanted to ask first off, in terms of Security business, I think you said about $25 million of the revenues related to security are service-related is that right? And is that mostly revenues we should expect this year or should we also expect some orders on top of that?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No. I mean, that's maybe not quite half. I mean, a little bit more than half of the total revenue we should have on the year.",26,"No. I mean, that's maybe not quite half. I mean, a little bit more than half of the total revenue we should have on the year."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, that's about right.",4,"Yes, that's about right."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And just to understand Toshiba, they're looking to sell that business. I assume they're one of your larger customers. And I assume they're still a decent percentage of the imaging business? Is that the right way to think about it? And I guess, a pre",76,"Okay. And just to understand Toshiba, they're looking to sell that business. I assume they're one of your larger customers. And I assume they're still a decent percentage of the imaging business? Is that the right way to think about it? And I guess, a presumption would be they're right now working inventories, but they'll have to start reordering at some point, whether or not that's after seller are not, I guess, is harder to determine."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, here's what I can tell you. They are our largest customer. In fact, they're a terrific customer. They account for about $150 million of our Imaging Components revenue. The split on that is $125 million tubes, about $25 million in panel. We expect",106,"I mean, here's what I can tell you. They are our largest customer. In fact, they're a terrific customer. They account for about $150 million of our Imaging Components revenue. The split on that is $125 million tubes, about $25 million in panel. We expect -- we expect to continue supplying high-end CT tubes to whoever it is that buys Toshiba. We're designing future products for them, having very good conversations. So we think that -- I mean, there's obviously kind of some uncertainty as it goes through that process. But we're well designed in and I think that that'll continue whoever the new owner is."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's very helpful. And then maybe just switch to proton. I mean, you mentioned sort of global turmoil impacting your core Oncology business. Should we assume that the proton business may also be impacted this year?",37,"Okay. That's very helpful. And then maybe just switch to proton. I mean, you mentioned sort of global turmoil impacting your core Oncology business. Should we assume that the proton business may also be impacted this year?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","It's tough to say. When you look at our funnel, our funnel remains positive. We have had 1 or 2 fallout. I don't know how much of that -- some of that I think some of their own decisions. I don't know how much of it was that kind of macro economy. We are",171,"It's tough to say. When you look at our funnel, our funnel remains positive. We have had 1 or 2 fallout. I don't know how much of that -- some of that I think some of their own decisions. I don't know how much of it was that kind of macro economy. We are competing on a number of compact units. And I do think we'll see our first compact orders this year. So we're encouraged about that. There remains to be a lot of customer interest. And I guess, I would say that versus -- in 2009 -- in 2008, 2009 when we went through this, we were just selling big systems. So that market dried up. Now when you look at our funnel, our funnel has a lot of compact units. And customers are hanging in there. We're having a lot of conversations and also the funnel remains pretty good, and our objective is to see if we can win a few of those single-room orders this year."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Sorry, just to get a clarification. The large centers there's really not much of a market this year for them. It's mostly compact centers that people are looking out right now.",31,"Sorry, just to get a clarification. The large centers there's really not much of a market this year for them. It's mostly compact centers that people are looking out right now."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That was a comparison to 2008, 2009. 2008, 2009, that's what the market was. And when you're looking at $50 million to $90 million of expense into that kind of recession, that market just went away during 2008, 2009. We're not seeing that. There still a g",106,"That was a comparison to 2008, 2009. 2008, 2009, that's what the market was. And when you're looking at $50 million to $90 million of expense into that kind of recession, that market just went away during 2008, 2009. We're not seeing that. There still a good multi-room market out there. But we're also seeing a very good funnel of these compact rooms. We're competing on both. But just to say that in terms of as it relates to kind of global macroeconomic environment, I think these compact customers are hanging in there a little more in terms of the funnel -- strength of the funnel."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Tycho Peterson from JPMorgan.",9,"Our next question comes from Tycho Peterson from JPMorgan."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And maybe just a higher-level strategic question on some of the emerging markets that you've called out as being kind of problematic. I mean, given that a lot of the issues here are kind of structural rather than cyclical some of these markets. Does this",80,"And maybe just a higher-level strategic question on some of the emerging markets that you've called out as being kind of problematic. I mean, given that a lot of the issues here are kind of structural rather than cyclical some of these markets. Does this change your thinking about how you address these markets the resources you put to them? Any change in the where you're placing incremental efforts internationally, based on what we've seen last couple of quarters?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me kind of underscore one of the things I pointed out in the call weak in Japan, weak in Europe. Emerging markets, weaken Russia for sure. But we had some Latin America activity that wasn't too bad. China, as I mentioned, was down, but we've kind of h",150,"Let me kind of underscore one of the things I pointed out in the call weak in Japan, weak in Europe. Emerging markets, weaken Russia for sure. But we had some Latin America activity that wasn't too bad. China, as I mentioned, was down, but we've kind of have a timing issue with a fairly large protested order. So we actually think China is going to be okay. The long term is we're -- we still think these markets are going to grow. We've built that market development team. We're investing in our access to care program to bring new operators into the business, and we're still bullish about the long-term opportunities. I mean, when we replace somebody that leaves as fast as maybe we used to while we go through maybe some downturns, maybe not. But we're clearly looking at this very opportunistically and strategically for the long term."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And any hope on Japan turning we talked in the past about only 20%, 25% of patients receiving radiation there so clearly, there's a clinical need.",27,"And any hope on Japan turning we talked in the past about only 20%, 25% of patients receiving radiation there so clearly, there's a clinical need."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, the clinical need remains. I just think between the currency movement, the market restructure, it's -- we are investing a little bit in government affairs there to kind of get the government a little bit more supportive. But at least, for kind of",67,"I mean, the clinical need remains. I just think between the currency movement, the market restructure, it's -- we are investing a little bit in government affairs there to kind of get the government a little bit more supportive. But at least, for kind of market outlook this year, I wouldn't say I'm seeing anything that dramatically changes what we've been seeing over the last year anyway."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then you called out the EDGE orders in China. I mean, any thoughts on how the mix there all TrueBeam EDGE.",22,"And then you called out the EDGE orders in China. I mean, any thoughts on how the mix there all TrueBeam EDGE."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think it's been pretty consistent. It's a bimodal market. There is a value market that's aggressive, where people are looking at entry-level products. But there's also a high-end market. EDGE is part of that. We're really glad to get those 3 Q1 EDGE ord",152,"I think it's been pretty consistent. It's a bimodal market. There is a value market that's aggressive, where people are looking at entry-level products. But there's also a high-end market. EDGE is part of that. We're really glad to get those 3 Q1 EDGE orders. And then one of the exciting pieces of news is that TrueBeam -- the TrueBeam volume there still remains pretty good. It is a category A product, so it puts it in a little more -- a little bit more of a regulatory process to get through. But -- so there's limited licenses at that end of the market. But I'd say our mix of product remains pretty consistent, and the high end of that market remains a really important market for us. And we've been expanding our share in China over the last 18 months. So we're doing that by winning in the value market."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Backlog declines a bit this quarter was that just the order slippage from last quarter? And any thoughts on backlog stability, I guess, going forward?",25,"Backlog declines a bit this quarter was that just the order slippage from last quarter? And any thoughts on backlog stability, I guess, going forward?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So first it's a year-ago quarter backlog sequentially. Yes. Yes. So I mean, we came in ahead -- a little bit ahead on Oncology revenues. And the order. So that's all it is.",34,"So first it's a year-ago quarter backlog sequentially. Yes. Yes. So I mean, we came in ahead -- a little bit ahead on Oncology revenues. And the order. So that's all it is."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Two other quick ones, I guess, on kind of the software initiatives. Dow, in the past, you talked about a $300 million opportunity over the next couple of years. Can you just give us a sense of the magnitude, the growth you think you can capture from",70,"Okay. Two other quick ones, I guess, on kind of the software initiatives. Dow, in the past, you talked about a $300 million opportunity over the next couple of years. Can you just give us a sense of the magnitude, the growth you think you can capture from all the initiatives RapidPlan and everything else you've been highlighting over the last couple of quarters that you can capture this year?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean, I think the RapidPlan is certainly our single-biggest opportunity, maybe talking about it in terms of units. If we have -- if we've taken 300  to 350 units, there's probably an installed base of 3,500 to 4,000, so we're just nicking that. And",226,"Yes. I mean, I think the RapidPlan is certainly our single-biggest opportunity, maybe talking about it in terms of units. If we have -- if we've taken 300  to 350 units, there's probably an installed base of 3,500 to 4,000, so we're just nicking that. And I think that's what encourages me is the early evidence, both for clinical outcome and productivity, is outstanding. So I think it really helps us make the economic case for people to invest. And the -- of course, the ASPs, the selling prices and the margins there remain very good. InSightive Analytics and kind of the transition to coordinated care on ARIA, maybe not as far advanced a product as released a little bit later, but we also really like the progress there. And we do think it's driving share. We'd love to see where it drives just a little bit more volume. We are investing in some software sales resources outside of the U.S. to kind of help us attack some markets that we haven't maybe attacked as aggressively on the software side. Much of our software business is still, frankly, U.S.-based. So we're trying to drive that piece as well. But we're still -- we're very encouraged by what we see, both in terms of kind of the market opportunity and a share opportunity by our software products."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then just lastly, obviously there's been a lot of news earlier this year on the cancer program and a lot of them into a liquid biopsy. Of this it and you have that change your view in the long-term outlook on U.S. market in particular with the better",50,"And then just lastly, obviously there's been a lot of news earlier this year on the cancer program and a lot of them into a liquid biopsy. Of this it and you have that change your view in the long-term outlook on U.S. market in particular with the better detection?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","The short version is we love it. We do know that there's been some reach out to some of our customers in the radiation therapies going to be part of it. So that's -- frankly, any other clarity beyond that is difficult. But we're encouraged that at least o",55,"The short version is we love it. We do know that there's been some reach out to some of our customers in the radiation therapies going to be part of it. So that's -- frankly, any other clarity beyond that is difficult. But we're encouraged that at least our thought leaders are at the table."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Steve Beuchaw from Morgan Stanley.",10,"Our next question comes from Steve Beuchaw from Morgan Stanley."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Just a few housekeeping items for me at this point. I guess, first for MeVis and Claymount do you have a sense for what the contribution was in the top line from those specifically for the quarter. I know we had a number we have for the quarter.",48,"Just a few housekeeping items for me at this point. I guess, first for MeVis and Claymount do you have a sense for what the contribution was in the top line from those specifically for the quarter. I know we had a number we have for the quarter."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. It's roughly $15 million.",5,"Yes. It's roughly $15 million."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","$15 million. Okay. And then on the proton financing, now that you guys have a little bit more of that on the balance sheet. Do you have a sense for what the contribution was on the P&L in the quarter?",40,"$15 million. Okay. And then on the proton financing, now that you guys have a little bit more of that on the balance sheet. Do you have a sense for what the contribution was on the P&L in the quarter?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Oh. The total income was like 1.7. So I don't have that number right in front of me, Steve, but that's close enough.",23,"Oh. The total income was like 1.7. So I don't have that number right in front of me, Steve, but that's close enough."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Got it. And then last one for me is I'm thinking back to the fourth quarter call and the delivery slippages. I think Tycho might have alluded to this, but there was a $0.10 a impact from delivery. I think it was predominantly TrueBeam's slipping from the",73,"Got it. And then last one for me is I'm thinking back to the fourth quarter call and the delivery slippages. I think Tycho might have alluded to this, but there was a $0.10 a impact from delivery. I think it was predominantly TrueBeam's slipping from the fourth quarter. Did we recapture that in the first quarter? Is there more in the second quarter? How do we think about those layering in here?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I think you should assume that was built into our guidance for FY '16 and the bulk of that in Q1. So we took that into account when we send the guidance for Q1.",35,"Well, I think you should assume that was built into our guidance for FY '16 and the bulk of that in Q1. So we took that into account when we send the guidance for Q1."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Charley Jones from Doherty markets.",10,"Our next question comes from Charley Jones from Doherty markets."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","I put some numbers around some comments he you may Dow and then had a question around some comments Elisha had around the guidance for the year-end revenue. And wondering if you could tease out what the growth well, I think this is kind of a $500 million",247,"I put some numbers around some comments he you may Dow and then had a question around some comments Elisha had around the guidance for the year-end revenue. And wondering if you could tease out what the growth well, I think this is kind of a $500 million service software business. If you could kind of breakout how much of it is maybe just software only and then particularly I'm interested in trying to figure out the opportunity of this. I was guessing it was going to be international. And I was curious, Elisha, if you could talk about the growth rates of service and software for 2015 kind of between international and U.S. and how that's going to change in '16 really trying to understand what this business can look like if we did get into a lower unit kind of environment. And it goes to my second question around the guidance of revenue. Seems like you're putting a lot in the fourth quarter, if I'm reading you right about pull in revenue out of the third quarter, Elisha, in the second quarter. So I'm just curious, where does that come from? Is that more Oncology or proton or X-ray? And I think, Dow, last quarter you said maybe we get a little bit of growth from X-ray as we went through the back half of the year. But curious if you have any better visibility on that as well. So those are my questions."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Okay. Hopefully I can remember all that.",7,"Okay. Hopefully I can remember all that."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me start on that software servicing. I mean, first of all, around us, our service business is about $1 billion business. Our software business is about $0.5 billion business, much of which is equipment and much of which is service. So it kind of gets",116,"Let me start on that software servicing. I mean, first of all, around us, our service business is about $1 billion business. Our software business is about $0.5 billion business, much of which is equipment and much of which is service. So it kind of gets double counted as we look at it because there's software service agreement pays -- piece that goes into our service business and then the upfront licenses that we sell as part of the customer getting in the business or ongoing equipment transactions as booked in our equipment business. So as we've said, the service business historically has been a double-digit business. I think constant currency adjusted last year was 9%."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","9%.",2,"9%."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","9% and it was constant currency adjusted growth in Q1 was 6%. So I think on the year, we clearly kind of see it at high single-digit kind of growth, that growth range. And now if we stretch and everything double-digit business. But that's kind of what we'",168,"9% and it was constant currency adjusted growth in Q1 was 6%. So I think on the year, we clearly kind of see it at high single-digit kind of growth, that growth range. And now if we stretch and everything double-digit business. But that's kind of what we're seeing on the software -- in the service business. But software is a big piece of that growth in the service business. software business itself is about $0.5 billion business, call it 50-50. 50%-ish equipment, 50% ongoing service agreement with our service installed these. Last year, that business grew a little faster than the average. So if the constant currency growth and Oncology last year was 6%, it was call it, 7% or 8%. So we'd love to stretch that business to get double-digit growth. That's what we'd love to see. I think stretching to get there but right now, we'd love to see it grow at a bit faster than the Oncology average. Elisha, you can fix all that."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No. But I am reluctant to give a whole lot of breakdown on our guidance. I mean, this is, again, we're in Q1. We're looking out at the full year. We are confident from where we sit today. I think you're correct that more growth is going to come in the sec",244,"No. But I am reluctant to give a whole lot of breakdown on our guidance. I mean, this is, again, we're in Q1. We're looking out at the full year. We are confident from where we sit today. I think you're correct that more growth is going to come in the second half. But the reason for that is the anniversary-ed 2 really big FX of last year. The first being, FX. We still have a little bit quarter-over-quarter impact in this second fiscal quarter that we're currently in. But as we -- assuming currency stay where they are today, that impact gets reduced significantly if we go into Q3 and Q4. And so obviously, we expect the dollar growth rates are going to be higher in the second half of the year. The other thing that we anniversary-ed that was huge last year is the pricing impact on particularly the flat panel business. And all of the declines that we saw there, which again, were laid in second quarter and really large in Q3 and Q4. So our hope is that we're going to get a little more linear in our Oncology business as we go through this fiscal year. And if you look at the guidance for the first half versus the full year, it's right around at the midpoint, 45% of the year, and that is very common with historical performance, having about 45% of our EPS in the first half."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Maybe I can just follow up, I guess, on a question around X-ray. You made comments last quarter, Dow, about maybe seeing some stabilization in X-ray. Obviously, you talked about Toshiba and there's an unknown there. But if you look at what's happened here",88,"Maybe I can just follow up, I guess, on a question around X-ray. You made comments last quarter, Dow, about maybe seeing some stabilization in X-ray. Obviously, you talked about Toshiba and there's an unknown there. But if you look at what's happened here currency and some of these other different suppliers in that business, do you feel like your position is a little bit better and you've got more visibility or stability? Are you still in this kind of unknown position there as you look for it?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I guess, kind of essay said, SIP stabilizing Security business is stabilizing. Like that. As Elisha said, fennel pricing probably anniversaries Q3-ish. We're still absorbing a loss of a major customer. That's going on. I think the only thing that's change",129,"I guess, kind of essay said, SIP stabilizing Security business is stabilizing. Like that. As Elisha said, fennel pricing probably anniversaries Q3-ish. We're still absorbing a loss of a major customer. That's going on. I think the only thing that's changed from last quarter has been this Toshiba announcement. And with that, some readjustment of their inventory and order level. I think that's probably going to go on for a while as they adjust. So that be the one piece of new news. We still think it's a good business and look for it to return to growth. I think in terms of whether it's stabilizing or not, well, the numbers aren't great we, at least, made our internal goals for the business, and we feel good about that."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Brandon Henry from RBC.",9,"Our next question comes from Brandon Henry from RBC."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","You guys have been reporting pretty strong order numbers in the EMEA and Asia Pacific regions over the last couple of quarters. But it looks like that growth rate number for Oncology Systems in those 2 regions was a little weaker this quarter. So just hel",79,"You guys have been reporting pretty strong order numbers in the EMEA and Asia Pacific regions over the last couple of quarters. But it looks like that growth rate number for Oncology Systems in those 2 regions was a little weaker this quarter. So just help me understand how much of this is market related versus like market share related. And have you seen any changes in the competitive dynamics of pricing with in either one of those markets?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","When I think -- as I've talked a little bit about on the market side last quarter, we were very gratified by the European volume we saw at the end of last year. And frankly, we'd love the market to perform at that level all the time. But as we look forwar",60,"When I think -- as I've talked a little bit about on the market side last quarter, we were very gratified by the European volume we saw at the end of last year. And frankly, we'd love the market to perform at that level all the time. But as we look forward, we didn't think that it's kind of 12%."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","25% of Q4 constant currency.",5,"25% of Q4 constant currency."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","25% constant currency growth 12% real dollar growth last quarter. That's just not going to continue. It probably is the mid-single digit-ish market. So that's probably the European market. What was the other part of the question that my jet lag is not hel",159,"25% constant currency growth 12% real dollar growth last quarter. That's just not going to continue. It probably is the mid-single digit-ish market. So that's probably the European market. What was the other part of the question that my jet lag is not helping me remember. So yes, competitively, our share is up. As we reported the last quarters, when you look at last 12 months, our share is up pretty significantly. So -- and it's worldwide. We're seeing share growth literally in every geography. So some of it has come from share growth. We obviously like that. We have seen elective be a little more aggressive, especially challenging tenders that are awarded. So that maybe that is a bit different competitive practice than we've seen in the past. Not quite sure why they're doing that. I think that hurts them with the customers frankly. But anyway, that might be the one competitive change we're seeing a little bit."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then on the Imaging Components side. Can you talk about some of the strategies and longer term after we see some stabilization that you're looking to kind of reaccelerate this business? Is it something that can be done internally with a product",80,"Okay. And then on the Imaging Components side. Can you talk about some of the strategies and longer term after we see some stabilization that you're looking to kind of reaccelerate this business? Is it something that can be done internally with a product pipeline? Or will it require M&A? And also can you give us an update on kind of the strategic review process for the Security and Inspection business? Is that a business that still fits for Varian?"
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Sure. The -- in terms of the strategy, it remains a product development business. So I alluded to the fact that with Toshiba, we started with some new pilot programs. This remains a very innovation-driven segment. And especially in tubes, it's innova",188,"Yes. Sure. The -- in terms of the strategy, it remains a product development business. So I alluded to the fact that with Toshiba, we started with some new pilot programs. This remains a very innovation-driven segment. And especially in tubes, it's innovation driven. In flat panel, it's innovation and cost reduction-driven. So one of the things that we've got coming, we just announced and it's being worked into our customers' supply chain, a new low-cost flat panel. I think that, that gives us both some margin opportunity as well as some share play. So we'd like to see that come back. As I mentioned last quarter in the call, the Security business, on the one hand, we've seen its volume come down. It's profitability still remains very, very good. So even though we've gone from $80 million, $85 million to $45 million, $50 million it's still a 20% return on sales business. It's technology that we leverage throughout our product line, both in imaging and in Oncology. So that's -- we're continuing to look at it, but replacing that revenue and profit is not an easy thing."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then one last question for me. On the services side for Oncology Systems, can you kind of talk about what the installed base for you guys how quickly that's growing. And then in the medium term, how do you grow the services business? How do you",71,"Okay. And then one last question for me. On the services side for Oncology Systems, can you kind of talk about what the installed base for you guys how quickly that's growing. And then in the medium term, how do you grow the services business? How do you continue to grow the services business high single digits kind of above the growth in the installed base? Just talk about that strategy."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","The short version is the installed base is growing. Our unit volume remains very good. As we've said before, the U.S. market remains a replacement market. But outside of the U.S., it's  we still get very good socket growth. And the TrueBeam percentage is",147,"The short version is the installed base is growing. Our unit volume remains very good. As we've said before, the U.S. market remains a replacement market. But outside of the U.S., it's  we still get very good socket growth. And the TrueBeam percentage is still quite high -- I'm sorry, the TrueBeam percentage is still quite low. When you look TrueBeam as a percent of our overall installed base, I'd say -- I'm guessing now here but call it maybe 20%, 15% to 20%. So the -- and we get a big price adjustment as we go through that. So that's true in the U.S. and it's even more true outside of the U.S. So between the installed base growth, the price growth and then the software opportunity that we get in the service, we think that, that high single-digit growth number constant currency is very doable."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","At this time, we have no further questions. I will turn the call back the Spencer Sias for closing comments.",20,"At this time, we have no further questions. I will turn the call back the Spencer Sias for closing comments."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you all for participating. A replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S, or (201) 612",69,"Thank you all for participating. A replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S, or (201) 612-7415 from outside the U.S, and entering confirmation code 13627253. The telephone replay will be available through 5 p.m. this Friday, January 29. Thank you."
311907,320073825,921832,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation.",20,"Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems First Quarter Full Year 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I'll now turn the conference over to your host, Spencer Sias, V",58,"Greetings, and welcome to the Varian Medical Systems First Quarter Full Year 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I'll now turn the conference over to your host, Spencer Sias, Vice President of Investor Relations and Corporate Communications for Varian Medical Systems. Thank you, Mr. Sias. You may now begin."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Good afternoon, and welcome to Varian Medical Systems conference call for the first quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will",274,"Thank you. Good afternoon, and welcome to Varian Medical Systems conference call for the first quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. To simplify our discussion, unless otherwise stated, all references to the quarter or year are fiscal quarters and fiscal years. Quarterly comparisons are for the first quarter of fiscal year 2016 versus the first quarter of fiscal year 2015. References to financial results for our orders are to gross orders unless otherwise indicated. This discussion includes non-GAAP financial measures in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. A reconciliation to the most comparable GAAP measure is included in our earnings release, which can be accessed on our website. Please be advised that this discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, should, will, slated and scheduled and similar expressions are intended to identify those statements, which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks relating to our business are described in our first quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise. 
And now here's Dow."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Varian is reporting revenues and earnings above our expectations for the first quarter of fiscal 2016 while managing through some challenging conditions in our markets, and we're raising our earnings guidance for the year. In",913,"Good afternoon, and welcome. Varian is reporting revenues and earnings above our expectations for the first quarter of fiscal 2016 while managing through some challenging conditions in our markets, and we're raising our earnings guidance for the year. In summary, we are reporting non-GAAP net earnings of $0.99 per diluted share and $0.91 per diluted share on a GAAP basis. Revenues of $757 million, up 3% in dollars and 7% in constant currency. Soft orders in our Oncology Systems business, the expected declines in Imaging Components orders and revenues, and good news on the tax fronts with a permanent R&D tax credit and the suspension of the medical device excise tax. 
Focusing on operational highlights. In our Oncology business, gross orders totaled $533 million for the quarter, down 5% in dollars and down 1% in constant currency. Gross orders in the Americas for the quarter increased by 3% in both dollars and constant currency with the fastest growth in Latin America. Gross orders in North America rose by 2% in dollars and constant currency. In EMEA, gross orders declined by 14% in dollars and 5% in constant currency. Gross orders in APAC declined by 12% in dollars and 7% in constant currency with continued market contraction in Japan and a modest decline in China. 
Global markets have been weakened by ongoing political unrest, weak oil prices and economic uncertainty. In EMEA, for example, Russia announced further delays in its cancer plan. Germany scaled back investments, and the Middle East was negatively impacted by political unrest and falling oil prices. 
On a positive note, in EMEA, we received an order from the U.K.'s National Health Service for a further 10 TrueBeam Systems during the quarter. The National Health System has now ordered more than 50 TrueBeams in the last few years for its cancer programs. Economic uncertainty was also a prime cause of weakness in Japan, which led to an overall orders decline in APAC. 
In China, gross orders declined slightly. As of the end of the first quarter, we continue to see hospitals in China aiming to invest in advanced radiotherapy and radiosurgery systems for their cancer patients. We booked several orders for EDGE radiosurgery systems in China during the quarter. 
In the Americas, the multimillion-dollar Siemens replacement project in Argentina and a key Ministry of Health win in Chile drove the growth in Latin America while North America continued to move forward with investments in our new product platforms to replace aging systems. 
We're focused on global market development through our access to care initiative, an educational program that seeks to bridge the gap between the growing need for modern radiotherapy treatment machines in developing countries and the lack of trained personnel to operate them. This program is already working in Africa and Vietnam, and we took steps during the quarter to initiate this program in India to an educational partnership with Apollo Hospitals group. This program will train radiation technologists in India. 
We made good progress with our software business during the quarter. Licenses for RapidPlan, our tool for enhancing efficiency and quality in treatment planning, have tripled since the end of the fiscal year and are now installed at over 50 sites. Clinical networks, including a health care system in Victoria, Australia that took 4 licenses during the quarter, are rebuilding treatment capabilities around RapidPlan. 
Turning to our Oncology service business. Orders were up 1% in dollars but up 6% in constant currency compared with a strong year-ago quarter. 
Let me turn now to Imaging Components, where orders shrank by 22% to $127 million for the quarter, and revenues fell by 15% to $141 million. Beginning in the second half of last fiscal year, this business has been confronted with currency-related pricing pressures, weak market conditions for Security and Inspection Products and an in-sourcing at a major panel customer. These challenges, together with excess tube inventory at a key customer, contributed to the declines in this business during the quarter. Volumes for tubes were down in the quarter, while demand for our higher-margin dynamic fluoroscopic panels increased and led to a sequential improvement in the growth margin for Imaging Components. 
Our recent acquisitions, MeVis and Claymount, gained momentum in the quarter and are performing well. As a reminder, we're aiming for about $50 million in revenue from these newly acquired businesses this fiscal year. 
Moving to protons. We made good progress with installations. During the quarter, we turned over the first room of the Maryland Proton Therapy Center for clinical commissioning, and first treatments are slated to begin next month. We have successfully extracted beams from the cyclotron at Cincinnati Children's Hospital, where patient treatments are scheduled to begin before the end of the year. Installation is also underway at the Paul Scherrer Institute in Switzerland, and we are scheduled to begin installations at sites in Holland, Russia and Saudi Arabia later this year. 
Proton order activity was quiet in the quarter, but our prospects for booking several more systems this year continue to look good. 
Before I hand it over to Elisha, I'd like to say how proud I am that Varian has been honored for its commitment to sustainability by being included for the second year in a row on the Corporate Knights Global 100 Most Sustainable Corporations list, which compares the sustainability performance of some 4,600 companies globally. This was announced last week at the World Economic Forum in Davos. 
Now I'll turn it over to Elisha."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 7% from the year-ago period. Backlog adjustments during the quarter totaled $55 million, bringing net orders fo",536,"Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 7% from the year-ago period. Backlog adjustments during the quarter totaled $55 million, bringing net orders for the company to $617 million. 
Now let me walk you through the P&L. First quarter revenues for the total company increased 3% in dollars and 7% in constant currency. Oncology posted a 5% gain in revenues during the quarter with a 9% gain in constant currency. There was a significant geographic mix shift towards international revenues, which grew 21% in dollars and 31% in constant currency versus the year-ago quarter, while North American revenues declined by about 10%. 
International business constituted 55% of total Oncology revenues in the quarter. Imaging Components posted a first quarter revenue decline of 15% with decreases in tubes, panels and Security and Inspection Products. 
Our Particle Therapy business posted revenues of $27 million, up $18 million from the year-ago quarter as we continue to make progress on projects in backlog. 
The total company gross margin for the quarter was 41.1%, down as expected by a little more than 3 points. Oncology Systems gross margin also fell by about 3 points to 42.4% due to geographic and product mix shifts as well as minor currency effects. Imaging Components gross margin for the quarter fell by about 1.5 points to 40.7% due largely to lower pricing and volumes. 
First quarter SG&A expenses were $124 million or 16% of revenue, an improvement of about 1 point as a percentage of revenue with the year-ago quarter. First quarter R&D expenses were $60 million or 8% of revenues, equal to the year-ago quarter as a percentage of revenue. First quarter operating earnings totaled $128 million or 17% of revenue, down about 2 points as a percentage of revenue from the year-ago quarter and in line with our expectation for the quarter. 
Depreciation and amortization totaled $19 million for the quarter. The effective tax rate was 24.8%, down almost 4 points from the year-ago quarter due largely to the geographic mix of profits and the R&D tax credit that was reinstated in late December. We now expect that the tax rate will be about 26% to 27% for the year. 
Fully diluted shares outstanding decreased almost 4 million from the year-ago quarter to 97.8 million due to our ongoing share repurchase program. Diluted EPS was $0.99 for the quarter.
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $953 million, debt of $728 million and stockholders equity of $1.6 billion. DSO at 99 days was up significantly from the year-ago quarter due to a lower mix of Imaging Components business, a higher mix of proton business and the timing of collections in Oncology. 
First quarter cash flow from operations fell slightly from the year-ago period to $77 million. Primary uses of cash were $27 million for CapEx and $192 million for the repurchase of 2.4 million shares of stock. At the end of the quarter, we had 7 million shares remaining under the existing repurchase authorization that extends through calendar year 2016. 
Now back to Dow for the outlook."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. Including the effects of the R&D tax credit reenactment and the suspension of the medical device excise tax in the U.S., we now believe that for fiscal year 2016, total company non-GAAP earnings will be in the range of $4.55 to $4.65 per d",122,"Thanks, Elisha. Including the effects of the R&D tax credit reenactment and the suspension of the medical device excise tax in the U.S., we now believe that for fiscal year 2016, total company non-GAAP earnings will be in the range of $4.55 to $4.65 per diluted share. We continue to expect that revenues for fiscal year 2016 will increase by about 4% to 5% over fiscal year 2015. For the second quarter of fiscal year 2016, we expect revenues to be up 1% to 2% from the year-ago quarter in dollars. We expect non-GAAP earnings for the second quarter of fiscal year 2016 to be in the range of $1.06 to $1.10 per diluted share. 
We are now ready for your questions."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] Our first question comes from Jeff Johnson from Robert Baird.",12,"[Operator Instructions] Our first question comes from Jeff Johnson from Robert Baird."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So Dow, I have one question for you and one question for Elisha, and let me start off with a question for you, Dow. So you sound a little bit maybe more cautious on some of the European and, given that the Middle East is in your European number on the Onc",145,"So Dow, I have one question for you and one question for Elisha, and let me start off with a question for you, Dow. So you sound a little bit maybe more cautious on some of the European and, given that the Middle East is in your European number on the Oncology side, a little more cautious on Europe and APAC. Is that the right read here? And I guess, as I look back over the last several quarters, we've seen Oncology orders in both those markets in negative territory, I think, 3 out of the last 4 quarters. Is that kind of where we should level set? I know you don't guide to orders, but just given your comments and kind of the last several quarter trendline, is that kind of where we should be still hanging out with our thoughts for the year?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me say that -- maybe just kind of cast it in a broader view for a second, Jeff, and then kind of come to some of the regional data. When you look at the last 12 months in Oncology in dollars, it's down 2%. In constant currency, it's up 4%. I mean this",334,"Let me say that -- maybe just kind of cast it in a broader view for a second, Jeff, and then kind of come to some of the regional data. When you look at the last 12 months in Oncology in dollars, it's down 2%. In constant currency, it's up 4%. I mean this first quarter is not the greatest growth that we've ever had. Our funnel remains very good, so we like what we see. The fourth quarter was huge for us in Europe. Constant currency and dollar growth in Europe was outstanding in Q4. So our Q4 was 12.5% constant currency growth last quarter. So maybe there was a little bit of quarter-over-quarter balancing going on. So I think the 12-month trailing is kind of what we're feeling right now. Clearly, we're reading the papers like everybody and some of the macroeconomic weakness in Europe is real. I mean we did have a light Q1. But I think we're -- we still see markets growing in that low- to mid-single-digit range at this point. We haven't seen anything that would pull us off that. Japan has been kind of the ongoing structural change in Japan. In China, we did have a win in the quarter that was protested. So I mean we're very close to flat in China. Our funnel remains very good in China. I mean I think Japan is probably going to be kind of more of same. That's been a pretty consistent story the last few quarters. But I do think China will come back. That order that was protested was a fairly large order. So if that was in our numbers, then China would have been great. But anyway, I mean, those are the kinds of things that happen around the quarter. I'd say over the long haul, looking at the last 12 months, we haven't seen anything that would, at this point, pull us off of market growth number in that kind of 3 to 5 range."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And yes, the 4% you cited is a trailing 12 months you're referring to kind of worldwide. So kind of mix-wise, we think North America a little bit stronger maybe than others going forward. Is that fair?",40,"Okay. That's helpful. And yes, the 4% you cited is a trailing 12 months you're referring to kind of worldwide. So kind of mix-wise, we think North America a little bit stronger maybe than others going forward. Is that fair?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Last -- when you look at it in pure dollars, America's last 12 months is at 4.5% and international is down 6.5% in dollars. Constant currency adjustment the whole thing, it's 4% up. So that's kind of -- I think last 12 months is -- that's kind of the",57,"Yes. Last -- when you look at it in pure dollars, America's last 12 months is at 4.5% and international is down 6.5% in dollars. Constant currency adjustment the whole thing, it's 4% up. So that's kind of -- I think last 12 months is -- that's kind of the market that, I think, we're still feeling."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And then, Elisha, the question for you just around EPS guidance. Since you guided back in October, the euro's kind of worked a little bit more against you, I think a little bit a stronger dollar against the euro since you guided some",141,"Okay. That's helpful. And then, Elisha, the question for you just around EPS guidance. Since you guided back in October, the euro's kind of worked a little bit more against you, I think a little bit a stronger dollar against the euro since you guided some of the emerging market currency is still going the wrong way. So as I look at the $0.10 raised to guidance here, how much was med tech tax in R&D driving that $0.10 raise? How much is kind of in the guidance number is coming from those 2 things? How much of an incremental currency headwind was there, if any, included in your guidance? And then maybe how are you thinking about the core underlying business? So just trying to bucket kind of those 3 areas on what contributed to the dime change in guidance."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. So Jeff, the simple answer is if I take the R&D tax credit and the medical device excise tax together, it's a $0.10 for the year. So -- and that's roughly even at about $0.05 each. So we got a benefit of $0.04 in Q1 for those 2 impacts. And what we'",91,"Sure. So Jeff, the simple answer is if I take the R&D tax credit and the medical device excise tax together, it's a $0.10 for the year. So -- and that's roughly even at about $0.05 each. So we got a benefit of $0.04 in Q1 for those 2 impacts. And what we're saying is the additional $0.06 is going to come from Q2 to Q4. So essentially, we took the benefit from those 2 things, packed it on to the prior guidance and got us to the 4 60 midpoint."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then underlying then kind of the core business. Are you -- I'm trying to figure out if currency I thought was an incremental headwind since you last guided. Does that imply that your core expectations have improved a little bit?",42,"Okay. And then underlying then kind of the core business. Are you -- I'm trying to figure out if currency I thought was an incremental headwind since you last guided. Does that imply that your core expectations have improved a little bit?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I mean, certainly Q1, we feel good about. And in terms of what I would refer to as an operational update, if you take out the $0.04 related to the tax impact, we had about a $0.05 update and that was due to higher Oncology revenue and frankly, very",229,"Well, I mean, certainly Q1, we feel good about. And in terms of what I would refer to as an operational update, if you take out the $0.04 related to the tax impact, we had about a $0.05 update and that was due to higher Oncology revenue and frankly, very good cost controls on SG&A. Little bit on share repurchase was a little bit more than we historically done but in line with that 1 million to 2 million shares per quarter. I think your next question's going to be why aren't you giving me that $0.05? And I'm still a little black and blue after Q4, frankly. And when we missed on that revenue number, it's very early in the year. And I think this just had to do with some timing. And I think Oncology did a fantastic job and probably pulled a little bit revenue forward from Q2 and Q3 to make sure we didn't have a repeat performance. But for the year, we -- it still looks good with the revenue guidance and the EPS from where we stand today. Currency, from when I last guided, has been relatively stable. I mean it may have hurt us, I don't know, I think I was at $1.12 versus $1.09. But again, we built some of that into the range for the guidance when we give it."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Amit Hazan from Citi.",9,"Our next question comes from Amit Hazan from Citi."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So start on the gross margin line. Just maybe a question on Oncology gross margin. So I was looking back just kind of taking a little bit several quarter view. And if I strip out service, I mean just kind of look at your product gross margin on the Oncolo",151,"So start on the gross margin line. Just maybe a question on Oncology gross margin. So I was looking back just kind of taking a little bit several quarter view. And if I strip out service, I mean just kind of look at your product gross margin on the Oncology side, it kind of implies this pretty big decline over the past year. I don't know, it's about 36% in fiscal '14 down to 31% in fiscal '15. And that's just, obviously, just the product side. So I'm wondering if you can share with us whether that trend continued this quarter, first of all, and what the driver share might be outside of FX because you've kind of actually had a nice mix shift in revenue towards the U.S. up until this quarter. And -- so I'm wondering why product margins in Oncology would be down as much as they were."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. So Amit, the biggest impact on Q1 was just the geographic mix shift. We had a 7-point shift to international delivery in particularly the Middle East and Eastern Europe, which are our lower-margin countries. And that was just based on scheduled deliv",166,"Yes. So Amit, the biggest impact on Q1 was just the geographic mix shift. We had a 7-point shift to international delivery in particularly the Middle East and Eastern Europe, which are our lower-margin countries. And that was just based on scheduled delivery date. So we fully anticipated we were going to have margin declines in Oncology and for the total company, and I think that was reflected in the guidance that we gave last quarter. So for the year, I still expect, even with the -- we still had some currency impact in Q1. We'll have a little bit in Q2 and then it should anniversary. For the year, we still think Oncology is right in that 43% range, so holding in line with our long-term expectations. I would point out service was a bigger proportion in the year-ago quarter, and that is one of our highest-margin product lines. So that impacted it as well. But I think Oncology is performing well at this point."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And just to reiterate, nothing outside -- anything that's outside of FX that is hurting the product side of gross margins in Oncology. That's what seems to have been down over the course of a year.",36,"And just to reiterate, nothing outside -- anything that's outside of FX that is hurting the product side of gross margins in Oncology. That's what seems to have been down over the course of a year."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Region mix.",2,"Region mix."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Region, yes. The region mix, the geographic mix, yes. So international went from 48% of total revenue in the year-ago period to 55%, it's just a very big geographic mix shift. But on an apples-to-apples basis, it's really just the geography that was impac",55,"Region, yes. The region mix, the geographic mix, yes. So international went from 48% of total revenue in the year-ago period to 55%, it's just a very big geographic mix shift. But on an apples-to-apples basis, it's really just the geography that was impacting it. And again, less service as a percentage of the total."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Let me jump to Imaging. Just a couple questions on that. Number one, I'm wondering if you're reiterating kind of the guidance you laid out for the fiscal year, which I think was about flat or so on imaging revenues. And then secondly, specifically,",70,"Okay. Let me jump to Imaging. Just a couple questions on that. Number one, I'm wondering if you're reiterating kind of the guidance you laid out for the fiscal year, which I think was about flat or so on imaging revenues. And then secondly, specifically, has your assessment of the risk around losing more business in flat panel and in tubes changed at all since the earnings call last quarter?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think maybe the one difference we'd have here is Toshiba announced during the quarter that they're selling their medical unit. Otherwise, I think it's very much consistent with what we guided a quarter ago. The challenges continue. The Security and Insp",218,"I think maybe the one difference we'd have here is Toshiba announced during the quarter that they're selling their medical unit. Otherwise, I think it's very much consistent with what we guided a quarter ago. The challenges continue. The Security and Inspection business has stabilized -- stabilizing, clearly, at the lower revenue levels. The panel pricing declines should anniversary in the second half, and we're still absorbing the loss of major -- of a major customer that went in-sourcing on flat panel. That's probably not going to -- that's happening every quarter to us and it probably doesn't anniversary until Q4-ish. Toshiba's volume. The good news is most of that business is a service business. So that is going to continue to need to be replaced, but their ongoing forward production with the uncertainty around their sale and kind of who picks it up, et cetera, we might see a little bit of a volume adjustment there. As I did say in the script, they do have some inventory that they're working through as they kind of manage through this whole thing. The good news is the MeVis and Claymount acquisitions seem to be performing for us. So we're looking for a return to growth, I think, consistent with what we said before in 2017 and 2018."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Anthony Petrone from Jefferies.",9,"Our next question comes from Anthony Petrone from Jefferies."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Couple questions, maybe on proton. A couple of questions on proton. I'll begin with proton and then we can follow up with some of the geographies as well in Oncology. But maybe just an update on the potential to hit the $0.15 swing factor in proton specif",99,"Couple questions, maybe on proton. A couple of questions on proton. I'll begin with proton and then we can follow up with some of the geographies as well in Oncology. But maybe just an update on the potential to hit the $0.15 swing factor in proton specifically. So I think it hinged on the Emory deal. And then in your prepared comments, Dow, you mentioned potentially an installation in Russia. But you also touched upon some dislocations in an marketplace. So maybe just proton overall, the potential to the $0.15, where Emory is and how Russia plays into that."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. I mean the sites I named were all in our guidance, so that -- they were orders that we have and no mystery around those. We have not guided to Emory. It is not a booked order yet. Until the financing is complete, we won't put it into guidance. If th",62,"Sure. I mean the sites I named were all in our guidance, so that -- they were orders that we have and no mystery around those. We have not guided to Emory. It is not a booked order yet. Until the financing is complete, we won't put it into guidance. If that were to happen, it'd be a nice upside for us."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. We lived that problem. We're not doing that. And it's just -- it's our customer who is securing the financing. We are working with them but it really is somewhat outside of Varian's control, and we're monitoring it closely.",40,"Yes. We lived that problem. We're not doing that. And it's just -- it's our customer who is securing the financing. We are working with them but it really is somewhat outside of Varian's control, and we're monitoring it closely."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Great, great. And then just on geographies. You touched on China a bit, but Brazil is also sort of in the headlines out there with struggles. And so maybe just an update on that specific tender. I think if you go back, it was 50 Linacs, several of which h",66,"Great, great. And then just on geographies. You touched on China a bit, but Brazil is also sort of in the headlines out there with struggles. And so maybe just an update on that specific tender. I think if you go back, it was 50 Linacs, several of which had already been sort of shipped and installed. So maybe just an update on that specific tender."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We're seeing the Ministry of Health is continuing their program. I mean obviously that order was placed with us a year ago, but we are completing first installations this year and it is going as expected. So from a backlog point of view, we haven't seen a",68,"We're seeing the Ministry of Health is continuing their program. I mean obviously that order was placed with us a year ago, but we are completing first installations this year and it is going as expected. So from a backlog point of view, we haven't seen a change in their approach on these. So that's good. Market's a little bit quiet there, but it hasn't been bad."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then just a last one for me would just be on software specifically. So last year, that really seemed to be a driver, particularly on share gains, I think, both on information management and even treatment planning. So maybe do you see that as still a",77,"And then just a last one for me would just be on software specifically. So last year, that really seemed to be a driver, particularly on share gains, I think, both on information management and even treatment planning. So maybe do you see that as still a share gain story for 2016? And may be just an update on how many RapidPlans have sort of -- how many Eclipse users have migrated to RapidPlan at this point?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean first of all, for the overall software business, it continues to do very well. We just got news a couple of weeks ago that both Eclipse and ARIA got top ranking from class. Classes [ph], the Gartner of our industry, independent organization th",153,"Yes. I mean first of all, for the overall software business, it continues to do very well. We just got news a couple of weeks ago that both Eclipse and ARIA got top ranking from class. Classes [ph], the Gartner of our industry, independent organization that evaluates products for customers. So we were very thrilled by that external validation. The -- and then in terms of RapidPlan, as I said in the script, it's now installed over 50 sites. I'd have to get you the exact number of orders, but it's well over 300 now. So the momentum continues there. I think from a overall differentiation point of view, our treatment planning position is terrific. I think we're way ahead with our knowledge-based tools. And then in ARIA, our workflow tools and our informatics are very good differentiators for us, and we continue to see very strong competitive takeout with both those products."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from David Roman from Goldman Sachs.",10,"Our next question comes from David Roman from Goldman Sachs."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","I wanted just to start with a clarification on the proton. I understand that Emory is not in the guidance and with -- and sort of a context for why you did that. But are Russia and Saudi Arabia that you talked about are -- to what extent are those reflect",55,"I wanted just to start with a clarification on the proton. I understand that Emory is not in the guidance and with -- and sort of a context for why you did that. But are Russia and Saudi Arabia that you talked about are -- to what extent are those reflected in the forward guidance?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","They're very small amounts. They are in the guidance.",10,"They're very small amounts. They are in the guidance."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So all of our -- under the percentage of completion, all of our projects where we have actually identified material specific to a customer, we are taking revenue on those projects. So Saudi and Russia would be included in that number.",41,"So all of our -- under the percentage of completion, all of our projects where we have actually identified material specific to a customer, we are taking revenue on those projects. So Saudi and Russia would be included in that number."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Saudi, for example, I know we already took a fair amount last year.",13,"Saudi, for example, I know we already took a fair amount last year."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We've taken about $43 million in total. And Russia, about $25 million in total.",15,"We've taken about $43 million in total. And Russia, about $25 million in total."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then maybe a more strategic question. I mean, Dow, obviously, we focus a lot on the quarter-to-quarter order trends and how you're doing by region. But as you kind of take a step back and think about your growth rate, how things have progressed",91,"Okay. And then maybe a more strategic question. I mean, Dow, obviously, we focus a lot on the quarter-to-quarter order trends and how you're doing by region. But as you kind of take a step back and think about your growth rate, how things have progressed the past several quarters versus where you kind of want them to be, how much of the forward outlook depends on factors over which you have control and can invest to drive growth versus being dependent on macro factors or sort of end market conditions?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean for the whole company, I think the cancer business remains a terrific business for us. Constant currency growth last year was 5%, 6% in Oncology, very strong fourth quarter. We're a little weak this quarter, but our funnel still looks good. And we",337,"I mean for the whole company, I think the cancer business remains a terrific business for us. Constant currency growth last year was 5%, 6% in Oncology, very strong fourth quarter. We're a little weak this quarter, but our funnel still looks good. And we think that the cancer business, unfortunately, weathers economic downturns. I mean people get cancer regardless of economics. And now if you look back when economic times were bad, we weathered those storms pretty well. It's not to say that we might see something in our orders if the economy really turns south. But there was this nice external validation of that last quarter with the global task force on the utilization of radiation Oncology published in the Lancet journal that called for thousands more machines. Basically, 2.5x the installed base that we have today and really asking international organizations to help countries develop cancer plans. So especially outside of U.S., a huge focus on utilizing radiation therapy for cancer. I think one of our big challenges, I mentioned in the script there, is making sure the people side of that comes along with it because we've got to have the people to be able to do the work. But I think as you look at the long term health of the Oncology business, the franchise is in as good a product position as we've ever had. And I think the market remains in the long term, very, very solid. Now on the Imaging business, we're clearly going through a big storm right now. And we still like the fundamentals of the business. We do think it's an industry that has some consolidation opportunity, and we've got to kind of figure out how to play that hand a little bit. But the -- as we get through the in-sourcing of this one customer, this kind of short-term Toshiba perturbations and look to the long term, the digitization of especially the radiographic market remains a huge opportunity. And we like the long-term fundamentals there."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then maybe just a last one, maybe sort of a follow-up to that. As you sort of think about the opportunities that sit in front of you, what was sort of the thought process around what to do with the medical device tax? I know in dollars it's not all th",98,"And then maybe just a last one, maybe sort of a follow-up to that. As you sort of think about the opportunities that sit in front of you, what was sort of the thought process around what to do with the medical device tax? I know in dollars it's not all that material for you compared to some of the other companies in the group. But why not plow some of those savings back into the business? And how should we sort of think about your spending patterns on a go-forward basis to support some of that growth?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean at a high level, let me take first crack at this and I'll have Elisha walk you through some of the detail, but at a high level, we have actually taken up our R&D spend as a percent of sales over the last couple of years. So we're investing a l",155,"Yes. I mean at a high level, let me take first crack at this and I'll have Elisha walk you through some of the detail, but at a high level, we have actually taken up our R&D spend as a percent of sales over the last couple of years. So we're investing a lot in the business. We want to make sure we get pop for that growth. So we're challenging the spend as we do it because we want to see the growth kind of linking it to your previous question. But we have taken up the R&D investment as a percent of the total over the last couple years. So we were never kind of making the R&D decision as a result of our tax impact. I mean clearly it would've been a little easier if we didn't have to pay that, but we were making that decision independent of the tax stuff."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And I would just add. I mean our road map is kind of set for the year. We've got the people, the projects. It may be more disruptive to try and even accelerate some of those things at this point. And the last point is when we increased R&D, it comes from",75,"And I would just add. I mean our road map is kind of set for the year. We've got the people, the projects. It may be more disruptive to try and even accelerate some of those things at this point. And the last point is when we increased R&D, it comes from people. And that tends to be permanent in nature, whereas this is only a reprieve for 2 years as drafted at this point."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Jason Wittes from Brean Capital.",10,"Our next question comes from Jason Wittes from Brean Capital."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So I just wanted to ask first off, in terms of Security business, I think you said about $25 million of the revenues related to Security are service related. And that's -- is that mostly revenues we should expect this year or should we also expect some or",52,"So I just wanted to ask first off, in terms of Security business, I think you said about $25 million of the revenues related to Security are service related. And that's -- is that mostly revenues we should expect this year or should we also expect some orders on top of that?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No. I mean that's maybe not quite half -- I mean a little bit more than half of the total revenue we should have on the year.",27,"No. I mean that's maybe not quite half -- I mean a little bit more than half of the total revenue we should have on the year."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, that's about right.",4,"Yes, that's about right."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then just to understand Toshiba, they're looking to sell that business. I assume they're one of your larger customers. And I assume they're still a decent percentage of the imaging business? Is that the right way to think about it? And I guess t",80,"Okay. And then just to understand Toshiba, they're looking to sell that business. I assume they're one of your larger customers. And I assume they're still a decent percentage of the imaging business? Is that the right way to think about it? And I guess the presumption would be they're right now working down their inventories, but they'll have to start reordering at some point. Whether or not that's after a sale or not, I guess, is harder to determine."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean here's what I can tell you. They are our largest customer. In fact, they're a terrific customer. They account for about $150 million of our Imaging Components revenue. The split on that is $125 million tubes, about $25 million in panel. We expect t",105,"I mean here's what I can tell you. They are our largest customer. In fact, they're a terrific customer. They account for about $150 million of our Imaging Components revenue. The split on that is $125 million tubes, about $25 million in panel. We expect to continue supplying high-end CT tubes to whoever it is that buys Toshiba. We're designing future products for them, having very good conversations. So we think that -- I mean there's obviously kind of some uncertainty as it goes through that process. But we're well designed in and I think that, that will continue whoever the new owner is."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's very helpful. And then maybe just switch to proton. I mean you mentioned sort of global turmoil impacting your core Oncology business. Should we assume that the proton business may also be impacted this year?",37,"Okay. That's very helpful. And then maybe just switch to proton. I mean you mentioned sort of global turmoil impacting your core Oncology business. Should we assume that the proton business may also be impacted this year?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean it's tough to say. When you look at our funnel, our funnel remains positive. We have had 1 or 2 fallout. I don't know how much of that -- some of that is, I think, some of their own decisions. I don't know how much of it was the kind of macro econo",173,"I mean it's tough to say. When you look at our funnel, our funnel remains positive. We have had 1 or 2 fallout. I don't know how much of that -- some of that is, I think, some of their own decisions. I don't know how much of it was the kind of macro economy. We are competing on a number of compact units, and I do think we'll see our first compact orders this year. So we're encouraged about that. There remains to be a lot of customer interest. And I guess I would say that versus -- in 2009 -- 2008, 2009 when we went through this, we were just selling big systems. So that market dried up. Now when you look at our funnel, our funnel has a lot of compact units and customers are hanging in there. We're having a lot of conversations and also the funnel remains pretty good, and our objective is to see if we can win a few of those single-room orders this year."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Sorry, just to get a clarification. The large centers, there's really not much of a market this year for them. It's mostly compact centers that people are looking at right now.",31,"Sorry, just to get a clarification. The large centers, there's really not much of a market this year for them. It's mostly compact centers that people are looking at right now."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, that was a comparison to 2008, 2009. 2008, 2009, that's what the market was. And when you're looking at $50 million to $90 million of expense into that kind of recession, that market just went away during 2008, 2009. We're not seeing that. There's s",108,"Well, that was a comparison to 2008, 2009. 2008, 2009, that's what the market was. And when you're looking at $50 million to $90 million of expense into that kind of recession, that market just went away during 2008, 2009. We're not seeing that. There's still a good multi-room market out there. But we're also seeing a very good funnel of these compact rooms. We're competing on both. But just to say that in terms of as it relates to kind of the global macroeconomic environment, I think these compact customers are hanging in there a little more in terms of the funnel -- strength of the funnel."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Tycho Peterson from JPMorgan.",9,"Our next question comes from Tycho Peterson from JPMorgan."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Maybe just a higher-level strategic question on some of the emerging markets that you've called out as being kind of problematic. I mean given that a lot of the issues here are kind of structural rather than cyclical in some of these markets. Does this ch",80,"Maybe just a higher-level strategic question on some of the emerging markets that you've called out as being kind of problematic. I mean given that a lot of the issues here are kind of structural rather than cyclical in some of these markets. Does this change your thinking around how you address these markets, the resources you put to them? Any change in where you're placing incremental efforts internationally based on what we've seen the last couple of quarters?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me kind of underscore one of the things I pointed out in the call is weak in Japan, weak in Europe. Emerging markets, weak in Russia for sure. But we had some Latin America activity that wasn't too bad. China, as I mentioned, was down, but we've kind",152,"Let me kind of underscore one of the things I pointed out in the call is weak in Japan, weak in Europe. Emerging markets, weak in Russia for sure. But we had some Latin America activity that wasn't too bad. China, as I mentioned, was down, but we've kind of have a timing issue with a fairly large protested order. So we actually think China is going to be okay. The long term is we're -- we still think these markets are going to grow. We've built a market development team. We're investing in our access to care program to bring new operators into the business, and we're still bullish about the long-term opportunities. I mean do we replace somebody that leaves as fast as maybe we're used to while we go through maybe some downturns? Maybe not. But we're clearly looking at this very opportunistically and strategically for the long term."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And any hope on Japan turning? I mean I know you talked in the past about only 20%, 25% of patients receiving radiation there. So clearly, there's a clinical need.",30,"And any hope on Japan turning? I mean I know you talked in the past about only 20%, 25% of patients receiving radiation there. So clearly, there's a clinical need."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean the clinical need remains. I just think between the currency movement, the market restructure, it's -- we are investing a little bit in government affairs there to kind of get the government a little bit more supportive. But at least for kind",68,"Yes. I mean the clinical need remains. I just think between the currency movement, the market restructure, it's -- we are investing a little bit in government affairs there to kind of get the government a little bit more supportive. But at least for kind of market outlook this year, I wouldn't say I'm seeing anything that dramatically changes what we've been seeing over the last year anyway."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then you called out the EDGE orders in China. Just -- I mean any thoughts on how the mix there evolves TrueBeam, EDGE?",24,"And then you called out the EDGE orders in China. Just -- I mean any thoughts on how the mix there evolves TrueBeam, EDGE?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think it's been pretty consistent. It's a bimodal market. There is a value market that's aggressive, where people are looking at entry-level products. But there's also a high-end market. EDGE is part of that. We're really glad to get those 3 Q1 EDGE ord",152,"I think it's been pretty consistent. It's a bimodal market. There is a value market that's aggressive, where people are looking at entry-level products. But there's also a high-end market. EDGE is part of that. We're really glad to get those 3 Q1 EDGE orders. And then one of the exciting pieces of news is that TrueBeam -- the TrueBeam volume there still remains pretty good. It is a category A product, so it puts it in a little more -- a little bit more of a regulatory process to get through. But -- so there's limited licenses at that end of the market. But I'd say our mix of product remains pretty consistent, and the high end of that market remains a really important market for us. And we've been expanding our share in China over the last 18 months. So we're doing that by winning in the value market."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Backlog declined a bit this quarter. Was that just the order slippage from last quarter? And any thoughts on backlog stability, I guess, going forward?",25,"Backlog declined a bit this quarter. Was that just the order slippage from last quarter? And any thoughts on backlog stability, I guess, going forward?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So first, it's a year-ago quarter backlog was up sequentially. Yes. Yes. So I mean we came in ahead, a little bit ahead on Oncology revenues and the order. So that's all it is.",34,"So first, it's a year-ago quarter backlog was up sequentially. Yes. Yes. So I mean we came in ahead, a little bit ahead on Oncology revenues and the order. So that's all it is."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Two other quick ones, I guess. On kind of the software initiatives. Dow, in the past, you talked about a $300 million opportunity over the next couple of years. Can you just give us a sense of the magnitude -- the growth you think you can capture fr",71,"Okay. Two other quick ones, I guess. On kind of the software initiatives. Dow, in the past, you talked about a $300 million opportunity over the next couple of years. Can you just give us a sense of the magnitude -- the growth you think you can capture from all the initiatives, RapidPlan, and everything else you've been highlighting over the last couple of quarters that you can capture this year?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean I think the -- RapidPlan is certainly our single biggest opportunity, maybe talking about it in terms of units. If we have -- if we've taken 300 to 350 units, there's probably an installed base of 3,500 to 4,000, so we're just nicking that. An",233,"Yes. I mean I think the -- RapidPlan is certainly our single biggest opportunity, maybe talking about it in terms of units. If we have -- if we've taken 300 to 350 units, there's probably an installed base of 3,500 to 4,000, so we're just nicking that. And I think what encourages me is the early evidence, both for clinical outcome and productivity, is outstanding. So I think it really helps us make the economic case for people to invest. And the -- of course, the ASPs, the selling prices and the margins there remain very good. InSightive Analytics and our kind of the transition to coordinated care on ARIA is maybe not as far advanced. The product was released a little bit later, but we also really like the progress there. And we do think it's driving share. We'd love -- really like to see where it drives a little bit more volume. We are investing in some software sales resources outside of the U.S. to kind of help us attack some markets that we haven't maybe attacked as aggressively on the software side. Much of our software business is still, frankly, U.S.-based. So we're trying to drive that piece as well. But we're still -- we're very encouraged by what we see and -- both in terms of kind of the market opportunity and the share opportunity by our software products."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then just lastly. Obviously, there's been a lot of news earlier this year on the cancer moonshot program and a lot of developments in liquid biopsy. Does any of that change your view on the long term outlook on the U.S. market in particular with bette",50,"And then just lastly. Obviously, there's been a lot of news earlier this year on the cancer moonshot program and a lot of developments in liquid biopsy. Does any of that change your view on the long term outlook on the U.S. market in particular with better and earlier detection?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","The short version is we love it. We do know that there's been some reach out to some of our customers and that radiation therapy is going to be part of it. So that's -- frankly, any other clarity beyond that is difficult. But we're encouraged that at leas",56,"The short version is we love it. We do know that there's been some reach out to some of our customers and that radiation therapy is going to be part of it. So that's -- frankly, any other clarity beyond that is difficult. But we're encouraged that at least our thought leaders are at the table."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Steve Beuchaw from Morgan Stanley.",10,"Our next question comes from Steve Beuchaw from Morgan Stanley."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Just a few housekeeping items for me at this point. I guess first, for MeVis and Claymount, do you have a sense for what the contribution was in the top line from those specifically for the quarter? I know we had a number for the year. I don't know that w",55,"Just a few housekeeping items for me at this point. I guess first, for MeVis and Claymount, do you have a sense for what the contribution was in the top line from those specifically for the quarter? I know we had a number for the year. I don't know that we have for the quarter."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. It's roughly $15 million.",5,"Yes. It's roughly $15 million."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","$15 million. Okay. And then on the proton financing. Now that you guys have a little bit more of that on the balance sheet, do you have a sense for what the contribution was on the P&L in the quarter?",40,"$15 million. Okay. And then on the proton financing. Now that you guys have a little bit more of that on the balance sheet, do you have a sense for what the contribution was on the P&L in the quarter?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","The total interest income was like $1.7 million. So call it $1.5 million maybe? I don't have that number right in front of me, Steve, but that's close enough.",29,"The total interest income was like $1.7 million. So call it $1.5 million maybe? I don't have that number right in front of me, Steve, but that's close enough."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Got it. And then last one for me is I'm thinking back to the fourth quarter call and the delivery slippages. I think Tycho might have alluded to this, but there was a $0.10 impact from delivery. I believe it was predominantly TrueBeam's slipping from the",72,"Got it. And then last one for me is I'm thinking back to the fourth quarter call and the delivery slippages. I think Tycho might have alluded to this, but there was a $0.10 impact from delivery. I believe it was predominantly TrueBeam's slipping from the fourth quarter. Did we recapture that in the first quarter? Is there more in the second quarter? How do we think about those layering in here?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I think you should just assume that was built into our guidance for FY '16 and the bulk of that in Q1. So we took that into account when we set the guidance for Q1.",36,"Well, I think you should just assume that was built into our guidance for FY '16 and the bulk of that in Q1. So we took that into account when we set the guidance for Q1."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Charley Jones from Dougherty Markets.",10,"Our next question comes from Charley Jones from Dougherty Markets."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","I want to go and put some numbers around some comments you made around software down and I had a question around some comments Elisha had around the guidance for the year on revenue. And wondering if you could tease out what the growth -- well, I think th",254,"I want to go and put some numbers around some comments you made around software down and I had a question around some comments Elisha had around the guidance for the year on revenue. And wondering if you could tease out what the growth -- well, I think this is kind of a $500 million service software business. If you could kind of breakout how much of it is maybe just software only. And then particularly, I'm interested in trying to figure out the opportunity of this. And I was guessing it was going to be international. And I was curious, Elisha, if you could talk about the growth rates of service and software for 2015 kind of between international and U.S. and how that's going to change in '16. Really trying to understand what this business can look like if we did get into a lower unit kind of environment. And it goes to my second question around the guidance of revenue. Seems like you're putting a lot in the fourth quarter, if I'm reading you right, about pull in revenue out of the third quarter, Elisha, in the second quarter. So I'm just curious, where does that come from? Is it more Oncology or proton or X-ray? And I think, Dow, last quarter you said maybe we get a little bit of growth from X-ray as we went through the back half of the year. But curious if you have any better visibility on that as well. So those are my questions."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Okay. Hopefully I can remember all that.",7,"Okay. Hopefully I can remember all that."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me start on that software servicing. I mean first of all, just to ground us, our service business is about $1 billion business. Our software business is about $0.5 billion business, much of which is equipment and much of which is service. So it kind o",119,"Let me start on that software servicing. I mean first of all, just to ground us, our service business is about $1 billion business. Our software business is about $0.5 billion business, much of which is equipment and much of which is service. So it kind of gets double counted as we look at it because there's that software service agreement pays -- piece that goes into our service business and then the upfront licenses that we sell as part of the customer getting in the business or ongoing equipment transactions as booked in our equipment business. So as we've said, the service business historically has been a double-digit business. I think constant currency adjusted last year was 9%."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","9%.",2,"9%."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","9% and it was constant currency adjusted growth in Q1 was 6%. So I think on the year, it -- we clearly kind of see it at high single-digit kind of growth range. And now if we stretch and everything goes for us, it will be double-digit business. But that's",178,"9% and it was constant currency adjusted growth in Q1 was 6%. So I think on the year, it -- we clearly kind of see it at high single-digit kind of growth range. And now if we stretch and everything goes for us, it will be double-digit business. But that's kind of what we're seeing on the software -- in the service business. But software is a big piece of that growth in the service business. Software business itself is about $0.5 billion business, call it 50-50. 50%-ish equipment, 50% ongoing service agreements with our service installed base. Last year, that business grew a little faster than the average. So if the constant currency growth in Oncology last year was 6%, it was, call it, 7% or 8%. And so we'd love to stretch that business to get double-digit growth. That's what we'd love to see. I think we'll be stretching to get there but right now, we'd love to see it grow a little bit faster than the Oncology average. Elisha, if you can fix all that."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No. But I am reluctant to give a whole lot of breakdown on our guidance. I mean this is -- again, we're in Q1. We're looking out at the full year. We are confident from where we sit today. I think you're correct that more growth is going to come in the se",246,"No. But I am reluctant to give a whole lot of breakdown on our guidance. I mean this is -- again, we're in Q1. We're looking out at the full year. We are confident from where we sit today. I think you're correct that more growth is going to come in the second half. But the reason for that is we anniversary-ed 2 really big effects of last year. The first being FX will still have a little bit of quarter-over-quarter impact in this second fiscal quarter that we're currently in. But as we -- assuming currency stay where they are today, that impact gets reduced significantly if we go into Q3 and Q4. And so obviously, we expect the dollar growth rates are going to be higher in the second half of the year. The other thing that we anniversary-ed that was huge last year is the pricing impact on particularly the flat panel business. And all of the declines that we saw there, which again, were late in second quarter and really large in Q3 and Q4. So our hope is that we're going to get a little more linear in our Oncology business as we go through this fiscal year. And if you look at the guidance for the first half versus the full year, it's right around at the midpoint, 45% of the year, and that is very common with historical performance, having about 45% of our EPS in the first half."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Maybe I can just follow up, I guess, on a question around X-ray. You made comments last quarter, Dow, about maybe seeing some stabilization in X-ray. Obviously, you talked about Toshiba and there's an unknown there. But if you look at what's happened to y",90,"Maybe I can just follow up, I guess, on a question around X-ray. You made comments last quarter, Dow, about maybe seeing some stabilization in X-ray. Obviously, you talked about Toshiba and there's an unknown there. But if you look at what's happened to your currency and some of these other Korean different suppliers into that business, do you feel like your position is a little bit better and you've got more visibility or stability? Or are you still on this kind of unknown position there as you look forward?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I guess kind of as I said, SIP is stabilizing, the Security business is stabilizing. We like that. As Elisha said, panel pricing probably anniversaries Q3-ish. We're still absorbing a loss of a major customer. That's going on. I think the only thing that'",134,"I guess kind of as I said, SIP is stabilizing, the Security business is stabilizing. We like that. As Elisha said, panel pricing probably anniversaries Q3-ish. We're still absorbing a loss of a major customer. That's going on. I think the only thing that's changed from last quarter has been this Toshiba announcement. And with that, some readjustment of their inventory and order level. I think that's probably going to go on for a while as they adjust. So that would be the one piece of new news. We still think it's a good business and look for it to return to growth. I think in terms of whether it's stabilizing or not, well, the numbers aren't great. We, at least, made our internal goals for the business, and we feel good about that."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Brandon Henry from RBC.",9,"Our next question comes from Brandon Henry from RBC."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","You guys have been reporting pretty strong order numbers in the EMEA and Asia Pacific regions over the last couple of quarters. But it looks like the growth order number for Oncology Systems in those 2 regions was a little weaker this quarter. So just hel",80,"You guys have been reporting pretty strong order numbers in the EMEA and Asia Pacific regions over the last couple of quarters. But it looks like the growth order number for Oncology Systems in those 2 regions was a little weaker this quarter. So just help me understand how much of this is market related versus like market share related. And have you seen any change in the competitive dynamics of pricing with Elekta in either one of those markets?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","When I think -- as I've talked a little bit about on the market side last quarter, we were very gratified by the European volume we saw at the end of last year. And frankly, we'd love the market to perform at that level all the time. But as we look forwar",60,"When I think -- as I've talked a little bit about on the market side last quarter, we were very gratified by the European volume we saw at the end of last year. And frankly, we'd love the market to perform at that level all the time. But as we look forward, we didn't think that it's kind of 12%."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","25% of Q4 constant currency.",5,"25% of Q4 constant currency."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, 25% constant currency growth. 12% real dollar growth last quarter. That's just not going to continue. It probably is the mid-single digit-ish market. So that's probably the European market. There was one other part of the question that my jet lag is",166,"Yes, 25% constant currency growth. 12% real dollar growth last quarter. That's just not going to continue. It probably is the mid-single digit-ish market. So that's probably the European market. There was one other part of the question that my jet lag is not helping me remember. Oh, Elekta. So yes, competitively, I mean, our share is up. As we reported the last quarter, when you look at last 12 months, our share is up pretty significantly. So -- and it's worldwide. We're seeing share growth literally in every geography. So some of it has come from share growth. We obviously like that. We have seen Elekta be a little more aggressive, especially at challenging tenders that are awarded. So that maybe is a little bit different competitive practice than we've seen in the past. Not quite sure why they're doing that. I think that hurts them with the customers, frankly. But anyway, that might be the one competitive change that we're seeing a little bit."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then on the Imaging Components side. Can you talk about some of the strategies longer term after we see some stabilization that you're looking to kind of reaccelerate this business? Is it something that can be done internally with the product pi",80,"Okay. And then on the Imaging Components side. Can you talk about some of the strategies longer term after we see some stabilization that you're looking to kind of reaccelerate this business? Is it something that can be done internally with the product pipeline? Or will it require M&A? And then also, can you give us an update on kind of the strategic review process for the Security and Inspection business? Is that a business that still fits for Varian?"
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Sure. The -- in terms of the strategy, it remains a product development business. So I alluded to the fact that with Toshiba, we started some new product programs. This remains a very innovation-driven segment. And especially in tubes, it's innovatio",187,"Yes. Sure. The -- in terms of the strategy, it remains a product development business. So I alluded to the fact that with Toshiba, we started some new product programs. This remains a very innovation-driven segment. And especially in tubes, it's innovation driven. In flat panel, it's innovation and cost reduction-driven. So one of the things that we've got coming, we just announced and it's being worked into our customers' supply chain, a new low-cost flat panel. I think that, that gives us both some margin opportunity as well as some share play. So we'd like to see that come back. As I mentioned last quarter in the call, the Security business, on the one hand, we've seen its volume come down. It's profitability still remains very, very good. So even though we've gone from $80 million, $85 million to $45 million, $50 million, it's still a 20% return on sales business. It's technology that we leverage throughout our product line, both in Imaging and in Oncology. So that's -- we're continuing to look at it, but replacing that revenue and profit is not an easy thing."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then one last question for me. On the services side for Oncology Systems, can you kind of talk about what the installed base for you guys? How quickly that's growing. And then in the medium term, how do you grow the Services business? How do you",71,"Okay. And then one last question for me. On the services side for Oncology Systems, can you kind of talk about what the installed base for you guys? How quickly that's growing. And then in the medium term, how do you grow the Services business? How do you continue to grow the Services business high single digits kind of above the growth in the installed base? Just talk about that strategy."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","The short version is the installed base is growing. Our unit volume remains very good. As we've said before, the U.S. market remains a replacement market. But outside of the U.S., it's -- we still get very good socket growth. And the TrueBeam percentage i",148,"The short version is the installed base is growing. Our unit volume remains very good. As we've said before, the U.S. market remains a replacement market. But outside of the U.S., it's -- we still get very good socket growth. And the TrueBeam percentage is still quite high -- I'm sorry, the TrueBeam percentage is still quite low. When you look TrueBeam as a percent of our overall installed base, I'd say -- I'm guessing now here, but call it maybe 20%, 15% to 20%. So the -- and we get a big price adjustment as we go through that. So that's true in the U.S. and it's even more true outside of the U.S. So between the installed base growth, the price growth and then the software opportunity that we get in the Service, we think that, that high single-digit growth number constant currency is very doable."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","At this time, we have no further questions. I will turn the call back over to Spencer Sias for closing comments.",21,"At this time, we have no further questions. I will turn the call back over to Spencer Sias for closing comments."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you all for participating. A replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S, or (201) 612",69,"Thank you all for participating. A replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S, or (201) 612-7415 from outside the U.S, and entering confirmation code 13627253. The telephone replay will be available through 5 p.m. this Friday, January 29. Thank you."
311907,320073825,921929,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation.",20,"Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems First Quarter Full Year 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I'll now turn the conference over to your host, Spencer Sias, V",58,"Greetings, and welcome to the Varian Medical Systems First Quarter Full Year 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I'll now turn the conference over to your host, Spencer Sias, Vice President of Investor Relations and Corporate Communications for Varian Medical Systems. Thank you, Mr. Sias. You may now begin."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Good afternoon, and welcome to Varian Medical Systems conference call for the first quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will",274,"Thank you. Good afternoon, and welcome to Varian Medical Systems conference call for the first quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. To simplify our discussion, unless otherwise stated, all references to the quarter or year are fiscal quarters and fiscal years. Quarterly comparisons are for the first quarter of fiscal year 2016 versus the first quarter of fiscal year 2015. References to financial results for our orders are to gross orders unless otherwise indicated. This discussion includes non-GAAP financial measures in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. A reconciliation to the most comparable GAAP measure is included in our earnings release, which can be accessed on our website. Please be advised that this discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, should, will, slated and scheduled and similar expressions are intended to identify those statements, which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks relating to our business are described in our first quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise. 
And now here's Dow."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Varian is reporting revenues and earnings above our expectations for the first quarter of fiscal 2016 while managing through some challenging conditions in our markets, and we're raising our earnings guidance for the year. In",913,"Good afternoon, and welcome. Varian is reporting revenues and earnings above our expectations for the first quarter of fiscal 2016 while managing through some challenging conditions in our markets, and we're raising our earnings guidance for the year. In summary, we are reporting non-GAAP net earnings of $0.99 per diluted share and $0.91 per diluted share on a GAAP basis. Revenues of $757 million, up 3% in dollars and 7% in constant currency. Soft orders in our Oncology Systems business, the expected declines in Imaging Components orders and revenues, and good news on the tax fronts with a permanent R&D tax credit and the suspension of the medical device excise tax. 
Focusing on operational highlights. In our Oncology business, gross orders totaled $533 million for the quarter, down 5% in dollars and down 1% in constant currency. Gross orders in the Americas for the quarter increased by 3% in both dollars and constant currency with the fastest growth in Latin America. Gross orders in North America rose by 2% in dollars and constant currency. In EMEA, gross orders declined by 14% in dollars and 5% in constant currency. Gross orders in APAC declined by 12% in dollars and 7% in constant currency with continued market contraction in Japan and a modest decline in China. 
Global markets have been weakened by ongoing political unrest, weak oil prices and economic uncertainty. In EMEA, for example, Russia announced further delays in its cancer plan. Germany scaled back investments, and the Middle East was negatively impacted by political unrest and falling oil prices. 
On a positive note, in EMEA, we received an order from the U.K.'s National Health Service for a further 10 TrueBeam Systems during the quarter. The National Health System has now ordered more than 50 TrueBeams in the last few years for its cancer programs. Economic uncertainty was also a prime cause of weakness in Japan, which led to an overall orders decline in APAC. 
In China, gross orders declined slightly. As of the end of the first quarter, we continue to see hospitals in China aiming to invest in advanced radiotherapy and radiosurgery systems for their cancer patients. We booked several orders for EDGE radiosurgery systems in China during the quarter. 
In the Americas, the multimillion-dollar Siemens replacement project in Argentina and a key Ministry of Health win in Chile drove the growth in Latin America while North America continued to move forward with investments in our new product platforms to replace aging systems. 
We're focused on global market development through our access to care initiative, an educational program that seeks to bridge the gap between the growing need for modern radiotherapy treatment machines in developing countries and the lack of trained personnel to operate them. This program is already working in Africa and Vietnam, and we took steps during the quarter to initiate this program in India to an educational partnership with Apollo Hospitals group. This program will train radiation technologists in India. 
We made good progress with our software business during the quarter. Licenses for RapidPlan, our tool for enhancing efficiency and quality in treatment planning, have tripled since the end of the fiscal year and are now installed at over 50 sites. Clinical networks, including a health care system in Victoria, Australia that took 4 licenses during the quarter, are rebuilding treatment capabilities around RapidPlan. 
Turning to our Oncology service business. Orders were up 1% in dollars but up 6% in constant currency compared with a strong year-ago quarter. 
Let me turn now to Imaging Components, where orders shrank by 22% to $127 million for the quarter, and revenues fell by 15% to $141 million. Beginning in the second half of last fiscal year, this business has been confronted with currency-related pricing pressures, weak market conditions for Security and Inspection Products and an in-sourcing at a major panel customer. These challenges, together with excess tube inventory at a key customer, contributed to the declines in this business during the quarter. Volumes for tubes were down in the quarter, while demand for our higher-margin dynamic fluoroscopic panels increased and led to a sequential improvement in the growth margin for Imaging Components. 
Our recent acquisitions, MeVis and Claymount, gained momentum in the quarter and are performing well. As a reminder, we're aiming for about $50 million in revenue from these newly acquired businesses this fiscal year. 
Moving to protons. We made good progress with installations. During the quarter, we turned over the first room of the Maryland Proton Therapy Center for clinical commissioning, and first treatments are slated to begin next month. We have successfully extracted beam from the cyclotron at Cincinnati Children's Hospital, where patient treatments are scheduled to begin before the end of the year. Installation is also underway at the Paul Scherrer Institute in Switzerland, and we are scheduled to begin installations at sites in Holland, Russia and Saudi Arabia later this year. 
Proton order activity was quiet in the quarter, but our prospects for booking several more systems this year continue to look good. 
Before I hand it over to Elisha, I'd like to say how proud I am that Varian has been honored for its commitment to sustainability by being included for the second year in a row on the Corporate Knights Global 100 Most Sustainable Corporations list, which compares the sustainability performance of some 4,600 companies globally. This was announced last week at the World Economic Forum in Davos. 
Now I'll turn it over to Elisha."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 7% from the year-ago period. Backlog adjustments during the quarter totaled $55 million, bringing net orders fo",536,"Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 7% from the year-ago period. Backlog adjustments during the quarter totaled $55 million, bringing net orders for the company to $617 million. 
Now let me walk you through the P&L. First quarter revenues for the total company increased 3% in dollars and 7% in constant currency. Oncology posted a 5% gain in revenues during the quarter with a 9% gain in constant currency. There was a significant geographic mix shift towards international revenues, which grew 21% in dollars and 31% in constant currency versus the year-ago quarter, while North American revenues declined by about 10%. 
International business constituted 55% of total Oncology revenues in the quarter. Imaging Components posted a first quarter revenue decline of 15% with decreases in tubes, panels and Security and Inspection Products. 
Our Particle Therapy business posted revenues of $27 million, up $18 million from the year-ago quarter as we continue to make progress on projects in backlog. 
The total company gross margin for the quarter was 41.1%, down as expected by a little more than 3 points. Oncology Systems gross margin also fell by about 3 points to 42.4% due to geographic and product mix shifts as well as minor currency effects. Imaging Components gross margin for the quarter fell by about 1.5 points to 40.7% due largely to lower pricing and volumes. 
First quarter SG&A expenses were $124 million or 16% of revenue, an improvement of about 1 point as a percentage of revenue with the year-ago quarter. First quarter R&D expenses were $60 million or 8% of revenues, equal to the year-ago quarter as a percentage of revenue. First quarter operating earnings totaled $128 million or 17% of revenue, down about 2 points as a percentage of revenue from the year-ago quarter and in line with our expectation for the quarter. 
Depreciation and amortization totaled $19 million for the quarter. The effective tax rate was 24.8%, down almost 4 points from the year-ago quarter due largely to the geographic mix of profits and the R&D tax credit that was reinstated in late December. We now expect that the tax rate will be about 26% to 27% for the year. 
Fully diluted shares outstanding decreased almost 4 million from the year-ago quarter to 97.8 million due to our ongoing share repurchase program. Diluted EPS was $0.99 for the quarter.
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $953 million, debt of $728 million and stockholders equity of $1.6 billion. DSO at 99 days was up significantly from the year-ago quarter due to a lower mix of Imaging Components business, a higher mix of proton business and the timing of collections in Oncology. 
First quarter cash flow from operations fell slightly from the year-ago period to $77 million. Primary uses of cash were $27 million for CapEx and $192 million for the repurchase of 2.4 million shares of stock. At the end of the quarter, we had 7 million shares remaining under the existing repurchase authorization that extends through calendar year 2016. 
Now back to Dow for the outlook."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. Including the effects of the R&D tax credit reenactment and the suspension of the medical device excise tax in the U.S., we now believe that for fiscal year 2016, total company non-GAAP earnings will be in the range of $4.55 to $4.65 per d",122,"Thanks, Elisha. Including the effects of the R&D tax credit reenactment and the suspension of the medical device excise tax in the U.S., we now believe that for fiscal year 2016, total company non-GAAP earnings will be in the range of $4.55 to $4.65 per diluted share. We continue to expect that revenues for fiscal year 2016 will increase by about 4% to 5% over fiscal year 2015. For the second quarter of fiscal year 2016, we expect revenues to be up 1% to 2% from the year-ago quarter in dollars. We expect non-GAAP earnings for the second quarter of fiscal year 2016 to be in the range of $1.06 to $1.10 per diluted share. 
We are now ready for your questions."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] Our first question comes from Jeff Johnson from Robert Baird.",12,"[Operator Instructions] Our first question comes from Jeff Johnson from Robert Baird."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So Dow, I have one question for you and one question for Elisha, and let me start off with a question for you, Dow. So you sound a little bit maybe more cautious on some of the European and, given that the Middle East is in your European number on the Onc",145,"So Dow, I have one question for you and one question for Elisha, and let me start off with a question for you, Dow. So you sound a little bit maybe more cautious on some of the European and, given that the Middle East is in your European number on the Oncology side, a little more cautious on Europe and APAC. Is that the right read here? And I guess, as I look back over the last several quarters, we've seen Oncology orders in both those markets in negative territory, I think, 3 out of the last 4 quarters. Is that kind of where we should level set? I know you don't guide to orders, but just given your comments and kind of the last several quarter trendline, is that kind of where we should be still hanging out with our thoughts for the year?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me say that -- maybe just kind of cast it in a broader view for a second, Jeff, and then kind of come to some of the regional data. When you look at the last 12 months in Oncology in dollars, it's down 2%. In constant currency, it's up 4%. I mean this",335,"Let me say that -- maybe just kind of cast it in a broader view for a second, Jeff, and then kind of come to some of the regional data. When you look at the last 12 months in Oncology in dollars, it's down 2%. In constant currency, it's up 4%. I mean this first quarter is not the greatest growth that we've ever had. Our funnel remains very good, so we like what we see. The fourth quarter was huge for us in Europe. Constant currency and dollar growth in Europe was outstanding in Q4. So our Q4 was 12.5% constant currency growth last quarter. So maybe there was a little bit of quarter-over-quarter balancing going on. So I think the 12-month trailing is kind of what we're feeling right now. Clearly, we're reading the papers like everybody and some of the macroeconomic weakness in Europe is real. I mean we did have a light Q1. But I think we're -- we still see markets growing in that low- to mid-single-digit range at this point. We haven't seen anything that would pull us off that. Japan has been kind of the ongoing structural change in Japan. In China, we did have a win in the quarter that was protested. So I mean we were very close to flat in China. Our funnel remains very good in China. I mean I think Japan is probably going to be kind of more of same. That's been a pretty consistent story the last few quarters. But I do think China will come back. The order that was protested was a fairly large order. So if that was in our numbers, then China would have been great. But anyway, I mean, those are the kinds of things that happen around the quarter. I'd say over the long haul, looking at the last 12 months, we haven't seen anything that would, at this point, pull us off of market growth number in that kind of 3 to 5 range."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And yes, the 4% you cited is a trailing 12 months you're referring to kind of worldwide. So kind of mix-wise, we think North America a little bit stronger maybe than others going forward. Is that fair?",40,"Okay. That's helpful. And yes, the 4% you cited is a trailing 12 months you're referring to kind of worldwide. So kind of mix-wise, we think North America a little bit stronger maybe than others going forward. Is that fair?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Last -- when you look at it in pure dollars, America's last 12 months is at 4.5% and international is down 6.5% in dollars. Constant currency adjust the whole thing, it's 4% up. So that's kind of -- I think last 12 months is -- that's kind of the mar",57,"Yes. Last -- when you look at it in pure dollars, America's last 12 months is at 4.5% and international is down 6.5% in dollars. Constant currency adjust the whole thing, it's 4% up. So that's kind of -- I think last 12 months is -- that's kind of the market that, I think, we're still feeling."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And then, Elisha, the question for you just around EPS guidance. Since you guided back in October, the euro's kind of worked a little bit more against you, I think a little bit a stronger dollar against the euro since you guided some",141,"Okay. That's helpful. And then, Elisha, the question for you just around EPS guidance. Since you guided back in October, the euro's kind of worked a little bit more against you, I think a little bit a stronger dollar against the euro since you guided some of the emerging market currency is still going the wrong way. So as I look at the $0.10 raise to guidance here, how much was med tech tax and R&D driving that $0.10 raise? How much is kind of in the guidance number is coming from those 2 things? How much of an incremental currency headwind was there, if any, included in your guidance? And then maybe how are you thinking about the core underlying business? So just trying to bucket kind of those 3 areas on what contributed to the dime change in guidance."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. So Jeff, the simple answer is if I take the R&D tax credit and the medical device excise tax together, it's a $0.10 for the year. So -- and that's roughly even at about $0.05 each. So we got a benefit of $0.04 in Q1 for those 2 impacts. And what we'",90,"Sure. So Jeff, the simple answer is if I take the R&D tax credit and the medical device excise tax together, it's a $0.10 for the year. So -- and that's roughly even at about $0.05 each. So we got a benefit of $0.04 in Q1 for those 2 impacts. And what we're saying is the additional $0.06 is going to come from Q2 to Q4. So essentially, we took the benefit from those 2 things, tacked it on to the prior guidance and got us to the $4.60 midpoint."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then underlying then kind of the core business. Are you -- I'm trying to figure out if currency I thought was an incremental headwind since you last guided. Does that imply that your core expectations have improved a little bit?",42,"Okay. And then underlying then kind of the core business. Are you -- I'm trying to figure out if currency I thought was an incremental headwind since you last guided. Does that imply that your core expectations have improved a little bit?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I mean, certainly Q1, we feel good about. And in terms of what I would refer to as an operational bead, if you take out the $0.04 related to the tax impact, we had about a $0.05 beat and that was due to higher Oncology revenue and frankly, very good",229,"Well, I mean, certainly Q1, we feel good about. And in terms of what I would refer to as an operational bead, if you take out the $0.04 related to the tax impact, we had about a $0.05 beat and that was due to higher Oncology revenue and frankly, very good cost controls on SG&A. Little bit on share repurchase, was a little bit more than we historically done but in line with that 1 million to 2 million shares per quarter. I think your next question's going to be why aren't you giving me that $0.05? And I'm still a little black and blue after Q4, frankly. And when we missed on that revenue number, it's very early in the year. And I think this just had to do with some timing. And I think Oncology did a fantastic job and probably pulled a little bit revenue forward from Q2 and Q3 to make sure we didn't have a repeat performance. But for the year, we -- it still looks good with the revenue guidance and the EPS from where we stand today. 
Currency, from when I last guided, has been relatively stable. I mean it may have hurt us, I don't know, I think I was at $1.12 versus $1.09. But again, we built some of that into the range for the guidance when we give it."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Amit Hazan from Citi.",9,"Our next question comes from Amit Hazan from Citi."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So start on the gross margin line. Just maybe a question on Oncology gross margin. So I was looking back just kind of taking a little bit several quarter view. And if I strip out service, I mean just kind of look at your product gross margin on the Oncolo",150,"So start on the gross margin line. Just maybe a question on Oncology gross margin. So I was looking back just kind of taking a little bit several quarter view. And if I strip out service, I mean just kind of look at your product gross margin on the Oncology side, it kind of implies this pretty big decline over the past year. I don't know, it's about 36% in fiscal '14 down to 31% in fiscal '15. And that's just, obviously, just the product side. So I'm wondering if you can share with us whether that trend continued this quarter, first of all, and what the drivers here might be outside of FX because you've kind of actually had a nice mix shift in revenue towards the U.S. up until this quarter. And so I'm wondering why product margins in Oncology would be down as much as they were."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. So Amit, the biggest impact on Q1 was just the geographic mix shift. We had a 7-point shift to international deliveries in particularly the Middle East and Eastern Europe, which are our lower-margin countries. And that was just based on scheduled del",166,"Yes. So Amit, the biggest impact on Q1 was just the geographic mix shift. We had a 7-point shift to international deliveries in particularly the Middle East and Eastern Europe, which are our lower-margin countries. And that was just based on scheduled delivery date. So we fully anticipated we were going to have margin declines in Oncology and for the total company, and I think that was reflected in the guidance that we gave last quarter. So for the year, I still expect, even with the -- we still had some currency impact in Q1. We'll have a little bit in Q2 and then it should anniversary. For the year, we still think Oncology is right in that 43% range, so holding in line with our long-term expectations. I would point out service was a bigger proportion in the year-ago quarter, and that is one of our highest-margin product lines. So that impacted it as well. But I think Oncology is performing well at this point."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And just to reiterate, nothing outside -- anything that's outside of FX that is hurting the product side of gross margins in Oncology. That's what seems to have been down over the course of a year.",36,"And just to reiterate, nothing outside -- anything that's outside of FX that is hurting the product side of gross margins in Oncology. That's what seems to have been down over the course of a year."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Region mix.",2,"Region mix."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Region, yes. The region mix, the geographic mix, yes. So international went from 48% of total revenue in the year-ago period to 55%, it's just a very big geographic mix shift. But on an apples-to-apples basis, it's really just the geography that was impac",55,"Region, yes. The region mix, the geographic mix, yes. So international went from 48% of total revenue in the year-ago period to 55%, it's just a very big geographic mix shift. But on an apples-to-apples basis, it's really just the geography that was impacting it. And again, less service as a percentage of the total."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Let me jump to Imaging. Just a couple questions on that. Number one, I'm wondering if you're reiterating kind of the guidance you laid out for the fiscal year, which I think was about flat or so on imaging revenues. And then secondly, specifically,",70,"Okay. Let me jump to Imaging. Just a couple questions on that. Number one, I'm wondering if you're reiterating kind of the guidance you laid out for the fiscal year, which I think was about flat or so on imaging revenues. And then secondly, specifically, has your assessment of the risk around losing more business in flat panel and in tubes changed at all since the earnings call last quarter?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think maybe the one difference we'd have here is Toshiba announced during the quarter that they're selling their medical unit. Otherwise, I think it's very much consistent with what we guided a quarter ago. The challenges continue. The Security and Insp",218,"I think maybe the one difference we'd have here is Toshiba announced during the quarter that they're selling their medical unit. Otherwise, I think it's very much consistent with what we guided a quarter ago. The challenges continue. The Security and Inspection business has stabilized -- stabilizing, clearly, at the lower revenue levels. The panel pricing declines should anniversary in the second half, and we're still absorbing the loss of major -- of a major customer that went in-sourcing on flat panel. That's probably not going to -- that's happening every quarter to us and it probably doesn't anniversary until Q4-ish. Toshiba's volume. The good news is most of that business is a service business. So that is going to continue to need to be replaced, but their ongoing forward production with the uncertainty around their sale and kind of who picks it up, et cetera, we might see a little bit of a volume adjustment there. As I did say in the script, they do have some inventory that they're working through as they kind of manage through this whole thing. The good news is the MeVis and Claymount acquisitions seem to be performing for us. So we're looking for a return to growth, I think, consistent with what we said before in 2017 and 2018."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Anthony Petrone from Jefferies.",9,"Our next question comes from Anthony Petrone from Jefferies."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Couple questions, maybe on proton. A couple of questions on proton. I'll begin with proton and then we can follow up with some of the geographies as well in Oncology. But maybe just an update on the potential to hit the $0.15 swing factor in proton specif",99,"Couple questions, maybe on proton. A couple of questions on proton. I'll begin with proton and then we can follow up with some of the geographies as well in Oncology. But maybe just an update on the potential to hit the $0.15 swing factor in proton specifically. So I think it hinged on the Emory deal. And then in your prepared comments, Dow, you mentioned potentially an installation in Russia. But you also touched upon some dislocations in that marketplace. So maybe just proton overall, the potential to the $0.15, where Emory is and how Russia plays into that."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. I mean the sites I named were all in our guidance, so that -- they're orders that we have and no mystery around those. We have not guided to Emory. It is not a booked order yet. Until the financing is complete, we won't put it into guidance. If that",61,"Sure. I mean the sites I named were all in our guidance, so that -- they're orders that we have and no mystery around those. We have not guided to Emory. It is not a booked order yet. Until the financing is complete, we won't put it into guidance. If that were to happen, it'd be a nice upside for us."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. We lived that problem.",5,"Yes. We lived that problem."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We aren't guiding.",4,"We aren't guiding."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We're not doing that. And it's just -- it's our customer who is securing the financing. We are working with them but it really is somewhat outside of Varian's control, and we're monitoring it closely.",36,"We're not doing that. And it's just -- it's our customer who is securing the financing. We are working with them but it really is somewhat outside of Varian's control, and we're monitoring it closely."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Great, great. And then just on geographies. You touched on China a bit, but Brazil is also sort of in the headlines out there with struggles. And so maybe just an update on that specific tender. I think if you go back, it was 50 Linacs, several of which h",66,"Great, great. And then just on geographies. You touched on China a bit, but Brazil is also sort of in the headlines out there with struggles. And so maybe just an update on that specific tender. I think if you go back, it was 50 Linacs, several of which had already been sort of shipped and installed. So maybe just an update on that specific tender."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We're seeing the Ministry of Health is continuing their program. I mean obviously that order was placed with us a year ago, but we are completing first installations this year and it is going as expected. So from a backlog point of view, we haven't seen a",68,"We're seeing the Ministry of Health is continuing their program. I mean obviously that order was placed with us a year ago, but we are completing first installations this year and it is going as expected. So from a backlog point of view, we haven't seen a change in their approach on these. So that's good. Market's a little bit quiet there, but it hasn't been bad."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then just a last one for me would just be on software specifically. So last year, that really seemed to be a driver, particularly on share gains, I think, both on information management and even treatment planning. So maybe do you see that as still a",77,"And then just a last one for me would just be on software specifically. So last year, that really seemed to be a driver, particularly on share gains, I think, both on information management and even treatment planning. So maybe do you see that as still a share gain story for 2016? And may be just an update on how many RapidPlans have sort of -- how many Eclipse users have migrated to RapidPlan at this point?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean first of all, for the overall software business, it continues to do very well. We just got news a couple of weeks ago that both Eclipse and ARIA got top ranking from KLAS. KLAS is the Gartner of our industry, independent organization that eval",154,"Yes. I mean first of all, for the overall software business, it continues to do very well. We just got news a couple of weeks ago that both Eclipse and ARIA got top ranking from KLAS. KLAS is the Gartner of our industry, independent organization that evaluates products for customers. So we were very thrilled by that external validation. The -- and then in terms of RapidPlan, as I said in the script, it's now installed to over 50 sites. I'd have to get you the exact number of orders, but it's well over 300 now. So the momentum continues there. I think from an overall differentiation point of view, our treatment planning position is terrific. I think we're way ahead with our knowledge-based tools. And then in ARIA, our workflow tools and our informatics are very good differentiators for us, and we continue to see very strong competitive takeout with both those products."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Your next question comes from David Roman from Goldman Sachs.",10,"Your next question comes from David Roman from Goldman Sachs."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","I wanted just to start with a clarification on the proton. I understand that Emory is not in the guidance and with historical context for why you did that. But are Russia and Saudi Arabia that you talked about are -- to what extent are those reflected in",51,"I wanted just to start with a clarification on the proton. I understand that Emory is not in the guidance and with historical context for why you did that. But are Russia and Saudi Arabia that you talked about are -- to what extent are those reflected in the forward guidance?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","They're very small amounts. They are in the guidance.",10,"They're very small amounts. They are in the guidance."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So all of our -- under the percentage of completion, all of our projects where we have actually identified materials specific to a customer, we are taking revenue on those projects. So Saudi and Russia would be included in that number.",41,"So all of our -- under the percentage of completion, all of our projects where we have actually identified materials specific to a customer, we are taking revenue on those projects. So Saudi and Russia would be included in that number."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Saudi, for example, I know we already took a fair amount last year.",13,"Saudi, for example, I know we already took a fair amount last year."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We've taken about $43 million in total. And Russia, about $25 million in total.",15,"We've taken about $43 million in total. And Russia, about $25 million in total."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then maybe a more strategic question. I mean, Dow, obviously, we focus a lot on the quarter-to-quarter order trends and how you're doing by region. But as you kind of take a step back and think about your growth rate, how things have progressed",91,"Okay. And then maybe a more strategic question. I mean, Dow, obviously, we focus a lot on the quarter-to-quarter order trends and how you're doing by region. But as you kind of take a step back and think about your growth rate, how things have progressed the past several quarters versus where you kind of want them to be, how much of the forward outlook depends on factors over which you have control and can invest to drive growth versus being dependent on macro factors or sort of end market conditions?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean for the whole company, I think the cancer business remains a terrific business for us. Constant currency growth last year was 5%, 6% in Oncology, very strong fourth quarter. We're a little weak this quarter, but our funnel still looks good. And we",338,"I mean for the whole company, I think the cancer business remains a terrific business for us. Constant currency growth last year was 5%, 6% in Oncology, very strong fourth quarter. We're a little weak this quarter, but our funnel still looks good. And we think that the cancer business, unfortunately, weathers economic downturns. I mean people get cancer regardless of economics. And now if you look back when economic times were bad, we've weathered those storms pretty well. It's not to say that we might see something in our orders if the economy really turns south. But there was this nice external validation of that last quarter with the global task force on the utilization of radiation oncology published in the Lancet journal that called for thousands more machines. Basically, 2.5x the installed base that we have today and really asking international organizations to help countries develop cancer plans. So especially outside of the U.S., a huge focus on utilizing radiation therapy for cancer. I think one of our big challenges, I mentioned in the script there, is making sure the people side of that comes along with it because we've got to have the people to be able to do the work. But I think as you look at the long term health of the Oncology business, the franchise is in as good a product position as we've ever had. And I think the market remains in the long term, very, very solid. Now on the Imaging business, we're clearly going through a big storm right now. And we still like the fundamentals of the business. We do think it's an industry that has some consolidation opportunity, and we've got to kind of figure out how to play that hand a little bit. But the -- as we get through the in-sourcing of this one customer, these kind of short-term Toshiba perturbations and look to the long term, the digitization of especially the radiographic market remains a huge opportunity. And we like the long-term fundamentals there."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then maybe just a last one, maybe sort of a follow-up to that. As you sort of think about the opportunities that sit in front of you, what was sort of the thought process around what to do with the medical device tax? I know in dollars it's not all th",98,"And then maybe just a last one, maybe sort of a follow-up to that. As you sort of think about the opportunities that sit in front of you, what was sort of the thought process around what to do with the medical device tax? I know in dollars it's not all that material for you compared to some of the other companies in the group. But why not plow some of those savings back into the business? And how should we sort of think about your spending patterns on a go-forward basis to support some of that growth?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean at a high level, let me take first crack at this and I'll have Elisha walk you through some of the detail, but at a high level, we have actually taken up our R&D spend as a percent of sales over the last couple of years. So we're investing a l",155,"Yes. I mean at a high level, let me take first crack at this and I'll have Elisha walk you through some of the detail, but at a high level, we have actually taken up our R&D spend as a percent of sales over the last couple of years. So we're investing a lot in the business. We want to make sure we get pop for that growth. So we're challenging the spend as we do it because we want to see the growth kind of linking it to your previous question. But we have taken up the R&D investment as a percent of the total over the last couple years. So we were never kind of making the R&D decision as a result of our tax impact. I mean clearly it would've been a little easier if we didn't have to pay that, but we were making that decision independent of the tax stuff."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And I would just add. I mean our road map is kind of set for the year. We've got the people, the projects. It may be more disruptive to try and even accelerate some of those things at this point. And the last point is when we increased R&D, it comes from",75,"And I would just add. I mean our road map is kind of set for the year. We've got the people, the projects. It may be more disruptive to try and even accelerate some of those things at this point. And the last point is when we increased R&D, it comes from people. And that tends to be permanent in nature, whereas this is only a reprieve for 2 years as drafted at this point."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Jason Wittes from Brean Capital.",10,"Our next question comes from Jason Wittes from Brean Capital."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So I just wanted to ask first off, in terms of Security business, I think you said about $25 million of the revenues related to Security are service related.",29,"So I just wanted to ask first off, in terms of Security business, I think you said about $25 million of the revenues related to Security are service related."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sounds about right.",3,"Sounds about right."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And that's -- is that most of the revenues we should expect this year or should we also expect some orders on top of that?",26,"And that's -- is that most of the revenues we should expect this year or should we also expect some orders on top of that?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No. I mean that's maybe not quite half -- I mean a little bit more than half of the total revenue we should have on the year.",27,"No. I mean that's maybe not quite half -- I mean a little bit more than half of the total revenue we should have on the year."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, that's about right.",4,"Yes, that's about right."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then just to understand Toshiba, they're looking to sell that business. I assume they're one of your larger customers. And I assume they're still a decent percentage of the imaging business? Is that the right way to think about it?",42,"Okay. And then just to understand Toshiba, they're looking to sell that business. I assume they're one of your larger customers. And I assume they're still a decent percentage of the imaging business? Is that the right way to think about it?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes.",1,"Yes."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And I guess the presumption would be they're right now working down their inventories, but they'll have to start reordering at some point. Whether or not that's after a sale or not, I guess, is harder to determine.",39,"And I guess the presumption would be they're right now working down their inventories, but they'll have to start reordering at some point. Whether or not that's after a sale or not, I guess, is harder to determine."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean here's what I can tell you. They are our largest customer. In fact, they're a terrific customer. They account for about $150 million of our Imaging Components revenue. The split on that is $125 million tubes, about $25 million in panel. We expect t",105,"I mean here's what I can tell you. They are our largest customer. In fact, they're a terrific customer. They account for about $150 million of our Imaging Components revenue. The split on that is $125 million tubes, about $25 million in panel. We expect to continue supplying high-end CT tubes to whoever it is that buys Toshiba. We're designing future products for them, having very good conversations. So we think that -- I mean there's obviously kind of some uncertainty as it goes through that process. But we're well designed in and I think that, that will continue whoever the new owner is."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's very helpful. And then maybe just switch to proton. I mean you mentioned sort of global turmoil impacting your core Oncology business. Should we assume that the proton business may also be impacted this year?",37,"Okay. That's very helpful. And then maybe just switch to proton. I mean you mentioned sort of global turmoil impacting your core Oncology business. Should we assume that the proton business may also be impacted this year?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean it's tough to say. When you look at our funnel, our funnel remains positive. We have had 1 or 2 fall out. I don't know how much of that -- some of that is, I think, some of their own decisions. I don't know how much of it was the kind of macro econ",174,"I mean it's tough to say. When you look at our funnel, our funnel remains positive. We have had 1 or 2 fall out. I don't know how much of that -- some of that is, I think, some of their own decisions. I don't know how much of it was the kind of macro economy. We are competing on a number of compact units, and I do think we'll see our first compact orders this year. So we're encouraged about that. There remains to be a lot of customer interest. And I guess I would say that versus -- in 2009 -- 2008, 2009 when we went through this, we were just selling big systems. So that market dried up. Now when you look at our funnel, our funnel has a lot of compact units and customers are hanging in there. We're having a lot of conversations and so the funnel remains pretty good, and our objective is to see if we can win a few of those single-room orders this year."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Sorry, just to get a clarification. The large centers, there's really not much of a market this year for them. It's mostly compact centers that people are looking at right now.",31,"Sorry, just to get a clarification. The large centers, there's really not much of a market this year for them. It's mostly compact centers that people are looking at right now."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, that was a comparison to 2008, 2009. 2008, 2009, that's what the market was. And when you're looking at $50 million to $90 million of expense into that kind of recession, that market just went away during 2008, 2009. No, we're not seeing that. There",109,"Well, that was a comparison to 2008, 2009. 2008, 2009, that's what the market was. And when you're looking at $50 million to $90 million of expense into that kind of recession, that market just went away during 2008, 2009. No, we're not seeing that. There's still a good multi-room market out there. But we're also seeing a very good funnel of these compact rooms. We're competing on both. But just to say that in terms of as it relates to kind of the global macroeconomic environment, I think these compact customers are hanging in there a little more in terms of the funnel -- strength of the funnel."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Tycho Peterson from JPMorgan.",9,"Our next question comes from Tycho Peterson from JPMorgan."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Maybe just a higher-level strategic question on some of the emerging markets that you've called out as being kind of problematic. I mean given that a lot of the issues here are kind of structural rather than cyclical in some of these markets. Does this ch",80,"Maybe just a higher-level strategic question on some of the emerging markets that you've called out as being kind of problematic. I mean given that a lot of the issues here are kind of structural rather than cyclical in some of these markets. Does this change your thinking around how you address these markets, the resources you put to them? Any change in where you're placing incremental efforts internationally based on what we've seen the last couple of quarters?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me kind of underscore one of the things I pointed out in the call is weak in Japan, weak in Europe. Emerging markets -- weak in Russia for sure. But we had some Latin America activity that wasn't too bad. China, as I mentioned, was down, but we've kin",153,"Let me kind of underscore one of the things I pointed out in the call is weak in Japan, weak in Europe. Emerging markets -- weak in Russia for sure. But we had some Latin America activity that wasn't too bad. China, as I mentioned, was down, but we've kind of have a timing issue with a fairly large protested order. So we actually think China is going to be okay. The long term is we're -- we still think these markets are going to grow. We've built a market development team. We're investing in our access to care program to bring new operators into the business, and we're still bullish about the long-term opportunities. I mean do we replace somebody that leaves as fast as maybe we're used to while we go through maybe some downturns? Maybe not. But we're clearly looking at this very opportunistically and strategically for the long term."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And any hope on Japan turning? I mean I know you talked in the past about only 20%, 25% of patients receiving radiation there. So clearly, there's a clinical need.",30,"And any hope on Japan turning? I mean I know you talked in the past about only 20%, 25% of patients receiving radiation there. So clearly, there's a clinical need."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean the clinical need remains. I just think between the currency movement, the market restructure, it's -- we are investing a little bit in government affairs there to kind of get the government a little bit more supportive. But at least for kind",68,"Yes. I mean the clinical need remains. I just think between the currency movement, the market restructure, it's -- we are investing a little bit in government affairs there to kind of get the government a little bit more supportive. But at least for kind of market outlook this year, I wouldn't say I'm seeing anything that dramatically changes what we've been seeing over the last year anyway."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then you called out the EDGE orders in China. Just -- I mean any thoughts on how the mix there evolves? TrueBeam, EDGE?",24,"And then you called out the EDGE orders in China. Just -- I mean any thoughts on how the mix there evolves? TrueBeam, EDGE?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think it's been pretty consistent. It's a bimodal market. There is a value market that's aggressive, where people are looking at entry-level products. But there's also a high-end market. EDGE is part of that. We're really glad to get those 3 Q1 EDGE ord",152,"I think it's been pretty consistent. It's a bimodal market. There is a value market that's aggressive, where people are looking at entry-level products. But there's also a high-end market. EDGE is part of that. We're really glad to get those 3 Q1 EDGE orders. And then one of the exciting pieces of news is that TrueBeam -- the TrueBeam volume there still remains pretty good. It is a category A product, so it puts it in a little more -- a little bit more of a regulatory process to get through. But -- so there's limited licenses at that end of the market. But I'd say our mix of product remains pretty consistent, and the high end of that market remains a really important market for us. And we've been expanding our share in China over the last 18 months. So we're doing that by winning in the value market."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Backlog declined a bit this quarter. Was that just the order slippage from last quarter? And any thoughts on backlog stability, I guess, going forward?",25,"Backlog declined a bit this quarter. Was that just the order slippage from last quarter? And any thoughts on backlog stability, I guess, going forward?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So versus a year ago quarter backlog was up sequentially. Yes. Yes. So I mean we came in ahead, a little bit ahead on Oncology revenues and the order. So that's all it is.",34,"So versus a year ago quarter backlog was up sequentially. Yes. Yes. So I mean we came in ahead, a little bit ahead on Oncology revenues and the order. So that's all it is."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Two other quick ones, I guess. On kind of the software initiatives. Dow, in the past, you talked about a $300 million opportunity over the next couple of years. Can you just give us a sense of the magnitude -- the growth you think you can capture fr",71,"Okay. Two other quick ones, I guess. On kind of the software initiatives. Dow, in the past, you talked about a $300 million opportunity over the next couple of years. Can you just give us a sense of the magnitude -- the growth you think you can capture from all the initiatives, RapidPlan, and everything else you've been highlighting over the last couple of quarters that you can capture this year?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean I think the -- RapidPlan is certainly our single biggest opportunity, maybe talking about it in terms of units. If we have -- if we've taken 300 to 350 units, there's probably an installed base of 3,500 to 4,000, so we're just nicking that. An",233,"Yes. I mean I think the -- RapidPlan is certainly our single biggest opportunity, maybe talking about it in terms of units. If we have -- if we've taken 300 to 350 units, there's probably an installed base of 3,500 to 4,000, so we're just nicking that. And I think what encourages me is the early evidence, both for clinical outcome and productivity, is outstanding. So I think it really helps us make the economic case for people to invest. And the -- of course, the ASPs, the selling prices and the margins there remain very good. InSightive Analytics and our kind of the transition to coordinated care on ARIA is maybe not as far advanced. The product was released a little bit later, but we also really like the progress there. And we do think it's driving share. We'd love -- really like to see where it drives a little bit more volume. We are investing in some software sales resources outside of the U.S. to kind of help us attack some markets that we haven't maybe attacked as aggressively on the software side. Much of our software business is still, frankly, U.S.-based. So we're trying to drive that piece as well. But we're still -- we're very encouraged by what we see and -- both in terms of kind of the market opportunity and the share opportunity by our software products."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then just lastly. Obviously, there's been a lot of news earlier this year on the cancer moonshot program and a lot of developments in liquid biopsy. Does any of that change your view on the long term outlook on the U.S. market in particular with bette",50,"And then just lastly. Obviously, there's been a lot of news earlier this year on the cancer moonshot program and a lot of developments in liquid biopsy. Does any of that change your view on the long term outlook on the U.S. market in particular with better and earlier detection?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","The short version is we love it. We do know that there's been some reach out to some of our customers and that radiation therapy is going to be part of it. So that's -- frankly, any other clarity beyond that is difficult. But we're encouraged that at leas",56,"The short version is we love it. We do know that there's been some reach out to some of our customers and that radiation therapy is going to be part of it. So that's -- frankly, any other clarity beyond that is difficult. But we're encouraged that at least our thought leaders are at the table."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Steve Beuchaw from Morgan Stanley.",10,"Our next question comes from Steve Beuchaw from Morgan Stanley."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Just a few housekeeping items for me at this point. I guess first, for MeVis and Claymount, do you have a sense for what the contribution was in the top line from those specifically for the quarter? I know we had a number for the year. I don't know that w",55,"Just a few housekeeping items for me at this point. I guess first, for MeVis and Claymount, do you have a sense for what the contribution was in the top line from those specifically for the quarter? I know we had a number for the year. I don't know that we have for the quarter."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. It's roughly $15 million.",5,"Yes. It's roughly $15 million."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","$15 million. Okay. And then on the proton financing. Now that you guys have a little bit more of that on the balance sheet, do you have a sense for what the contribution was on the P&L in the quarter?",40,"$15 million. Okay. And then on the proton financing. Now that you guys have a little bit more of that on the balance sheet, do you have a sense for what the contribution was on the P&L in the quarter?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","The total interest income was like $1.7 million. So call it $1.5 million maybe? I don't have that number right in front of me, Steve, but that's close enough.",29,"The total interest income was like $1.7 million. So call it $1.5 million maybe? I don't have that number right in front of me, Steve, but that's close enough."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Got it. And then last one for me is I'm thinking back to the fourth quarter call and the delivery slippages. I think Tycho might have alluded to this, but there was a $0.10 impact from delivery. I believe it was predominantly TrueBeams slipping from the f",72,"Got it. And then last one for me is I'm thinking back to the fourth quarter call and the delivery slippages. I think Tycho might have alluded to this, but there was a $0.10 impact from delivery. I believe it was predominantly TrueBeams slipping from the fourth quarter. Did we recapture that in the first quarter? Is there more in the second quarter? How do we think about those layering in here?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I think you should just assume that was built into our guidance for FY '16 and the bulk of that in Q1. So we took that into account when we set the guidance for Q1.",36,"Well, I think you should just assume that was built into our guidance for FY '16 and the bulk of that in Q1. So we took that into account when we set the guidance for Q1."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Charley Jones from Dougherty Markets.",10,"Our next question comes from Charley Jones from Dougherty Markets."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","I want to go and put some numbers around some comments you made around software down and I had a question around some comments Elisha had around the guidance for the year on revenue. And wondering if you could tease out what the growth -- well, I think th",255,"I want to go and put some numbers around some comments you made around software down and I had a question around some comments Elisha had around the guidance for the year on revenue. And wondering if you could tease out what the growth -- well, I think this is kind of a $500 million service software business. If you could kind of break out how much of it is maybe just software only. And then particularly, I'm interested in trying to figure out the opportunity of this. And I was guessing it was going to be international. And I was curious, Elisha, if you could talk about the growth rates of service and software for 2015 kind of between international and U.S. and how that's going to change in '16. Really trying to understand what this business can look like if we did get into a lower unit kind of environment. 
And it goes to my second question around the guidance of revenue. Seems like you're putting a lot in the fourth quarter, if I'm reading you right, about pull in revenue out of the third quarter, Elisha, in the second quarter. So I'm just curious, where does that come from? Is it more Oncology or proton or X-ray? 
And I think, Dow, last quarter you said maybe we get a little bit of growth from X-ray as we went through the back half of the year. But curious if you have any better visibility on that as well. So those are my questions."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Okay. Hopefully I can remember all that.",7,"Okay. Hopefully I can remember all that."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me start on that software service thing. I mean first of all, just to ground us, our service business is about $1 billion business. Our software business is about $0.5 billion business, much of which is equipment and much of which is service. So it ki",120,"Let me start on that software service thing. I mean first of all, just to ground us, our service business is about $1 billion business. Our software business is about $0.5 billion business, much of which is equipment and much of which is service. So it kind of gets double counted as we look at it because there's that software service agreement pays -- piece that goes into our service business and then the upfront licenses that we sell as part of the customer getting in the business or ongoing equipment transactions as booked in our equipment business. So as we've said, the service business historically has been a double-digit business. I think constant currency adjusted last year was 9%."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","9%.",2,"9%."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","9% and it was constant currency adjusted growth in Q1 was 6%. So I think on the year, it -- we clearly kind of see it at high single-digit kind of growth range. And now if we stretch and everything goes for us, it will be double-digit business. But that's",180,"9% and it was constant currency adjusted growth in Q1 was 6%. So I think on the year, it -- we clearly kind of see it at high single-digit kind of growth range. And now if we stretch and everything goes for us, it will be double-digit business. But that's kind of what we're seeing on the software -- in the service business. But software is a big piece of that growth in the service business. And the software business itself is about $0.5 billion business, call it 50-50. 50%-ish equipment, 50% ongoing service agreements with our service installed base. Last year, that business grew a little faster than the average. So if the constant currency growth in Oncology last year was 6%, it was, call it, 7% or 8%. And so we'd love to stretch that business to get double-digit growth. That's what we'd love to see. I think it'll be stretching to get there but right now, we'd love to see it grow a little bit faster than the Oncology average. Elisha, if you can fix all that."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No. But I am reluctant to give a whole lot of breakdown on our guidance. I mean this is -- again, we're in Q1. We're looking out at the full year. We are confident from where we sit today. I think you're correct that more growth is going to come in the se",246,"No. But I am reluctant to give a whole lot of breakdown on our guidance. I mean this is -- again, we're in Q1. We're looking out at the full year. We are confident from where we sit today. I think you're correct that more growth is going to come in the second half. But the reason for that is we anniversary 2 really big effects of last year. The first being FX will still have a little bit of quarter-over-quarter impact in this second fiscal quarter that we're currently in. But as we -- assuming currencies stay where they are today, that impact gets reduced significantly as we go into Q3 and Q4. And so obviously, we expect the dollar growth rates are going to be higher in the second half of the year. The other thing that we anniversary that was huge last year is the pricing impact on particularly the flat panel business. And all of the declines that we saw there, which again, were late in second quarter and really large in Q3 and Q4. So our hope is that we're going to get a little more linear in our Oncology business as we go through this fiscal year. And if you look at the guidance for the first half versus the full year, it's right around at the midpoint, 45% of the year, and that is very common with historical performance, having about 45% of our EPS in the first half."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Maybe I can just follow up, I guess, on a question around X-ray. You made comments last quarter, Dow, about maybe seeing some stabilization in X-ray. Obviously, you talked about Toshiba and there's an unknown there. But if you look at what's happened to y",90,"Maybe I can just follow up, I guess, on a question around X-ray. You made comments last quarter, Dow, about maybe seeing some stabilization in X-ray. Obviously, you talked about Toshiba and there's an unknown there. But if you look at what's happened to your currency and some of these other Korean different suppliers into that business, do you feel like your position is a little bit better and you've got more visibility or stability? Or are you still on this kind of unknown position there as you look forward?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I guess kind of as I said, SIP is stabilizing, the Security business is stabilizing. We like that. As Elisha said, panel pricing probably anniversaries Q3-ish. We're still absorbing a loss of a major customer. That's going on. I think the only thing that'",134,"I guess kind of as I said, SIP is stabilizing, the Security business is stabilizing. We like that. As Elisha said, panel pricing probably anniversaries Q3-ish. We're still absorbing a loss of a major customer. That's going on. I think the only thing that's changed from last quarter has been this Toshiba announcement. And with that, some readjustment of their inventory and order level. I think that's probably going to go on for a while as they adjust. So that would be the one piece of new news. We still think it's a good business and look for it to return to growth. I think in terms of whether it's stabilizing or not, well, the numbers aren't great. We, at least, made our internal goals for the business, and we feel good about that."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Brandon Henry from RBC.",9,"Our next question comes from Brandon Henry from RBC."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","You guys have been reporting pretty strong order numbers in the EMEA and Asia Pacific regions over the last couple of quarters. But it looks like the gross order number for Oncology Systems in those 2 regions was a little weaker this quarter. So just help",80,"You guys have been reporting pretty strong order numbers in the EMEA and Asia Pacific regions over the last couple of quarters. But it looks like the gross order number for Oncology Systems in those 2 regions was a little weaker this quarter. So just help me understand how much of this is market related versus like market share related. And have you seen any change in the competitive dynamics of pricing with Elekta in either one of those markets?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","When I think -- as I've talked a little bit about on the market side last quarter, we were very gratified by the European volume we saw at the end of last year. And frankly, we'd love the market to perform at that level all the time. But as we look forwar",59,"When I think -- as I've talked a little bit about on the market side last quarter, we were very gratified by the European volume we saw at the end of last year. And frankly, we'd love the market to perform at that level all the time. But as we look forward, we didn't think that kind of 12%..."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","25% of Q4 constant currency.",5,"25% of Q4 constant currency."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, 25% constant currency growth. 12% real dollar growth last quarter. That's just not going to continue. It probably is the mid-single digit-ish market. So that's probably the European market. There was one other part of the question that my jet lag is",165,"Yes, 25% constant currency growth. 12% real dollar growth last quarter. That's just not going to continue. It probably is the mid-single digit-ish market. So that's probably the European market. There was one other part of the question that my jet lag is not helping me remember. 
Elekta. So yes, competitively, I mean, our share is up. As we reported the last quarter, when you look at last 12 months, our share is up pretty significantly. So -- and it's worldwide. We're seeing share growth literally in every geography. So some of it has come from share growth. We obviously like that. We have seen Elekta be a little more aggressive, especially at challenging tenders that are awarded. So that maybe is a little bit different competitive practice than we've seen in the past. Not quite sure why they're doing that. I think that hurts them with the customers, frankly. But anyway, that might be the one competitive change that we're seeing a little bit."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then on the Imaging Components side. Can you talk about some of the strategies that longer term, after we see some stabilization, that you're looking to kind of reaccelerate this business? Is it something that can be done internally with the pro",81,"Okay. And then on the Imaging Components side. Can you talk about some of the strategies that longer term, after we see some stabilization, that you're looking to kind of reaccelerate this business? Is it something that can be done internally with the product pipeline? Or will it require M&A? 
And then also, can you give us an update on kind of the strategic review process for the Security and Inspection business? Is that a business that still fits for Varian?"
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Sure. The -- in terms of the strategy, it remains a product development business. So I alluded to the fact that with Toshiba, we started some new product programs. This remains a very innovation-driven segment. And especially in tubes, it's innovatio",187,"Yes. Sure. The -- in terms of the strategy, it remains a product development business. So I alluded to the fact that with Toshiba, we started some new product programs. This remains a very innovation-driven segment. And especially in tubes, it's innovation driven. In flat panel, it's innovation and cost reduction-driven. So one of the things that we've got coming, we've just announced and it's being worked into our customers' supply chain, a new low-cost flat panel. I think that, that gives us both some margin opportunity as well as some share play. So we'd like to see that come back. As I mentioned last quarter in the call, the Security business, on the one hand, we've seen its volume come down. It's profitability still remains very, very good. So even though we've gone from $80 million, $85 million to $45 million, $50 million, it's still a 20% return on sales business. It's technology that we leverage throughout our product line, both in Imaging and in Oncology. So that's -- we're continuing to look at it, but replacing that revenue and profit is not an easy thing."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then one last question for me. On the services side for Oncology Systems, can you kind of talk about what the installed base for you guys? How quickly that's growing. And then in the medium term, how do you grow the Services business? How do you",71,"Okay. And then one last question for me. On the services side for Oncology Systems, can you kind of talk about what the installed base for you guys? How quickly that's growing. And then in the medium term, how do you grow the Services business? How do you continue to grow the Services business high single digits kind of above the growth in the installed base? Just talk about that strategy."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","The short version is the installed base is growing. Our unit volume remains very good. As we've said before, the U.S. market remains a replacement market. But outside of the U.S., it's -- we still get very good socket growth. And the TrueBeam percentage i",148,"The short version is the installed base is growing. Our unit volume remains very good. As we've said before, the U.S. market remains a replacement market. But outside of the U.S., it's -- we still get very good socket growth. And the TrueBeam percentage is still quite high -- I'm sorry, the TrueBeam percentage is still quite low. When you look TrueBeam as a percent of our overall installed base, I'd say -- I'm guessing now here, but call it maybe 20%, 15% to 20%. So the -- and we get a big price adjustment as we go through that. So that's true in the U.S. and it's even more true outside of the U.S. So between the installed base growth, the price growth and then the software opportunity that we get in the Service, we think that, that high single-digit growth number constant currency is very doable."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","At this time, we have no further questions. I will turn the call back over to Spencer Sias for closing comments.",21,"At this time, we have no further questions. I will turn the call back over to Spencer Sias for closing comments."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you all for participating. A replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S., or (201) 61",69,"Thank you all for participating. A replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S., or (201) 612-7415 from outside the U.S., and entering confirmation code 13627253. The telephone replay will be available through 5 p.m. this Friday, January 29. Thank you."
311907,320073825,921975,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation.",20,"Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems First Quarter Full Year 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I'll now turn the conference over to your host, Spencer Sias, V",58,"Greetings, and welcome to the Varian Medical Systems First Quarter Full Year 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I'll now turn the conference over to your host, Spencer Sias, Vice President of Investor Relations and Corporate Communications for Varian Medical Systems. Thank you, Mr. Sias. You may now begin."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Good afternoon, and welcome to Varian Medical Systems conference call for the first quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will",274,"Thank you. Good afternoon, and welcome to Varian Medical Systems conference call for the first quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. To simplify our discussion, unless otherwise stated, all references to the quarter or year are fiscal quarters and fiscal years. Quarterly comparisons are for the first quarter of fiscal year 2016 versus the first quarter of fiscal year 2015. References to financial results for our orders are to gross orders unless otherwise indicated. This discussion includes non-GAAP financial measures in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. A reconciliation to the most comparable GAAP measure is included in our earnings release, which can be accessed on our website. Please be advised that this discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, should, will, slated and scheduled and similar expressions are intended to identify those statements, which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks relating to our business are described in our first quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise. 
And now here's Dow."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Varian is reporting revenues and earnings above our expectations for the first quarter of fiscal 2016 while managing through some challenging conditions in our markets, and we're raising our earnings guidance for the year. In",913,"Good afternoon, and welcome. Varian is reporting revenues and earnings above our expectations for the first quarter of fiscal 2016 while managing through some challenging conditions in our markets, and we're raising our earnings guidance for the year. In summary, we are reporting non-GAAP net earnings of $0.99 per diluted share and $0.91 per diluted share on a GAAP basis. Revenues of $757 million, up 3% in dollars and 7% in constant currency. Soft orders in our Oncology Systems business, the expected declines in Imaging Components orders and revenues, and good news on the tax fronts with a permanent R&D tax credit and the suspension of the medical device excise tax. 
Focusing on operational highlights. In our Oncology business, gross orders totaled $533 million for the quarter, down 5% in dollars and down 1% in constant currency. Gross orders in the Americas for the quarter increased by 3% in both dollars and constant currency with the fastest growth in Latin America. Gross orders in North America rose by 2% in dollars and constant currency. In EMEA, gross orders declined by 14% in dollars and 5% in constant currency. Gross orders in APAC declined by 12% in dollars and 7% in constant currency with continued market contraction in Japan and a modest decline in China. 
Global markets have been weakened by ongoing political unrest, weak oil prices and economic uncertainty. In EMEA, for example, Russia announced further delays in its cancer plan. Germany scaled back investments, and the Middle East was negatively impacted by political unrest and falling oil prices. 
On a positive note, in EMEA, we received an order from the U.K.'s National Health Service for a further 10 TrueBeam Systems during the quarter. The National Health System has now ordered more than 50 TrueBeams in the last few years for its cancer programs. Economic uncertainty was also a prime cause of weakness in Japan, which led to an overall orders decline in APAC. 
In China, gross orders declined slightly. As of the end of the first quarter, we continue to see hospitals in China aiming to invest in advanced radiotherapy and radiosurgery systems for their cancer patients. We booked several orders for EDGE radiosurgery systems in China during the quarter. 
In the Americas, the multimillion-dollar Siemens replacement project in Argentina and a key Ministry of Health win in Chile drove the growth in Latin America while North America continued to move forward with investments in our new product platforms to replace aging systems. 
We're focused on global market development through our access to care initiative, an educational program that seeks to bridge the gap between the growing need for modern radiotherapy treatment machines in developing countries and the lack of trained personnel to operate them. This program is already working in Africa and Vietnam, and we took steps during the quarter to initiate this program in India to an educational partnership with Apollo Hospitals group. This program will train radiation technologists in India. 
We made good progress with our software business during the quarter. Licenses for RapidPlan, our tool for enhancing efficiency and quality in treatment planning, have tripled since the end of the fiscal year and are now installed at over 50 sites. Clinical networks, including a health care system in Victoria, Australia that took 4 licenses during the quarter, are rebuilding treatment capabilities around RapidPlan. 
Turning to our Oncology service business. Orders were up 1% in dollars but up 6% in constant currency compared with a strong year-ago quarter. 
Let me turn now to Imaging Components, where orders shrank by 22% to $127 million for the quarter, and revenues fell by 15% to $141 million. Beginning in the second half of last fiscal year, this business has been confronted with currency-related pricing pressures, weak market conditions for Security and Inspection Products and an in-sourcing at a major panel customer. These challenges, together with excess tube inventory at a key customer, contributed to the declines in this business during the quarter. Volumes for tubes were down in the quarter, while demand for our higher-margin dynamic fluoroscopic panels increased and led to a sequential improvement in the growth margin for Imaging Components. 
Our recent acquisitions, MeVis and Claymount, gained momentum in the quarter and are performing well. As a reminder, we're aiming for about $50 million in revenue from these newly acquired businesses this fiscal year. 
Moving to protons. We made good progress with installations. During the quarter, we turned over the first room of the Maryland Proton Therapy Center for clinical commissioning, and first treatments are slated to begin next month. We have successfully extracted beam from the cyclotron at Cincinnati Children's Hospital, where patient treatments are scheduled to begin before the end of the year. Installation is also underway at the Paul Scherrer Institute in Switzerland, and we are scheduled to begin installations at sites in Holland, Russia and Saudi Arabia later this year. 
Proton order activity was quiet in the quarter, but our prospects for booking several more systems this year continue to look good. 
Before I hand it over to Elisha, I'd like to say how proud I am that Varian has been honored for its commitment to sustainability by being included for the second year in a row on the Corporate Knights Global 100 Most Sustainable Corporations list, which compares the sustainability performance of some 4,600 companies globally. This was announced last week at the World Economic Forum in Davos. 
Now I'll turn it over to Elisha."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 7% from the year-ago period. Backlog adjustments during the quarter totaled $55 million, bringing net orders fo",536,"Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 7% from the year-ago period. Backlog adjustments during the quarter totaled $55 million, bringing net orders for the company to $617 million. 
Now let me walk you through the P&L. First quarter revenues for the total company increased 3% in dollars and 7% in constant currency. Oncology posted a 5% gain in revenues during the quarter with a 9% gain in constant currency. There was a significant geographic mix shift towards international revenues, which grew 21% in dollars and 31% in constant currency versus the year-ago quarter, while North American revenues declined by about 10%. 
International business constituted 55% of total Oncology revenues in the quarter. Imaging Components posted a first quarter revenue decline of 15% with decreases in tubes, panels and Security and Inspection Products. 
Our Particle Therapy business posted revenues of $27 million, up $18 million from the year-ago quarter as we continue to make progress on projects in backlog. 
The total company gross margin for the quarter was 41.1%, down as expected by a little more than 3 points. Oncology Systems gross margin also fell by about 3 points to 42.4% due to geographic and product mix shifts as well as minor currency effects. Imaging Components gross margin for the quarter fell by about 1.5 points to 40.7% due largely to lower pricing and volumes. 
First quarter SG&A expenses were $124 million or 16% of revenue, an improvement of about 1 point as a percentage of revenue with the year-ago quarter. First quarter R&D expenses were $60 million or 8% of revenues, equal to the year-ago quarter as a percentage of revenue. First quarter operating earnings totaled $128 million or 17% of revenue, down about 2 points as a percentage of revenue from the year-ago quarter and in line with our expectation for the quarter. 
Depreciation and amortization totaled $19 million for the quarter. The effective tax rate was 24.8%, down almost 4 points from the year-ago quarter due largely to the geographic mix of profits and the R&D tax credit that was reinstated in late December. We now expect that the tax rate will be about 26% to 27% for the year. 
Fully diluted shares outstanding decreased almost 4 million from the year-ago quarter to 97.8 million due to our ongoing share repurchase program. Diluted EPS was $0.99 for the quarter.
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $953 million, debt of $728 million and stockholders equity of $1.6 billion. DSO at 99 days was up significantly from the year-ago quarter due to a lower mix of Imaging Components business, a higher mix of proton business and the timing of collections in Oncology. 
First quarter cash flow from operations fell slightly from the year-ago period to $77 million. Primary uses of cash were $27 million for CapEx and $192 million for the repurchase of 2.4 million shares of stock. At the end of the quarter, we had 7 million shares remaining under the existing repurchase authorization that extends through calendar year 2016. 
Now back to Dow for the outlook."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. Including the effects of the R&D tax credit reenactment and the suspension of the medical device excise tax in the U.S., we now believe that for fiscal year 2016, total company non-GAAP earnings will be in the range of $4.55 to $4.65 per d",122,"Thanks, Elisha. Including the effects of the R&D tax credit reenactment and the suspension of the medical device excise tax in the U.S., we now believe that for fiscal year 2016, total company non-GAAP earnings will be in the range of $4.55 to $4.65 per diluted share. We continue to expect that revenues for fiscal year 2016 will increase by about 4% to 5% over fiscal year 2015. For the second quarter of fiscal year 2016, we expect revenues to be up 1% to 2% from the year-ago quarter in dollars. We expect non-GAAP earnings for the second quarter of fiscal year 2016 to be in the range of $1.06 to $1.10 per diluted share. 
We are now ready for your questions."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] Our first question comes from Jeff Johnson from Robert Baird.",12,"[Operator Instructions] Our first question comes from Jeff Johnson from Robert Baird."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So Dow, I have one question for you and one question for Elisha, and let me start off with a question for you, Dow. So you sound a little bit maybe more cautious on some of the European and, given that the Middle East is in your European number on the Onc",145,"So Dow, I have one question for you and one question for Elisha, and let me start off with a question for you, Dow. So you sound a little bit maybe more cautious on some of the European and, given that the Middle East is in your European number on the Oncology side, a little more cautious on Europe and APAC. Is that the right read here? And I guess, as I look back over the last several quarters, we've seen Oncology orders in both those markets in negative territory, I think, 3 out of the last 4 quarters. Is that kind of where we should level set? I know you don't guide to orders, but just given your comments and kind of the last several quarter trendline, is that kind of where we should be still hanging out with our thoughts for the year?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me say that -- maybe just kind of cast it in a broader view for a second, Jeff, and then kind of come to some of the regional data. When you look at the last 12 months in Oncology in dollars, it's down 2%. In constant currency, it's up 4%. I mean this",335,"Let me say that -- maybe just kind of cast it in a broader view for a second, Jeff, and then kind of come to some of the regional data. When you look at the last 12 months in Oncology in dollars, it's down 2%. In constant currency, it's up 4%. I mean this first quarter is not the greatest growth that we've ever had. Our funnel remains very good, so we like what we see. The fourth quarter was huge for us in Europe. Constant currency and dollar growth in Europe was outstanding in Q4. So our Q4 was 12.5% constant currency growth last quarter. So maybe there was a little bit of quarter-over-quarter balancing going on. So I think the 12-month trailing is kind of what we're feeling right now. Clearly, we're reading the papers like everybody and some of the macroeconomic weakness in Europe is real. I mean we did have a light Q1. But I think we're -- we still see markets growing in that low- to mid-single-digit range at this point. We haven't seen anything that would pull us off that. Japan has been kind of the ongoing structural change in Japan. In China, we did have a win in the quarter that was protested. So I mean we were very close to flat in China. Our funnel remains very good in China. I mean I think Japan is probably going to be kind of more of same. That's been a pretty consistent story the last few quarters. But I do think China will come back. The order that was protested was a fairly large order. So if that was in our numbers, then China would have been great. But anyway, I mean, those are the kinds of things that happen around the quarter. I'd say over the long haul, looking at the last 12 months, we haven't seen anything that would, at this point, pull us off of market growth number in that kind of 3 to 5 range."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And yes, the 4% you cited is a trailing 12 months you're referring to kind of worldwide. So kind of mix-wise, we think North America a little bit stronger maybe than others going forward. Is that fair?",40,"Okay. That's helpful. And yes, the 4% you cited is a trailing 12 months you're referring to kind of worldwide. So kind of mix-wise, we think North America a little bit stronger maybe than others going forward. Is that fair?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Last -- when you look at it in pure dollars, America's last 12 months is at 4.5% and international is down 6.5% in dollars. Constant currency adjust the whole thing, it's 4% up. So that's kind of -- I think last 12 months is -- that's kind of the mar",57,"Yes. Last -- when you look at it in pure dollars, America's last 12 months is at 4.5% and international is down 6.5% in dollars. Constant currency adjust the whole thing, it's 4% up. So that's kind of -- I think last 12 months is -- that's kind of the market that, I think, we're still feeling."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And then, Elisha, the question for you just around EPS guidance. Since you guided back in October, the euro's kind of worked a little bit more against you, I think a little bit a stronger dollar against the euro since you guided some",141,"Okay. That's helpful. And then, Elisha, the question for you just around EPS guidance. Since you guided back in October, the euro's kind of worked a little bit more against you, I think a little bit a stronger dollar against the euro since you guided some of the emerging market currency is still going the wrong way. So as I look at the $0.10 raise to guidance here, how much was med tech tax and R&D driving that $0.10 raise? How much is kind of in the guidance number is coming from those 2 things? How much of an incremental currency headwind was there, if any, included in your guidance? And then maybe how are you thinking about the core underlying business? So just trying to bucket kind of those 3 areas on what contributed to the dime change in guidance."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. So Jeff, the simple answer is if I take the R&D tax credit and the medical device excise tax together, it's a $0.10 for the year. So -- and that's roughly even at about $0.05 each. So we got a benefit of $0.04 in Q1 for those 2 impacts. And what we'",90,"Sure. So Jeff, the simple answer is if I take the R&D tax credit and the medical device excise tax together, it's a $0.10 for the year. So -- and that's roughly even at about $0.05 each. So we got a benefit of $0.04 in Q1 for those 2 impacts. And what we're saying is the additional $0.06 is going to come from Q2 to Q4. So essentially, we took the benefit from those 2 things, tacked it on to the prior guidance and got us to the $4.60 midpoint."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then underlying then kind of the core business. Are you -- I'm trying to figure out if currency I thought was an incremental headwind since you last guided. Does that imply that your core expectations have improved a little bit?",42,"Okay. And then underlying then kind of the core business. Are you -- I'm trying to figure out if currency I thought was an incremental headwind since you last guided. Does that imply that your core expectations have improved a little bit?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I mean, certainly Q1, we feel good about. And in terms of what I would refer to as an operational bead, if you take out the $0.04 related to the tax impact, we had about a $0.05 bead and that was due to higher Oncology revenue and frankly, very good",229,"Well, I mean, certainly Q1, we feel good about. And in terms of what I would refer to as an operational bead, if you take out the $0.04 related to the tax impact, we had about a $0.05 bead and that was due to higher Oncology revenue and frankly, very good cost controls on SG&A. Little bit on share repurchase, was a little bit more than we historically done but in line with that 1 million to 2 million shares per quarter. I think your next question's going to be why aren't you giving me that $0.05? And I'm still a little black and blue after Q4, frankly. And when we missed on that revenue number, it's very early in the year. And I think this just had to do with some timing. And I think Oncology did a fantastic job and probably pulled a little bit revenue forward from Q2 and Q3 to make sure we didn't have a repeat performance. But for the year, we -- it still looks good with the revenue guidance and the EPS from where we stand today. 
Currency, from when I last guided, has been relatively stable. I mean it may have hurt us, I don't know, I think I was at $1.12 versus $1.09. But again, we built some of that into the range for the guidance when we give it."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Amit Hazan from Citi.",9,"Our next question comes from Amit Hazan from Citi."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So start on the gross margin line. Just maybe a question on Oncology gross margin. So I was looking back just kind of taking a little bit several quarter view. And if I strip out service, I mean just kind of look at your product gross margin on the Oncolo",150,"So start on the gross margin line. Just maybe a question on Oncology gross margin. So I was looking back just kind of taking a little bit several quarter view. And if I strip out service, I mean just kind of look at your product gross margin on the Oncology side, it kind of implies this pretty big decline over the past year. I don't know, it's about 36% in fiscal '14 down to 31% in fiscal '15. And that's just, obviously, just the product side. So I'm wondering if you can share with us whether that trend continued this quarter, first of all, and what the drivers here might be outside of FX because you've kind of actually had a nice mix shift in revenue towards the U.S. up until this quarter. And so I'm wondering why product margins in Oncology would be down as much as they were."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. So Amit, the biggest impact on Q1 was just the geographic mix shift. We had a 7-point shift to international deliveries in particularly the Middle East and Eastern Europe, which are our lower-margin countries. And that was just based on scheduled del",166,"Yes. So Amit, the biggest impact on Q1 was just the geographic mix shift. We had a 7-point shift to international deliveries in particularly the Middle East and Eastern Europe, which are our lower-margin countries. And that was just based on scheduled delivery date. So we fully anticipated we were going to have margin declines in Oncology and for the total company, and I think that was reflected in the guidance that we gave last quarter. So for the year, I still expect, even with the -- we still had some currency impact in Q1. We'll have a little bit in Q2 and then it should anniversary. For the year, we still think Oncology is right in that 43% range, so holding in line with our long-term expectations. I would point out service was a bigger proportion in the year-ago quarter, and that is one of our highest-margin product lines. So that impacted it as well. But I think Oncology is performing well at this point."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And just to reiterate, nothing outside -- anything that's outside of FX that is hurting the product side of gross margins in Oncology. That's what seems to have been down over the course of a year.",36,"And just to reiterate, nothing outside -- anything that's outside of FX that is hurting the product side of gross margins in Oncology. That's what seems to have been down over the course of a year."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Region mix.",2,"Region mix."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Region, yes. The region mix, the geographic mix, yes. So international went from 48% of total revenue in the year-ago period to 55%, it's just a very big geographic mix shift. But on an apples-to-apples basis, it's really just the geography that was impac",55,"Region, yes. The region mix, the geographic mix, yes. So international went from 48% of total revenue in the year-ago period to 55%, it's just a very big geographic mix shift. But on an apples-to-apples basis, it's really just the geography that was impacting it. And again, less service as a percentage of the total."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Let me jump to Imaging. Just a couple questions on that. Number one, I'm wondering if you're reiterating kind of the guidance you laid out for the fiscal year, which I think was about flat or so on imaging revenues. And then secondly, specifically,",70,"Okay. Let me jump to Imaging. Just a couple questions on that. Number one, I'm wondering if you're reiterating kind of the guidance you laid out for the fiscal year, which I think was about flat or so on imaging revenues. And then secondly, specifically, has your assessment of the risk around losing more business in flat panel and in tubes changed at all since the earnings call last quarter?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think maybe the one difference we'd have here is Toshiba announced during the quarter that they're selling their medical unit. Otherwise, I think it's very much consistent with what we guided a quarter ago. The challenges continue. The Security and Insp",218,"I think maybe the one difference we'd have here is Toshiba announced during the quarter that they're selling their medical unit. Otherwise, I think it's very much consistent with what we guided a quarter ago. The challenges continue. The Security and Inspection business has stabilized -- stabilizing, clearly, at the lower revenue levels. The panel pricing declines should anniversary in the second half, and we're still absorbing the loss of major -- of a major customer that went in-sourcing on flat panel. That's probably not going to -- that's happening every quarter to us and it probably doesn't anniversary until Q4-ish. Toshiba's volume. The good news is most of that business is a service business. So that is going to continue to need to be replaced, but their ongoing forward production with the uncertainty around their sale and kind of who picks it up, et cetera, we might see a little bit of a volume adjustment there. As I did say in the script, they do have some inventory that they're working through as they kind of manage through this whole thing. The good news is the MeVis and Claymount acquisitions seem to be performing for us. So we're looking for a return to growth, I think, consistent with what we said before in 2017 and 2018."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Anthony Petrone from Jefferies.",9,"Our next question comes from Anthony Petrone from Jefferies."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Couple questions, maybe on proton. A couple of questions on proton. I'll begin with proton and then we can follow up with some of the geographies as well in Oncology. But maybe just an update on the potential to hit the $0.15 swing factor in proton specif",99,"Couple questions, maybe on proton. A couple of questions on proton. I'll begin with proton and then we can follow up with some of the geographies as well in Oncology. But maybe just an update on the potential to hit the $0.15 swing factor in proton specifically. So I think it hinged on the Emory deal. And then in your prepared comments, Dow, you mentioned potentially an installation in Russia. But you also touched upon some dislocations in that marketplace. So maybe just proton overall, the potential to the $0.15, where Emory is and how Russia plays into that."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. I mean the sites I named were all in our guidance, so that -- they're orders that we have and no mystery around those. We have not guided to Emory. It is not a booked order yet. Until the financing is complete, we won't put it into guidance. If that",61,"Sure. I mean the sites I named were all in our guidance, so that -- they're orders that we have and no mystery around those. We have not guided to Emory. It is not a booked order yet. Until the financing is complete, we won't put it into guidance. If that were to happen, it'd be a nice upside for us."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. We lived that problem.",5,"Yes. We lived that problem."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We aren't guiding.",4,"We aren't guiding."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We're not doing that. And it's just -- it's our customer who is securing the financing. We are working with them but it really is somewhat outside of Varian's control, and we're monitoring it closely.",36,"We're not doing that. And it's just -- it's our customer who is securing the financing. We are working with them but it really is somewhat outside of Varian's control, and we're monitoring it closely."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Great, great. And then just on geographies. You touched on China a bit, but Brazil is also sort of in the headlines out there with struggles. And so maybe just an update on that specific tender. I think if you go back, it was 50 Linacs, several of which h",66,"Great, great. And then just on geographies. You touched on China a bit, but Brazil is also sort of in the headlines out there with struggles. And so maybe just an update on that specific tender. I think if you go back, it was 50 Linacs, several of which had already been sort of shipped and installed. So maybe just an update on that specific tender."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We're seeing the Ministry of Health is continuing their program. I mean obviously that order was placed with us a year ago, but we are completing first installations this year and it is going as expected. So from a backlog point of view, we haven't seen a",68,"We're seeing the Ministry of Health is continuing their program. I mean obviously that order was placed with us a year ago, but we are completing first installations this year and it is going as expected. So from a backlog point of view, we haven't seen a change in their approach on these. So that's good. Market's a little bit quiet there, but it hasn't been bad."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then just a last one for me would just be on software specifically. So last year, that really seemed to be a driver, particularly on share gains, I think, both on information management and even treatment planning. So maybe do you see that as still a",77,"And then just a last one for me would just be on software specifically. So last year, that really seemed to be a driver, particularly on share gains, I think, both on information management and even treatment planning. So maybe do you see that as still a share gain story for 2016? And may be just an update on how many RapidPlans have sort of -- how many Eclipse users have migrated to RapidPlan at this point?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean first of all, for the overall software business, it continues to do very well. We just got news a couple of weeks ago that both Eclipse and ARIA got top ranking from KLAS. KLAS is the Gartner of our industry, independent organization that eval",154,"Yes. I mean first of all, for the overall software business, it continues to do very well. We just got news a couple of weeks ago that both Eclipse and ARIA got top ranking from KLAS. KLAS is the Gartner of our industry, independent organization that evaluates products for customers. So we were very thrilled by that external validation. The -- and then in terms of RapidPlan, as I said in the script, it's now installed to over 50 sites. I'd have to get you the exact number of orders, but it's well over 300 now. So the momentum continues there. I think from an overall differentiation point of view, our treatment planning position is terrific. I think we're way ahead with our knowledge-based tools. And then in ARIA, our workflow tools and our informatics are very good differentiators for us, and we continue to see very strong competitive takeout with both those products."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Your next question comes from David Roman from Goldman Sachs.",10,"Your next question comes from David Roman from Goldman Sachs."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","I wanted just to start with a clarification on the proton. I understand that Emory is not in the guidance and with historical context for why you did that. But are Russia and Saudi Arabia that you talked about are -- to what extent are those reflected in",51,"I wanted just to start with a clarification on the proton. I understand that Emory is not in the guidance and with historical context for why you did that. But are Russia and Saudi Arabia that you talked about are -- to what extent are those reflected in the forward guidance?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","They're very small amounts. They are in the guidance.",10,"They're very small amounts. They are in the guidance."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So all of our -- under the percentage of completion, all of our projects where we have actually identified materials specific to a customer, we are taking revenue on those projects. So Saudi and Russia would be included in that number.",41,"So all of our -- under the percentage of completion, all of our projects where we have actually identified materials specific to a customer, we are taking revenue on those projects. So Saudi and Russia would be included in that number."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Saudi, for example, I know we already took a fair amount last year.",13,"Saudi, for example, I know we already took a fair amount last year."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We've taken about $43 million in total. And Russia, about $25 million in total.",15,"We've taken about $43 million in total. And Russia, about $25 million in total."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then maybe a more strategic question. I mean, Dow, obviously, we focus a lot on the quarter-to-quarter order trends and how you're doing by region. But as you kind of take a step back and think about your growth rate, how things have progressed",91,"Okay. And then maybe a more strategic question. I mean, Dow, obviously, we focus a lot on the quarter-to-quarter order trends and how you're doing by region. But as you kind of take a step back and think about your growth rate, how things have progressed the past several quarters versus where you kind of want them to be, how much of the forward outlook depends on factors over which you have control and can invest to drive growth versus being dependent on macro factors or sort of end market conditions?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean for the whole company, I think the cancer business remains a terrific business for us. Constant currency growth last year was 5%, 6% in Oncology, very strong fourth quarter. We're a little weak this quarter, but our funnel still looks good. And we",338,"I mean for the whole company, I think the cancer business remains a terrific business for us. Constant currency growth last year was 5%, 6% in Oncology, very strong fourth quarter. We're a little weak this quarter, but our funnel still looks good. And we think that the cancer business, unfortunately, weathers economic downturns. I mean people get cancer regardless of economics. And now if you look back when economic times were bad, we've weathered those storms pretty well. It's not to say that we might see something in our orders if the economy really turns south. But there was this nice external validation of that last quarter with the global task force on the utilization of radiation oncology published in the Lancet journal that called for thousands more machines. Basically, 2.5x the installed base that we have today and really asking international organizations to help countries develop cancer plans. So especially outside of the U.S., a huge focus on utilizing radiation therapy for cancer. I think one of our big challenges, I mentioned in the script there, is making sure the people side of that comes along with it because we've got to have the people to be able to do the work. But I think as you look at the long term health of the Oncology business, the franchise is in as good a product position as we've ever had. And I think the market remains in the long term, very, very solid. Now on the Imaging business, we're clearly going through a big storm right now. And we still like the fundamentals of the business. We do think it's an industry that has some consolidation opportunity, and we've got to kind of figure out how to play that hand a little bit. But the -- as we get through the in-sourcing of this one customer, these kind of short-term Toshiba perturbations and look to the long term, the digitization of especially the radiographic market remains a huge opportunity. And we like the long-term fundamentals there."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then maybe just a last one, maybe sort of a follow-up to that. As you sort of think about the opportunities that sit in front of you, what was sort of the thought process around what to do with the medical device tax? I know in dollars it's not all th",98,"And then maybe just a last one, maybe sort of a follow-up to that. As you sort of think about the opportunities that sit in front of you, what was sort of the thought process around what to do with the medical device tax? I know in dollars it's not all that material for you compared to some of the other companies in the group. But why not plow some of those savings back into the business? And how should we sort of think about your spending patterns on a go-forward basis to support some of that growth?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean at a high level, let me take first crack at this and I'll have Elisha walk you through some of the detail, but at a high level, we have actually taken up our R&D spend as a percent of sales over the last couple of years. So we're investing a l",155,"Yes. I mean at a high level, let me take first crack at this and I'll have Elisha walk you through some of the detail, but at a high level, we have actually taken up our R&D spend as a percent of sales over the last couple of years. So we're investing a lot in the business. We want to make sure we get pop for that growth. So we're challenging the spend as we do it because we want to see the growth kind of linking it to your previous question. But we have taken up the R&D investment as a percent of the total over the last couple years. So we were never kind of making the R&D decision as a result of our tax impact. I mean clearly it would've been a little easier if we didn't have to pay that, but we were making that decision independent of the tax stuff."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And I would just add. I mean our road map is kind of set for the year. We've got the people, the projects. It may be more disruptive to try and even accelerate some of those things at this point. And the last point is when we increased R&D, it comes from",75,"And I would just add. I mean our road map is kind of set for the year. We've got the people, the projects. It may be more disruptive to try and even accelerate some of those things at this point. And the last point is when we increased R&D, it comes from people. And that tends to be permanent in nature, whereas this is only a reprieve for 2 years as drafted at this point."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Jason Wittes from Brean Capital.",10,"Our next question comes from Jason Wittes from Brean Capital."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So I just wanted to ask first off, in terms of Security business, I think you said about $25 million of the revenues related to Security are service related.",29,"So I just wanted to ask first off, in terms of Security business, I think you said about $25 million of the revenues related to Security are service related."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sounds about right.",3,"Sounds about right."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And that's -- is that most of the revenues we should expect this year or should we also expect some orders on top of that?",26,"And that's -- is that most of the revenues we should expect this year or should we also expect some orders on top of that?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No. I mean that's maybe not quite half -- I mean a little bit more than half of the total revenue we should have on the year.",27,"No. I mean that's maybe not quite half -- I mean a little bit more than half of the total revenue we should have on the year."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, that's about right.",4,"Yes, that's about right."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then just to understand Toshiba, they're looking to sell that business. I assume they're one of your larger customers. And I assume they're still a decent percentage of the imaging business? Is that the right way to think about it?",42,"Okay. And then just to understand Toshiba, they're looking to sell that business. I assume they're one of your larger customers. And I assume they're still a decent percentage of the imaging business? Is that the right way to think about it?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes.",1,"Yes."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And I guess the presumption would be they're right now working down their inventories, but they'll have to start reordering at some point. Whether or not that's after a sale or not, I guess, is harder to determine.",39,"And I guess the presumption would be they're right now working down their inventories, but they'll have to start reordering at some point. Whether or not that's after a sale or not, I guess, is harder to determine."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean here's what I can tell you. They are our largest customer. In fact, they're a terrific customer. They account for about $150 million of our Imaging Components revenue. The split on that is $125 million tubes, about $25 million in panel. We expect t",105,"I mean here's what I can tell you. They are our largest customer. In fact, they're a terrific customer. They account for about $150 million of our Imaging Components revenue. The split on that is $125 million tubes, about $25 million in panel. We expect to continue supplying high-end CT tubes to whoever it is that buys Toshiba. We're designing future products for them, having very good conversations. So we think that -- I mean there's obviously kind of some uncertainty as it goes through that process. But we're well designed in and I think that, that will continue whoever the new owner is."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's very helpful. And then maybe just switch to proton. I mean you mentioned sort of global turmoil impacting your core Oncology business. Should we assume that the proton business may also be impacted this year?",37,"Okay. That's very helpful. And then maybe just switch to proton. I mean you mentioned sort of global turmoil impacting your core Oncology business. Should we assume that the proton business may also be impacted this year?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean it's tough to say. When you look at our funnel, our funnel remains positive. We have had 1 or 2 fall out. I don't know how much of that -- some of that is, I think, some of their own decisions. I don't know how much of it was the kind of macro econ",174,"I mean it's tough to say. When you look at our funnel, our funnel remains positive. We have had 1 or 2 fall out. I don't know how much of that -- some of that is, I think, some of their own decisions. I don't know how much of it was the kind of macro economy. We are competing on a number of compact units, and I do think we'll see our first compact orders this year. So we're encouraged about that. There remains to be a lot of customer interest. And I guess I would say that versus -- in 2009 -- 2008, 2009 when we went through this, we were just selling big systems. So that market dried up. Now when you look at our funnel, our funnel has a lot of compact units and customers are hanging in there. We're having a lot of conversations and so the funnel remains pretty good, and our objective is to see if we can win a few of those single-room orders this year."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Sorry, just to get a clarification. The large centers, there's really not much of a market this year for them. It's mostly compact centers that people are looking at right now.",31,"Sorry, just to get a clarification. The large centers, there's really not much of a market this year for them. It's mostly compact centers that people are looking at right now."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, that was a comparison to 2008, 2009. 2008, 2009, that's what the market was. And when you're looking at $50 million to $90 million of expense into that kind of recession, that market just went away during 2008, 2009. No, we're not seeing that. There",109,"Well, that was a comparison to 2008, 2009. 2008, 2009, that's what the market was. And when you're looking at $50 million to $90 million of expense into that kind of recession, that market just went away during 2008, 2009. No, we're not seeing that. There's still a good multi-room market out there. But we're also seeing a very good funnel of these compact rooms. We're competing on both. But just to say that in terms of as it relates to kind of the global macroeconomic environment, I think these compact customers are hanging in there a little more in terms of the funnel -- strength of the funnel."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Tycho Peterson from JPMorgan.",9,"Our next question comes from Tycho Peterson from JPMorgan."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Maybe just a higher-level strategic question on some of the emerging markets that you've called out as being kind of problematic. I mean given that a lot of the issues here are kind of structural rather than cyclical in some of these markets. Does this ch",80,"Maybe just a higher-level strategic question on some of the emerging markets that you've called out as being kind of problematic. I mean given that a lot of the issues here are kind of structural rather than cyclical in some of these markets. Does this change your thinking around how you address these markets, the resources you put to them? Any change in where you're placing incremental efforts internationally based on what we've seen the last couple of quarters?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me kind of underscore one of the things I pointed out in the call is weak in Japan, weak in Europe. Emerging markets -- weak in Russia for sure. But we had some Latin America activity that wasn't too bad. China, as I mentioned, was down, but we've kin",153,"Let me kind of underscore one of the things I pointed out in the call is weak in Japan, weak in Europe. Emerging markets -- weak in Russia for sure. But we had some Latin America activity that wasn't too bad. China, as I mentioned, was down, but we've kind of have a timing issue with a fairly large protested order. So we actually think China is going to be okay. The long term is we're -- we still think these markets are going to grow. We've built a market development team. We're investing in our access to care program to bring new operators into the business, and we're still bullish about the long-term opportunities. I mean do we replace somebody that leaves as fast as maybe we're used to while we go through maybe some downturns? Maybe not. But we're clearly looking at this very opportunistically and strategically for the long term."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And any hope on Japan turning? I mean I know you talked in the past about only 20%, 25% of patients receiving radiation there. So clearly, there's a clinical need.",30,"And any hope on Japan turning? I mean I know you talked in the past about only 20%, 25% of patients receiving radiation there. So clearly, there's a clinical need."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean the clinical need remains. I just think between the currency movement, the market restructure, it's -- we are investing a little bit in government affairs there to kind of get the government a little bit more supportive. But at least for kind",68,"Yes. I mean the clinical need remains. I just think between the currency movement, the market restructure, it's -- we are investing a little bit in government affairs there to kind of get the government a little bit more supportive. But at least for kind of market outlook this year, I wouldn't say I'm seeing anything that dramatically changes what we've been seeing over the last year anyway."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then you called out the EDGE orders in China. Just -- I mean any thoughts on how the mix there evolves? TrueBeam, EDGE?",24,"And then you called out the EDGE orders in China. Just -- I mean any thoughts on how the mix there evolves? TrueBeam, EDGE?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think it's been pretty consistent. It's a bimodal market. There is a value market that's aggressive, where people are looking at entry-level products. But there's also a high-end market. EDGE is part of that. We're really glad to get those 3 Q1 EDGE ord",152,"I think it's been pretty consistent. It's a bimodal market. There is a value market that's aggressive, where people are looking at entry-level products. But there's also a high-end market. EDGE is part of that. We're really glad to get those 3 Q1 EDGE orders. And then one of the exciting pieces of news is that TrueBeam -- the TrueBeam volume there still remains pretty good. It is a category A product, so it puts it in a little more -- a little bit more of a regulatory process to get through. But -- so there's limited licenses at that end of the market. But I'd say our mix of product remains pretty consistent, and the high end of that market remains a really important market for us. And we've been expanding our share in China over the last 18 months. So we're doing that by winning in the value market."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Backlog declined a bit this quarter. Was that just the order slippage from last quarter? And any thoughts on backlog stability, I guess, going forward?",25,"Backlog declined a bit this quarter. Was that just the order slippage from last quarter? And any thoughts on backlog stability, I guess, going forward?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So versus a year ago quarter backlog was up sequentially. Yes. Yes. So I mean we came in ahead, a little bit ahead on Oncology revenues and the order. So that's all it is.",34,"So versus a year ago quarter backlog was up sequentially. Yes. Yes. So I mean we came in ahead, a little bit ahead on Oncology revenues and the order. So that's all it is."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Two other quick ones, I guess. On kind of the software initiatives. Dow, in the past, you talked about a $300 million opportunity over the next couple of years. Can you just give us a sense of the magnitude -- the growth you think you can capture fr",71,"Okay. Two other quick ones, I guess. On kind of the software initiatives. Dow, in the past, you talked about a $300 million opportunity over the next couple of years. Can you just give us a sense of the magnitude -- the growth you think you can capture from all the initiatives, RapidPlan, and everything else you've been highlighting over the last couple of quarters that you can capture this year?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. I mean I think the -- RapidPlan is certainly our single biggest opportunity, maybe talking about it in terms of units. If we have -- if we've taken 300 to 350 units, there's probably an installed base of 3,500 to 4,000, so we're just nicking that. An",233,"Yes. I mean I think the -- RapidPlan is certainly our single biggest opportunity, maybe talking about it in terms of units. If we have -- if we've taken 300 to 350 units, there's probably an installed base of 3,500 to 4,000, so we're just nicking that. And I think what encourages me is the early evidence, both for clinical outcome and productivity, is outstanding. So I think it really helps us make the economic case for people to invest. And the -- of course, the ASPs, the selling prices and the margins there remain very good. InSightive Analytics and our kind of the transition to coordinated care on ARIA is maybe not as far advanced. The product was released a little bit later, but we also really like the progress there. And we do think it's driving share. We'd love -- really like to see where it drives a little bit more volume. We are investing in some software sales resources outside of the U.S. to kind of help us attack some markets that we haven't maybe attacked as aggressively on the software side. Much of our software business is still, frankly, U.S.-based. So we're trying to drive that piece as well. But we're still -- we're very encouraged by what we see and -- both in terms of kind of the market opportunity and the share opportunity by our software products."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then just lastly. Obviously, there's been a lot of news earlier this year on the cancer moonshot program and a lot of developments in liquid biopsy. Does any of that change your view on the long term outlook on the U.S. market in particular with bette",50,"And then just lastly. Obviously, there's been a lot of news earlier this year on the cancer moonshot program and a lot of developments in liquid biopsy. Does any of that change your view on the long term outlook on the U.S. market in particular with better and earlier detection?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","The short version is we love it. We do know that there's been some reach out to some of our customers and that radiation therapy is going to be part of it. So that's -- frankly, any other clarity beyond that is difficult. But we're encouraged that at leas",56,"The short version is we love it. We do know that there's been some reach out to some of our customers and that radiation therapy is going to be part of it. So that's -- frankly, any other clarity beyond that is difficult. But we're encouraged that at least our thought leaders are at the table."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Steve Beuchaw from Morgan Stanley.",10,"Our next question comes from Steve Beuchaw from Morgan Stanley."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Just a few housekeeping items for me at this point. I guess first, for MeVis and Claymount, do you have a sense for what the contribution was in the top line from those specifically for the quarter? I know we had a number for the year. I don't know that w",55,"Just a few housekeeping items for me at this point. I guess first, for MeVis and Claymount, do you have a sense for what the contribution was in the top line from those specifically for the quarter? I know we had a number for the year. I don't know that we have for the quarter."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. It's roughly $15 million.",5,"Yes. It's roughly $15 million."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","$15 million. Okay. And then on the proton financing. Now that you guys have a little bit more of that on the balance sheet, do you have a sense for what the contribution was on the P&L in the quarter?",40,"$15 million. Okay. And then on the proton financing. Now that you guys have a little bit more of that on the balance sheet, do you have a sense for what the contribution was on the P&L in the quarter?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","The total interest income was like $1.7 million. So call it $1.5 million maybe? I don't have that number right in front of me, Steve, but that's close enough.",29,"The total interest income was like $1.7 million. So call it $1.5 million maybe? I don't have that number right in front of me, Steve, but that's close enough."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Got it. And then last one for me is I'm thinking back to the fourth quarter call and the delivery slippages. I think Tycho might have alluded to this, but there was a $0.10 impact from delivery. I believe it was predominantly TrueBeams slipping from the f",72,"Got it. And then last one for me is I'm thinking back to the fourth quarter call and the delivery slippages. I think Tycho might have alluded to this, but there was a $0.10 impact from delivery. I believe it was predominantly TrueBeams slipping from the fourth quarter. Did we recapture that in the first quarter? Is there more in the second quarter? How do we think about those layering in here?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I think you should just assume that was built into our guidance for FY '16 and the bulk of that in Q1. So we took that into account when we set the guidance for Q1.",36,"Well, I think you should just assume that was built into our guidance for FY '16 and the bulk of that in Q1. So we took that into account when we set the guidance for Q1."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Charley Jones from Dougherty Markets.",10,"Our next question comes from Charley Jones from Dougherty Markets."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","I want to go and put some numbers around some comments you made around software down and I had a question around some comments Elisha had around the guidance for the year on revenue. And wondering if you could tease out what the growth -- well, I think th",255,"I want to go and put some numbers around some comments you made around software down and I had a question around some comments Elisha had around the guidance for the year on revenue. And wondering if you could tease out what the growth -- well, I think this is kind of a $500 million service software business. If you could kind of break out how much of it is maybe just software only. And then particularly, I'm interested in trying to figure out the opportunity of this. And I was guessing it was going to be international. And I was curious, Elisha, if you could talk about the growth rates of service and software for 2015 kind of between international and U.S. and how that's going to change in '16. Really trying to understand what this business can look like if we did get into a lower unit kind of environment. 
And it goes to my second question around the guidance of revenue. Seems like you're putting a lot in the fourth quarter, if I'm reading you right, about pull in revenue out of the third quarter, Elisha, in the second quarter. So I'm just curious, where does that come from? Is it more Oncology or proton or X-ray? 
And I think, Dow, last quarter you said maybe we get a little bit of growth from X-ray as we went through the back half of the year. But curious if you have any better visibility on that as well. So those are my questions."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Okay. Hopefully I can remember all that.",7,"Okay. Hopefully I can remember all that."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me start on that software service thing. I mean first of all, just to ground us, our service business is about $1 billion business. Our software business is about $0.5 billion business, much of which is equipment and much of which is service. So it ki",120,"Let me start on that software service thing. I mean first of all, just to ground us, our service business is about $1 billion business. Our software business is about $0.5 billion business, much of which is equipment and much of which is service. So it kind of gets double counted as we look at it because there's that software service agreement pays -- piece that goes into our service business and then the upfront licenses that we sell as part of the customer getting in the business or ongoing equipment transactions as booked in our equipment business. So as we've said, the service business historically has been a double-digit business. I think constant currency adjusted last year was 9%."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","9%.",2,"9%."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","9% and it was constant currency adjusted growth in Q1 was 6%. So I think on the year, it -- we clearly kind of see it at high single-digit kind of growth range. And now if we stretch and everything goes for us, it will be double-digit business. But that's",180,"9% and it was constant currency adjusted growth in Q1 was 6%. So I think on the year, it -- we clearly kind of see it at high single-digit kind of growth range. And now if we stretch and everything goes for us, it will be double-digit business. But that's kind of what we're seeing on the software -- in the service business. But software is a big piece of that growth in the service business. And the software business itself is about $0.5 billion business, call it 50-50. 50%-ish equipment, 50% ongoing service agreements with our service installed base. Last year, that business grew a little faster than the average. So if the constant currency growth in Oncology last year was 6%, it was, call it, 7% or 8%. And so we'd love to stretch that business to get double-digit growth. That's what we'd love to see. I think it'll be stretching to get there but right now, we'd love to see it grow a little bit faster than the Oncology average. Elisha, if you can fix all that."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No. But I am reluctant to give a whole lot of breakdown on our guidance. I mean this is -- again, we're in Q1. We're looking out at the full year. We are confident from where we sit today. I think you're correct that more growth is going to come in the se",246,"No. But I am reluctant to give a whole lot of breakdown on our guidance. I mean this is -- again, we're in Q1. We're looking out at the full year. We are confident from where we sit today. I think you're correct that more growth is going to come in the second half. But the reason for that is we anniversary 2 really big effects of last year. The first being FX will still have a little bit of quarter-over-quarter impact in this second fiscal quarter that we're currently in. But as we -- assuming currencies stay where they are today, that impact gets reduced significantly as we go into Q3 and Q4. And so obviously, we expect the dollar growth rates are going to be higher in the second half of the year. The other thing that we anniversary that was huge last year is the pricing impact on particularly the flat panel business. And all of the declines that we saw there, which again, were late in second quarter and really large in Q3 and Q4. So our hope is that we're going to get a little more linear in our Oncology business as we go through this fiscal year. And if you look at the guidance for the first half versus the full year, it's right around at the midpoint, 45% of the year, and that is very common with historical performance, having about 45% of our EPS in the first half."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Maybe I can just follow up, I guess, on a question around X-ray. You made comments last quarter, Dow, about maybe seeing some stabilization in X-ray. Obviously, you talked about Toshiba and there's an unknown there. But if you look at what's happened to y",90,"Maybe I can just follow up, I guess, on a question around X-ray. You made comments last quarter, Dow, about maybe seeing some stabilization in X-ray. Obviously, you talked about Toshiba and there's an unknown there. But if you look at what's happened to your currency and some of these other Korean different suppliers into that business, do you feel like your position is a little bit better and you've got more visibility or stability? Or are you still on this kind of unknown position there as you look forward?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I guess kind of as I said, SIP is stabilizing, the Security business is stabilizing. We like that. As Elisha said, panel pricing probably anniversaries Q3-ish. We're still absorbing a loss of a major customer. That's going on. I think the only thing that'",134,"I guess kind of as I said, SIP is stabilizing, the Security business is stabilizing. We like that. As Elisha said, panel pricing probably anniversaries Q3-ish. We're still absorbing a loss of a major customer. That's going on. I think the only thing that's changed from last quarter has been this Toshiba announcement. And with that, some readjustment of their inventory and order level. I think that's probably going to go on for a while as they adjust. So that would be the one piece of new news. We still think it's a good business and look for it to return to growth. I think in terms of whether it's stabilizing or not, well, the numbers aren't great. We, at least, made our internal goals for the business, and we feel good about that."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Brandon Henry from RBC.",9,"Our next question comes from Brandon Henry from RBC."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","You guys have been reporting pretty strong order numbers in the EMEA and Asia Pacific regions over the last couple of quarters. But it looks like the gross order number for Oncology Systems in those 2 regions was a little weaker this quarter. So just help",80,"You guys have been reporting pretty strong order numbers in the EMEA and Asia Pacific regions over the last couple of quarters. But it looks like the gross order number for Oncology Systems in those 2 regions was a little weaker this quarter. So just help me understand how much of this is market related versus like market share related. And have you seen any change in the competitive dynamics of pricing with Elekta in either one of those markets?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","When I think -- as I've talked a little bit about on the market side last quarter, we were very gratified by the European volume we saw at the end of last year. And frankly, we'd love the market to perform at that level all the time. But as we look forwar",59,"When I think -- as I've talked a little bit about on the market side last quarter, we were very gratified by the European volume we saw at the end of last year. And frankly, we'd love the market to perform at that level all the time. But as we look forward, we didn't think that kind of 12%..."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","25% of Q4 constant currency.",5,"25% of Q4 constant currency."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, 25% constant currency growth. 12% real dollar growth last quarter. That's just not going to continue. It probably is the mid-single digit-ish market. So that's probably the European market. There was one other part of the question that my jet lag is",165,"Yes, 25% constant currency growth. 12% real dollar growth last quarter. That's just not going to continue. It probably is the mid-single digit-ish market. So that's probably the European market. There was one other part of the question that my jet lag is not helping me remember. 
Elekta. So yes, competitively, I mean, our share is up. As we reported the last quarter, when you look at last 12 months, our share is up pretty significantly. So -- and it's worldwide. We're seeing share growth literally in every geography. So some of it has come from share growth. We obviously like that. We have seen Elekta be a little more aggressive, especially at challenging tenders that are awarded. So that maybe is a little bit different competitive practice than we've seen in the past. Not quite sure why they're doing that. I think that hurts them with the customers, frankly. But anyway, that might be the one competitive change that we're seeing a little bit."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then on the Imaging Components side. Can you talk about some of the strategies that longer term, after we see some stabilization, that you're looking to kind of reaccelerate this business? Is it something that can be done internally with the pro",81,"Okay. And then on the Imaging Components side. Can you talk about some of the strategies that longer term, after we see some stabilization, that you're looking to kind of reaccelerate this business? Is it something that can be done internally with the product pipeline? Or will it require M&A? 
And then also, can you give us an update on kind of the strategic review process for the Security and Inspection business? Is that a business that still fits for Varian?"
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Sure. The -- in terms of the strategy, it remains a product development business. So I alluded to the fact that with Toshiba, we started some new product programs. This remains a very innovation-driven segment. And especially in tubes, it's innovatio",187,"Yes. Sure. The -- in terms of the strategy, it remains a product development business. So I alluded to the fact that with Toshiba, we started some new product programs. This remains a very innovation-driven segment. And especially in tubes, it's innovation driven. In flat panel, it's innovation and cost reduction-driven. So one of the things that we've got coming, we've just announced and it's being worked into our customers' supply chain, a new low-cost flat panel. I think that, that gives us both some margin opportunity as well as some share play. So we'd like to see that come back. As I mentioned last quarter in the call, the Security business, on the one hand, we've seen its volume come down. It's profitability still remains very, very good. So even though we've gone from $80 million, $85 million to $45 million, $50 million, it's still a 20% return on sales business. It's technology that we leverage throughout our product line, both in Imaging and in Oncology. So that's -- we're continuing to look at it, but replacing that revenue and profit is not an easy thing."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then one last question for me. On the services side for Oncology Systems, can you kind of talk about what the installed base for you guys? How quickly that's growing. And then in the medium term, how do you grow the Services business? How do you",71,"Okay. And then one last question for me. On the services side for Oncology Systems, can you kind of talk about what the installed base for you guys? How quickly that's growing. And then in the medium term, how do you grow the Services business? How do you continue to grow the Services business high single digits kind of above the growth in the installed base? Just talk about that strategy."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","The short version is the installed base is growing. Our unit volume remains very good. As we've said before, the U.S. market remains a replacement market. But outside of the U.S., it's -- we still get very good socket growth. And the TrueBeam percentage i",148,"The short version is the installed base is growing. Our unit volume remains very good. As we've said before, the U.S. market remains a replacement market. But outside of the U.S., it's -- we still get very good socket growth. And the TrueBeam percentage is still quite high -- I'm sorry, the TrueBeam percentage is still quite low. When you look TrueBeam as a percent of our overall installed base, I'd say -- I'm guessing now here, but call it maybe 20%, 15% to 20%. So the -- and we get a big price adjustment as we go through that. So that's true in the U.S. and it's even more true outside of the U.S. So between the installed base growth, the price growth and then the software opportunity that we get in the Service, we think that, that high single-digit growth number constant currency is very doable."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","At this time, we have no further questions. I will turn the call back over to Spencer Sias for closing comments.",21,"At this time, we have no further questions. I will turn the call back over to Spencer Sias for closing comments."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you all for participating. A replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S., or (201) 61",69,"Thank you all for participating. A replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S., or (201) 612-7415 from outside the U.S., and entering confirmation code 13627253. The telephone replay will be available through 5 p.m. this Friday, January 29. Thank you."
311907,320073825,923190,"Varian Medical Systems, Inc., Q1 2016 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation.",20,"Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems Second Quarter Fiscal Year 2015 Earnings Results Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Spencer Sias, Vice President of Investor Relations and Corporate C",48,"Greetings, and welcome to the Varian Medical Systems Second Quarter Fiscal Year 2015 Earnings Results Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Spencer Sias, Vice President of Investor Relations and Corporate Communications for Varian Medical Systems. Mr. Sias, you may now begin."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. First of all, quick apologies for the delay we had in getting the press release out, but we've got the [indiscernible]. By now, I think you guys all have the material and we're very ready for the call.So good afternoon and welcome to Varian M",313,"Thank you. First of all, quick apologies for the delay we had in getting the press release out, but we've got the [indiscernible]. By now, I think you guys all have the material and we're very ready for the call.
So good afternoon and welcome to Varian Medical Systems conference call for the second quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results and then we'll take your questions following the presentation. To simplify our discussion, unless otherwise stated, all references to the quarter or year are fiscal quarters, fiscal years. Quarterly comparisons are for the second quarter of fiscal 2016 versus the second quarter of fiscal 2015. References to financial results for orders are to gross orders unless otherwise indicated. The discussion include non-GAAP financial measures in order to provide quarter-over-quarter comparisons of operational performance excluding the unusual items. A reconciliation to the most comparable GAAP measure is included in our earnings release which can be accessed on our website.
Please be advised that this presentation and discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, should, will, feels like and similar expressions, are intended to identify those statements which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on the information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks relating to our business are described in our second quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise.
And now here's Dow."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon and welcome. Varian is reporting solid results for the second quarter of fiscal year 2016 with time order growth in our oncology business, promising progress in our Particle Therapy business and expected weakness in our Imaging Components b",911,"Good afternoon and welcome. Varian is reporting solid results for the second quarter of fiscal year 2016 with time order growth in our oncology business, promising progress in our Particle Therapy business and expected weakness in our Imaging Components business.
In summary, we are reporting non-GAAP net earnings of $1.09 per diluted share and $1.01 per diluted share on a GAAP basis. Revenue of $759 million equaled to the year-ago quarter in dollars and up 2% in constant currency. Strong orders in our oncology business with growth and strategic wins in all 3 geographies, expected order and revenue declines in Imaging Components and good momentum in our Particle Therapy business with growing customer interest in our single [indiscernible] system.
Focusing on operational highlights. In our oncology business, gross orders totaled $618 million for the quarter, up 6% in dollars and 8% in constant currency. Gross orders in the Americas for the quarter increased by 2% in dollars and 3% in constant currency with 7% growth in North America, offsetting a decline in Latin America.
In EMEA, gross orders were up 19% in dollars and 23% in constant currency helped by big wins in India and the Middle East. Gross orders in APAC rose 2% in dollars and 3% in constant currency driven by robust growth in China.
Oncology experienced healthy global demand in the quarter with higher unit orders as well as gains in our service and software businesses.
Looking at each of the regions in more detail. Our gross order growth in North America was driven in part by demand for newer products, particularly our VitalBeam accelerator as well as our RapidPlan and InSightive Analytics software for improving clinical efficiency.
As you know, North America is largely a replacement market and in this quarter, we generated orders to replace several hardware and software products from competitors as well as our own units. As usual, there were some big wins in the quarter including a major order from Andy Anderson for 6 TrueBeam systems. We also won a couple of large deals in Canada.
Orders in Latin America declined significantly from the year-ago quarter as results of political uncertainty in Brazil and political purchasing decisions.
During the quarter, we broke ground on a new 50,000 square foot facility in Brazil that will be used for training and product demos as well as product assembly and warehousing. This summer, we expect to complete the first few installations of the 80[ph] machines, aided by Brazil's Ministry of Health in 2014.
Turning to EMEA. We had a very good quarter with several sizable, the largest of these came in India where we received a multi-site order from the Apollo Hospital Group for 12 high-end linear accelerators and 10 5[ph] brachytherapy systems. We also booked several orders in the Middle East, including systems for 4 new sites in Turkey.
We had a terrific quarter China where more than 75% of the Varian linear accelerators ordered in the quarter were for new treatment [indiscernible]. Elsewhere in APAC, Japan remains slow, but appeared to be stabilizing.
We also had a key win at a large hospital in Indonesia that we believe will position us for further growth in that important market.
We're pleased with the progress in [indiscernible] software business during the quarter. Customer interest in RapidPlan continued to grow and it is now installed at nearly 170 sites around the world.
We also received multiple orders in the quarter for InSightive Analytics, bringing total orders in this introduction earlier in this fiscal year to 80.
We had another nice win at the Christy Hospital in Manchester, England, which ordered several software products, including Eclipse treatment planning for protons and our Velocity product that uses images to track tumor responses to treatment.
Turning to our Oncology Service business. Gross orders were up 11% in dollars and 12% in constant currency, with the help of higher capture rates, particularly in North America and China.
Looking now at Imaging Components second quarter performance versus the year-ago quarter, orders fell by 12% to $138 million and revenue fell by 8% to $144 million, largely in line with our expectations. Beginning in the second half of last fiscal year, this business has been confronted with currency-related pricing pressures, weak market conditions for security and inspection products, in-sourcing by a large panel customers and uncertainties related to the sale of a major tube[ph] customer. We believe we have largely absorbed these challenges from the last 4 quarters, and we feel that the business is beginning to stabilize at these levels.
Our MeVis and new Claymount businesses performed well in the quarter and we continue to believe [indiscernible] across China. With a growing number of imaging equipment manufacturers in China, this is going to be an important growth area for our components business.
In our Particle Therapy business, we continue to make good progress with installations and recorded $31 million in revenue during the quarter. It was great to see patient treatments commence as the Proton Therapy Center in February. We are proud to collaborate with the center to bring our advanced cancer fighting technology to patients in that region.
In the quarter, we successfully extracted beam from the [indiscernible] and Cincinnati Children's Hospital where patient treatments are scheduled to begin before the end of the year. We are also scheduled to begin installing equipment at sites in Holland, Russia and Saudi Arabia later this year.
Now I'll turn it over to Elisha."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog.We ended the quarter at $3.3 billion, up 6% from the year-ago period. Backlog adjustments during the quarter totaled $51[ph] million bringing net orders",586,"Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog.
We ended the quarter at $3.3 billion, up 6% from the year-ago period. Backlog adjustments during the quarter totaled $51[ph] million bringing net orders for the company to $707 million. Second quarter revenues for the total company were about equal with the year-ago period in dollars and up 2% in constant currency. For the first half, total company revenues were up 1% in dollars and up 4% in constant currency.
Oncology posted a 1% decline in revenues and a 1% gain in constant currency during the second quarter. Imaging Components posted a second quarter revenue decline of 8% with decreases in tubes, panels and Security and Inspection Products, partially offset by revenues from our new Claymount and MeVis businesses.
Our Particle Therapy business posted second quarter revenues of $31 million, more than double the year-ago period as we continue to make progress on projects and backlogs.
The total company gross margin for the quarter was 42%, down as expected by have 0.05 point due to lower volumes at Imaging Components and a higher mix of Proton business. For the first half, total company gross margin was 41.6%, down almost 2 points from the year-ago period.
Oncology Systems second quarter gross margin improved 73 basis points to 43.7% due to product mix shift toward software and service, variable cost productivity and suspension of the medical device excise tax.
Imaging Components second quarter gross margin fell by a little more than 2 points to 41.4% due largely from lower volumes.
Second quarter SG&A expenses were $112 million or 15% of revenue and our [indiscernible] were $62 million or about 8% of revenue, each equal as a percentage of revenue to the year-ago quarter. For the first half, SG&A expenses were 16%[ph] of revenue and R&D was 8% of revenue, both also equal to the year-ago period.
Second quarter operating earnings totaled $145 million or 19.1% of revenue, down about 1 point as a percentage of revenue from the year-ago quarter and in line with our expectations. For the first half, operating margin is 18%[ph] of revenue was down about 1.5 points from the year-ago period.
Depreciation and amortization totaled $20 million for the second quarter and $38 million for the first half. The effective tax rate was 28.1%, virtually equal to the year-ago quarter. We continue to expect that the tax rate will be about 26% to 27% for the year.
Fully diluted shares outstanding of 96.2 million were almost 5 million lower than a year-ago quarter due to our ongoing share repurchase program. Diluted EPS was $1.09 for the quarter.
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $961 million, debt of $794 million and software order equity of $1.7 billion. DSO at 109 days was up significantly from the year-ago quarter due to a lower mix of Imaging Components business, a higher mix of Proton business, more extended payment terms and lower collections for Oncology Systems.
Second quarter cash flow from operations was $32 million, bringing the total cash flow from operations for the first half to $109 million. Primary uses of cash were $19 million for CapEx and $57 million for the repurchase of 725,000 shares of stock. At the end of the quarter, we had 6 million shares remaining under the existing repurchase authorization that extends to calendar year 2016.
Now I'll turn it back to Dow for the outlook."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. Including the results of the second quarter, we continue to believe that total company non-GAAP earnings within the range of $4.55 to $4.65 per diluted share for fiscal year 2016. This expectations of a slower-than-anticipated recovery in",138,"Thanks, Elisha. Including the results of the second quarter, we continue to believe that total company non-GAAP earnings within the range of $4.55 to $4.65 per diluted share for fiscal year 2016. This expectations of a slower-than-anticipated recovery in our Imaging Components business due to high inventory levels for a major customer, we now believe revenues for fiscal year 2016 will increase by about 3% over fiscal year 2015.
For the third quarter of fiscal year 2016, we expect non-GAAP earnings to be in the range of $1.16 to $1.20 per diluted share. We expect third quarter revenues to be about equal to the year-ago period with grows in our businesses offset by a decline in our Proton business versus the year-ago quarter when we booked the big University of Maryland project.
We're now ready for your questions."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] Our first question comes from Jason Wittes from Brean Capital.",12,"[Operator Instructions] Our first question comes from Jason Wittes from Brean Capital."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So I guess, I'll start with the oncology [indiscernible], start with imaging. You mentioned -- you made some comments about the stability of the business. It seems like the only thing that's really sort of dragging and leading to the lower outlook for the",78,"So I guess, I'll start with the oncology [indiscernible], start with imaging. You mentioned -- you made some comments about the stability of the business. It seems like the only thing that's really sort of dragging and leading to the lower outlook for the year is the destocking. I assume that's with the Toshiba transfer to I think Canon. Is anything else out there? I mean, is that the main drag of the business at this point or?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I mean, I think that's the main drag. I mean, I talked a little bit about the kind of currency issues, that stabilizing [indiscernible]. We've had some of the price issues that's gone along with that, we see that stabilizing. We have a major flat pa",127,"Well, I mean, I think that's the main drag. I mean, I talked a little bit about the kind of currency issues, that stabilizing [indiscernible]. We've had some of the price issues that's gone along with that, we see that stabilizing. We have a major flat panel customer in source. We see a little bit of impact of that, but that should be largely anniversary-ed by Q4. And then it's really the sale that you mentioned that's been going on has caused some short-term volume issues that Toshiba clearly is managing for working capital in the short-term. I think when we look at the rest of our customer base, we're seeing very solid customer demand. And within that business, we'll turn around here in the second half."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Two related questions and I want to get comfortable with the imaging business. And that is I think in the past you made comments about half of the business [indiscernible], I think, at year-end '15, fiscal '15, was kind of commodity like and somewha",71,"Okay. Two related questions and I want to get comfortable with the imaging business. And that is I think in the past you made comments about half of the business [indiscernible], I think, at year-end '15, fiscal '15, was kind of commodity like and somewhat at-risk. It sounds to me like you feel that, that has stabilized in terms of the business, is that the right way to think about it?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I mean the short version is when you go customer by customer, our demand has really been very solid. I think this conversation came up in regards to some of the flat panel technology and how easy or difficult it might be for people to swift supplier",84,"Well, I mean the short version is when you go customer by customer, our demand has really been very solid. I think this conversation came up in regards to some of the flat panel technology and how easy or difficult it might be for people to swift suppliers in flat panel technology. In some areas of the detector business, that is a little bit easier to switch suppliers. In the tube business, that remains -- that can be done, but still remains very difficult."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. In terms of Toshiba moving to Canon, that business being bought by Canon, can you give an outlook in terms of [indiscernible] you have and how that might change the outlook for that piece of the business? Because they were. . .",43,"Okay. In terms of Toshiba moving to Canon, that business being bought by Canon, can you give an outlook in terms of [indiscernible] you have and how that might change the outlook for that piece of the business? Because they were. . ."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, sure, absolutely. The sale to Canon is still closing, first of all. And what we hear is that the Toshiba team is staying on. We have very good relationship with them and that gives us some optimism. And there is going to be some cautious purchasing a",82,"Yes, sure, absolutely. The sale to Canon is still closing, first of all. And what we hear is that the Toshiba team is staying on. We have very good relationship with them and that gives us some optimism. And there is going to be some cautious purchasing and inventory management in the short term from a competitive product point of view. Our biggest business there by far is the 2 business that we sell to Toshiba and Canon doesn't make any tubes."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And last question, I just wanted -- just you mentioned some on proton, interest in your single room offering. Can you give us a little more details around that in terms of what the pricing is and is it better?",41,"Okay. And last question, I just wanted -- just you mentioned some on proton, interest in your single room offering. Can you give us a little more details around that in terms of what the pricing is and is it better?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","First of all, there's lots of interest. So the kind of our funnel of activity is very large, that's good. In the quarter, we did have 3 contract decisions, one of those, in fact, issued a press release in Florida. The 3 of them all have a contingency of 1",87,"First of all, there's lots of interest. So the kind of our funnel of activity is very large, that's good. In the quarter, we did have 3 contract decisions, one of those, in fact, issued a press release in Florida. The 3 of them all have a contingency of 1 form of another, 2 are financing and 1 is some permitting. So with a little luck, we'll clear those contingencies on 1 or 2 of them this year. If everything goes our way, we'll get all 3."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Vijay Kumar from Evercore.",9,"Our next question comes from Vijay Kumar from Evercore."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is Scott in for P.J. I just had a question in terms of when you're talking about building up a facility in China, I was curious since you mentioned this is a growth area. What are your guys thinking in terms of where the growth is coming from? And wh",58,"This is Scott in for P.J. I just had a question in terms of when you're talking about building up a facility in China, I was curious since you mentioned this is a growth area. What are your guys thinking in terms of where the growth is coming from? And what's the interest and drivers behind that?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","There's a lot activity in China in our radiology area. So there's some very large customers, I'd say there's 3 or 4 emerging large manufacturers of radiology equipment in China. And there's another list, 15 to 20 smaller suppliers and it's a very active r",122,"There's a lot activity in China in our radiology area. So there's some very large customers, I'd say there's 3 or 4 emerging large manufacturers of radiology equipment in China. And there's another list, 15 to 20 smaller suppliers and it's a very active radiology market for locally-sourced products in China. So we are not -- we do support Toshiba's global effort in particular. But the big radiology companies at least in CT and kind of high-end X-ray, they manufacture their own tubes. So we're not supplying them in that market. This is really development at the local Chinese market. Our Chinese customers are looking for local service capability, that turnaround on spares and -- anyway, it's a very active market."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then a follow-up on the China market. Since we've seen, I guess, other industries, like diagnostics, [indiscernible] there's been auditing on large capital equipment purchasing. Do you see any sort of headwind? Or this has not been an issue for you gu",44,"And then a follow-up on the China market. Since we've seen, I guess, other industries, like diagnostics, [indiscernible] there's been auditing on large capital equipment purchasing. Do you see any sort of headwind? Or this has not been an issue for you guys?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think, I mean, that's an issue for us for the last 2, 2.5 years, I wouldn't say it's any worse. In fact, in our oncology business this quarter in China, we had a very, very good quarter, very strong double-digit growth in China. And what we were particu",78,"I think, I mean, that's an issue for us for the last 2, 2.5 years, I wouldn't say it's any worse. In fact, in our oncology business this quarter in China, we had a very, very good quarter, very strong double-digit growth in China. And what we were particularly pleased about is over 75% of the units were in new volts, new bunkers. And our funnel in China looks really good. So we remain very bullish about China."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Tycho Peterson from JPMorgan.",9,"Our next question comes from Tycho Peterson from JPMorgan."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Dow, maybe just to start, I'm wondering if you can touch on competitive dynamics in the market. [indiscernible] last night actually talked about a little bit pricing pressure in single and dual volt market in the U.S. I know you announced the [indiscernib",73,"Dow, maybe just to start, I'm wondering if you can touch on competitive dynamics in the market. [indiscernible] last night actually talked about a little bit pricing pressure in single and dual volt market in the U.S. I know you announced the [indiscernible] Andy Anderson order, but I think [indiscernible] as well. But just wondering, does the pricing is becoming more of an issue in the market, if you can touch on that."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I would say for us, pricing was not issue in the market. Especially here in the U.S. market, our prices are up. And our volumes is very, very good. I mean, as you saw, we had a 7% growth in U.S. and Canada on the quarter. That's got to be 1 of the best qu",94,"I would say for us, pricing was not issue in the market. Especially here in the U.S. market, our prices are up. And our volumes is very, very good. I mean, as you saw, we had a 7% growth in U.S. and Canada on the quarter. That's got to be 1 of the best quarters we've got in the U.S. in a long time. And our pricing looks very, very good. So I mean, you may have heard me say, I think that product is overpriced. So I'm not surprised they're getting pricing problems."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. How about the challenged tenders that you called out last quarter? Are those still being challenged? And do you expect that we'll see more of these?",27,"Okay. How about the challenged tenders that you called out last quarter? Are those still being challenged? And do you expect that we'll see more of these?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","They're still being challenged. [indiscernible] a little bit less this quarter than we had previously and the good news is as we saw a large percentage of them come to us, so that was good news on the quarter. That was some of the China growth was a catch",57,"They're still being challenged. [indiscernible] a little bit less this quarter than we had previously and the good news is as we saw a large percentage of them come to us, so that was good news on the quarter. That was some of the China growth was a catch up from that on the previous quarter."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then, Elisha, can you just break of the FX component to the guidance? In other words, how much did organic guidance change, if you back out the FX move?",30,"And then, Elisha, can you just break of the FX component to the guidance? In other words, how much did organic guidance change, if you back out the FX move?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","For the first time, Tycho, you did not hear me say currency headwinds in the script, which helped really good. So in the second quarter, it was minimal, maybe $0.01 or $0.02. As we move into Q3, the euro is exactly today where it was in the year-ago perio",69,"For the first time, Tycho, you did not hear me say currency headwinds in the script, which helped really good. So in the second quarter, it was minimal, maybe $0.01 or $0.02. As we move into Q3, the euro is exactly today where it was in the year-ago period. So it's going to be virtually not [indiscernible] in Q3 and Q4, assuming that rates hold where they are today."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Last one on Japan, Dow. I think you use the word slow but stabilizing. Again [indiscernible] talked about facility delays and new construction there, are you seeing any slippage for the new facility build out?",36,"Okay. Last one on Japan, Dow. I think you use the word slow but stabilizing. Again [indiscernible] talked about facility delays and new construction there, are you seeing any slippage for the new facility build out?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say, we're not seeing a slippage. We are seeing a contraction in the market. There's less government spending, but we're not seeing slippage. Maybe I'll come back to your first question just a bit on price. We did launch the VitalBeam product. And if",167,"I'd say, we're not seeing a slippage. We are seeing a contraction in the market. There's less government spending, but we're not seeing slippage. Maybe I'll come back to your first question just a bit on price. We did launch the VitalBeam product. And if that's priced right at or maybe even [indiscernible] of where it was landing, we're very excited to see its volume globally. Since the launch, we got 5[ph] orders with that product. And 36 of those came in the first half of this year. And it fills a midtier pricing market where, frankly, we have a coverage. But it's also enabled our TrueBeam pricing to move up a little bit. So we feel very good about where the product portfolio is and the pricing discipline that our team has. And frankly, that product, I mean, kind of backing to your comment, that product is a little bit aimed [indiscernible] as accurate. So I'm not sure what [indiscernible] on pricing challenges, I guess."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Jeff Johnson from Robert W. Baird.",11,"Our next question comes from Jeff Johnson from Robert W. Baird."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is Jason for Jeff. I just want to start on Europe, you had good growth in [indiscernible] and oncology business. There are actually companies that are bucking your trends here in the quarter in the capital equipment side in Europe. So just wonder if",71,"This is Jason for Jeff. I just want to start on Europe, you had good growth in [indiscernible] and oncology business. There are actually companies that are bucking your trends here in the quarter in the capital equipment side in Europe. So just wonder if you could discuss how you feel about the sustainability of the performance of that business, especially in light of [indiscernible] come up against the next quarters?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say this quarter was terrific. We love that we did have a couple of large orders. First of all, from the top, our orders, just to review, gross orders were up 19% in EMEA, 23% in constant currency. We did have a large multisite order from the Apollo g",266,"I'd say this quarter was terrific. We love that we did have a couple of large orders. First of all, from the top, our orders, just to review, gross orders were up 19% in EMEA, 23% in constant currency. We did have a large multisite order from the Apollo group in India and that was 11 TrueBeams, 1 EDGE and 5[ph] brachytherapy systems. We also had some major wins in the Middle East, which -- that was nice to see. I mean, I wouldn't say if that was anomalous that market's been kind of a little bit down with people dealing with oil price impact on federal budgets, the health care budgets. But that was nice to better see that come back. We had a very nice win in the U.K. And then I'd say, all across Europe, we had a very good mix of product, a little bit [indiscernible] of hardware mix and very good engagement of our software business in Europe. So I'd say, we're not going to the 20% every quarter, that's probably a little bit too much to ask. As it comes to the total, when you look at the overall market, last 12 months, our estimate is that it's 12 months constant currency growth rate, about 5%. At least kind of in the really big picture, that's kind of what we see going forward. We've clearly gained some market share the last 2, 3 years. And we're seeing that we're able to maintain that share and get a little price, which is kind of where our focus is right now."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, that's helpful. I just wanted to come back quickly on the FX side as it relates to guidance at least. How will you would expect a little bit upside, maybe the guidance given what FX has done here in the recent months. So is it fair to think that out",62,"Okay, that's helpful. I just wanted to come back quickly on the FX side as it relates to guidance at least. How will you would expect a little bit upside, maybe the guidance given what FX has done here in the recent months. So is it fair to think that outside FX, upside [indiscernible] offset by the weakness on the [indiscernible] business?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Look, we are taking somewhere call it $35 million or so out of top line for the year to come down by 1 point on the gross rate and maintaining EPS. And virtually, the currency impact is very, very small. This is -- our business is doing a fantastic job on",141,"Look, we are taking somewhere call it $35 million or so out of top line for the year to come down by 1 point on the gross rate and maintaining EPS. And virtually, the currency impact is very, very small. This is -- our business is doing a fantastic job on cost control. So the margin is coming in a little bit higher, and the gross margin level than we were expecting, which is great news due to pricing, due to MeVis software and our Imaging Components business grow about[ph] up maybe a point more than we were expecting in the second quarter. So as we anniversary now, currency is roughly neutral to us as we go into the second half of the year. And the business, we're just committed to offsetting that slight revenue mix by good cost control across-the-board."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Amit Hazan from Citi.",9,"Our next question comes from Amit Hazan from Citi."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is Lian for Amit. Quick question market on share gains, you guys have been talking a little bit more recently. Just wondering if you could give us what the drivers are that would drive incremental share right now versus where you guys were competitiv",52,"This is Lian for Amit. Quick question market on share gains, you guys have been talking a little bit more recently. Just wondering if you could give us what the drivers are that would drive incremental share right now versus where you guys were competitive last year over the last few years?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think our product line has never been better at every price point, we've got EDGE at the top. When you look at the ability to deliver those to small volumes, the ability to plan difficult treatments with an efficiency that nobody else can touch and the",321,"I think our product line has never been better at every price point, we've got EDGE at the top. When you look at the ability to deliver those to small volumes, the ability to plan difficult treatments with an efficiency that nobody else can touch and the speed of delivery at the high end, Gamma Knife or Cyber Knife can't touch us. When you look at the mid-tier of the market, our TrueBeam product is -- it is what everybody compares to. It is the gold standard of radiation therapy. And that's what we're seeing rich mix on there. And I think the other thing is both the high end and the mid-tier of the market as we've got the best total cost of ownership and the best through of anybody else out there. So that might be some of [indiscernible] problems is I don't know. But I think we are extremely competitive, but the total cost of ownership, especially when you look at our throughput advantages, we're far and away the most efficient product out there in terms of throughput and reliability. And we also have -- we've been focused very, very much the last few years on Net Promoter Score. And we believe when we measure this through independent groups, we believe we've got a significant lead in customer service. And then you add that to the VitalBeam launch that I just talked about. Our Eclipse and ARIA product lines recently both won the best-in-class award. We've that for a while in Eclipse. This was the first time for us in our ARIA oncology information system product. So I just think the strength of the product line is very, very good. On top of that, some of the vision that we shared with Astro around both our future around hardware and software is capturing the imagination of our customers for even better, stereotactic body radiation therapy and data analytics."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, great. And one follow-up...",5,"Okay, great. And one follow-up..."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Maybe one of the things to add there is that kind of the product side at the same time, you heard us talk 12, 15 months ago about a change to a new distribution organization. We've regionalized our distribution team and put it from a global sales organiza",92,"Maybe one of the things to add there is that kind of the product side at the same time, you heard us talk 12, 15 months ago about a change to a new distribution organization. We've regionalized our distribution team and put it from a global sales organization and cut it into 3 geographic structures. And I think that's [indiscernible] gotten as close to the customer. The decisions from Palo Alto, the MeVis field that made this part of this kind of improving Net Promoter Score and customer satisfaction and customer response."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, great. And then my follow-up is that we've been hearing some intuitive surgical as they've been reporting a fairly big revamp in volumes of several digits with sideline patients [indiscernible] post 2012 guideline changes. Is that coming up on your",57,"Okay, great. And then my follow-up is that we've been hearing some intuitive surgical as they've been reporting a fairly big revamp in volumes of several digits with sideline patients [indiscernible] post 2012 guideline changes. Is that coming up on your radar at all in terms of helping flow capacity or drive the interest to new system?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, I'd say when the watchful waiting guidelines went out in 2012, 2013, we did see -- our customers did see some drop off in their prostate volumes. I think it was back to where it was in 2012. I did not see the math that says that, but it's definite",56,"I mean, I'd say when the watchful waiting guidelines went out in 2012, 2013, we did see -- our customers did see some drop off in their prostate volumes. I think it was back to where it was in 2012. I did not see the math that says that, but it's definitely back up for sure."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from David Roman from Goldman Sachs.",10,"Our next question comes from David Roman from Goldman Sachs."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is actually Candace on for David. Just a quick question on the energy inside. Could you give a little more detail on the dynamic around customer inventory levels? And what's driving them to be elevated?",36,"This is actually Candace on for David. Just a quick question on the energy inside. Could you give a little more detail on the dynamic around customer inventory levels? And what's driving them to be elevated?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. We were just speaking in particular of our largest customer in that space. Toshiba has been out for 6 months[ph]. I think as part of that sale, their customers has probably gotten conservative up about seeing the transition happen. And so our demand",94,"Yes. We were just speaking in particular of our largest customer in that space. Toshiba has been out for 6 months[ph]. I think as part of that sale, their customers has probably gotten conservative up about seeing the transition happen. And so our demand is out there and their supply is up. So that's the driver. There's no -- that will bounce back we think. As the acquisition gets completed, they'll obviously, announce the sale to Canon. And I'd say otherwise, this business as usual in that shop. It's just 1 specific customer situation."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. So there's nothing further there and that's the only weakness, nothing beyond that consolidation?",15,"Okay. So there's nothing further there and that's the only weakness, nothing beyond that consolidation?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Right. That's the incremental fees, we talked a little bit about some of the other issues that businesses has had last year. But that's -- when you look at what we -- versus what we expected for this year, that would be the 1 slight miss of the year. It's",63,"Right. That's the incremental fees, we talked a little bit about some of the other issues that businesses has had last year. But that's -- when you look at what we -- versus what we expected for this year, that would be the 1 slight miss of the year. It's been volume in that business as they've gone through this change in strategy."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, that's very helpful. And then I know that you guys have talked about the impact of FX. But I was just curious about the indirect impact that you had spoken about on past calls. Could you maybe just shed some light on what your reception internationa",60,"Okay, that's very helpful. And then I know that you guys have talked about the impact of FX. But I was just curious about the indirect impact that you had spoken about on past calls. Could you maybe just shed some light on what your reception internationally has been? And if that's changed at all as the dollar has weakened."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No. I'd say when you look at it over 18 months, it's had a pretty significant impact. Elisha [indiscernible] the yen was down 20% and the euro was down 25%, is that about right?",34,"No. I'd say when you look at it over 18 months, it's had a pretty significant impact. Elisha [indiscernible] the yen was down 20% and the euro was down 25%, is that about right?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That is about right.",4,"That is about right."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Our competitors in this business are yen-based and euro-based. And rather taking this translation profit, they took the gift to pricing. So we worked very hard to maintain our share and I think we have. We're seeing those prices stabilize so that's good n",45,"Our competitors in this business are yen-based and euro-based. And rather taking this translation profit, they took the gift to pricing. So we worked very hard to maintain our share and I think we have. We're seeing those prices stabilize so that's good news."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And, Candace, I would just add. I mean, we've seen pricing stabilize in the Imaging Components business by product line. So we've largely anniversary-ed the impact, particularly as we get into Q3. But we're actually going to see some growth in the Imaging",62,"And, Candace, I would just add. I mean, we've seen pricing stabilize in the Imaging Components business by product line. So we've largely anniversary-ed the impact, particularly as we get into Q3. But we're actually going to see some growth in the Imaging Components business quarter-over-quarter, just not the level that we have first anticipated because of the issues we've talked about."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Steve Beuchaw from Morgan Stanley.",10,"Our next question comes from Steve Beuchaw from Morgan Stanley."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","It's actually Steve in for Steve. First question is, Elisha, on the seasonality in the model, the implied guide for the fourth quarter was a little bit more weight on earnings in the fourth quarter than normal. What is it about the model this year that's",60,"It's actually Steve in for Steve. First question is, Elisha, on the seasonality in the model, the implied guide for the fourth quarter was a little bit more weight on earnings in the fourth quarter than normal. What is it about the model this year that's a little different relative to, I don't know, last 3 years or so?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So a couple of things. First of all, FX we're going to completely anniversary the effect of FX at today's levels. So that take some pressure off. And in oncology, we're going to see a more linear year. Last year Q3, actually sequentially was down for onco",171,"So a couple of things. First of all, FX we're going to completely anniversary the effect of FX at today's levels. So that take some pressure off. And in oncology, we're going to see a more linear year. Last year Q3, actually sequentially was down for oncology. You're not going to see that for our expectations this quarter. So what you're seeing is really fluctuation mostly in our PT business. So if I look at the Q3 side, oncology should do high single-digit, we're going to have our Imaging Components, somewhere around the mid-single-digit. But we get a significant drop off in our Proton business because we booked Maryland in the year-ago period. So that's why you get to a 0% flat revenue. If you get into Q4, it's exactly the opposite, and our Proton business is going to grow significantly just based on the projects and the timing of revenue recognition under[ph] percentage of completion. So those are a few of the things that are different versus a year-ago period."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then sorry, if I missed this. But at this stage, [indiscernible] of the fiscal year, what would be for the full fiscal year the impact in pennies[ph] of currency at the bottom line?",35,"Okay. And then sorry, if I missed this. But at this stage, [indiscernible] of the fiscal year, what would be for the full fiscal year the impact in pennies[ph] of currency at the bottom line?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I would say, probably I'm going to say about $0.05, $0.06. I don't have it exactly, Steve. It was a little more in Q1 than in Q2. Q2 was only about $0.02 or so. Q3 should be roughly 0 at today's level.",42,"I would say, probably I'm going to say about $0.05, $0.06. I don't have it exactly, Steve. It was a little more in Q1 than in Q2. Q2 was only about $0.02 or so. Q3 should be roughly 0 at today's level."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","It's a nice thing, isn't it?",7,"It's a nice thing, isn't it?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, it is.",3,"Yes, it is."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then, Dow, just wanted to come back to your comments earlier on VitalBeam. Can you delve into just a bit more detail on the strategy for deploying in the U.S.? It puts in a position where obviously, high tier with TrueBeam and now mid-tier provider wi",78,"And then, Dow, just wanted to come back to your comments earlier on VitalBeam. Can you delve into just a bit more detail on the strategy for deploying in the U.S.? It puts in a position where obviously, high tier with TrueBeam and now mid-tier provider with VitalBeam. How do you think about segmenting the market? And how much more aggressive can you get in the rollout of VitalBeam? How much more push is in a plan there?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, we're very excited about the product. It's gone very well. I think the way the guys are using that a lot, the guys in the field are using it [indiscernible]. So often versus our competitors, it starts out in the canal waters from a pricing point o",317,"I mean, we're very excited about the product. It's gone very well. I think the way the guys are using that a lot, the guys in the field are using it [indiscernible]. So often versus our competitors, it starts out in the canal waters from a pricing point of view. And what we really want to do is we want to differentiate the TrueBeam and had so many, many significant advantages over everything else that's out there. And we've trained very hard on that. I think there's good discipline around it and we're seeing that in our numbers. From a product cost point of view, the team has also done a really great job getting the product cost out. So it's given us some flexibility to do that. So the margin dollars, margin percent at these price points are still pretty good. So we like that part of it. The -- I'd say, it might be a little bit ahead of our expectations in terms of its impact in the U.S., we thought we're having a little bit bigger impact outside of the U.S. And our team is just playing that through. So we do think we'll see some upside from the product outside of the U.S. It takes a little longer to train and the get into budget cycles and things like that. But it is -- for this market, in particular where we have an old install base that's looking to trade up and [indiscernible] chances are they're not depreciating the old asset anymore. It's been through its depreciation cycle. And they're looking how can they swap out that old stuff and get something new and competitive at a good price point that's just worked out very, very well. I think the proof is in the pudding in North America, the whole business was up 7% in the quarter. And our funnel remains pretty good."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And our next question comes from Toby Wann from Obsidian Research Group.",12,"And our next question comes from Toby Wann from Obsidian Research Group."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is [indiscernible] in for Toby. Can you guys talk quickly about the pipeline of potential new Particle Therapy business out there, [indiscernible] the healthy room?",26,"This is [indiscernible] in for Toby. Can you guys talk quickly about the pipeline of potential new Particle Therapy business out there, [indiscernible] the healthy room?"
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I never know what to say to this question. The short version is the pipeline of proton systems is gigantic. The pipeline for finance of Proton business is significantly smaller. I guess, what -- the good news is, as I mentioned, we've got 3 contracts that",218,"I never know what to say to this question. The short version is the pipeline of proton systems is gigantic. The pipeline for finance of Proton business is significantly smaller. I guess, what -- the good news is, as I mentioned, we've got 3 contracts that we signed for Compex[ph] this last quarter. We think they're all financeable. But we don't book them until they are in fact financed. And we've got a very good funnel that looks very strong. So we're optimistic about where it's going and it's global. It's not, this is not, I'd say, it's as much outside in the U.S. as it is in the U.S. at this point. So we like the global nature of it. I would say that one of the things that they like is we're seeing a little transition from a developer-driven market to more of that customer sovereign government Minister of Health kind of market, which has taken away some of these financing issues. And frankly, the other thing that's happening as the market is moving to smaller, smaller units. And so last year, we booked several 4- and 5-room systems and more of the market is in the 1, 2, 3 market, 1 or 2 [indiscernible] treatments vaults. And I think that's the trend that will continue."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And that's helpful. So you haven't really seen any global economic conditions unrest here, unrest there. Any impact, any changes in terms of the velocity of how people are thinking about, I guess, on the proton.",37,"And that's helpful. So you haven't really seen any global economic conditions unrest here, unrest there. Any impact, any changes in terms of the velocity of how people are thinking about, I guess, on the proton."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No, not at all. I think, one -- given that, one of the things that we really like is of the compact products in the market, ours is the only no-compromise compact product. And true scan beam, full rotational Gantry, highest throughput, most clinical capab",67,"No, not at all. I think, one -- given that, one of the things that we really like is of the compact products in the market, ours is the only no-compromise compact product. And true scan beam, full rotational Gantry, highest throughput, most clinical capability, it's really leveraged the advantage of Proton Therapy we need what we got. And I think that's beginning to resonate with customers."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","At this time, we have no further questions. I'll turn the call back over to Spencer Sias for closing comments.",20,"At this time, we have no further questions. I'll turn the call back over to Spencer Sias for closing comments."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Thank you for participating. The replay of this call can be heard on the Varian investor website at www.varian.com/investor where it will be archived for a year. To hear the telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or  1 (2",68,"Yes. Thank you for participating. The replay of this call can be heard on the Varian investor website at www.varian.com/investor where it will be archived for a year. To hear the telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or  1 (201) 612-7415 outside the U.S. and entering confirmation code 13632882. The telephone replay will be available 5:00 p.m. this Friday, April 29.
Thank you."
311907,328570774,964956,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation.",20,"Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems Second Quarter Fiscal Year 2016 Earnings Results Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Spencer Sias, Vice President of Investor Relations and Corporate C",48,"Greetings, and welcome to the Varian Medical Systems Second Quarter Fiscal Year 2016 Earnings Results Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Spencer Sias, Vice President of Investor Relations and Corporate Communications for Varian Medical Systems. Mr. Sias, you may now begin."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. First of all, quick apologies for the delay we had in getting the press release out, but we've got the gremlins solved. By now, I think you guys all have the material and we're very ready for the call.So good afternoon, and welcome to Varian",310,"Thank you. First of all, quick apologies for the delay we had in getting the press release out, but we've got the gremlins solved. By now, I think you guys all have the material and we're very ready for the call.
So good afternoon, and welcome to Varian Medical Systems conference call for the second quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. To simplify our discussion, unless otherwise stated, all references to the quarter or year are fiscal quarters and fiscal years. Quarterly comparisons are for the second quarter of fiscal 2016 versus the second quarter of fiscal 2015. References to financial results for orders are to gross orders unless otherwise indicated. The discussion include non-GAAP financial measures in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. A reconciliation to the most comparable GAAP measure is included in our earnings release which can be accessed on our website.
Please be advised that this discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, will, scheduled, feels like and similar expressions, are intended to identify those statements which represents our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks relating to our business are described in our second quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise.
And now here's Dow."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Varian is reporting solid results for the second quarter of fiscal year 2016 with strong order growth in our Oncology business, promising progress in our Particle Therapy business and expected weakness in our Imaging Component",944,"Good afternoon, and welcome. Varian is reporting solid results for the second quarter of fiscal year 2016 with strong order growth in our Oncology business, promising progress in our Particle Therapy business and expected weakness in our Imaging Components business.
In summary, we are reporting non-GAAP net earnings of $1.09 per diluted share and $1.01 per diluted share on a GAAP basis. Revenue of $759 million equal to the year-ago quarter in dollars and up 2% in constant currency. Strong orders in our Oncology business with growth and strategic wins in all 3 geographies, expected order and revenue declines in Imaging Components and good momentum in our Particle Therapy business with growing customer interest in our single-room system.
Focusing on operational highlights. In our Oncology business, gross orders totaled $618 million for the quarter, up 6% in dollars and 8% in constant currency. Gross orders in the Americas for the quarter increased by 2% in dollars and 3% in constant currency, with 7% growth in North America, offsetting a decline in Latin America.
In EMEA, gross orders were up 19% in dollars and 23% in constant currency helped by big wins in India and the Middle East. Gross orders in APAC rose 2% in dollars and 3% in constant currency, driven by robust growth in China.
Oncology experienced healthy global demand in the quarter with higher unit orders as well as gains in our service and software businesses.
Looking at each of the regions in more detail. Our gross order growth in North America was driven in part by demand for newer products, particularly our VitalBeam accelerator as well as our RapidPlan and InSightive Analytics software for improving clinical efficiency.
As you know, North America is largely a replacement market and in this quarter, we generated orders to replace several hardware and software products from competitors as well as our own units. As usual, there were some big wins in the quarter including a major order from MD Anderson for 6 TrueBeam systems. We also won a couple of large deals in Canada.
Orders in Latin America declined significantly from the year-ago quarter, as results of political uncertainty in Brazil and volatile currencies that slowed purchasing decisions.
During the quarter, we broke ground on a new 50,000 square foot facility in Brazil that will be used for training and product demos as well as product assembly and warehousing. This summer, we expect to complete the first few installations of the 80 machines handed by Brazil's Ministry of Health in 2014.
Turning to EMEA. We had a very good quarter with several sizable orders. The largest of these came in India where we received a multi-site order from the Apollo Hospital Group for 12 high-end linear accelerators and 5 brachytherapy systems. We also booked several orders in the Middle East, including systems for 4 new sites in Turkey.
We had a terrific quarter in China where more than 75% of the Varian linear accelerators ordered in the quarter were for new treatment vaults. Elsewhere in APAC, Japan remained slow, but appeared to be stabilizing.
We also had a key win at a large teaching hospital in Indonesia that we believe will position us for further growth in that important market.
We're pleased with the progress made in our software business during the quarter. Customer interest in RapidPlan continued to grow, and it is now installed at nearly 170 sites around the world.
We also received multiple orders in the quarter for InSightive Analytics, bringing total orders since its introduction earlier this fiscal year to 80.
We had another nice win at the Christie Hospital in Manchester, England, which ordered several software products, including Eclipse Treatment Planning for protons and our Velocity product that uses images to track tumor responses to treatment.
Turning to our Oncology Service business. Gross orders were up 11% in dollars and 12% in constant currency, with the help of higher capture rates, particularly in North America and China.
Looking now at Imaging Components' second quarter performance versus the year-ago quarter, orders fell by 12% to $138 million and revenue fell by 8% to $144 million, largely in line with our expectations. Beginning in the second half of last fiscal year, this business has been confronted with currency-related pricing pressures, weak market conditions for security and inspection products, in-sourcing by a large panel customer and uncertainties related to the sale of a major tube customer. We believe we have largely absorbed these challenges from the last 4 quarters, and we feel that the business is beginning to stabilize at these new levels.
Our new MeVis and Claymount businesses performed well in the quarter, and we continue to believe they will generate about $50 million in revenue this fiscal year. During the quarter, we opened a regional service center near Shanghai to support local x-ray equipment manufacturers across China. With the growing number of imaging equipment manufacturers in China, this is going to be an important growth area for our components business.
In our Particle Therapy business, we continued to make good progress with installations and recorded $31 million in revenue during the quarter. It was great to see patient treatments commence at the Maryland Proton Therapy Center in February. We are proud to collaborate with the center to bring our advanced cancer fighting technology to patients in that region.
In the quarter, we successfully extracted beam from the Cyclotron and Cincinnati Children's Hospital where patient treatments are scheduled to begin before the end of the year. We are also scheduled to begin installing equipment at sites in Holland, Russia and Saudi Arabia later this year.
Now I'll turn it over to Elisha."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog.We ended the quarter at $3.3 billion, up 6% from the year-ago period. Backlog adjustments during the quarter totaled $51 million bringing net orders for",584,"Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog.
We ended the quarter at $3.3 billion, up 6% from the year-ago period. Backlog adjustments during the quarter totaled $51 million bringing net orders for the company to $707 million. Second quarter revenues for the total company were about equal with the year-ago period in dollars and up 2% in constant currency. For the first half, total company revenues were up 1% in dollars and up 4% in constant currency.
Oncology posted a 1% decline in revenues and a 1% gain in constant currency during the second quarter. Imaging Components posted a second quarter revenue decline of 8%, with decreases in tubes, panels and Security and Inspection Products, partially offset by revenues from our new Claymount and MeVis businesses.
Our Particle Therapy business posted second quarter revenues of $31 million, more than double the year-ago period, as we continue to make progress on projects in backlog.
The total company gross margin for the quarter was 42%, down as expected by 0.5 point due to lower volumes in Imaging Components and a higher mix of Proton business. For the first half, total company gross margin was 41.6%, down almost 2 points from the year-ago period.
Oncology Systems second quarter gross margin improved 73 basis points to 43.7% due to product mix shift towards software and service, variable cost productivity and suspension of the medical device excise tax.
Imaging Components second quarter gross margin fell by a little more than 2 points to 41.4%, due largely to lower volumes.
Second quarter SG&A expenses were $112 million or 15% of revenue and R&D expenses were $62 million or about 8% of revenue, each equal as a percentage of revenue to the year-ago quarter. For the first half, SG&A expenses were 16% of revenue, and R&D was 8% of revenue, both also equal to the year-ago period.
Second quarter operating earnings totaled $145 million or 19.1% of revenue, down about 1 point as a percentage of revenue from the year-ago quarter and in line with our expectations. For the first half, operating margin at 18% of revenue was down about 1.5 points from the year-ago period.
Depreciation and amortization totaled $20 million for the second quarter and $38 million for the first half. The effective tax rate was 28.1%, virtually equal to the year-ago quarter. We continue to expect that the tax rate will be about 26% to 27% for the year.
Fully diluted shares outstanding of 96.2 million were almost 5 million lower than the year-ago quarter due to our ongoing share repurchase program. Diluted EPS was $1.09 for the quarter.
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $961 million, debt of $794 million and stockholders' equity of $1.7 billion. DSO at 109 days was up significantly from the year-ago quarter due to a lower mix of Imaging Components business, a higher mix of Proton business, more extended payment terms and slower collections for Oncology Systems.
Second quarter cash flow from operations was $32 million, bringing the total cash flow from operations for the first half to $109 million. Primary uses of cash were $19 million for CapEx and $57 million through the repurchase of 725,000 shares of stock. At the end of the quarter, we had 6 million shares remaining under the existing repurchase authorization that extends to calendar year 2016.
Now I'll turn it back to Dow for the outlook."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. Including the results of the second quarter, we continue to believe that total company non-GAAP earnings will be in the range of $4.55 to $4.65 per diluted share for fiscal year 2016. With expectations of a slower-than-anticipated recovery",141,"Thanks, Elisha. Including the results of the second quarter, we continue to believe that total company non-GAAP earnings will be in the range of $4.55 to $4.65 per diluted share for fiscal year 2016. With expectations of a slower-than-anticipated recovery in our Imaging Components business due to high inventory levels at a major customer, we now believe revenues for fiscal year 2016 will increase by about 3% over fiscal year 2015.
For the third quarter of fiscal year 2016, we expect non-GAAP earnings to be in the range of $1.16 to $1.20 per diluted share. We expect third quarter revenues to be about equal to the year-ago period with growth in our core businesses offset by a decline in our Proton business versus the year-ago quarter when we booked the big University of Maryland project.
We're now ready for your questions."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] Our first question comes from Jason Wittes from Brean Capital.",12,"[Operator Instructions] Our first question comes from Jason Wittes from Brean Capital."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So I guess, I'll start with -- we usually start with oncology, but I will start with imaging. You seem -- you mentioned -- you made some comments about the stability of the business. It seems like the only thing that's really sort of dragging and leading",90,"So I guess, I'll start with -- we usually start with oncology, but I will start with imaging. You seem -- you mentioned -- you made some comments about the stability of the business. It seems like the only thing that's really sort of dragging and leading to the lower outlook for the year is the destocking. I assume that's with the Toshiba transfer to, I think, Canon. Is there anything else out there? I mean, is that the main drag on the business at this point or is it..."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, I mean, I think that is the main drag. I mean, I talked a little bit about the constant currency issues, that's only stabilizing [indiscernible]. We've had some of the price issues that's gone along with that. We see that stabilizing. We had a major",130,"Yes, I mean, I think that is the main drag. I mean, I talked a little bit about the constant currency issues, that's only stabilizing [indiscernible]. We've had some of the price issues that's gone along with that. We see that stabilizing. We had a major flat panel customer in-sourced. We've still got a little bit of impact to that, but that should be largely anniversary-ed by Q4. And then it's really the sale that you mentioned that's been going on has caused some short-term volume issues at Toshiba. Clearly, they're managing for working capital in the short term. I think when we look at the rest of our customer base, we're seeing very solid customer demand. And we think that business will turn around here in the second half."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Two related questions and only because I think people want to get comfortable with the imaging business. And that is, I think in the past you made comments that about half of the business as it stands, I think, at year-end '15, fiscal '15, was kind",81,"Okay. Two related questions and only because I think people want to get comfortable with the imaging business. And that is, I think in the past you made comments that about half of the business as it stands, I think, at year-end '15, fiscal '15, was kind of commodity like and somewhat at-risk. It sounds to me like you feel that, that has stabilized in terms of the risk of that business. Is that the right way to think about it?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I mean the short version is when you go customer by customer, our demand has really been very solid. And I think this conversation came up in regards to some of the flat panel technology and how easy or difficult it might be for people to switch sup",87,"Well, I mean the short version is when you go customer by customer, our demand has really been very solid. And I think this conversation came up in regards to some of the flat panel technology and how easy or difficult it might be for people to switch suppliers in flat panel technology. In some areas of the detector business, that it is a little bit easier to switch suppliers. In the tube business, that remains -- that can be done, but it still remains very difficult."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then In terms of Toshiba moving to Canon or that business being bought by Canon, is that -- can you kind of give an outlook in terms of discussion you've had and how that might change the outlook for that piece of the business? Because they were",51,"Okay. And then In terms of Toshiba moving to Canon or that business being bought by Canon, is that -- can you kind of give an outlook in terms of discussion you've had and how that might change the outlook for that piece of the business? Because they were. . ."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, sure. Yes, absolutely. The sale to Canon is still closing, first of all. And what we hear is the Toshiba team is staying on. We have very good relationship with them, and that gives us some optimism. And there clearly is going to be some cautious pur",83,"Yes, sure. Yes, absolutely. The sale to Canon is still closing, first of all. And what we hear is the Toshiba team is staying on. We have very good relationship with them, and that gives us some optimism. And there clearly is going to be some cautious purchasing and inventory management in the short term from a competitive product point of view. Our biggest business there by far is the 2 business that we sell to Toshiba and Canon doesn't make any tubes."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And last question, I just wanted -- you mentioned on Proton, interest in your single-room offering. Can you just give us little more details around that in terms of what the pricing is and et cetera?",37,"Okay. And last question, I just wanted -- you mentioned on Proton, interest in your single-room offering. Can you just give us little more details around that in terms of what the pricing is and et cetera?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, there is -- I mean, first of all, there's lots of interest. So the kind of our funnel of activity is very large, so that's good. In the quarter, we did have 3 contract decisions. One of those, in fact, issued a press release [indiscernible] in Florid",97,"Yes, there is -- I mean, first of all, there's lots of interest. So the kind of our funnel of activity is very large, so that's good. In the quarter, we did have 3 contract decisions. One of those, in fact, issued a press release [indiscernible] in Florida. The 3 of them all have a contingency of one form or another, 2 are financing and 1 is some permitting. So with a little luck, we'll clear those contingencies on 1 or 2 of them this year. And if everything goes our way, maybe we'll get all 3."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Vijay Kumar from Evercore.",9,"Our next question comes from Vijay Kumar from Evercore."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is Scott in for Vijay. I just had a question in terms of when you're talking about building up a facility in China, I was curious since you mentioned this is a growth area, what are your guys thinking in terms of where is the growth coming from? And",57,"This is Scott in for Vijay. I just had a question in terms of when you're talking about building up a facility in China, I was curious since you mentioned this is a growth area, what are your guys thinking in terms of where is the growth coming from? And what's the interest and drivers behind that?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, there's just -- there's a lot activity in China in the radiology area. So there's some very large customers, I'd say there's 3 or 4 emerging large manufacturers of radiology equipment in China. And there's another list of 15 to 20 smaller supplier",128,"I mean, there's just -- there's a lot activity in China in the radiology area. So there's some very large customers, I'd say there's 3 or 4 emerging large manufacturers of radiology equipment in China. And there's another list of 15 to 20 smaller suppliers, and it's a very active radiology market for locally sourced products in China. So we are not -- we do support Toshiba's global effort in particular. But the big radiology companies, at least in CT and kind of high-end X-ray, they manufacture their own tubes. So we're not supplying them in that market. This is really development at the local Chinese market. Our Chinese customers are looking for local service capability, fast turnaround on spares and -- anyway, it's a very active market."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then back to the follow-up on the China market. We've seen for, I guess, other industries like diagnostics, there's been auditing on large capital equipment purchasing. Do you see if there's any sort of headwind? Or is this not really been an issue fo",48,"And then back to the follow-up on the China market. We've seen for, I guess, other industries like diagnostics, there's been auditing on large capital equipment purchasing. Do you see if there's any sort of headwind? Or is this not really been an issue for you guys?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think, I mean, that's been an issue for us for the last 2, 2.5 years, I wouldn't say it's any worse. And In fact, in our Oncology business this quarter in China, we had a very, very good quarter, very strong double-digit growth in China. And what we wer",82,"I think, I mean, that's been an issue for us for the last 2, 2.5 years, I wouldn't say it's any worse. And In fact, in our Oncology business this quarter in China, we had a very, very good quarter, very strong double-digit growth in China. And what we were particularly pleased about is over 3/4 of the units were in new vaults, new bunkers. So -- and our funnel in China looks really good. So we remain very bullish about China."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Tycho Peterson from JPMorgan.",9,"Our next question comes from Tycho Peterson from JPMorgan."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Dow, maybe just to start, I'm wondering if you can touch on competitive dynamics in the market. Accuray last night talked about a little bit more pricing pressure in the single and dual vault market in the U.S. I know you announced the MD Anderson order,",77,"Dow, maybe just to start, I'm wondering if you can touch on competitive dynamics in the market. Accuray last night talked about a little bit more pricing pressure in the single and dual vault market in the U.S. I know you announced the MD Anderson order, but Elekta got in there as well. So just wondering to the degree that pricing is becoming more of an issue in the market, if you can touch on that dynamic?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I would say for us, pricing was not at all an issue in the market. Especially here in the U.S. market, our prices are up. And our volume is very, very good. I mean, as you saw, we had 7% growth in U.S. and Canada on the quarter. That's got to be one of th",97,"I would say for us, pricing was not at all an issue in the market. Especially here in the U.S. market, our prices are up. And our volume is very, very good. I mean, as you saw, we had 7% growth in U.S. and Canada on the quarter. That's got to be one of the best quarters we've had in the U.S. in a long time. And our pricing looks very, very good. So I mean, you may have heard me say, I think their product was way overpriced. So I'm not surprised I've got pricing problems."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. How about the challenged tenders that you called that out last quarter? Are those still being challenged? And do you expect that we'll see more of these?",28,"Okay. How about the challenged tenders that you called that out last quarter? Are those still being challenged? And do you expect that we'll see more of these?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","They're still being challenged. Let's say, we saw a little bit less this quarter than we had previously and the good news is as we saw a large percentage of them come to us, so that was good news on the quarter. And that will sum up the China -- sum up th",66,"They're still being challenged. Let's say, we saw a little bit less this quarter than we had previously and the good news is as we saw a large percentage of them come to us, so that was good news on the quarter. And that will sum up the China -- sum up the China growth with the catch up on that from the previous quarter."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then, for Elisha, can you just break out the FX component to the guidance? In other words, how much did organic guidance change, if we back out the FX move?",31,"And then, for Elisha, can you just break out the FX component to the guidance? In other words, how much did organic guidance change, if we back out the FX move?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","For the first time, Tycho, you did not hear me say currency headwinds in the script, which felt really good. So in the second quarter, it was minimal, maybe $0.01 or $0.02. As we move into Q3, the euro is exactly today where it was in the year-ago period.",68,"For the first time, Tycho, you did not hear me say currency headwinds in the script, which felt really good. So in the second quarter, it was minimal, maybe $0.01 or $0.02. As we move into Q3, the euro is exactly today where it was in the year-ago period. So it's going to be virtually nonexistent in Q3 and Q4, assuming that rates hold where they are today."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then last one on Japan, Dow. I think you used the word slow, but stabilizing. Again, last night, Accuray, I think, talked about facility delays and new construction there. Are you seeing any slippage in terms of new facility buildout?",42,"Okay. And then last one on Japan, Dow. I think you used the word slow, but stabilizing. Again, last night, Accuray, I think, talked about facility delays and new construction there. Are you seeing any slippage in terms of new facility buildout?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say, we're not seeing a slippage. We have seen a contraction in the market. There's less government spending, but we're not seeing slippage. Maybe I'll just come back to your first question, just a little bit on price. We did launch the VitalBeam prod",181,"I'd say, we're not seeing a slippage. We have seen a contraction in the market. There's less government spending, but we're not seeing slippage. Maybe I'll just come back to your first question, just a little bit on price. We did launch the VitalBeam product. And it's priced right at or maybe even a hair north of where we thought it was landing. We were very excited to see its volume globally. Since the launch, we've taken 45 orders of that product. And 36 of those came in the first half of this year. And it fills a mid-tier pricing market where, frankly, we haven't had coverage. But it's also enabled our TrueBeam pricing to move up a little bit. So we feel very good about where the product portfolio is and the pricing discipline that our team has. And frankly, that product, I mean, coming back to your Accuray comment, that product's a little bit more aimed at Elekta than it is Accuray. So I'm not sure what -- let's talk to Josh about his pricing challenges, I guess."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Jeff Johnson from Robert W. Baird.",11,"Our next question comes from Jeff Johnson from Robert W. Baird."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is actually Jason on for Jeff. Just wanted to start on Europe. You had some very good growth out of your European oncology business. You seemed to be actually one of the companies that are bucking the trend here in the quarter in the capital equipmen",91,"This is actually Jason on for Jeff. Just wanted to start on Europe. You had some very good growth out of your European oncology business. You seemed to be actually one of the companies that are bucking the trend here in the quarter in the capital equipment side in Europe. So just wonder if you could discuss how you feel about the sustainability of the performance of that business, especially in light of what are some tougher comps that are going to be coming up against you in the next quarters?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say the quarter was terrific. And we love that we did have a couple of large orders. First of all, from the top, our orders, just to review, gross orders were up 19% in EMEA, 23% in constant currency. We did have a large multisite order from the Apoll",268,"I'd say the quarter was terrific. And we love that we did have a couple of large orders. First of all, from the top, our orders, just to review, gross orders were up 19% in EMEA, 23% in constant currency. We did have a large multisite order from the Apollo group in India, and that was 11 TrueBeams, 1 EDGE and 5 brachytherapy systems. We also had some major wins in the Middle East, which -- that was nice to see. I mean, I wouldn't say if that was anomalous. That market's been kind of a little bit down with people dealing with oil price impact on federal budgets, health care budgets. But that was nice to kind of see that come back. We had a very nice win in the U.K. And then I'd say, all across Europe, we had a very good mix of product, a little bit richer hardware mix and very good engagement of our software business in Europe. So I'd say, we're not going to do 20% every quarter, that's probably a little bit too much to ask. As it comes to the total, when you look at the overall market, last 12 months, our estimate is that it's 12 months constant currency growth rate at about 5%. And at least kind of in that really big picture, that's kind of what we see going forward. We've clearly gained some market share the last 2, 3 years. And we're seeing that we're able to maintain that share and get a little price, which is kind of where our focus is right now."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, that's helpful. And then just wanted to come back quickly on the FX side as it relates to guidance. At least your -- we'd expected actually a little bit of upside maybe to guidance given what FX has done here in the recent months. So is it fair to t",68,"Okay, that's helpful. And then just wanted to come back quickly on the FX side as it relates to guidance. At least your -- we'd expected actually a little bit of upside maybe to guidance given what FX has done here in the recent months. So is it fair to think that all that FX upside has basically just been offset by the weakness on the ICB business?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Look, we are taking somewhere, call it $35 million or so out of top line for the year to come down by 1 point on the gross rate and maintaining EPS. And virtually, the currency impact is very, very small. This is -- our business is doing a fantastic job o",143,"Look, we are taking somewhere, call it $35 million or so out of top line for the year to come down by 1 point on the gross rate and maintaining EPS. And virtually, the currency impact is very, very small. This is -- our business is doing a fantastic job on cost control. So the margin is coming in a little bit higher of the gross margin level than we were expecting, which is great news due to pricing due to MeVis software, and our Imaging Components business drove that up maybe a point more than we were expecting in the second quarter. So as we anniversary now, currency is roughly neutral to us as we go into the second half of the year. And the business, we're just committed to offsetting that slight revenue mix by good cost control across the board."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Amit Hazan from Citi.",9,"Our next question comes from Amit Hazan from Citi."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is actually Leon [ph] for Amit. Quick question about market share gains. You guys have been talking just a little bit more recently. Just hoping you can give us what you think the drivers are that would drive incremental share right now versus where",58,"This is actually Leon [ph] for Amit. Quick question about market share gains. You guys have been talking just a little bit more recently. Just hoping you can give us what you think the drivers are that would drive incremental share right now versus where you guys stood competitive during last year or over the last few years?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think our product line has never been better at every price point. We've got EDGE at the top. When you look at the ability to deliver dose to small volumes, the ability to plan difficult treatments with an efficiency that nobody else can touch and the s",327,"I think our product line has never been better at every price point. We've got EDGE at the top. When you look at the ability to deliver dose to small volumes, the ability to plan difficult treatments with an efficiency that nobody else can touch and the speed of delivery at the high end. Gamma Knife or Cyber Knife can't touch us. When you look at the mid-tier of the market, our TrueBeam product is -- it is what everybody compares to. It is the gold standard of radiation therapy. And that's -- we're seeing a rich in mix on there. I think the other thing at both the high end and the mid-tier of the market is we've got the best total cost of ownership and the best throughput of anybody else out there. So that might be some of Accuray's problems is, I don't know. But I think we are extremely competitive, but the total cost of ownership, especially when you look at our throughput advantages, we're far and away the most efficient product out there in terms of throughput and reliability. And we also have -- we've been focused very, very much the last few years on Net Promoter Score. And we believe -- when we measure this through independent groups, we believe that we've got a significant lead in customer service. And then you add that with our -- the VitalBeam launch that I just talked about. Our Eclipse and ARIA product lines recently both won the best-in-class award. So we've that for a while in Eclipse. This was the first time for us in our ARIA oncology information system product. So I just think the strength of the product line is very, very good. On top of that, some of the vision that we shared at ASTRO around both our future around hardware and software is capturing the imagination of our customers for even better, stereotactic body radiation therapy and data analytics."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, great. And then one follow-up with...",7,"Okay, great. And then one follow-up with..."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Maybe one of the thing to add there is that's kind of the product side of it. At the same time, you heard us talk 12, 15 months ago about a change to a new distribution organization. And we regionalized our distribution team and took it from a global sale",105,"Maybe one of the thing to add there is that's kind of the product side of it. At the same time, you heard us talk 12, 15 months ago about a change to a new distribution organization. And we regionalized our distribution team and took it from a global sales organization and cut it into 3 geographic structures. And I think that's a nice difference. It's gotten us close to the customer. Decisions don't have to come to Palo Alto. They're made in the field, and [indiscernible] made this part of this kind of improving Net Promoter Score and customer satisfaction and customer response."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, great. And then my follow-up is that we've been hearing from Intuitive Surgical and they've been reporting a fairly big rebound in [indiscernible] volumes and that's about several digits with sidelined patients tossed between that back post 2012 gui",63,"Okay, great. And then my follow-up is that we've been hearing from Intuitive Surgical and they've been reporting a fairly big rebound in [indiscernible] volumes and that's about several digits with sidelined patients tossed between that back post 2012 guideline changes. Is that [indiscernible] coming up on your radar at all in terms of helping flow capacity or drive interest in these systems?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, I'd say when the watchful waiting guidelines went out in 2012, 2013, we did see -- our customers did see some dropoff in their prostate volumes. I think, is it back to where it was in 2012? I hadn't seen any math that says that, but it's definitel",54,"I mean, I'd say when the watchful waiting guidelines went out in 2012, 2013, we did see -- our customers did see some dropoff in their prostate volumes. I think, is it back to where it was in 2012? I hadn't seen any math that says that, but it's definitely back up for sure."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from David Roman from Goldman Sachs.",10,"Our next question comes from David Roman from Goldman Sachs."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is actually Candace on for David. Just a quick question on the energy inside. Could you give a little more detail on the dynamic around customer inventory levels? And what's driving them to be elevated?",36,"This is actually Candace on for David. Just a quick question on the energy inside. Could you give a little more detail on the dynamic around customer inventory levels? And what's driving them to be elevated?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. We were just speaking in particular of our largest customer in that space. Toshiba has been out [indiscernible]. I think as part of that sale, their customers have probably gotten conservative about seeing the transition happen. And so our demand is",91,"Yes. We were just speaking in particular of our largest customer in that space. Toshiba has been out [indiscernible]. I think as part of that sale, their customers have probably gotten conservative about seeing the transition happen. And so our demand is off there, and their supply is up. So that's the driver. There's no -- that will bounce back we think. As the acquisition gets completed, they've obviously announced the sale to Canon. And I'd say otherwise, its business as usual in that shop. It's just one specific customer situation."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. So there's nothing further there and that's the only weakness, nothing beyond that consolidation?",15,"Okay. So there's nothing further there and that's the only weakness, nothing beyond that consolidation?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Right. That's the incremental fees. I mean, we talked a little bit about some of the other issues that business has had last year. But that's -- when you look at what we -- versus what we expected for this year, that would be the one slight miss to the ye",65,"Right. That's the incremental fees. I mean, we talked a little bit about some of the other issues that business has had last year. But that's -- when you look at what we -- versus what we expected for this year, that would be the one slight miss to the year has been volume in that business, as they've gone through this change in strategy."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, that's very helpful. And then I know that you guys have talked about the impact of FX. But I was just curious about the indirect impact that you had spoken about on past calls. Could you maybe just shed some light on what your reception internationa",60,"Okay, that's very helpful. And then I know that you guys have talked about the impact of FX. But I was just curious about the indirect impact that you had spoken about on past calls. Could you maybe just shed some light on what your reception internationally has been? And if that's changed at all as the dollar has weakened."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No. I'd say when you look at it over 18 months, it's had a pretty significant impact. Elisha fixed this. I'm going to say the yen was down 20% and the euro was down 25%. Is that about right?",39,"No. I'd say when you look at it over 18 months, it's had a pretty significant impact. Elisha fixed this. I'm going to say the yen was down 20% and the euro was down 25%. Is that about right?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That is about right.",4,"That is about right."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And our competitors in this business are yen-based and euro-based. And rather taking it to translation profits, they took the gift to pricing. So we worked very hard to maintain our share and I think we have. We're seeing those prices stabilize so that's",47,"And our competitors in this business are yen-based and euro-based. And rather taking it to translation profits, they took the gift to pricing. So we worked very hard to maintain our share and I think we have. We're seeing those prices stabilize so that's good news."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And Candace, I would just add. I mean, we've seen pricing stabilize in the Imaging Components business by product line. So we've largely anniversary-ed the impact, particularly as we get into Q3. But we're actually going to see some growth in the Imaging",63,"And Candace, I would just add. I mean, we've seen pricing stabilize in the Imaging Components business by product line. So we've largely anniversary-ed the impact, particularly as we get into Q3. But we're actually going to see some growth in the Imaging Components business quarter-over-quarter, just not to the level that we had first anticipated because of the issues we've talked about."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Steve Beuchaw from Morgan Stanley.",10,"Our next question comes from Steve Beuchaw from Morgan Stanley."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","It's actually Steve in for Steve. First question is, Elisha, on the seasonality in the model, the implied guide for the fourth quarter puts a little bit more weight on earnings in the fourth quarter than normal. What is it about the model this year that's",61,"It's actually Steve in for Steve. First question is, Elisha, on the seasonality in the model, the implied guide for the fourth quarter puts a little bit more weight on earnings in the fourth quarter than normal. What is it about the model this year that's a little different relative to the last, I don't know, 3 years or so?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, so a couple of things. First of all, FX, we're going to completely anniversary the effect of FX at today's levels. So that takes some pressure off. And in oncology, we're going to see a more linear year. Last year Q3, actually sequentially was down f",175,"Yes, so a couple of things. First of all, FX, we're going to completely anniversary the effect of FX at today's levels. So that takes some pressure off. And in oncology, we're going to see a more linear year. Last year Q3, actually sequentially was down for oncology. You're not going to see that for our expectations this quarter. So what you're seeing is really some fluctuations, mostly in our PT business. So if I look at Q3 guidance, oncology should do high single digit. We're going to have our Imaging Components somewhere around the mid-single digit. But we get a significant drop off in our Proton business because we booked Maryland in the year-ago period. So that's why you get to a 0% flat revenue. If you get into Q4, it's exactly the opposite, and our Proton business is going to grow significantly just based on the projects and the timing of revenue recognition and the percentage of completion. So those are a few of the things that are different versus a year-ago period."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then sorry, if I missed this. But at this stage, halfway through the fiscal year, what would be, for the full fiscal year, the impact in pennies, I suppose, of currency at the bottom line?",37,"Okay. And then sorry, if I missed this. But at this stage, halfway through the fiscal year, what would be, for the full fiscal year, the impact in pennies, I suppose, of currency at the bottom line?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I would say, probably I'm going to say about $0.05, $0.06. I don't have it exactly, Steve. It was a little more in Q1 than in Q2. Q2 was only about $0.02 or so. Q3 should be roughly 0 at today's level.",42,"I would say, probably I'm going to say about $0.05, $0.06. I don't have it exactly, Steve. It was a little more in Q1 than in Q2. Q2 was only about $0.02 or so. Q3 should be roughly 0 at today's level."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","It's a nice thing, isn't it?",7,"It's a nice thing, isn't it?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, it is.",3,"Yes, it is."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then, Dow, I just wanted to come back to your comments earlier on VitalBeam. Can you go into just a bit more detail on the strategy for deploying it in the U.S.? It puts you in a position where you're obviously, high tier with TrueBeam and now mid-tie",82,"And then, Dow, I just wanted to come back to your comments earlier on VitalBeam. Can you go into just a bit more detail on the strategy for deploying it in the U.S.? It puts you in a position where you're obviously, high tier with TrueBeam and now mid-tier provider with VitalBeam. How do you think about segmenting the market? And how much more aggressive can you get in the rollout of VitalBeam? How much more push is in the plan there?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, we're very excited about the product. It's gone very well. I think the way the guys are using it a lot, the guys and girls in the field are using it. It's really to sell up. So often versus our competitors, it starts out in the canal water from a",335,"I mean, we're very excited about the product. It's gone very well. I think the way the guys are using it a lot, the guys and girls in the field are using it. It's really to sell up. So often versus our competitors, it starts out in the canal water from a pricing point of view. And what we really want to do is we want to differentiate the TrueBeam and as you know, it has many, many significant advantages over everything else that's out there. And we've trained very hard on that. I think there's good discipline around it and we're seeing that in our numbers. From a product cost point of view, the team has also done a really great job getting the product cost out. So it's given us some flexibility to do that. So the margin dollars, margin percent at these price points are still pretty good. So we like that part of it. The -- I'd say, we're -- it might be a little bit ahead of our expectations in terms of its impact in the U.S. We thought we'd have a little bit bigger impact outside of the U.S. And our team is just playing in that, true. So we do think we'll see some upside from the product outside of the U.S. It typically takes us a little longer to train and get it into budget cycles and things like that. But it is -- for this market, in particular where we have an old install base that's looking to trade up and how can they --  chances are, they're not depreciating the old asset anymore. It's been through its depreciation cycle. And they're looking to how can they swap out that old stuff and get something new and competitive at a good price point that's just worked out very, very well. I think the proof is in the pudding in North America, the whole business was up 7% in the quarter. And our funnel remains pretty good."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And our next question comes from Toby Wann from Obsidian Research Group.",12,"And our next question comes from Toby Wann from Obsidian Research Group."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Steve [indiscernible] and I will be on for Toby. Can you guys kind of  talk quickly about the pipeline of potential new Particle Therapy business out there with, I guess, multi-room systems?",32,"Steve [indiscernible] and I will be on for Toby. Can you guys kind of  talk quickly about the pipeline of potential new Particle Therapy business out there with, I guess, multi-room systems?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I never know what to say to this question. The short version is the pipeline of Proton systems is gigantic. The pipeline for financeable Proton systems is significantly smaller. And I guess, what -- the good news is, as I mentioned, we've got 3 contracts",219,"I never know what to say to this question. The short version is the pipeline of Proton systems is gigantic. The pipeline for financeable Proton systems is significantly smaller. And I guess, what -- the good news is, as I mentioned, we've got 3 contracts that we signed for Compact this last quarter. We think they're all financeable. But we don't book them until they are in fact financed. And we've got a very good funnel that looks very strong. So we're optimistic about where it's going, and it's global. It's not -- this is not, I'd say, it's just as much outside of the U.S. as it is in the U.S. at this point. So we like the global nature of it. I would say that one of the other things that we like is we're seeing a little transition from a developer-driven market to more of a customer sovereign government Minister of Health kind of market, which has taken away some of these financing issues. And frankly, the other thing that's happening is the market is moving to smaller, smaller units. So last year, we booked several 4- and 5-room systems. More of the market is in the 1, 2, 3 market, 1 or 2 treatment vaults now. And I think that's a trend that will continue."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Great. That's helpful. So I guess, you haven't really seen any given kind of global economic conditions, unrest here, unrest there. Any impact, any changes in terms of the velocity of how people are thinking about getting the Proton?",39,"Great. That's helpful. So I guess, you haven't really seen any given kind of global economic conditions, unrest here, unrest there. Any impact, any changes in terms of the velocity of how people are thinking about getting the Proton?"
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No, not at all. I think, one -- given that, one of the things that we really like is of the compact products in the market, ours is the only no-compromise compact product. And a true scan beam, full rotational Gantry, highest throughput, most clinical cap",69,"No, not at all. I think, one -- given that, one of the things that we really like is of the compact products in the market, ours is the only no-compromise compact product. And a true scan beam, full rotational Gantry, highest throughput, most clinical capability, to really leverage the physics advantage of Proton Therapy, you need what we got. And I think that's beginning to resonate with customers."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","At this time, we have no further questions. I will turn the call back over to the speakers for closing comments.",21,"At this time, we have no further questions. I will turn the call back over to the speakers for closing comments."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Thank you for participating. A replay of this call can be heard on the Varian investor website at www.varian.com/investor where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or  1 (201)",70,"Yes. Thank you for participating. A replay of this call can be heard on the Varian investor website at www.varian.com/investor where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or  1 (201) 612-7415 from outside the U.S. and entering confirmation code 13632882. The telephone replay will be available through 5:00 p.m. this Friday, April 29.
Thank you."
311907,328570774,965192,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation.",20,"Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems Second Quarter Fiscal Year 2016 Earnings Results Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Spencer Sias, Vice President of Investor Relations and Corporate C",48,"Greetings, and welcome to the Varian Medical Systems Second Quarter Fiscal Year 2016 Earnings Results Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Spencer Sias, Vice President of Investor Relations and Corporate Communications for Varian Medical Systems. Mr. Sias, you may now begin."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. First of all, quick apologies for the delay we had in getting the press release out, but we've got the gremlins solved. By now, I think you guys all have the material and we're very ready for the call.So good afternoon, and welcome to Varian",310,"Thank you. First of all, quick apologies for the delay we had in getting the press release out, but we've got the gremlins solved. By now, I think you guys all have the material and we're very ready for the call.
So good afternoon, and welcome to Varian Medical Systems conference call for the second quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. To simplify our discussion, unless otherwise stated, all references to the quarter or year are fiscal quarters and fiscal years. Quarterly comparisons are for the second quarter of fiscal 2016 versus the second quarter of fiscal 2015. References to financial results for orders are to gross orders unless otherwise indicated. The discussion includes non-GAAP financial measures in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. A reconciliation to the most comparable GAAP measure is included in our earnings release which can be accessed on our website.
Please be advised that this discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, will, scheduled, feels like and similar expressions, are intended to identify those statements which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks relating to our business are described in our second quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise.
And now here's Dow."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Varian is reporting solid results for the second quarter of fiscal year 2016 with strong order growth in our Oncology business, promising progress in our Particle Therapy business and expected weakness in our Imaging Component",944,"Good afternoon, and welcome. Varian is reporting solid results for the second quarter of fiscal year 2016 with strong order growth in our Oncology business, promising progress in our Particle Therapy business and expected weakness in our Imaging Components business.
In summary, we are reporting non-GAAP net earnings of $1.09 per diluted share and $1.01 per diluted share on a GAAP basis. Revenue of $759 million equal to the year-ago quarter in dollars and up 2% in constant currency. Strong orders in our Oncology business with growth and strategic wins in all 3 geographies, expected order and revenue declines in Imaging Components and good momentum in our Particle Therapy business with growing customer interest in our single-room system.
Focusing on operational highlights. In our Oncology business, gross orders totaled $618 million for the quarter, up 6% in dollars and 8% in constant currency. Gross orders in the Americas for the quarter increased by 2% in dollars and 3% in constant currency, with 7% growth in North America, offsetting a decline in Latin America.
In EMEA, gross orders were up 19% in dollars and 23% in constant currency helped by big wins in India and the Middle East. Gross orders in APAC rose 2% in dollars and 3% in constant currency, driven by robust growth in China.
Oncology experienced healthy global demand in the quarter with higher unit orders as well as gains in our service and software businesses.
Looking at each of the regions in more detail. Our gross order growth in North America was driven in part by demand for newer products, particularly our VitalBeam accelerator as well as our RapidPlan and InSightive Analytics software for improving clinical efficiency.
As you know, North America is largely a replacement market and in this quarter, we generated orders to replace several hardware and software products from competitors as well as our own units. As usual, there were some big wins in the quarter including a major order from MD Anderson for 6 TrueBeam systems. We also won a couple of large deals in Canada.
Orders in Latin America declined significantly from the year-ago quarter, as results of political uncertainty in Brazil and volatile currencies that slowed purchasing decisions.
During the quarter, we broke ground on a new 50,000 square foot facility in Brazil that will be used for training and product demos as well as product assembly and warehousing. This summer, we expect to complete the first few installations of the 80 machines tended by Brazil's Ministry of Health in 2014.
Turning to EMEA. We had a very good quarter with several sizable orders. The largest of these came in India where we received a multi-site order from the Apollo Hospital Group for 12 high-end linear accelerators and 5 brachytherapy systems. We also booked several orders in the Middle East, including systems for 4 new sites in Turkey.
We had a terrific quarter in China where more than 75% of the Varian linear accelerators ordered in the quarter were for new treatment vaults. Elsewhere in APAC, Japan remained slow, but appeared to be stabilizing.
We also had a key win at a large teaching hospital in Indonesia that we believe will position us for further growth in that important market.
We're pleased with the progress made in our software business during the quarter. Customer interest in RapidPlan continued to grow, and it is now installed at nearly 170 sites around the world.
We also received multiple orders in the quarter for InSightive Analytics, bringing total orders since its introduction earlier this fiscal year to 80.
We had another nice win at the Christie Hospital in Manchester, England, which ordered several software products, including Eclipse Treatment Planning for protons and our Velocity product that uses images to track tumor responses to treatment.
Turning to our Oncology Service business. Gross orders were up 11% in dollars and 12% in constant currency, with the help of higher capture rates, particularly in North America and China.
Looking now at Imaging Components' second quarter performance versus the year-ago quarter, orders fell by 12% to $138 million and revenue fell by 8% to $144 million, largely in line with our expectations. Beginning in the second half of last fiscal year, this business has been confronted with currency-related pricing pressures, weak market conditions for security and inspection products, in-sourcing by a large panel customer and uncertainties related to the sale of a major tube customer. We believe we have largely absorbed these challenges from the last 4 quarters, and we feel that the business is beginning to stabilize at these new levels.
Our new MeVis and Claymount businesses performed well in the quarter, and we continue to believe they will generate about $50 million in revenue this fiscal year. During the quarter, we opened a regional service center near Shanghai to support local x-ray equipment manufacturers across China. With the growing number of imaging equipment manufacturers in China, this is going to be an important growth area for our components business.
In our Particle Therapy business, we continued to make good progress with installations and recorded $31 million in revenue during the quarter. It was great to see patient treatments commence at the Maryland Proton Therapy Center in February. We are proud to collaborate with the center to bring our advanced cancer fighting technology to patients in that region.
In the quarter, we successfully extracted beam from the Cyclotron and Cincinnati Children's Hospital where patient treatments are scheduled to begin before the end of the year. We are also scheduled to begin installing equipment at sites in Holland, Russia and Saudi Arabia later this year.
Now I'll turn it over to Elisha."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog.We ended the quarter at $3.3 billion, up 6% from the year-ago period. Backlog adjustments during the quarter totaled $51 million bringing net orders for",584,"Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog.
We ended the quarter at $3.3 billion, up 6% from the year-ago period. Backlog adjustments during the quarter totaled $51 million bringing net orders for the company to $707 million. Second quarter revenues for the total company were about equal with the year-ago period in dollars and up 2% in constant currency. For the first half, total company revenues were up 1% in dollars and up 4% in constant currency.
Oncology posted a 1% decline in revenues and a 1% gain in constant currency during the second quarter. Imaging Components posted a second quarter revenue decline of 8%, with decreases in tubes, panels and Security and Inspection Products, partially offset by revenues from our new Claymount and MeVis businesses.
Our Particle Therapy business posted second quarter revenues of $31 million, more than double the year-ago period, as we continue to make progress on projects in backlog.
The total company gross margin for the quarter was 42%, down as expected by 0.5 point due to lower volumes in Imaging Components and a higher mix of Proton business. For the first half, total company gross margin was 41.6%, down almost 2 points from the year-ago period.
Oncology Systems second quarter gross margin improved 73 basis points to 43.7% due to product mix shift towards software and service, variable cost productivity and suspension of the medical device excise tax.
Imaging Components second quarter gross margin fell by a little more than 2 points to 41.4%, due largely to lower volumes.
Second quarter SG&A expenses were $112 million or 15% of revenue and R&D expenses were $62 million or about 8% of revenue, each equal as a percentage of revenue to the year-ago quarter. For the first half, SG&A expenses were 16% of revenue, and R&D was 8% of revenue, both also equal to the year-ago period.
Second quarter operating earnings totaled $145 million or 19.1% of revenue, down about 1 point as a percentage of revenue from the year-ago quarter and in line with our expectations. For the first half, operating margin at 18% of revenue was down about 1.5 points from the year-ago period.
Depreciation and amortization totaled $20 million for the second quarter and $38 million for the first half. The effective tax rate was 28.1%, virtually equal to the year-ago quarter. We continue to expect that the tax rate will be about 26% to 27% for the year.
Fully diluted shares outstanding of 96.2 million were almost 5 million lower than the year-ago quarter due to our ongoing share repurchase program. Diluted EPS was $1.09 for this quarter.
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $961 million, debt of $794 million and stockholders' equity of $1.7 billion. DSO at 109 days was up significantly from the year-ago quarter due to a lower mix of Imaging Components business, a higher mix of Proton business, more extended payment terms and slower collections for Oncology Systems.
Second quarter cash flow from operations was $32 million, bringing the total cash flow from operations for the first half to $109 million. Primary uses of cash were $19 million for CapEx and $57 million through the repurchase of 725,000 shares of stock. At the end of the quarter, we had 6 million shares remaining under the existing repurchase authorization that extends through calendar year 2016.
Now I'll turn it back to Dow for the outlook."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. Including the results of the second quarter, we continue to believe that total company non-GAAP earnings will be in the range of $4.55 to $4.65 per diluted share for fiscal year 2016. With expectations of a slower-than-anticipated recovery",141,"Thanks, Elisha. Including the results of the second quarter, we continue to believe that total company non-GAAP earnings will be in the range of $4.55 to $4.65 per diluted share for fiscal year 2016. With expectations of a slower-than-anticipated recovery in our Imaging Components business due to high inventory levels at a major customer, we now believe revenues for fiscal year 2016 will increase by about 3% over fiscal year 2015.
For the third quarter of fiscal year 2016, we expect non-GAAP earnings to be in the range of $1.16 to $1.20 per diluted share. We expect third quarter revenues to be about equal to the year-ago period with growth in our core businesses offset by a decline in our Proton business versus the year-ago quarter when we booked the big University of Maryland project.
We're now ready for your questions."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] Our first question comes from Jason Wittes from Brean Capital.",12,"[Operator Instructions] Our first question comes from Jason Wittes from Brean Capital."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So I guess, I'll start with -- we usually start with oncology, but I will start with imaging. You seem -- you mentioned -- you made some comments about the stability of the business. It seems like the only thing that's really sort of dragging and leading",90,"So I guess, I'll start with -- we usually start with oncology, but I will start with imaging. You seem -- you mentioned -- you made some comments about the stability of the business. It seems like the only thing that's really sort of dragging and leading to the lower outlook for the year is the destocking. I assume that's with the Toshiba transfer to, I think, Canon. Is there anything else out there? I mean, is that the main drag on the business at this point or is it..."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, I mean, I think that is the main drag. I mean, I talked a little bit about the constant currency issues, that's now stabilizing. Happy day. We've had some of the price issues that's gone along with that. We see that stabilizing. We had a major flat p",131,"Yes, I mean, I think that is the main drag. I mean, I talked a little bit about the constant currency issues, that's now stabilizing. Happy day. We've had some of the price issues that's gone along with that. We see that stabilizing. We had a major flat panel customer in-sourced. We've still got a little bit of impact to that, but that should be largely anniversaried by Q4. And then it's really the sale that you mentioned that's been going on has caused some short-term volume issues at Toshiba. Clearly, they're managing for working capital in the short term. I think when we look at the rest of our customer base, we're seeing very solid customer demand. And we think that business will turn around here in the second half."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Two related questions and only because I think people want to get comfortable with the imaging business. And that is, I think in the past you made comments that about half of the business as it stands, I think, at year-end '15, fiscal '15, was kind",81,"Okay. Two related questions and only because I think people want to get comfortable with the imaging business. And that is, I think in the past you made comments that about half of the business as it stands, I think, at year-end '15, fiscal '15, was kind of commodity like and somewhat at-risk. It sounds to me like you feel that, that has stabilized in terms of the risk of that business. Is that the right way to think about it?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I mean the short version is when you go customer by customer, our demand has really been very solid. And I think this conversation came up in regards to some of the flat panel technology and how easy or difficult it might be for people to switch sup",86,"Well, I mean the short version is when you go customer by customer, our demand has really been very solid. And I think this conversation came up in regards to some of the flat panel technology and how easy or difficult it might be for people to switch suppliers in flat panel technology. In some areas of the detector business, that is a little bit easier to switch suppliers. In the tube business, that remains -- it can be done, but it still remains very difficult."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then In terms of Toshiba moving to Canon or that business being bought by Canon, is that -- can you kind of give an outlook in terms of discussion you've had and how that might change the outlook for that piece of the business? Because they were",51,"Okay. And then In terms of Toshiba moving to Canon or that business being bought by Canon, is that -- can you kind of give an outlook in terms of discussion you've had and how that might change the outlook for that piece of the business? Because they were. . ."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, sure. Yes, absolutely. The sale to Canon is still closing, first of all. And what we hear is the Toshiba team is staying on. We have very good relationship with them, and that gives us some optimism. And there clearly is going to be some cautious pur",83,"Yes, sure. Yes, absolutely. The sale to Canon is still closing, first of all. And what we hear is the Toshiba team is staying on. We have very good relationship with them, and that gives us some optimism. And there clearly is going to be some cautious purchasing and inventory management in the short term from a competitive product point of view. Our biggest business there by far is the tube business that we sell to Toshiba and Canon doesn't make any tubes."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And last question, I just wanted -- you mentioned on Proton, interest in your single-room offering. Can you just give us little more details around that in terms of what the pricing is and et cetera?",37,"Okay. And last question, I just wanted -- you mentioned on Proton, interest in your single-room offering. Can you just give us little more details around that in terms of what the pricing is and et cetera?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, there is -- I mean, first of all, there's lots of interest. So the kind of our funnel of activity is very large, so that's good. In the quarter, we did have 3 contract decisions. One of those, in fact, issued a press release, Delray in Florida. The 3",97,"Yes, there is -- I mean, first of all, there's lots of interest. So the kind of our funnel of activity is very large, so that's good. In the quarter, we did have 3 contract decisions. One of those, in fact, issued a press release, Delray in Florida. The 3 of them all have a contingency of one form or another, 2 are financing and 1 is some permitting. So with a little luck, we'll clear those contingencies on 1 or 2 of them this year. And if everything goes our way, maybe we'll get all 3."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Vijay Kumar from Evercore.",9,"Our next question comes from Vijay Kumar from Evercore."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is Scott in for Vijay. I just had a question in terms of when you're talking about building up a facility in China, I was curious since you mentioned this is a growth area, what are your guys thinking in terms of where the growth is coming from? And",57,"This is Scott in for Vijay. I just had a question in terms of when you're talking about building up a facility in China, I was curious since you mentioned this is a growth area, what are your guys thinking in terms of where the growth is coming from? And what's the interest and drivers behind that?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, there's just -- there's a lot activity in China in the radiology area. So there's some very large customers, I'd say there's 3 or 4 emerging large manufacturers of radiology equipment in China. And there's another list of 15 to 20 smaller supplier",128,"I mean, there's just -- there's a lot activity in China in the radiology area. So there's some very large customers, I'd say there's 3 or 4 emerging large manufacturers of radiology equipment in China. And there's another list of 15 to 20 smaller suppliers, and it's a very active radiology market for locally sourced products in China. So we are not -- we do support Toshiba's global effort in particular. But the big radiology companies, at least in CT and kind of high-end X-ray, they manufacture their own tubes. So we're not supplying them in that market. This is really development at the local Chinese market. Our Chinese customers are looking for local service capability, fast turnaround on spares and -- anyway, it's a very active market."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then back to the follow-up on the China market. We've seen for, I guess, other industries like diagnostics, there's been auditing on large capital equipment purchasing. Do you see if there's any sort of headwind? Or is this not really been an issue fo",48,"And then back to the follow-up on the China market. We've seen for, I guess, other industries like diagnostics, there's been auditing on large capital equipment purchasing. Do you see if there's any sort of headwind? Or is this not really been an issue for you guys?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think, I mean, that's been an issue for us for the last 2, 2.5 years, I wouldn't say it's any worse. And In fact, in our Oncology business this quarter in China, we had a very, very good quarter, very strong double-digit growth in China. And what we wer",82,"I think, I mean, that's been an issue for us for the last 2, 2.5 years, I wouldn't say it's any worse. And In fact, in our Oncology business this quarter in China, we had a very, very good quarter, very strong double-digit growth in China. And what we were particularly pleased about is over 3/4 of the units were in new vaults, new bunkers. So -- and our funnel in China looks really good. So we remain very bullish about China."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Tycho Peterson from JPMorgan.",9,"Our next question comes from Tycho Peterson from JPMorgan."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Dow, maybe just to start, I'm wondering if you can touch on competitive dynamics in the market. Accuray last night talked about a little bit more pricing pressure in the single and dual vault market in the U.S. I know you announced the MD Anderson order,",77,"Dow, maybe just to start, I'm wondering if you can touch on competitive dynamics in the market. Accuray last night talked about a little bit more pricing pressure in the single and dual vault market in the U.S. I know you announced the MD Anderson order, but Elekta got in there as well. So just wondering to the degree that pricing is becoming more of an issue in the market, if you can touch on that dynamic?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I would say for us, pricing was not at all an issue in the market. Especially here in the U.S. market, our prices are up. And our volume is very, very good. I mean, as you saw, we had 7% growth in U.S. and Canada on the quarter. That's got to be one of th",97,"I would say for us, pricing was not at all an issue in the market. Especially here in the U.S. market, our prices are up. And our volume is very, very good. I mean, as you saw, we had 7% growth in U.S. and Canada on the quarter. That's got to be one of the best quarters we've had in the U.S. in a long time. And our pricing looks very, very good. So I mean, you may have heard me say, I think their product was way overpriced. So I'm not surprised they've got pricing problems."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. How about the challenged tenders that -- you called that out last quarter? Are those still being challenged? And do you expect that we'll see more of these?",29,"Okay. How about the challenged tenders that -- you called that out last quarter? Are those still being challenged? And do you expect that we'll see more of these?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","They're still being challenged. Let's say, we saw a little bit less this quarter than we had previously and the good news is as we saw a large percentage of them come to us, so that was good news on the quarter. And that was some of the China -- some of t",66,"They're still being challenged. Let's say, we saw a little bit less this quarter than we had previously and the good news is as we saw a large percentage of them come to us, so that was good news on the quarter. And that was some of the China -- some of the China growth with a catch up on that from the previous quarter."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then, for Elisha, can you just break out the FX component to the guidance? In other words, how much did organic guidance change, if we back out the FX move?",31,"And then, for Elisha, can you just break out the FX component to the guidance? In other words, how much did organic guidance change, if we back out the FX move?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","For the first time, Tycho, you did not hear me say currency headwinds in the script, which felt really good. So in the second quarter, it was minimal, maybe $0.01 or $0.02. As we move into Q3, the euro is exactly today where it was in the year-ago period.",68,"For the first time, Tycho, you did not hear me say currency headwinds in the script, which felt really good. So in the second quarter, it was minimal, maybe $0.01 or $0.02. As we move into Q3, the euro is exactly today where it was in the year-ago period. So it's going to be virtually nonexistent in Q3 and Q4, assuming that rates hold where they are today."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then last one on Japan, Dow. I think you used the word slow, but stabilizing. Again, last night, Accuray, I think, talked about facility delays and new construction there. Are you seeing any slippage in terms of new facility buildout?",42,"Okay. And then last one on Japan, Dow. I think you used the word slow, but stabilizing. Again, last night, Accuray, I think, talked about facility delays and new construction there. Are you seeing any slippage in terms of new facility buildout?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say, we're not seeing a slippage. We have seen a contraction in the market. There's less government spending, but we're not seeing slippage. Maybe that to just come back to your first question, just a little bit on price. We did launch the VitalBeam p",182,"I'd say, we're not seeing a slippage. We have seen a contraction in the market. There's less government spending, but we're not seeing slippage. Maybe that to just come back to your first question, just a little bit on price. We did launch the VitalBeam product. And it's priced right at or maybe even a hair north of where we thought it was landing. We were very excited to see its volume globally. Since the launch, we've taken 45 orders with that product. And 36 of those came in the first half of this year. And it fills a mid-tier pricing market where, frankly, we haven't had coverage. But it's also enabled our TrueBeam pricing to move up a little bit. So we feel very good about where the product portfolio is and the pricing discipline that our team has. And frankly, that product, I mean, coming back to your Accuray comment, that product's a little bit more aimed at Elekta than it is Accuray. So I'm not sure what -- let's talk to Josh about his pricing challenges, I guess."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Jeff Johnson from Robert W. Baird.",11,"Our next question comes from Jeff Johnson from Robert W. Baird."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is actually Jason on for Jeff. Just wanted to start on Europe. You had some very good growth out of your European oncology business. You seemed to be actually one of the companies that are bucking the trend here in the quarter in the capital equipmen",91,"This is actually Jason on for Jeff. Just wanted to start on Europe. You had some very good growth out of your European oncology business. You seemed to be actually one of the companies that are bucking the trend here in the quarter in the capital equipment side in Europe. So just wonder if you could discuss how you feel about the sustainability of the performance of that business, especially in light of what are some tougher comps that are going to be coming up against you in the next quarters?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say, yes, the quarter was terrific. And we love that we did have a couple of large orders. First of all, from the top, our orders, just to review, gross orders were up 19% in EMEA, 23% in constant currency. We did have a large multisite order from the",269,"I'd say, yes, the quarter was terrific. And we love that we did have a couple of large orders. First of all, from the top, our orders, just to review, gross orders were up 19% in EMEA, 23% in constant currency. We did have a large multisite order from the Apollo group in India, and that was 11 TrueBeams, 1 EDGE and 5 brachytherapy systems. We also had some major wins in the Middle East, which -- that was nice to see. I mean, I wouldn't say that, that was anomalous. That market's been kind of a little bit down with people dealing with oil price impact on federal budgets, health care budgets. But that was nice to kind of see that come back. We had a very nice win in the U.K. And then I'd say, all across Europe, we had a very good mix of product, a little bit richer hardware mix and very good engagement of our software business in Europe. So I'd say, we're not going to do 20% every quarter, that's probably a little bit too much to ask. As it comes to the total, when you look at the overall market, last 12 months, our estimate is that it's 12 months constant currency growth rate at about 5%. And at least kind of in that really big picture, that's kind of what we see going forward. We've clearly gained some market share the last 2, 3 years. And we're seeing that we're able to maintain that share and get a little price, which is kind of where our focus is right now."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, that's helpful. And then just wanted to come back quickly on the FX side as it relates to guidance. At least your -- we'd expected actually a little bit of upside maybe to guidance given what FX has done here in the recent months. So is it fair to t",68,"Okay, that's helpful. And then just wanted to come back quickly on the FX side as it relates to guidance. At least your -- we'd expected actually a little bit of upside maybe to guidance given what FX has done here in the recent months. So is it fair to think that all that FX upside has basically just been offset by the weakness on the ICB business?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Look, we are taking somewhere, call it $35 million or so out of top line for the year to come down by 1 point on the growth rate and maintaining EPS. And virtually, the currency impact is very, very small. This is -- our business is doing a fantastic job",143,"Look, we are taking somewhere, call it $35 million or so out of top line for the year to come down by 1 point on the growth rate and maintaining EPS. And virtually, the currency impact is very, very small. This is -- our business is doing a fantastic job on cost control. So the margin is coming in a little bit higher of the gross margin level than we were expecting, which is great news due to pricing due to MeVis software, and our Imaging Components business drove that up maybe a point more than we were expecting in the second quarter. So as we anniversary now, currency is roughly neutral to us as we go into the second half of the year. And the business, we're just committed to offsetting that slight revenue mix by good cost controls across the board."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Amit Hazan from Citi.",9,"Our next question comes from Amit Hazan from Citi."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is actually Lee on for Amit. Quick question about market share gains. You guys have been talking just a little bit more recently. Just hoping you can give us what you think the drivers are that would drive incremental share right now versus where you",57,"This is actually Lee on for Amit. Quick question about market share gains. You guys have been talking just a little bit more recently. Just hoping you can give us what you think the drivers are that would drive incremental share right now versus where you guys stood competitively last year -- over the last few years?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think our product line has never been better at every price point. We've got EDGE at the top. When you look at the ability to deliver dose to small volumes, the ability to plan difficult treatments with an efficiency that nobody else can touch and the s",328,"I think our product line has never been better at every price point. We've got EDGE at the top. When you look at the ability to deliver dose to small volumes, the ability to plan difficult treatments with an efficiency that nobody else can touch and the speed of delivery at the high end. Gamma Knife or Cyber Knife can't touch us. When you look at the mid-tier of the market, our TrueBeam product is -- it is what everybody compares to. It is the gold standard of radiation therapy. And that's -- we're seeing a rich in mix on there. I think the other thing at both the high end and the mid-tier of the market is we've got the best total cost of ownership and the best throughput of anybody else out there. So that might be some of Accuray's problems is, I don't know. But I think we are extremely competitive at the total cost of ownership, especially when you look at our throughput advantages, we have far and away the most efficient product out there in terms of throughput and reliability. And we also have -- we've been focused very, very much the last few years on Net Promoter Score. And we believe -- when we measure this through independent groups, we believe that we've got a significant lead in customer service. And then you add that with our -- the VitalBeam launch that I just talked about. Our Eclipse and ARIA product lines recently both won the best-in-class award. So we've that for a while in Eclipse. This was the first time for us in our ARIA oncology information system product. So I just think the strength of the product line is very, very good. On top of that, some of the vision that we shared at ASTRO around both our future around hardware and software is capturing the imagination of our customers for even better, stereotactic body radiation therapy and data analytics."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, great. And then one follow-up with...",7,"Okay, great. And then one follow-up with..."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Maybe one of the thing to add there is that's kind of the product side of it. At the same time, you heard us talk 12, 15 months ago about a change to a new distribution organization. And we regionalized our distribution team into -- took it from a global",106,"Maybe one of the thing to add there is that's kind of the product side of it. At the same time, you heard us talk 12, 15 months ago about a change to a new distribution organization. And we regionalized our distribution team into -- took it from a global sales organization and cut it into 3 geographic structures. And I think that's a nice difference. It's gotten us close to the customer. Decisions don't have to come to Palo Alto. They're made in the field, and it's made this part of this kind of improving Net Promoter Score and customer satisfaction and customer response."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, great. And then my follow-up is that we've been hearing from Intuitive Surgical, they've been reporting a fairly big rebound in brachytherapy volumes and that's about several digits with sidelined patients possibly coming back post 2012 guideline ch",61,"Okay, great. And then my follow-up is that we've been hearing from Intuitive Surgical, they've been reporting a fairly big rebound in brachytherapy volumes and that's about several digits with sidelined patients possibly coming back post 2012 guideline changes. Is that something coming up on your radar at all in terms of helping flow capacity or drive interest in these systems?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, I'd say when the watchful waiting guidelines went out in 2012, 2013, we did see -- our customers did see some dropoff in their prostate volumes. I think, is it back to where it was in 2012? I hadn't seen any math that says that, but it's definitel",54,"I mean, I'd say when the watchful waiting guidelines went out in 2012, 2013, we did see -- our customers did see some dropoff in their prostate volumes. I think, is it back to where it was in 2012? I hadn't seen any math that says that, but it's definitely back up for sure."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from David Roman from Goldman Sachs.",10,"Our next question comes from David Roman from Goldman Sachs."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is actually Candace on for David. Just a quick question on the imaging inside. Could you give a little more detail on the dynamic around customer inventory levels? And what's driving them to be elevated?",36,"This is actually Candace on for David. Just a quick question on the imaging inside. Could you give a little more detail on the dynamic around customer inventory levels? And what's driving them to be elevated?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. We were just speaking in particular of our largest customer in that space. Toshiba has been up for sale. I think as part of that sale, their customers have probably gotten conservative about seeing the transition happen. And so our demand is off ther",92,"Yes. We were just speaking in particular of our largest customer in that space. Toshiba has been up for sale. I think as part of that sale, their customers have probably gotten conservative about seeing the transition happen. And so our demand is off there, and their supply is up. So that's the driver. There's no -- that will bounce back we think. As the acquisition gets completed, they've obviously announced the sale to Canon. And I'd say otherwise, its business as usual in that shop. It's just one specific customer situation."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. So there's nothing further there and that's the only weakness, nothing beyond that consolidation?",15,"Okay. So there's nothing further there and that's the only weakness, nothing beyond that consolidation?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Right. That's the incremental fees. I mean, we talked a little bit about some of the other issues that business has had last year. But that's -- when you look at what we -- versus what we expected for this year, that would be the one slight miss to the ye",65,"Right. That's the incremental fees. I mean, we talked a little bit about some of the other issues that business has had last year. But that's -- when you look at what we -- versus what we expected for this year, that would be the one slight miss to the year has been volume in that business, as they've gone through this change in strategy."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, that's very helpful. And then I know that you guys have talked about the impact of FX. But I was just curious about the indirect impact that you had spoken about on past calls. Could you maybe just shed some light on what your reception internationa",60,"Okay, that's very helpful. And then I know that you guys have talked about the impact of FX. But I was just curious about the indirect impact that you had spoken about on past calls. Could you maybe just shed some light on what your reception internationally has been? And if that's changed at all as the dollar has weakened."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say when you look at it over 18 months, it's had a pretty significant impact. Elisha fixed this. I'm going to say the yen was down 20% and the euro was down 25%. Is that about right?",39,"I'd say when you look at it over 18 months, it's had a pretty significant impact. Elisha fixed this. I'm going to say the yen was down 20% and the euro was down 25%. Is that about right?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That is about right.",4,"That is about right."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And our competitors in this business are yen-based and euro-based. And rather taking it to translation profits, they took the gift to pricing. So we worked very hard to maintain our share and I think we have. We're seeing those prices stabilize so that's",47,"And our competitors in this business are yen-based and euro-based. And rather taking it to translation profits, they took the gift to pricing. So we worked very hard to maintain our share and I think we have. We're seeing those prices stabilize so that's good news."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And Candace, I would just add. I mean, we've seen pricing stabilize in the Imaging Components business by product line. So we've largely anniversary-ed the impact, particularly as we get into Q3. But we're actually going to see some growth in the Imaging",63,"And Candace, I would just add. I mean, we've seen pricing stabilize in the Imaging Components business by product line. So we've largely anniversary-ed the impact, particularly as we get into Q3. But we're actually going to see some growth in the Imaging Components business quarter-over-quarter, just not to the level that we had first anticipated because of the issues we've talked about."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Steve Beuchaw from Morgan Stanley.",10,"Our next question comes from Steve Beuchaw from Morgan Stanley."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","It's actually Steve in for Steve. So first question is, Elisha, on the seasonality in the model, the implied guide for the fourth quarter puts a little bit more weight on earnings in the fourth quarter than normal. What is it about the model this year tha",62,"It's actually Steve in for Steve. So first question is, Elisha, on the seasonality in the model, the implied guide for the fourth quarter puts a little bit more weight on earnings in the fourth quarter than normal. What is it about the model this year that's a little different relative to the last, I don't know, 3 years or so?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, so a couple of things. First of all, FX, we're going to completely anniversary the effect of FX at today's levels. So that takes some pressure off. And in oncology, we're going to see a more linear year. Last year Q3, actually sequentially was down f",175,"Yes, so a couple of things. First of all, FX, we're going to completely anniversary the effect of FX at today's levels. So that takes some pressure off. And in oncology, we're going to see a more linear year. Last year Q3, actually sequentially was down for oncology. You're not going to see that for our expectations this quarter. So what you're seeing is really some fluctuations, mostly in our PT business. So if I look at Q3 guidance, oncology should do high single digit. We're going to have our Imaging Components somewhere around the mid-single digit. But we get a significant drop off in our Proton business because we booked Maryland in the year-ago period. So that's why you get to a 0% flat revenue. If you get into Q4, it's exactly the opposite, and our Proton business is going to grow significantly just based on the projects and the timing of revenue recognition and the percentage of completion. So those are a few of the things that are different versus a year-ago period."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then sorry, if I missed this. But at this stage, halfway through the fiscal year, what would be, for the full fiscal year, the impact in pennies, I suppose, of currency at the bottom line?",37,"Okay. And then sorry, if I missed this. But at this stage, halfway through the fiscal year, what would be, for the full fiscal year, the impact in pennies, I suppose, of currency at the bottom line?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I would say, probably I'm going to say about $0.05, $0.06. I don't have it exactly, Steve. It was a little more in Q1 than in Q2. Q2 was only about $0.02 or so. Q3 should be roughly 0 at today's level.",42,"I would say, probably I'm going to say about $0.05, $0.06. I don't have it exactly, Steve. It was a little more in Q1 than in Q2. Q2 was only about $0.02 or so. Q3 should be roughly 0 at today's level."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","It's a nice thing, isn't it?",7,"It's a nice thing, isn't it?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, it sure is.",4,"Yes, it sure is."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then, Dow, I just wanted to come back to your comments earlier on VitalBeam. Can you go into just a bit more detail on the strategy for deploying it in the U.S.? It puts you in a position where you're obviously, high tier with TrueBeam and now mid-tie",82,"And then, Dow, I just wanted to come back to your comments earlier on VitalBeam. Can you go into just a bit more detail on the strategy for deploying it in the U.S.? It puts you in a position where you're obviously, high tier with TrueBeam and now mid-tier provider with VitalBeam. How do you think about segmenting the market? And how much more aggressive can you get in the rollout of VitalBeam? How much more push is in the plan there?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, we're very excited about the product. It's gone very well. I think the way the guys are using it a lot, the guys and girls in the field are using it. It's really to sell up. So often versus our competitors, it starts out in the canal water from a",332,"I mean, we're very excited about the product. It's gone very well. I think the way the guys are using it a lot, the guys and girls in the field are using it. It's really to sell up. So often versus our competitors, it starts out in the canal water from a pricing point of view. And what we really want to do is we want to differentiate the TrueBeam and it has many, many significant advantages over everything else that's out there. And we've trained very hard on that. I think there's good discipline around it and we're seeing that in our numbers. From a product cost point of view, the team has also done a really great job getting the product cost out. So it's given us some flexibility to do that. So the margin dollars, margin percent at these price points are still pretty good. So we like that part of it. The -- I'd say, we're -- it might be a little bit ahead of our expectations in terms of its impact in the U.S. We thought we'd have a little bit bigger impact outside of the U.S. And our team is just playing in that, true. So we do think we'll see some upside from the product outside of the U.S. It typically takes us a little longer to train and get it into budget cycles and things like that. But it is -- for this market, in particular where we have an old install base that's looking to trade up and how can they --  chances are, they're not depreciating the old asset anymore. It's been through its depreciation cycle. And they're looking to how can they swap out that old stuff and get something new and competitive at a good price point that's just worked out very, very well. I think the proof is in the pudding.  In North America, the whole business was up 7% in the quarter. And our funnel remains pretty good."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And our next question comes from Toby Wann from Obsidian Research Group.",12,"And our next question comes from Toby Wann from Obsidian Research Group."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Steve [indiscernible].  I guess I'll be on for Toby. Can you guys kind of  talk quickly about the pipeline of potential new Particle Therapy business out there with, I guess, multi-room systems?",32,"Steve [indiscernible].  I guess I'll be on for Toby. Can you guys kind of  talk quickly about the pipeline of potential new Particle Therapy business out there with, I guess, multi-room systems?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I never know what to say to this question. The short version is the pipeline of Proton systems is gigantic. The pipeline for financeable Proton systems is significantly smaller. And I guess, what -- the good news is, as I mentioned, we've got 3 contracts",219,"I never know what to say to this question. The short version is the pipeline of Proton systems is gigantic. The pipeline for financeable Proton systems is significantly smaller. And I guess, what -- the good news is, as I mentioned, we've got 3 contracts that we signed for compacts this last quarter. We think they're all financeable. But we don't book them until they are in fact financed. And we've got a very good funnel that looks very strong. So we're optimistic about where it's going, and it's global. It's not -- this is not, I'd say, it's just as much outside of the U.S. as it is in the U.S. at this point. So we like the global nature of it. I would say that one of the other things that we like is we're seeing a little transition from a developer-driven market to more of a customer sovereign government Minister of Health kind of market, which has taken away some of these financing issues. And frankly, the other thing that's happening is the market is moving to smaller, smaller units. So last year, we booked several 4- and 5-room systems. More of the market is in the 1, 2, 3 market, 1 or 2 treatment vaults now. And I think that's a trend that will continue."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Great. That's helpful. So I guess, you haven't really seen any given kind of global economic conditions, unrest here, unrest there. Any impact, any changes in terms of the velocity of kind of how people are thinking about getting into Protons?",41,"Great. That's helpful. So I guess, you haven't really seen any given kind of global economic conditions, unrest here, unrest there. Any impact, any changes in terms of the velocity of kind of how people are thinking about getting into Protons?"
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No, not at all. I think, one -- given that, one of the things that we really like is of the compact products in the market, ours is the only no-compromise compact product. And a true scan beam, full rotational Gantry, highest throughput, most clinical cap",69,"No, not at all. I think, one -- given that, one of the things that we really like is of the compact products in the market, ours is the only no-compromise compact product. And a true scan beam, full rotational Gantry, highest throughput, most clinical capability, to really leverage the physics advantage of Proton Therapy, you need what we got. And I think that's beginning to resonate with customers."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","At this time, we have no further questions. I will turn the call back over to our speakers for closing comments.",21,"At this time, we have no further questions. I will turn the call back over to our speakers for closing comments."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Thank you for participating. A replay of this call can be heard on the Varian investor website at www.varian.com/investor where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or  1 (201)",70,"Yes. Thank you for participating. A replay of this call can be heard on the Varian investor website at www.varian.com/investor where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or  1 (201) 612-7415 from outside the U.S. and entering confirmation code 13632882. The telephone replay will be available through 5:00 p.m. this Friday, April 29.
Thank you."
311907,328570774,965252,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation.",20,"Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems Second Quarter Fiscal Year 2016 Earnings Results Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Spencer Sias, Vice President of Investor Relations and Corporate C",48,"Greetings, and welcome to the Varian Medical Systems Second Quarter Fiscal Year 2016 Earnings Results Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Spencer Sias, Vice President of Investor Relations and Corporate Communications for Varian Medical Systems. Mr. Sias, you may now begin."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. First of all, quick apologies for the delay we had in getting the press release out, but we've got the gremlins solved. By now, I think you guys all have the material and we're very ready for the call.So good afternoon, and welcome to Varian",310,"Thank you. First of all, quick apologies for the delay we had in getting the press release out, but we've got the gremlins solved. By now, I think you guys all have the material and we're very ready for the call.
So good afternoon, and welcome to Varian Medical Systems conference call for the second quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. To simplify our discussion, unless otherwise stated, all references to the quarter or year are fiscal quarters and fiscal years. Quarterly comparisons are for the second quarter of fiscal 2016 versus the second quarter of fiscal 2015. References to financial results for orders are to gross orders unless otherwise indicated. The discussion includes non-GAAP financial measures in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. A reconciliation to the most comparable GAAP measure is included in our earnings release which can be accessed on our website.
Please be advised that this discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, will, scheduled, feels like and similar expressions, are intended to identify those statements which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks relating to our business are described in our second quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise.
And now here's Dow."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Varian is reporting solid results for the second quarter of fiscal year 2016 with strong order growth in our Oncology business, promising progress in our Particle Therapy business and expected weakness in our Imaging Component",944,"Good afternoon, and welcome. Varian is reporting solid results for the second quarter of fiscal year 2016 with strong order growth in our Oncology business, promising progress in our Particle Therapy business and expected weakness in our Imaging Components business.
In summary, we are reporting non-GAAP net earnings of $1.09 per diluted share and $1.01 per diluted share on a GAAP basis. Revenue of $759 million equal to the year-ago quarter in dollars and up 2% in constant currency. Strong orders in our Oncology business with growth and strategic wins in all 3 geographies, expected order and revenue declines in Imaging Components and good momentum in our Particle Therapy business with growing customer interest in our single-room system.
Focusing on operational highlights. In our Oncology business, gross orders totaled $618 million for the quarter, up 6% in dollars and 8% in constant currency. Gross orders in the Americas for the quarter increased by 2% in dollars and 3% in constant currency, with 7% growth in North America, offsetting a decline in Latin America.
In EMEA, gross orders were up 19% in dollars and 23% in constant currency helped by big wins in India and the Middle East. Gross orders in APAC rose 2% in dollars and 3% in constant currency, driven by robust growth in China.
Oncology experienced healthy global demand in the quarter with higher unit orders as well as gains in our service and software businesses.
Looking at each of the regions in more detail. Our gross order growth in North America was driven in part by demand for newer products, particularly our VitalBeam accelerator as well as our RapidPlan and InSightive Analytics software for improving clinical efficiency.
As you know, North America is largely a replacement market and in this quarter, we generated orders to replace several hardware and software products from competitors as well as our own units. As usual, there were some big wins in the quarter including a major order from MD Anderson for 6 TrueBeam systems. We also won a couple of large deals in Canada.
Orders in Latin America declined significantly from the year-ago quarter, as results of political uncertainty in Brazil and volatile currencies that slowed purchasing decisions.
During the quarter, we broke ground on a new 50,000 square foot facility in Brazil that will be used for training and product demos as well as product assembly and warehousing. This summer, we expect to complete the first few installations of the 80 machines tended by Brazil's Ministry of Health in 2014.
Turning to EMEA. We had a very good quarter with several sizable orders. The largest of these came in India where we received a multi-site order from the Apollo Hospital Group for 12 high-end linear accelerators and 5 brachytherapy systems. We also booked several orders in the Middle East, including systems for 4 new sites in Turkey.
We had a terrific quarter in China where more than 75% of the Varian linear accelerators ordered in the quarter were for new treatment vaults. Elsewhere in APAC, Japan remained slow, but appeared to be stabilizing.
We also had a key win at a large teaching hospital in Indonesia that we believe will position us for further growth in that important market.
We're pleased with the progress made in our software business during the quarter. Customer interest in RapidPlan continued to grow, and it is now installed at nearly 170 sites around the world.
We also received multiple orders in the quarter for InSightive Analytics, bringing total orders since its introduction earlier this fiscal year to 80.
We had another nice win at the Christie Hospital in Manchester, England, which ordered several software products, including Eclipse Treatment Planning for protons and our Velocity product that uses images to track tumor responses to treatment.
Turning to our Oncology Service business. Gross orders were up 11% in dollars and 12% in constant currency, with the help of higher capture rates, particularly in North America and China.
Looking now at Imaging Components' second quarter performance versus the year-ago quarter, orders fell by 12% to $138 million and revenue fell by 8% to $144 million, largely in line with our expectations. Beginning in the second half of last fiscal year, this business has been confronted with currency-related pricing pressures, weak market conditions for security and inspection products, in-sourcing by a large panel customer and uncertainties related to the sale of a major tube customer. We believe we have largely absorbed these challenges from the last 4 quarters, and we feel that the business is beginning to stabilize at these new levels.
Our new MeVis and Claymount businesses performed well in the quarter, and we continue to believe they will generate about $50 million in revenue this fiscal year. During the quarter, we opened a regional service center near Shanghai to support local x-ray equipment manufacturers across China. With the growing number of imaging equipment manufacturers in China, this is going to be an important growth area for our components business.
In our Particle Therapy business, we continued to make good progress with installations and recorded $31 million in revenue during the quarter. It was great to see patient treatments commence at the Maryland Proton Therapy Center in February. We are proud to collaborate with the center to bring our advanced cancer fighting technology to patients in that region.
In the quarter, we successfully extracted beam from the Cyclotron and Cincinnati Children's Hospital where patient treatments are scheduled to begin before the end of the year. We are also scheduled to begin installing equipment at sites in Holland, Russia and Saudi Arabia later this year.
Now I'll turn it over to Elisha."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog.We ended the quarter at $3.3 billion, up 6% from the year-ago period. Backlog adjustments during the quarter totaled $51 million bringing net orders for",584,"Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog.
We ended the quarter at $3.3 billion, up 6% from the year-ago period. Backlog adjustments during the quarter totaled $51 million bringing net orders for the company to $707 million. Second quarter revenues for the total company were about equal with the year-ago period in dollars and up 2% in constant currency. For the first half, total company revenues were up 1% in dollars and up 4% in constant currency.
Oncology posted a 1% decline in revenues and a 1% gain in constant currency during the second quarter. Imaging Components posted a second quarter revenue decline of 8%, with decreases in tubes, panels and Security and Inspection Products, partially offset by revenues from our new Claymount and MeVis businesses.
Our Particle Therapy business posted second quarter revenues of $31 million, more than double the year-ago period, as we continue to make progress on projects in backlog.
The total company gross margin for the quarter was 42%, down as expected by 0.5 point due to lower volumes in Imaging Components and a higher mix of Proton business. For the first half, total company gross margin was 41.6%, down almost 2 points from the year-ago period.
Oncology Systems second quarter gross margin improved 73 basis points to 43.7% due to product mix shift towards software and service, variable cost productivity and suspension of the medical device excise tax.
Imaging Components second quarter gross margin fell by a little more than 2 points to 41.4%, due largely to lower volumes.
Second quarter SG&A expenses were $112 million or 15% of revenue and R&D expenses were $62 million or about 8% of revenue, each equal as a percentage of revenue to the year-ago quarter. For the first half, SG&A expenses were 16% of revenue, and R&D was 8% of revenue, both also equal to the year-ago period.
Second quarter operating earnings totaled $145 million or 19.1% of revenue, down about 1 point as a percentage of revenue from the year-ago quarter and in line with our expectations. For the first half, operating margin at 18% of revenue was down about 1.5 points from the year-ago period.
Depreciation and amortization totaled $20 million for the second quarter and $38 million for the first half. The effective tax rate was 28.1%, virtually equal to the year-ago quarter. We continue to expect that the tax rate will be about 26% to 27% for the year.
Fully diluted shares outstanding of 96.2 million were almost 5 million lower than the year-ago quarter due to our ongoing share repurchase program. Diluted EPS was $1.09 for this quarter.
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $961 million, debt of $794 million and stockholders' equity of $1.7 billion. DSO at 109 days was up significantly from the year-ago quarter due to a lower mix of Imaging Components business, a higher mix of Proton business, more extended payment terms and slower collections for Oncology Systems.
Second quarter cash flow from operations was $32 million, bringing the total cash flow from operations for the first half to $109 million. Primary uses of cash were $19 million for CapEx and $57 million through the repurchase of 725,000 shares of stock. At the end of the quarter, we had 6 million shares remaining under the existing repurchase authorization that extends through calendar year 2016.
Now I'll turn it back to Dow for the outlook."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. Including the results of the second quarter, we continue to believe that total company non-GAAP earnings will be in the range of $4.55 to $4.65 per diluted share for fiscal year 2016. With expectations of a slower-than-anticipated recovery",141,"Thanks, Elisha. Including the results of the second quarter, we continue to believe that total company non-GAAP earnings will be in the range of $4.55 to $4.65 per diluted share for fiscal year 2016. With expectations of a slower-than-anticipated recovery in our Imaging Components business due to high inventory levels at a major customer, we now believe revenues for fiscal year 2016 will increase by about 3% over fiscal year 2015.
For the third quarter of fiscal year 2016, we expect non-GAAP earnings to be in the range of $1.16 to $1.20 per diluted share. We expect third quarter revenues to be about equal to the year-ago period with growth in our core businesses offset by a decline in our Proton business versus the year-ago quarter when we booked the big University of Maryland project.
We're now ready for your questions."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] Our first question comes from Jason Wittes from Brean Capital.",12,"[Operator Instructions] Our first question comes from Jason Wittes from Brean Capital."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So I guess, I'll start with -- we usually start with oncology, but I will start with imaging. You seem -- you mentioned -- you made some comments about the stability of the business. It seems like the only thing that's really sort of dragging and leading",90,"So I guess, I'll start with -- we usually start with oncology, but I will start with imaging. You seem -- you mentioned -- you made some comments about the stability of the business. It seems like the only thing that's really sort of dragging and leading to the lower outlook for the year is the destocking. I assume that's with the Toshiba transfer to, I think, Canon. Is there anything else out there? I mean, is that the main drag on the business at this point or is it..."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, I mean, I think that is the main drag. I mean, I talked a little bit about the constant currency issues, that's now stabilizing. Happy day. We've had some of the price issues that's gone along with that. We see that stabilizing. We had a major flat p",131,"Yes, I mean, I think that is the main drag. I mean, I talked a little bit about the constant currency issues, that's now stabilizing. Happy day. We've had some of the price issues that's gone along with that. We see that stabilizing. We had a major flat panel customer in-sourced. We've still got a little bit of impact to that, but that should be largely anniversaried by Q4. And then it's really the sale that you mentioned that's been going on has caused some short-term volume issues at Toshiba. Clearly, they're managing for working capital in the short term. I think when we look at the rest of our customer base, we're seeing very solid customer demand. And we think that business will turn around here in the second half."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Two related questions and only because I think people want to get comfortable with the imaging business. And that is, I think in the past you made comments that about half of the business as it stands, I think, at year-end '15, fiscal '15, was kind",81,"Okay. Two related questions and only because I think people want to get comfortable with the imaging business. And that is, I think in the past you made comments that about half of the business as it stands, I think, at year-end '15, fiscal '15, was kind of commodity like and somewhat at-risk. It sounds to me like you feel that, that has stabilized in terms of the risk of that business. Is that the right way to think about it?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I mean the short version is when you go customer by customer, our demand has really been very solid. And I think this conversation came up in regards to some of the flat panel technology and how easy or difficult it might be for people to switch sup",86,"Well, I mean the short version is when you go customer by customer, our demand has really been very solid. And I think this conversation came up in regards to some of the flat panel technology and how easy or difficult it might be for people to switch suppliers in flat panel technology. In some areas of the detector business, that is a little bit easier to switch suppliers. In the tube business, that remains -- it can be done, but it still remains very difficult."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then In terms of Toshiba moving to Canon or that business being bought by Canon, is that -- can you kind of give an outlook in terms of discussion you've had and how that might change the outlook for that piece of the business? Because they were",51,"Okay. And then In terms of Toshiba moving to Canon or that business being bought by Canon, is that -- can you kind of give an outlook in terms of discussion you've had and how that might change the outlook for that piece of the business? Because they were. . ."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, sure. Yes, absolutely. The sale to Canon is still closing, first of all. And what we hear is the Toshiba team is staying on. We have very good relationship with them, and that gives us some optimism. And there clearly is going to be some cautious pur",83,"Yes, sure. Yes, absolutely. The sale to Canon is still closing, first of all. And what we hear is the Toshiba team is staying on. We have very good relationship with them, and that gives us some optimism. And there clearly is going to be some cautious purchasing and inventory management in the short term from a competitive product point of view. Our biggest business there by far is the tube business that we sell to Toshiba and Canon doesn't make any tubes."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And last question, I just wanted -- you mentioned on Proton, interest in your single-room offering. Can you just give us little more details around that in terms of what the pricing is and et cetera?",37,"Okay. And last question, I just wanted -- you mentioned on Proton, interest in your single-room offering. Can you just give us little more details around that in terms of what the pricing is and et cetera?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, there is -- I mean, first of all, there's lots of interest. So the kind of our funnel of activity is very large, so that's good. In the quarter, we did have 3 contract decisions. One of those, in fact, issued a press release, Delray in Florida. The 3",97,"Yes, there is -- I mean, first of all, there's lots of interest. So the kind of our funnel of activity is very large, so that's good. In the quarter, we did have 3 contract decisions. One of those, in fact, issued a press release, Delray in Florida. The 3 of them all have a contingency of one form or another, 2 are financing and 1 is some permitting. So with a little luck, we'll clear those contingencies on 1 or 2 of them this year. And if everything goes our way, maybe we'll get all 3."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Vijay Kumar from Evercore.",9,"Our next question comes from Vijay Kumar from Evercore."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is Scott in for Vijay. I just had a question in terms of when you're talking about building up a facility in China, I was curious since you mentioned this is a growth area, what are your guys thinking in terms of where the growth is coming from? And",57,"This is Scott in for Vijay. I just had a question in terms of when you're talking about building up a facility in China, I was curious since you mentioned this is a growth area, what are your guys thinking in terms of where the growth is coming from? And what's the interest and drivers behind that?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, there's just -- there's a lot activity in China in the radiology area. So there's some very large customers, I'd say there's 3 or 4 emerging large manufacturers of radiology equipment in China. And there's another list of 15 to 20 smaller supplier",128,"I mean, there's just -- there's a lot activity in China in the radiology area. So there's some very large customers, I'd say there's 3 or 4 emerging large manufacturers of radiology equipment in China. And there's another list of 15 to 20 smaller suppliers, and it's a very active radiology market for locally sourced products in China. So we are not -- we do support Toshiba's global effort in particular. But the big radiology companies, at least in CT and kind of high-end X-ray, they manufacture their own tubes. So we're not supplying them in that market. This is really development at the local Chinese market. Our Chinese customers are looking for local service capability, fast turnaround on spares and -- anyway, it's a very active market."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then back to the follow-up on the China market. We've seen for, I guess, other industries like diagnostics, there's been auditing on large capital equipment purchasing. Do you see if there's any sort of headwind? Or is this not really been an issue fo",48,"And then back to the follow-up on the China market. We've seen for, I guess, other industries like diagnostics, there's been auditing on large capital equipment purchasing. Do you see if there's any sort of headwind? Or is this not really been an issue for you guys?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think, I mean, that's been an issue for us for the last 2, 2.5 years, I wouldn't say it's any worse. And In fact, in our Oncology business this quarter in China, we had a very, very good quarter, very strong double-digit growth in China. And what we wer",82,"I think, I mean, that's been an issue for us for the last 2, 2.5 years, I wouldn't say it's any worse. And In fact, in our Oncology business this quarter in China, we had a very, very good quarter, very strong double-digit growth in China. And what we were particularly pleased about is over 3/4 of the units were in new vaults, new bunkers. So -- and our funnel in China looks really good. So we remain very bullish about China."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Tycho Peterson from JPMorgan.",9,"Our next question comes from Tycho Peterson from JPMorgan."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Dow, maybe just to start, I'm wondering if you can touch on competitive dynamics in the market. Accuray last night talked about a little bit more pricing pressure in the single and dual vault market in the U.S. I know you announced the MD Anderson order,",77,"Dow, maybe just to start, I'm wondering if you can touch on competitive dynamics in the market. Accuray last night talked about a little bit more pricing pressure in the single and dual vault market in the U.S. I know you announced the MD Anderson order, but Elekta got in there as well. So just wondering to the degree that pricing is becoming more of an issue in the market, if you can touch on that dynamic?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I would say for us, pricing was not at all an issue in the market. Especially here in the U.S. market, our prices are up. And our volume is very, very good. I mean, as you saw, we had 7% growth in U.S. and Canada on the quarter. That's got to be one of th",97,"I would say for us, pricing was not at all an issue in the market. Especially here in the U.S. market, our prices are up. And our volume is very, very good. I mean, as you saw, we had 7% growth in U.S. and Canada on the quarter. That's got to be one of the best quarters we've had in the U.S. in a long time. And our pricing looks very, very good. So I mean, you may have heard me say, I think their product was way overpriced. So I'm not surprised they've got pricing problems."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. How about the challenged tenders that -- you called that out last quarter? Are those still being challenged? And do you expect that we'll see more of these?",29,"Okay. How about the challenged tenders that -- you called that out last quarter? Are those still being challenged? And do you expect that we'll see more of these?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","They're still being challenged. Let's say, we saw a little bit less this quarter than we had previously and the good news is as we saw a large percentage of them come to us, so that was good news on the quarter. And that was some of the China -- some of t",66,"They're still being challenged. Let's say, we saw a little bit less this quarter than we had previously and the good news is as we saw a large percentage of them come to us, so that was good news on the quarter. And that was some of the China -- some of the China growth with a catch up on that from the previous quarter."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then, for Elisha, can you just break out the FX component to the guidance? In other words, how much did organic guidance change, if we back out the FX move?",31,"And then, for Elisha, can you just break out the FX component to the guidance? In other words, how much did organic guidance change, if we back out the FX move?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","For the first time, Tycho, you did not hear me say currency headwinds in the script, which felt really good. So in the second quarter, it was minimal, maybe $0.01 or $0.02. As we move into Q3, the euro is exactly today where it was in the year-ago period.",68,"For the first time, Tycho, you did not hear me say currency headwinds in the script, which felt really good. So in the second quarter, it was minimal, maybe $0.01 or $0.02. As we move into Q3, the euro is exactly today where it was in the year-ago period. So it's going to be virtually nonexistent in Q3 and Q4, assuming that rates hold where they are today."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then last one on Japan, Dow. I think you used the word slow, but stabilizing. Again, last night, Accuray, I think, talked about facility delays and new construction there. Are you seeing any slippage in terms of new facility buildout?",42,"Okay. And then last one on Japan, Dow. I think you used the word slow, but stabilizing. Again, last night, Accuray, I think, talked about facility delays and new construction there. Are you seeing any slippage in terms of new facility buildout?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say, we're not seeing a slippage. We have seen a contraction in the market. There's less government spending, but we're not seeing slippage. Maybe that to just come back to your first question, just a little bit on price. We did launch the VitalBeam p",182,"I'd say, we're not seeing a slippage. We have seen a contraction in the market. There's less government spending, but we're not seeing slippage. Maybe that to just come back to your first question, just a little bit on price. We did launch the VitalBeam product. And it's priced right at or maybe even a hair north of where we thought it was landing. We were very excited to see its volume globally. Since the launch, we've taken 45 orders with that product. And 36 of those came in the first half of this year. And it fills a mid-tier pricing market where, frankly, we haven't had coverage. But it's also enabled our TrueBeam pricing to move up a little bit. So we feel very good about where the product portfolio is and the pricing discipline that our team has. And frankly, that product, I mean, coming back to your Accuray comment, that product's a little bit more aimed at Elekta than it is Accuray. So I'm not sure what -- let's talk to Josh about his pricing challenges, I guess."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Jeff Johnson from Robert W. Baird.",11,"Our next question comes from Jeff Johnson from Robert W. Baird."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is actually Jason on for Jeff. Just wanted to start on Europe. You had some very good growth out of your European oncology business. You seemed to be actually one of the companies that are bucking the trend here in the quarter in the capital equipmen",91,"This is actually Jason on for Jeff. Just wanted to start on Europe. You had some very good growth out of your European oncology business. You seemed to be actually one of the companies that are bucking the trend here in the quarter in the capital equipment side in Europe. So just wonder if you could discuss how you feel about the sustainability of the performance of that business, especially in light of what are some tougher comps that are going to be coming up against you in the next quarters?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say, yes, the quarter was terrific. And we love that we did have a couple of large orders. First of all, from the top, our orders, just to review, gross orders were up 19% in EMEA, 23% in constant currency. We did have a large multisite order from the",269,"I'd say, yes, the quarter was terrific. And we love that we did have a couple of large orders. First of all, from the top, our orders, just to review, gross orders were up 19% in EMEA, 23% in constant currency. We did have a large multisite order from the Apollo group in India, and that was 11 TrueBeams, 1 EDGE and 5 brachytherapy systems. We also had some major wins in the Middle East, which -- that was nice to see. I mean, I wouldn't say that, that was anomalous. That market's been kind of a little bit down with people dealing with oil price impact on federal budgets, health care budgets. But that was nice to kind of see that come back. We had a very nice win in the U.K. And then I'd say, all across Europe, we had a very good mix of product, a little bit richer hardware mix and very good engagement of our software business in Europe. So I'd say, we're not going to do 20% every quarter, that's probably a little bit too much to ask. As it comes to the total, when you look at the overall market, last 12 months, our estimate is that it's 12 months constant currency growth rate at about 5%. And at least kind of in that really big picture, that's kind of what we see going forward. We've clearly gained some market share the last 2, 3 years. And we're seeing that we're able to maintain that share and get a little price, which is kind of where our focus is right now."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, that's helpful. And then just wanted to come back quickly on the FX side as it relates to guidance. At least your -- we'd expected actually a little bit of upside maybe to guidance given what FX has done here in the recent months. So is it fair to t",68,"Okay, that's helpful. And then just wanted to come back quickly on the FX side as it relates to guidance. At least your -- we'd expected actually a little bit of upside maybe to guidance given what FX has done here in the recent months. So is it fair to think that all that FX upside has basically just been offset by the weakness on the ICB business?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Look, we are taking somewhere, call it $35 million or so out of top line for the year to come down by 1 point on the growth rate and maintaining EPS. And virtually, the currency impact is very, very small. This is -- our business is doing a fantastic job",143,"Look, we are taking somewhere, call it $35 million or so out of top line for the year to come down by 1 point on the growth rate and maintaining EPS. And virtually, the currency impact is very, very small. This is -- our business is doing a fantastic job on cost control. So the margin is coming in a little bit higher of the gross margin level than we were expecting, which is great news due to pricing due to MeVis software, and our Imaging Components business drove that up maybe a point more than we were expecting in the second quarter. So as we anniversary now, currency is roughly neutral to us as we go into the second half of the year. And the business, we're just committed to offsetting that slight revenue mix by good cost controls across the board."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Amit Hazan from Citi.",9,"Our next question comes from Amit Hazan from Citi."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is actually Lee on for Amit. Quick question about market share gains. You guys have been talking just a little bit more recently. Just hoping you can give us what you think the drivers are that would drive incremental share right now versus where you",57,"This is actually Lee on for Amit. Quick question about market share gains. You guys have been talking just a little bit more recently. Just hoping you can give us what you think the drivers are that would drive incremental share right now versus where you guys stood competitively last year -- over the last few years?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think our product line has never been better at every price point. We've got EDGE at the top. When you look at the ability to deliver dose to small volumes, the ability to plan difficult treatments with an efficiency that nobody else can touch and the s",328,"I think our product line has never been better at every price point. We've got EDGE at the top. When you look at the ability to deliver dose to small volumes, the ability to plan difficult treatments with an efficiency that nobody else can touch and the speed of delivery at the high end. Gamma Knife or Cyber Knife can't touch us. When you look at the mid-tier of the market, our TrueBeam product is -- it is what everybody compares to. It is the gold standard of radiation therapy. And that's -- we're seeing a rich in mix on there. I think the other thing at both the high end and the mid-tier of the market is we've got the best total cost of ownership and the best throughput of anybody else out there. So that might be some of Accuray's problems is, I don't know. But I think we are extremely competitive at the total cost of ownership, especially when you look at our throughput advantages, we have far and away the most efficient product out there in terms of throughput and reliability. And we also have -- we've been focused very, very much the last few years on Net Promoter Score. And we believe -- when we measure this through independent groups, we believe that we've got a significant lead in customer service. And then you add that with our -- the VitalBeam launch that I just talked about. Our Eclipse and ARIA product lines recently both won the best-in-class award. So we've that for a while in Eclipse. This was the first time for us in our ARIA oncology information system product. So I just think the strength of the product line is very, very good. On top of that, some of the vision that we shared at ASTRO around both our future around hardware and software is capturing the imagination of our customers for even better, stereotactic body radiation therapy and data analytics."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, great. And then one follow-up with...",7,"Okay, great. And then one follow-up with..."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Maybe one of the thing to add there is that's kind of the product side of it. At the same time, you heard us talk 12, 15 months ago about a change to a new distribution organization. And we regionalized our distribution team into -- took it from a global",106,"Maybe one of the thing to add there is that's kind of the product side of it. At the same time, you heard us talk 12, 15 months ago about a change to a new distribution organization. And we regionalized our distribution team into -- took it from a global sales organization and cut it into 3 geographic structures. And I think that's a nice difference. It's gotten us close to the customer. Decisions don't have to come to Palo Alto. They're made in the field, and it's made this part of this kind of improving Net Promoter Score and customer satisfaction and customer response."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, great. And then my follow-up is that we've been hearing from Intuitive Surgical, they've been reporting a fairly big rebound in brachytherapy volumes and that's about several digits with sidelined patients possibly coming back post 2012 guideline ch",61,"Okay, great. And then my follow-up is that we've been hearing from Intuitive Surgical, they've been reporting a fairly big rebound in brachytherapy volumes and that's about several digits with sidelined patients possibly coming back post 2012 guideline changes. Is that something coming up on your radar at all in terms of helping flow capacity or drive interest in these systems?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, I'd say when the watchful waiting guidelines went out in 2012, 2013, we did see -- our customers did see some dropoff in their prostate volumes. I think, is it back to where it was in 2012? I hadn't seen any math that says that, but it's definitel",54,"I mean, I'd say when the watchful waiting guidelines went out in 2012, 2013, we did see -- our customers did see some dropoff in their prostate volumes. I think, is it back to where it was in 2012? I hadn't seen any math that says that, but it's definitely back up for sure."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from David Roman from Goldman Sachs.",10,"Our next question comes from David Roman from Goldman Sachs."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","This is actually Candace on for David. Just a quick question on the imaging inside. Could you give a little more detail on the dynamic around customer inventory levels? And what's driving them to be elevated?",36,"This is actually Candace on for David. Just a quick question on the imaging inside. Could you give a little more detail on the dynamic around customer inventory levels? And what's driving them to be elevated?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. We were just speaking in particular of our largest customer in that space. Toshiba has been up for sale. I think as part of that sale, their customers have probably gotten conservative about seeing the transition happen. And so our demand is off ther",92,"Yes. We were just speaking in particular of our largest customer in that space. Toshiba has been up for sale. I think as part of that sale, their customers have probably gotten conservative about seeing the transition happen. And so our demand is off there, and their supply is up. So that's the driver. There's no -- that will bounce back we think. As the acquisition gets completed, they've obviously announced the sale to Canon. And I'd say otherwise, it's business as usual in that shop. It's just one specific customer situation."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. So there's nothing further there and that's the only weakness, nothing beyond that consolidation?",15,"Okay. So there's nothing further there and that's the only weakness, nothing beyond that consolidation?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Right. That's the incremental fees. I mean, we talked a little bit about some of the other issues that business has had last year. But that's -- when you look at what we -- versus what we expected for this year, that would be the one slight miss to the ye",65,"Right. That's the incremental fees. I mean, we talked a little bit about some of the other issues that business has had last year. But that's -- when you look at what we -- versus what we expected for this year, that would be the one slight miss to the year has been volume in that business, as they've gone through this change in strategy."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, that's very helpful. And then I know that you guys have talked about the impact of FX. But I was just curious about the indirect impact that you had spoken about on past calls. Could you maybe just shed some light on what your reception internationa",60,"Okay, that's very helpful. And then I know that you guys have talked about the impact of FX. But I was just curious about the indirect impact that you had spoken about on past calls. Could you maybe just shed some light on what your reception internationally has been? And if that's changed at all as the dollar has weakened."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say when you look at it over 18 months, it's had a pretty significant impact. Elisha fixed this. I'm going to say the yen was down 20% and the euro was down 25%. Is that about right?",39,"I'd say when you look at it over 18 months, it's had a pretty significant impact. Elisha fixed this. I'm going to say the yen was down 20% and the euro was down 25%. Is that about right?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That is about right.",4,"That is about right."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And our competitors in this business are yen-based and euro-based. And rather taking it to translation profits, they took the gift to pricing. So we worked very hard to maintain our share and I think we have. We're seeing those prices stabilize so that's",47,"And our competitors in this business are yen-based and euro-based. And rather taking it to translation profits, they took the gift to pricing. So we worked very hard to maintain our share and I think we have. We're seeing those prices stabilize so that's good news."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And Candace, I would just add. I mean, we've seen pricing stabilize in the Imaging Components business by product line. So we've largely anniversaried the impact, particularly as we get into Q3. But we're actually going to see some growth in the Imaging C",63,"And Candace, I would just add. I mean, we've seen pricing stabilize in the Imaging Components business by product line. So we've largely anniversaried the impact, particularly as we get into Q3. But we're actually going to see some growth in the Imaging Components business quarter-over-quarter, just not to the level that we had first anticipated because of the issues we've talked about."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question comes from Steve Beuchaw from Morgan Stanley.",10,"Our next question comes from Steve Beuchaw from Morgan Stanley."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","It's actually Steve in for Steve. So first question is, Elisha, on the seasonality in the model, the implied guide for the fourth quarter puts a little bit more weight on earnings in the fourth quarter than normal. What is it about the model this year tha",62,"It's actually Steve in for Steve. So first question is, Elisha, on the seasonality in the model, the implied guide for the fourth quarter puts a little bit more weight on earnings in the fourth quarter than normal. What is it about the model this year that's a little different relative to the last, I don't know, 3 years or so?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, so a couple of things. First of all, FX, we're going to completely anniversary the effect of FX at today's levels. So that takes some pressure off. And in oncology, we're going to see a more linear year. Last year Q3, actually sequentially was down f",175,"Yes, so a couple of things. First of all, FX, we're going to completely anniversary the effect of FX at today's levels. So that takes some pressure off. And in oncology, we're going to see a more linear year. Last year Q3, actually sequentially was down for oncology. You're not going to see that for our expectations this quarter. So what you're seeing is really some fluctuations, mostly in our PT business. So if I look at Q3 guidance, oncology should do high single digit. We're going to have our Imaging Components somewhere around the mid-single digit. But we get a significant drop off in our Proton business because we booked Maryland in the year-ago period. So that's why you get to a 0% flat revenue. If you get into Q4, it's exactly the opposite, and our Proton business is going to grow significantly just based on the projects and the timing of revenue recognition and the percentage of completion. So those are a few of the things that are different versus a year-ago period."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then sorry, if I missed this. But at this stage, halfway through the fiscal year, what would be, for the full fiscal year, the impact in pennies, I suppose, of currency at the bottom line?",37,"Okay. And then sorry, if I missed this. But at this stage, halfway through the fiscal year, what would be, for the full fiscal year, the impact in pennies, I suppose, of currency at the bottom line?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I would say, probably I'm going to say about $0.05, $0.06. I don't have it exactly, Steve. It was a little more in Q1 than in Q2. Q2 was only about $0.02 or so. Q3 should be roughly 0 at today's level.",42,"I would say, probably I'm going to say about $0.05, $0.06. I don't have it exactly, Steve. It was a little more in Q1 than in Q2. Q2 was only about $0.02 or so. Q3 should be roughly 0 at today's level."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","It's a nice thing, isn't it?",7,"It's a nice thing, isn't it?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, it sure is.",4,"Yes, it sure is."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then, Dow, I just wanted to come back to your comments earlier on VitalBeam. Can you go into just a bit more detail on the strategy for deploying it in the U.S.? It puts you in a position where you're obviously, high tier with TrueBeam and now mid-tie",82,"And then, Dow, I just wanted to come back to your comments earlier on VitalBeam. Can you go into just a bit more detail on the strategy for deploying it in the U.S.? It puts you in a position where you're obviously, high tier with TrueBeam and now mid-tier provider with VitalBeam. How do you think about segmenting the market? And how much more aggressive can you get in the rollout of VitalBeam? How much more push is in the plan there?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, we're very excited about the product. It's gone very well. I think the way the guys are using it a lot, the guys and girls in the field are using it. It's really to sell up. So often versus our competitors, it starts out in the canal water from a",332,"I mean, we're very excited about the product. It's gone very well. I think the way the guys are using it a lot, the guys and girls in the field are using it. It's really to sell up. So often versus our competitors, it starts out in the canal water from a pricing point of view. And what we really want to do is we want to differentiate the TrueBeam and it has many, many significant advantages over everything else that's out there. And we've trained very hard on that. I think there's good discipline around it and we're seeing that in our numbers. From a product cost point of view, the team has also done a really great job getting the product cost out. So it's given us some flexibility to do that. So the margin dollars, margin percent at these price points are still pretty good. So we like that part of it. The -- I'd say, we're -- it might be a little bit ahead of our expectations in terms of its impact in the U.S. We thought we'd have a little bit bigger impact outside of the U.S. And our team is just playing in that, true. So we do think we'll see some upside from the product outside of the U.S. It typically takes us a little longer to train and get it into budget cycles and things like that. But it is -- for this market, in particular where we have an old install base that's looking to trade up and how can they -- chances are, they're not depreciating the old asset anymore. It's been through its depreciation cycle. And they're looking to how can they swap out that old stuff and get something new and competitive at a good price point that's just worked out very, very well. I think the proof is in the pudding. In North America, the whole business was up 7% in the quarter. And our funnel remains pretty good."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And our next question comes from Toby Wann from Obsidian Research Group.",12,"And our next question comes from Toby Wann from Obsidian Research Group."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Steve [indiscernible]. I guess I'll be on for Toby. Can you guys kind of talk quickly about the pipeline of potential new Particle Therapy business out there with, I guess, multi-room systems?",32,"Steve [indiscernible]. I guess I'll be on for Toby. Can you guys kind of talk quickly about the pipeline of potential new Particle Therapy business out there with, I guess, multi-room systems?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I never know what to say to this question. The short version is the pipeline of Proton systems is gigantic. The pipeline for financeable Proton systems is significantly smaller. And I guess, what -- the good news is, as I mentioned, we've got 3 contracts",219,"I never know what to say to this question. The short version is the pipeline of Proton systems is gigantic. The pipeline for financeable Proton systems is significantly smaller. And I guess, what -- the good news is, as I mentioned, we've got 3 contracts that we signed for compacts this last quarter. We think they're all financeable. But we don't book them until they are in fact financed. And we've got a very good funnel that looks very strong. So we're optimistic about where it's going, and it's global. It's not -- this is not, I'd say, it's just as much outside of the U.S. as it is in the U.S. at this point. So we like the global nature of it. I would say that one of the other things that we like is we're seeing a little transition from a developer-driven market to more of a customer sovereign government Minister of Health kind of market, which has taken away some of these financing issues. And frankly, the other thing that's happening is the market is moving to smaller, smaller units. So last year, we booked several 4- and 5-room systems. More of the market is in the 1, 2, 3 market, 1 or 2 treatment vaults now. And I think that's a trend that will continue."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Great. That's helpful. So I guess, you haven't really seen any given kind of global economic conditions, unrest here, unrest there. Any impact, any changes in terms of the velocity of kind of how people are thinking about getting into Protons?",41,"Great. That's helpful. So I guess, you haven't really seen any given kind of global economic conditions, unrest here, unrest there. Any impact, any changes in terms of the velocity of kind of how people are thinking about getting into Protons?"
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No, not at all. I think, one -- given that, one of the things that we really like is of the compact products in the market, ours is the only no-compromise compact product. And a true scan beam, full rotational Gantry, highest throughput, most clinical cap",69,"No, not at all. I think, one -- given that, one of the things that we really like is of the compact products in the market, ours is the only no-compromise compact product. And a true scan beam, full rotational Gantry, highest throughput, most clinical capability, to really leverage the physics advantage of Proton Therapy, you need what we got. And I think that's beginning to resonate with customers."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","At this time, we have no further questions. I will turn the call back over to our speakers for closing comments.",21,"At this time, we have no further questions. I will turn the call back over to our speakers for closing comments."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Thank you for participating. A replay of this call can be heard on the Varian investor website at www.varian.com/investor where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or 1 (201) 6",70,"Yes. Thank you for participating. A replay of this call can be heard on the Varian investor website at www.varian.com/investor where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or 1 (201) 612-7415 from outside the U.S. and entering confirmation code 13632882. The telephone replay will be available through 5:00 p.m. this Friday, April 29.
Thank you."
311907,328570774,966411,"Varian Medical Systems, Inc., Q2 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation.",20,"Thank you. This does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems teleconference. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Spencer Sias, VP Investor Relations for Varian Medical. Thank you,",44,"Greetings, and welcome to the Varian Medical Systems teleconference. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Spencer Sias, VP Investor Relations for Varian Medical. Thank you, Mr. Sias you may now begin."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Good afternoon, and welcome the Varian Medical Systems conference call for the third quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will",268,"Thank you. Good afternoon, and welcome the Varian Medical Systems conference call for the third quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. 
To simplify our discussion, unless otherwise stated, all references to the quarter or year are fiscal quarters and fiscal years, quarterly comparisons are for the third quarter of fiscal 2016 versus the third quarter of fiscal 2015. References to financial results for orders are to gross orders unless otherwise indicated. This discussion includes non-GAAP financial measures in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. 
A reconciliation to the most comparable GAAP measure is included in our earnings release which can be accessed on our website. Please be advised that this discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, will, scheduled, and similar expressions, are intended to identify those statements which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks relating to our business are described in our third quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise.
And now, here's Dow."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Varian is reporting solid results for the third quarter of fiscal year 2016, a strong growth order and revenue growth in our Oncology Systems and Imaging Components businesses, together with substantial improvements in gross a",1048,"Good afternoon, and welcome. Varian is reporting solid results for the third quarter of fiscal year 2016, a strong growth order and revenue growth in our Oncology Systems and Imaging Components businesses, together with substantial improvements in gross and operating margins for both. In summary, the company is reporting GAAP net earnings of $1.04 per diluted share and $1.22 per diluted share on a non-GAAP basis. Revenues of $789 million, up 1% versus the year-ago quarter and nearly 4 point improvement in the company's overall gross margin and in order for new -- for a new multi-room proton installation in China, our first proton order there. 
Focusing on operational highlights. Our Oncology business generated third quarter gross orders of $676 million, up 6% in both dollars and constant currency. Gross orders in the Americas rose by 8% during the quarter with 15% growth in North America, more than offsetting a greater than 40% decline in Latin America. Here today, gross order growth in North America is 8%, driven by a more stable reimbursement environment and in this replacement market, a transition to more advanced clinically efficient systems. 
Gross orders in APAC increased 19% in dollars and 17% in constant currency during the quarter, driven by robust growth in China and Australia. In EMEA, gross orders declined 3% in dollars and 4% in constant currency reflecting weakness in Western European markets. Looking at each of the regions in more detail. Our growth in North America was driven by demand for our TrueBeam platform, including EDGE radiosurgery systems and our software offerings. Among the highlights of North America were several large multi system orders from consolidated networks as well as competitive takeouts. 
Order activity in Latin America continued to be weak due to macroeconomic factors. During the quarter, we shipped the first units for the large tender conducted by Brazil's Ministry of Health, a couple of years ago. Turning to APAC. The group placed the largest Varian ever in Australia for 10 tubing systems, 7 of which are going to new sites along with the full complement of our information management and treatment planning software. The headwinds were several new accelerator installation in China where we saw good orders growth. We also saw strong demand for our EDGE radiosurgery system in this market where we continue to be the share leader. 
Elsewhere in APAC. We made good progress in Thailand, Vietnam and Indonesia. Business was stable in Japan where we saw good service growth. Turning to EMEA. Healthy growth, order growth in emerging markets, including Iran, Russia, Ethiopia and Libya was offset by weakness in Western Europe. Our third quarter business in Africa was outstanding with more than $25 million in gross orders. Among other wins, we saw Ethiopia order its first modern linear accelerators for cancer treatment. 
I'm pleased to report that overall, unit order volumes was up in the quarter and year-to-date and that average pricing is stable, for winning with clinically efficient advanced technology that makes quality cancer care affordable and accessible. This was requested during the quarter and strong orders to our RapidPlan and InSightive Analytics software. We booked our 500th order for RapidPlan, which is a game changer that enables clinics to improve the speed and quality of care for their patients. As of this quarter, treatment plans are now being shared among clinics through our ongoing onco peer Web portal. 
As you all know, CMS has announced modest adjustments to reimbursement for 2017 for both hospitals and freestanding clinics. We don't expect for reimbursement to have a material impact on the radiation oncology markets in the U.S. next year. Following the topic of reimbursement. CMS did move forward with policies that will incentivize the adoption of digital X-ray imaging systems in place of film and computed radiography systems, and this should help support growth in our Imaging Components business. 
Speaking of Imaging Components. The business returned to growth during the quarter. Orders grew by 13% to $138 million and revenues rose by 9% to $147 million, improvement in margins were driven by productivity gains and a favorable product mix. Our 2 business saw good growth in the quarter. We recently celebrated the 40th year of our relationship with the Sheba medical systems and look forward to continuing this relationship when they become part of Canon. 
Our recently acquired software and X-ray accessory businesses also helped to drive growth. Touching on the industrial imaging business orders for security products are up in the quarter but we continue to have a cautious outlook in the face of ongoing customer consolidation. We continue to focus on generating growth in nondestructive testing and inspection. Let me update you on our progress towards the separation of the Imaging Components business into a new, independent publicly-traded company via tax-free distribution Varian stockholders. 
As you probably saw in the press release issued last week, the name of the new company will be Varik Imaging Corporation. We are now making good progress from the development of detailed plans and activities needed to execute the separation. We're on track to file an initial Form 10 with the SEC in the next several weeks and we are currently on schedule to complete the separation at the end of calendar year. We continue to be excited about the prospects of creating 2 great companies. 
Turning now to our Particle Therapy business. We booked an order during the quarter for a multi-room probing installation at the new medical in China. This is China's first government-funded proton facility. Installation is waiting to take place in late 2017 with patient treatments scheduled to begin in late 2018. Our installation at Cincinnati Children's Hospital is on track with the first patient treatments scheduled to commence later this summer. We've now successfully commissioned the third room at the Merrill Lynch Proton Therapy Center and installations are underway in Holland, Russia and Saudi Arabia. 
In total, we have 13 proton projects generating revenue. As you probably saw from our 8-K filing with the SEC at the end of June, we sold our $73 million senior loan for the New York Proton Therapy Center to Deutsche Bank, freeing up capital to help finance other proton projects. The proton sales funnel continues to look good. 
And now I'll turn it over to Elisha."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Great. Thanks, Dow, and hello, everyone. Dow has already covered growth orders. So let me start with backlog. We ended the quarter at $3.3 billion, up 5% from the year-ago period. Backlog adjustments during the quarter, totaled $51 million bringing net or",590,"Great. Thanks, Dow, and hello, everyone. Dow has already covered growth orders. So let me start with backlog. We ended the quarter at $3.3 billion, up 5% from the year-ago period. Backlog adjustments during the quarter, totaled $51 million bringing net orders for the company to $814 million. Third quarter revenues for the total company were $789 million, up 1% in dollars and even with the year-ago period in constant currency. Year-to-date, total company revenues were $2.3 billion, up 1% in dollars and up 3% in constant currency. Oncology posted a revenue gain of 8% both in dollars and in constant currency, driven by strength in our high-end equipment as well as our software and service businesses. Imaging Components posted a third-quarter revenue gain of 9%, driven by our newly acquired X-ray accessories business as well as higher tube sales. 
Our Particle Therapy business [indiscernible] third quarter revenue of $37 million, down from the year-ago period when we booked $91 million of revenues, including a substantial amount for the proton installation at the University of Maryland. Total company gross margin for the quarter was 43.9%, up by nearly 4 points with significant contribution from both Oncology and Imaging Components. Oncology Systems third quarter gross margin improved by more than 4 points to 46% with the help of a larger mix of TrueBeam's and software as well as productivity gains. Imaging Components third quarter gross margin also rose by more than 4 points to 42.9% due largely to factory productivity gains and favorable product mix.
R&D expenses were $65 million or 8% of revenue, equal as a percentage of revenue to the year-ago period. On a GAAP basis, third quarter SG&A expenses were $151 million or 19% of revenue. We had about $22 million of unusual expenses in SG&A for items, including ongoing patent litigation and the recently announced initiative to separate the Imaging Components business into a new publicly-traded company. Excluding these items, SG&A expenses on a non-GAAP basis for the quarter were $129 million or 16% of revenue. 
GAAP operating earnings for the quarter were 16.5% of revenue and 19.5% of revenue on a non-GAAP basis, reflecting our solid gross margin performance in the quarter. Depreciation and amortization totaled $18 million for the quarter. The effective tax rate was 25.1%, up 3 points from the year-ago quarter when we benefited from the favorable geographic mix of profits and tax loss carryforwards associated with the Proton business. We continue to expect that the tax rate will be about 26% to 27% for the year. Fully diluted shares outstanding were $95.4 million, more than $5 million lower than the year-ago quarter due to our ongoing share repurchase program. Diluted EPS was $1.04 for the quarter on a GAAP basis and was $1.22 on a non-GAAP basis.
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $836 million, debt of $701 million and stockholders equity of $1.7 billion. DSO at 101 days was up significantly from the year-ago quarter, but improved sequentially from the second quarter. Third quarter cash flow from operations was $95 million, bringing the total cash flow from operations year-to-date to $204 million. Primary uses of cash were $126 million for the repurchase of 1.5 million shares of stock, $95 million to reduce debt and $15 million for capital expenditure. At the end of the quarter, we had 4.8 million shares remaining under the existing repurchase authorization that extends to calendar year 2016. 
Now I'll turn it back to Dow for the outlook."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. Including the results of the third quarter, we believe that total company non-GAAP earnings will be in the range of $4.62 to $4.66 per diluted share for fiscal year 2016. We continue to believe revenues for fiscal year 2016 will increase b",56,"Thanks, Elisha. Including the results of the third quarter, we believe that total company non-GAAP earnings will be in the range of $4.62 to $4.66 per diluted share for fiscal year 2016. We continue to believe revenues for fiscal year 2016 will increase by about 3% over fiscal year 2015. 
We're now ready for your questions."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] and our first question will come from the line of Anthony Petrone with Jefferies.",16,"[Operator Instructions] and our first question will come from the line of Anthony Petrone with Jefferies."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Congratulations on a good quarter. Maybe to start a little bit with just the North American order growth in Oncology there, which sort of reached a multi-quarter high here. Maybe a little bit more in terms of the underlying drivers there. How much was mar",82,"Congratulations on a good quarter. Maybe to start a little bit with just the North American order growth in Oncology there, which sort of reached a multi-quarter high here. Maybe a little bit more in terms of the underlying drivers there. How much was market related? Maybe even replacement cycle related. And how much was it from share gains? And then a follow-up there would be on the product side, how much was driven by VitalBeam, which was a driver last quarter?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Good questions. I would start by saying our rolling 4 quarter growth in the Americas has been 7%. So we feel very good about kind of where that is. North America has certainly been the driver. And you're right, North America did get a high this quart",292,"Yes. Good questions. I would start by saying our rolling 4 quarter growth in the Americas has been 7%. So we feel very good about kind of where that is. North America has certainly been the driver. And you're right, North America did get a high this quarter, but it is kind of a sustained trend that we're seeing, which is good. We did have a couple of multi-system orders, including one with HCA. We also had very strong demand, as I mentioned in the call, for software products. And VitalBeam, I think a little more than half of our VitalBeams have been sold in the Americas. So that VitalBeam has been part of the story. But I think the overall story though is TrueBeam. When you clearly look at what's going on, TrueBeam is what's driving both the Americas growth and the global growth, both in orders and in revenues. I mean some on the revenue side, Elisha talked about this on the revenue side, we had very good tubing mix on the quarter as some of the margin uptick. But it's -- from a kind of a market perspective. No, the U.S. is a replacement market, that's true. As I said on the call, we are seeing people trade-out aggressively to try to get new capability especially for advanced radiosurgery and body radiosurgery. I think reimbursement may have been a small factor, certainly not over last year, but having that be calm in the quarter, kind of short of -- short things up a little bit, and I think from a high level, that's kind of the story. From the market share point of view, we think we gained a little bit of share. But most of this is market."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","No, very, very helpful. And maybe to shift gears just to imaging and then one for Elisha. The one of the headwinds for that business over the past couple of quarters was destocking from several key customers, including Toshiba. I'm just wondering if that",62,"No, very, very helpful. And maybe to shift gears just to imaging and then one for Elisha. The one of the headwinds for that business over the past couple of quarters was destocking from several key customers, including Toshiba. I'm just wondering if that has reversed at this point, and specifically, with regards to Toshiba, they back ordering anything at this point?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say Toshiba is back a little bit. I wouldn't say that they are fully back yet. I mean, we have an okay-quarter from Toshiba. The 2 business is actually quite strong in the quarter and some of that was Toshiba, but we also had that very good tube, perf",89,"I'd say Toshiba is back a little bit. I wouldn't say that they are fully back yet. I mean, we have an okay-quarter from Toshiba. The 2 business is actually quite strong in the quarter and some of that was Toshiba, but we also had that very good tube, performance from our other tube customers on the quarter and much on their backs that we drove this. So I'd say that the Toshiba days are frankly, still ahead of us. We're not totally out of that headwind yet."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And the applications helped us out, Anthony.",7,"And the applications helped us out, Anthony."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes.",1,"Yes."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes, sure. And then last, just quick then I'll hop on queue, is Elisha, Oncology gross margin, 46% you called out. That's beyond the normalized 44% level. I mean is this sort of the new normal? Do you expect it to sort of moderate back down to that 44% le",52,"Yes, sure. And then last, just quick then I'll hop on queue, is Elisha, Oncology gross margin, 46% you called out. That's beyond the normalized 44% level. I mean is this sort of the new normal? Do you expect it to sort of moderate back down to that 44% level over time?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I would like to say yes, Anthony. But I'm -- we just had a really favorable products mix in the quarter. And I just can't count on that every single quarter going forward. What I would say is Oncology has done a fantastic job on pricing, holding sta",118,"Well, I would like to say yes, Anthony. But I'm -- we just had a really favorable products mix in the quarter. And I just can't count on that every single quarter going forward. What I would say is Oncology has done a fantastic job on pricing, holding stable pricing and on product cost reduction and on productivity gains. And so the hope is, yes, that will last as we move forward. But again, product mix drives our margin much more than any other factor. I do think for this fiscal year, they should be at the high end of that 43% to 44% range that we've talked about. It really helps by this time this last quarter."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And our next question comes from the line of Amit Hazan of Citibank.",13,"And our next question comes from the line of Amit Hazan of Citibank."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","It's Lisa [ph] for Amit. A couple of questions here, I'll start with margin, on the back of the gross margin question, is there anything stronger in gross margin in this quarter that you would call out, is more sustainable in as opposed to good mix than s",58,"It's Lisa [ph] for Amit. A couple of questions here, I'll start with margin, on the back of the gross margin question, is there anything stronger in gross margin in this quarter that you would call out, is more sustainable in as opposed to good mix than some of the other items that you've already called out."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, mix -- product mix drives the margin first and foremost, in Oncology. Geographic mix secondly. The geographic mix was identical this quarter versus the year-ago quarter. So that has no impact. I would say the cost -- the product cost reduction is re",86,"Well, mix -- product mix drives the margin first and foremost, in Oncology. Geographic mix secondly. The geographic mix was identical this quarter versus the year-ago quarter. So that has no impact. I would say the cost -- the product cost reduction is real and we should continue to have the benefit of that going forward as there's many, many -- much fewer C Series, our old legacy equipment and many more TrueBeam at a higher margin. And so we're starting to see that flow through."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then just on operating margin for this year. It looks like there's been 2 good quarters at or around the 19%. The implication for fourth quarter looks above that 2. So is this kind of the range we should be thinking about going forward here? It'",85,"Okay. And then just on operating margin for this year. It looks like there's been 2 good quarters at or around the 19%. The implication for fourth quarter looks above that 2. So is this kind of the range we should be thinking about going forward here? It's a bit above your original guidance, is this FX-related to some extent? Or are you seeing some sustainability that makes you comfortable and we come off the bottom and maybe see some further gains heading into 2017?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, so I don't want to guide it all into 2017, particularly right at the moment with the spin-off going on. There is a lot of work that we're going to have to do in terms of looking into FY '17. You are correct. Once you run this model through, it's goi",114,"Well, so I don't want to guide it all into 2017, particularly right at the moment with the spin-off going on. There is a lot of work that we're going to have to do in terms of looking into FY '17. You are correct. Once you run this model through, it's going to put in a close to 19% operating margin for this year, which would help us out, 0.5 versus the year-ago period. So again, all businesses have been very focused on headcount and on travel, and on discretionary spending. And I think you're starting to see this flow through. But most of that improvement this year is coming through the gross margins."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And I should point out, it is consistent with our goal over the next 3, 4 years to get back to that higher return on sales. So it's kind of delivering on the track, 50 basis points-ish a year that we were kind of set on overall arching goal.",49,"And I should point out, it is consistent with our goal over the next 3, 4 years to get back to that higher return on sales. So it's kind of delivering on the track, 50 basis points-ish a year that we were kind of set on overall arching goal."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Great. And if I could sneak in one more, if I could. Can you talk about maybe the adjustments to the backlog this quarter? They're a little bit higher than trends. Maybe you could give us some context as to what's going on there.",45,"Okay. Great. And if I could sneak in one more, if I could. Can you talk about maybe the adjustments to the backlog this quarter? They're a little bit higher than trends. Maybe you could give us some context as to what's going on there."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Actually, the backlog adjustments were lower I believe in the prior quarter and were pretty consistent with our average. So the $51 million is really what we would refer to -- some cancellations in that number, maybe $20 million of it. The rest is what we",95,"Actually, the backlog adjustments were lower I believe in the prior quarter and were pretty consistent with our average. So the $51 million is really what we would refer to -- some cancellations in that number, maybe $20 million of it. The rest is what we call dormancy when we review the backlog and we feel like there's no longer a good probability of the machines delivering within 2 years, we just take it out of our backlog until it [indiscernible]. So but the $51 million level is very consistent with historically, how it's been."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then sorry, one last quick one. If you could maybe give us of why the CRM was up during the quarter?",23,"Okay. And then sorry, one last quick one. If you could maybe give us of why the CRM was up during the quarter?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. So we had done -- we've been seeing this the last couple of quarters. The good news is Q3, if you look at our cash flow from operations, returned back to a very strong level and was almost equal to net income. So I'm feeling very good that we're back",121,"Yes. So we had done -- we've been seeing this the last couple of quarters. The good news is Q3, if you look at our cash flow from operations, returned back to a very strong level and was almost equal to net income. So I'm feeling very good that we're back on track in terms of cash flow. What happened is we move that collection staff earlier in the fiscal year. We did a CRM implementation. I think those things just slowed down collections a little bit in the first half of the year. We've got some catching up to do. But in June and July, our corrections have actually been very strong. So I think we're getting back on track."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, and Q2 to Q3, we have had 10 days additional improvement going in the right direction.",17,"Yes, and Q2 to Q3, we have had 10 days additional improvement going in the right direction."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Brandon Henry with RBC Capital Markets.",15,"And the next question comes from the line of Brandon Henry with RBC Capital Markets."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","First just on the North America strengthening gross orders. Can you just help provide some more detail on how much of that performance was on better systems order versus software and services?",32,"First just on the North America strengthening gross orders. Can you just help provide some more detail on how much of that performance was on better systems order versus software and services?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","One of the things that we like about it is that it was broad-based. It was both -- it was hardware, it was software and it was service. So we saw in all 3 categories there wasn't 1 -- as I mentioned from a product mix point of view, that market has largel",128,"One of the things that we like about it is that it was broad-based. It was both -- it was hardware, it was software and it was service. So we saw in all 3 categories there wasn't 1 -- as I mentioned from a product mix point of view, that market has largely -- it's probably been a 90% shooting market for the last 18 months to 2 years. And it was at the high end of that. So maybe a little bit of product mix from an orders point of view. But as I said in the call, we had a couple of nice large strategic deals. And we had a number of competitive takeouts in both the hardware and software area, but it was rocky."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And did you guys give any growth rates in terms of software terms of this quarter? I might've missed that.",21,"Okay. And did you guys give any growth rates in terms of software terms of this quarter? I might've missed that."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No, we haven't broken it out.",6,"No, we haven't broken it out."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And the separate question. Could you provide an update on what portion of Siemens went active in traded out at this point? How much of the acceleration in the North American Oncology Systems business can be attributed to an acceleration in Siemens t",45,"Okay. And the separate question. Could you provide an update on what portion of Siemens went active in traded out at this point? How much of the acceleration in the North American Oncology Systems business can be attributed to an acceleration in Siemens trade outs?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think it's a small and maybe even very small factor. It's not coming off the trend line. I think when we first did the relationship with them 3, 4 years ago, there was probably a 2,000-ish unit installed base. And I'd say that's coming out 150-ish a yea",93,"I think it's a small and maybe even very small factor. It's not coming off the trend line. I think when we first did the relationship with them 3, 4 years ago, there was probably a 2,000-ish unit installed base. And I'd say that's coming out 150-ish a year or probably coming out. We haven't seen a -- an acceleration or deceleration of that trend. It's been kind of steady as it goes. It is a replacement market whether it's Siemens or everybody else and that's -- that is what we're seeing."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then last question for me, just on China. It looks like from first half '16 results from GE and Philips, it does look like Chinese activity and orders are picking up at least the market. But could you speak to a trends are seeing in China and se",61,"Okay. And then last question for me, just on China. It looks like from first half '16 results from GE and Philips, it does look like Chinese activity and orders are picking up at least the market. But could you speak to a trends are seeing in China and seeing somewhere pickup in activity in the radiation Oncology market in China?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, I think that's very consistent. We had an okay first half. But we had a very good third quarter. Our third quarter was -- China was up 13%. We had very strong demand, especially for high end products which our EDGE product as I mentioned, on the call",221,"Yes, I think that's very consistent. We had an okay first half. But we had a very good third quarter. Our third quarter was -- China was up 13%. We had very strong demand, especially for high end products which our EDGE product as I mentioned, on the call, the script was very good. One of the things that we really like about the demand we're seeing is it is almost 90% new [indiscernible]. So obviously, that's going to drive our long-term service business and offer a great opportunity et cetera, et cetera, et cetera. So these are new coming in, they're happening on schedule tender activity. We do continue to see some protest of that activity. It doesn't change that much the win it's kind of like the process they're also coming back to our previous question in China, there is a large installed base opportunity one of the geographies where they did that the event frankly, because of their price position frankly, before and I think over the next several years, that's going to be one to watch. The other thing to watch in China, we've got this half the growth in order as I mentioned. We see a reasonable funnel of proton activity in China. So maybe this as a order will stimulate some proton growth in China."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And our next session comes from the line of Jeff Johnson with Robert W. Baird.",15,"And our next session comes from the line of Jeff Johnson with Robert W. Baird."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Dow, one question for you. I don't think anybody's asked on your Western European comments at this point. It sounds like you mentioned that being soft this quarter. Last quarter, you guys put up a very strong EMEA number. This quarter's comp was a lot tou",105,"Dow, one question for you. I don't think anybody's asked on your Western European comments at this point. It sounds like you mentioned that being soft this quarter. Last quarter, you guys put up a very strong EMEA number. This quarter's comp was a lot tougher. So do you really see anything change? Or is it kind of comp-driven? I know you had some big orders last year and this quarter in the EMEA. So I'm just trying to figure out if you're really seeing anything sequentially change in that market or kind of how you describe market trends over in Western Europe right now?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We're watching Western Europe and Latin America. Those are the 2 bright spots. The Americas, we talked about that a lot. It continues very strong. China looks good. Japan, flat, which has been down so flat -- flat is the new in Japan so that's okay. Two w",138,"We're watching Western Europe and Latin America. Those are the 2 bright spots. The Americas, we talked about that a lot. It continues very strong. China looks good. Japan, flat, which has been down so flat -- flat is the new in Japan so that's okay. Two watch areas for us are, Western Europe and Latin America. On Latin America, was down more than 40% this quarter. That's natural economically driven. We do have it in Europe, there is a tough comp on the quarter, we had a large order in the U.K. last year. So we got a little bit of a comp issue going into Q4 as well. But I'd say, we're watching Western Europe. It's -- this may be hasn't been as strong as it has been on the last 18 months or so."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's very helpful. And then Elisha, may be a few clarifying questions for you. One, I think somebody asked on the software and service side, you said you haven't given that. But could you give that? I think in the past quarters you have given thos",65,"Okay. That's very helpful. And then Elisha, may be a few clarifying questions for you. One, I think somebody asked on the software and service side, you said you haven't given that. But could you give that? I think in the past quarters you have given those trends. See if you could just give us at least qualitatively where software and service was this quarter?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Higher in corporate and software than equipment and service.",10,"Yes. Higher in corporate and software than equipment and service."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And could we be any more specific there or double-digits, or upper single digits? I mean, I think -- I think let me phrase it this way. I think you had been double-digits for a long while, kind of flipped over the last couple of quarters, up or sing",55,"Okay. And could we be any more specific there or double-digits, or upper single digits? I mean, I think -- I think let me phrase it this way. I think you had been double-digits for a long while, kind of flipped over the last couple of quarters, up or single digits, are we seeing any..."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes.",1,"Yes."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes. Any continuation of that trend or sorry?",8,"Yes. Any continuation of that trend or sorry?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So for year-to-date, let me just -- in constant currency, service is up in the high single digits. So 7% to 8%, so a little off the double-digit, but not terribly so. So again, we still feel good the unit volume was up this quarter and orders, which bodes",73,"So for year-to-date, let me just -- in constant currency, service is up in the high single digits. So 7% to 8%, so a little off the double-digit, but not terribly so. So again, we still feel good the unit volume was up this quarter and orders, which bodes well for the service business going forward. So long-term, really, not coming off of our expectations for the service business at this point."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","All right. That's helpful. And then last 2 clarifying. Just on the EPS guide you took the low end up by a little over a nickel. Is there anything in there rather than just operational at this point? A couple of companies have been adopting an issue, 2016",68,"All right. That's helpful. And then last 2 clarifying. Just on the EPS guide you took the low end up by a little over a nickel. Is there anything in there rather than just operational at this point? A couple of companies have been adopting an issue, 2016 anything like that or anything else we should think about this impacting your guidance other than just pure operational factors?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Purely operational. And we just took the midpoint and took it out by the $0.04 deep [ph] from the midpoint in Q3. So, and there is a range a little bit given that we're down to the last quarter. But no, we are not adopting the new tax provision because of",69,"Purely operational. And we just took the midpoint and took it out by the $0.04 deep [ph] from the midpoint in Q3. So, and there is a range a little bit given that we're down to the last quarter. But no, we are not adopting the new tax provision because of the [indiscernible]. We're going to wait till we get through that. So nothing in there other than operational."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Makes sense. And then last question, just on ICB, the order's up 13%, and revenue up 13% -- or 9%, I'm sorry. How much of that was organic and how much was acquisition-driven?",33,"Makes sense. And then last question, just on ICB, the order's up 13%, and revenue up 13% -- or 9%, I'm sorry. How much of that was organic and how much was acquisition-driven?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We're year-over-year with MeVis, so that's in the base now. So Claymount was different and it would've been 8% revenue growth.",22,"We're year-over-year with MeVis, so that's in the base now. So Claymount was different and it would've been 8% revenue growth."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. So you're only 1 point on those acquisitions, is that right? Did I get that number, right?",18,"Okay. So you're only 1 point on those acquisitions, is that right? Did I get that number, right?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes,  you did.",3,"Yes,  you did."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","A little more than 1%.",6,"A little more than 1%."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Steve Beuchaw that Morgan Stanley.",14,"And the next question comes from the line of Steve Beuchaw that Morgan Stanley."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Dow, when you look at the [indiscernible] business and you look at some of the trends in commodity or oil sensitive countries, and you look at the mid-stage funnel, what does it tell you about how things play out? I know we've had a couple of tough quarte",79,"Dow, when you look at the [indiscernible] business and you look at some of the trends in commodity or oil sensitive countries, and you look at the mid-stage funnel, what does it tell you about how things play out? I know we've had a couple of tough quarters here and there for obvious reasons in places like Latin America. But we've seen commodity prices in a number of spots stick up. Is that a cause for optimism about 2017?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say -- I wish I could look you in the eye and say that about Latin America. I think it's a little broader base in Latin America. In the Middle East, maybe so. I think it's a good -- I don't know that we -- it's kind of interesting on this quarter a lo",151,"I'd say -- I wish I could look you in the eye and say that about Latin America. I think it's a little broader base in Latin America. In the Middle East, maybe so. I think it's a good -- I don't know that we -- it's kind of interesting on this quarter a lot of our Africa volume and its actually really like, a lot of the Africa volume was in nonoil countries. So it's great, that Ethiopia I mentioned in the call, that's the first time we had an order from Ethiopia. And that's the kind of activity we're seeing of markets. I would say the Middle East has been a little quieter this year, looking back 12 months because of oil prices. And what are we today? $40, $45 a barrel? I think that might be enough to see some of that market come back next year."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Got it. And then on the imaging spend. I wonder how the strategic conversations outside the company have a ball thing since the imaging spin. I mean, has that open any new doors for you in terms of collaborations, partnerships or other strategic activity?",44,"Got it. And then on the imaging spend. I wonder how the strategic conversations outside the company have a ball thing since the imaging spin. I mean, has that open any new doors for you in terms of collaborations, partnerships or other strategic activity?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","On that, we're continuing to look at how we reinforce the strategy of each company as we spin. As we're looking at a broader Oncology front for our remaining company and looking for a broader components beach head for our X-ray business. Now the good news",137,"On that, we're continuing to look at how we reinforce the strategy of each company as we spin. As we're looking at a broader Oncology front for our remaining company and looking for a broader components beach head for our X-ray business. Now the good news is, it has been a -- it's been pretty active. I think it's accomplishing both strategically and we think long-term from a value point of view what we want to do, and kind of unleashing a lot of energy around those initiatives. Frankly, we're a little bit in headdown mode to get the spin done. So that's continuous, it's pretty hard here for between now and the end of the year. But we're pushing very aggressive us well on that kind of of strategy front in the business -- both business."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Tycho Peterson with JPMorgan.",13,"And the next question comes from the line of Tycho Peterson with JPMorgan."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","First question. Installation this quarter was about $42 million, and I think you stepped from where you had the last quarter, so I'm just wondering if you could kind of talk to what you think was the underlying [indiscernible]",39,"First question. Installation this quarter was about $42 million, and I think you stepped from where you had the last quarter, so I'm just wondering if you could kind of talk to what you think was the underlying [indiscernible]"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","One of the big differences, Tyco, it was $51 million in total on backlog adjustment. I believe the actual cancellation was closer to 20 and the rest was dormancy where it just -- it's not probable at this point that this machine will ship within the 2-yea",114,"One of the big differences, Tyco, it was $51 million in total on backlog adjustment. I believe the actual cancellation was closer to 20 and the rest was dormancy where it just -- it's not probable at this point that this machine will ship within the 2-year period of time, so we take it out of our backlog. The big difference is, we did not have a big FX impact this quarter and we had a large one in some of the prior quarters because as you know, our backlog is held at historical rates. And so it gets trued up every quarter based on the FX, so that was very minimal this quarter."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And then maybe for Dow. Services, you could outgrow the market for the services could you just talk about the sustainability of that trend? How long do you think you can upload the market from the service perspective and do the attac",50,"Okay. That's helpful. And then maybe for Dow. Services, you could outgrow the market for the services could you just talk about the sustainability of that trend? How long do you think you can upload the market from the service perspective and do the attach rates very meaningfully by geography."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean we're very bullish about our service business still. It's a little bit a large numbers because it's now $1 billion business. I think on the quarter in Oncology, it was 41%, 42% of the total. And it continues to be a juggernaut for us. I would say o",206,"I mean we're very bullish about our service business still. It's a little bit a large numbers because it's now $1 billion business. I think on the quarter in Oncology, it was 41%, 42% of the total. And it continues to be a juggernaut for us. I would say one of the things that we really like about the stock had growth that we're seeing in Latin America and Asia in particular. That's going to help drive the growth. That software model going to more of a kind of a fast-paced model, strengthens that business. And we are seeing lots of positive on the upside. On -- we are seeing in some markets and some of these emerging markets, we're seeing a little bit of a lacking this from third-party competition. I wouldn't say that's the reason for the slowdown. I think the slowdown probably has more to do with large numbers and just kind of where we are. But in some of these emerging markets, we are seeing some growing presence especially in the older installed base. Some third-party competition. But I'd say, we're still in that high single-digit range. It's kind of what we're feeling about the long-term capability of our service business."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then just having stability in the reimbursement part. I mean we got -- the cycle relatively unscathed, the first 2 years of macro would be, however everybody gets a little bit of a bump. Does that free up the U.S. market a bit on the next couple of ye",50,"And then just having stability in the reimbursement part. I mean we got -- the cycle relatively unscathed, the first 2 years of macro would be, however everybody gets a little bit of a bump. Does that free up the U.S. market a bit on the next couple of years?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think it's too early to tell. But that would be our guess is would be consistent with that, Tyco. I think the macro fuel is a little bit like some of the reimbursement incentives that there were on some of this early IT adoption 3, 4 years ago. So I thi",61,"I think it's too early to tell. But that would be our guess is would be consistent with that, Tyco. I think the macro fuel is a little bit like some of the reimbursement incentives that there were on some of this early IT adoption 3, 4 years ago. So I think it's probably a little bit of an upside."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then last one. You made a comment earlier on kind of the protons funnel, any sense of how you big you think that market could be?",27,"And then last one. You made a comment earlier on kind of the protons funnel, any sense of how you big you think that market could be?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Every time I forecast it since, I've been wrong, so I'm not going to take the bait. I mean, it's just -- the good news is, these are government customers. And so I think we had our first discussion with SA 15 months ago. So we went from first conversation",141,"Every time I forecast it since, I've been wrong, so I'm not going to take the bait. I mean, it's just -- the good news is, these are government customers. And so I think we had our first discussion with SA 15 months ago. So we went from first conversation to order in 15 months and for that, for us, that's a record in proton therapy. When you get in the private market and we're financing instruments, this is frankly, the most difficult part of the transaction. These deals can take a really, really long time. And so where at sovereign finances it can move pretty fast. We are having -- I'd say there are 3 or 4 live conversations going on. Will they happen in the next 15, 18 months? Maybe. There's a -- at least we have 1 now.."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Vijay Kumar with Evercore ISI.",14,"And the next question comes from the line of Vijay Kumar with Evercore ISI."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So maybe, Dow a big picture question on that. Because I guess, now we'll have the numbers right a few months on standalone Oncology. I just wondered, can you just comment big picture, what's been the installed base over the last 3 years, right? Has it bee",89,"So maybe, Dow a big picture question on that. Because I guess, now we'll have the numbers right a few months on standalone Oncology. I just wondered, can you just comment big picture, what's been the installed base over the last 3 years, right? Has it been flattish? Has it been growing in North America? Is that -- I just feel like that's an important question just to give your really, really strong show here in North America and obviously, that has a lot of indications to margin progression."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say, starting at a very high level, we haven't about a 7,500 [ph] units installed base. We have had positive unit growth 1% or 2% of the installed days. One of the things that we like about the old U.S. growth is as I mentioned about China is those ar",116,"I'd say, starting at a very high level, we haven't about a 7,500 [ph] units installed base. We have had positive unit growth 1% or 2% of the installed days. One of the things that we like about the old U.S. growth is as I mentioned about China is those are all new stock and we did some new installed base out of it. We did have very -- in Q3, we had very good unit growth, one of the best unit growth quarters we've had in a while. So that's going to help our service business. So no, I don't know if I'm answering all your questions, Vijay, Elisha do you have anything else."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Just like you said, Vijay is largely a replacement market. So the installed base is not necessarily going up, but it is get there higher in equipment that does carry a higher level of service contracts.",36,"Just like you said, Vijay is largely a replacement market. So the installed base is not necessarily going up, but it is get there higher in equipment that does carry a higher level of service contracts."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And let me make that trade out, I'd say our contract capture rate of TrueBeams is 10 to 15 points higher than our -- than the historical products.",28,"And let me make that trade out, I'd say our contract capture rate of TrueBeams is 10 to 15 points higher than our -- than the historical products."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","That is very helpful, guys. And maybe just one on software. Because I -- this is the other question we had a lot on. What kind of disability do we have, right, on software option? Because I know at the Analyst Day, you guys put out that $0.5 billion oppor",139,"That is very helpful, guys. And maybe just one on software. Because I -- this is the other question we had a lot on. What kind of disability do we have, right, on software option? Because I know at the Analyst Day, you guys put out that $0.5 billion opportunity, right? But I guess, the reason -- when I look at your comments of the installed base, right, kind of 1% to 2% you guys have done better on the share front, that's showing up in the North America region from an orders perspective, right? But how much more software can you keep selling into the installed base, right? Or am I thinking about this the right way? Because I feel like having some clarity on that has a lot of implications on how people look at the company."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I hear there is some pretty simple math here, you've got an installed base of 7,500 units. We sold and we feel really good about it, 500 RapidPlan. We had 7,000 to go. We got inside of analytics, what have we sold? 250? 200-ish? We've got 7,300 to go. So",238,"I hear there is some pretty simple math here, you've got an installed base of 7,500 units. We sold and we feel really good about it, 500 RapidPlan. We had 7,000 to go. We got inside of analytics, what have we sold? 250? 200-ish? We've got 7,300 to go. So we're in the top half of the first inning. Sorry, Baseball analogy is my global friend. But the software is still very significant upside for us. And what I'm liking is we're getting very good customer response on the software products. I -- a decade ago, the shipping software it works, I don't love it. Now we're getting hey, that's what I likely to do. It's making me for productive in the workplace. I can do better care and take care of patients better. And you've had some external validation out of this with our class, the wind that's kind of the partner of radiation oncology class rate this #1 in treatment planning and in oncology information system. So we like that. So those were RapidPlan and InSightive Analytics are 2 examples. We do have -- in the 7,500 units win installed base, and that installed base, we also have 3,400, 3,500 software installation. So those are opportunities for us to take. That's the low-hanging fruit of the RapidPlan and InSightive Analytics opportunities. So I think Vijay, we still got a lot of opportunity on the software side."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","That was really helpful, Dow. And if I just may ask with regard to the baseball analogy, I think hitting a 6 [indiscernible].",23,"That was really helpful, Dow. And if I just may ask with regard to the baseball analogy, I think hitting a 6 [indiscernible]."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think I know what that means, which is a little scary.",12,"I think I know what that means, which is a little scary."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Jason Wittes with Brean Capital.",14,"And the next question comes from the line of Jason Wittes with Brean Capital."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Just want to get an update. I know that things are still moving. But in terms of the numbers you put out, when you first announced the spin-out. I know this you mentioned that I believe $37 million in overhead and synergies. Is that still the number that",65,"Just want to get an update. I know that things are still moving. But in terms of the numbers you put out, when you first announced the spin-out. I know this you mentioned that I believe $37 million in overhead and synergies. Is that still the number that we should be thinking about and in terms of who goes what? Is there any update there?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Jason, at this point, it was $20 million of disynergies that would be at co- Varian. And that number has not changed dramatically at this point. So I think it's still a good number to use. And again, with the goal of having that offset within 2 years, so",62,"Jason, at this point, it was $20 million of disynergies that would be at co- Varian. And that number has not changed dramatically at this point. So I think it's still a good number to use. And again, with the goal of having that offset within 2 years, so that we can get back to the same margin point, operating margin point."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And I believe that you're going to give the SpinCo will have a cash on hand. I believe that was $50 million. But will that be cash taken from overseas? Or will that be cash that's been patriated in the U.S.?",42,"And I believe that you're going to give the SpinCo will have a cash on hand. I believe that was $50 million. But will that be cash taken from overseas? Or will that be cash that's been patriated in the U.S.?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So no number has been determined. All we have said is that we will not have debt at the time of the spin. And we are working with our advisors on the capital structure at this point. So stay tuned and we'll be talking about how much cash ends up going wit",63,"So no number has been determined. All we have said is that we will not have debt at the time of the spin. And we are working with our advisors on the capital structure at this point. So stay tuned and we'll be talking about how much cash ends up going with SpinCo and how much of that is U.S. versus old U.S."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And when do you anticipate giving that update? Would that be in your fourth quarter or would that be more towards December?",23,"Okay. And when do you anticipate giving that update? Would that be in your fourth quarter or would that be more towards December?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","It's going to be more to words when we're going on the roadshow, closer to the spin date.",19,"It's going to be more to words when we're going on the roadshow, closer to the spin date."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Fair enough. And just on the Proton business. In terms of you've also put out sort of anticipation of reaching profitability. I assume that still goes. And what kind of revenue run rate do you need for that business to really sort of break even and",48,"Okay. Fair enough. And just on the Proton business. In terms of you've also put out sort of anticipation of reaching profitability. I assume that still goes. And what kind of revenue run rate do you need for that business to really sort of break even and [indiscernible]?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. It's a little hard to say, Jason. What we really need is the installs to be completed and the service business to become material to get a significant pop in the margins. But this year, it's going to be around $150 million. It's 200, 200 [ph] and --",61,"Yes. It's a little hard to say, Jason. What we really need is the installs to be completed and the service business to become material to get a significant pop in the margins. But this year, it's going to be around $150 million. It's 200, 200 [ph] and -- somewhere between $200 million and $225 million, it's starts looking very different."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","As you know, it's will -- I mean, this is going to change with time because the margin rates of the equipment, now today they're high teens, mid high teens. We hope to get back to the 20 to 30 range with time. But the margin rates on service are pretty go",76,"As you know, it's will -- I mean, this is going to change with time because the margin rates of the equipment, now today they're high teens, mid high teens. We hope to get back to the 20 to 30 range with time. But the margin rates on service are pretty good. So as the service contracts start to land, the geography of that profitability becomes a little easier with time. That's probably not next year."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And then the reimbursement was pretty benign, or actually it's positive not benign, more on that. But in terms of -- you did mentioned you're going to start to try coaxing the market into being more efficient. I believe that's what m",99,"Okay. That's helpful. And then the reimbursement was pretty benign, or actually it's positive not benign, more on that. But in terms of -- you did mentioned you're going to start to try coaxing the market into being more efficient. I believe that's what macro admits. There are centers out there who have adopted it. Have you noticed a change in their behavior in terms of what their equipment they want? How they're doing their procedures and things like that? Is there a shift towards or more concentrated in those centers or is it just too early to say?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say if anything, it might be an incentive for people to take our ARIA inside of analytics and other ARIA features into the market. ARIA is macro compliant. One of the things we get that is a lot of metrics, a lot of portability. These are some things",102,"I'd say if anything, it might be an incentive for people to take our ARIA inside of analytics and other ARIA features into the market. ARIA is macro compliant. One of the things we get that is a lot of metrics, a lot of portability. These are some things they're looking for. And that's part of that product. So short-term-ish, as you were talking about one of the other questions, it could be a little bit of upside maybe next year. I would say, we haven't really seen a behavior change in terms of peoples purchasing pattern at this point, the."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And also related to that. Do you have a sense of how much of the marketplace is actually ready to fully implement macro here? It has all the software in place, et cetera?",33,"And also related to that. Do you have a sense of how much of the marketplace is actually ready to fully implement macro here? It has all the software in place, et cetera?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I think the short version is people just got the standard. So 0. So we look at a hard look at it, we know that we've got a few product things to do, but then our product is pretty compliant. We're -- the -- we're pretty comfortable with where our pr",285,"Well, I think the short version is people just got the standard. So 0. So we look at a hard look at it, we know that we've got a few product things to do, but then our product is pretty compliant. We're -- the -- we're pretty comfortable with where our product is. It's not going to be like a major rewrite or something that we're going to have to do. But we do have to add a few features and we're very well positioned for background implementation. So we like that. But I would say come back to the main thrust of the question. I would say we have not seen a purchasing difference with those customers. And it's history, if anything, a lot of them tend to be -- they want to be clinically advanced and they want to be very productive and cost efficient. And sometimes it takes a little bit longer to convince them. But once they're convinced, they tend to move faster because they've got the clinical data or the productivity data to make their business case. And they may take a little bit longer to convince them. But once they're convinced, they a -- one of the examples, I've used historically on this is RapidArc with Fiserv. It tooks us a while to convince them that RapidArc was really clinically advantageous and was going to give them a productivity pop. Once they were convinced, Fiserv outfit every hospital within a year. It's just bang, they really moved. And I think that's typical from what we see from these kind of customers. They might take a little bit longer to convince them but went they are convinced, they go fast."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Just helpful and just sort of a follow on, on that, when that happens, which is going to take some time, I mean I think macro itself doesn't really have teeth and it's going to take a couple of years, but it does seem like there could be some upgrad",94,"Okay. Just helpful and just sort of a follow on, on that, when that happens, which is going to take some time, I mean I think macro itself doesn't really have teeth and it's going to take a couple of years, but it does seem like there could be some upgrade -- required upgrades for software that could help you or help I guess, your customers as well but there is an upgrade cycle to be had when this really starts to take over is that kind of the way you think about the?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, absolutely. And that's the outside opportunity I've been referring to.",11,"Yes, absolutely. And that's the outside opportunity I've been referring to."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And our next question comes from the line of Anthony Petrone of Jefferies.",13,"And our next question comes from the line of Anthony Petrone of Jefferies."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Just a couple of follow-ups actually on guidance in Imaging in particular. And then one on the spin. So for guidance, I guess, the 3% reiteration here, you're making quite an acceleration in the fourth quarter. And I'm just wondering how much of that is O",83,"Just a couple of follow-ups actually on guidance in Imaging in particular. And then one on the spin. So for guidance, I guess, the 3% reiteration here, you're making quite an acceleration in the fourth quarter. And I'm just wondering how much of that is Oncology related versus may be a rebound in imaging? And then you also spoke quite a bit on proton. So just trying to get a little bit more color on guidance and then I'll have the follow-ups."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. So Anthony, the guidance on Oncology and I'm assuming you're talking revenue here, should be in the mid-single digit growth. The Imaging Components business will be in the low single-digit growth versus the year-ago quarter. And we're going to get $",74,"Sure. So Anthony, the guidance on Oncology and I'm assuming you're talking revenue here, should be in the mid-single digit growth. The Imaging Components business will be in the low single-digit growth versus the year-ago quarter. And we're going to get $20 million to $25 million or so in additional proton revenue versus the year-ago period. So I'd say save on proton's is going to get you to around just 7% range in Q4."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","That's helpful. And then just Imaging Components again for the quarter. I know you mentioned in bookings the contribution from our gross orders rather from acquisitions. But I'm just wondering what the revenue contribution was in the quarter from Claymoun",43,"That's helpful. And then just Imaging Components again for the quarter. I know you mentioned in bookings the contribution from our gross orders rather from acquisitions. But I'm just wondering what the revenue contribution was in the quarter from Claymount and MeVis?"
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","About $11 million, I believe in total.",7,"About $11 million, I believe in total."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Helpful. And then last, just on spin. Have you announce if its is a 1 for 1 share distribution? Or we're still...",22,"Helpful. And then last, just on spin. Have you announce if its is a 1 for 1 share distribution? Or we're still..."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No, we have not. We have not. We're working with JPMorgan on that.",13,"No, we have not. We have not. We're working with JPMorgan on that."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","There are no other questions on the queue at this time. I would now like to turn the call over to management for any closing comments.",26,"There are no other questions on the queue at this time. I would now like to turn the call over to management for any closing comments."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Thank you all for participating. The replay of this call can be heard on the Varian Investor website at www.varian.com/investor where it will be archived for year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or",71,"Thank you. Thank you all for participating. The replay of this call can be heard on the Varian Investor website at www.varian.com/investor where it will be archived for year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or (201) 612-7415 from outside the U.S. and a confirmation code 13640722. A telephone replay will be available through 5:00 p.m. this Friday July 29. Thank you all."
311907,370528018,1014321,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. This concludes today's teleconference. You may disconnect your lines at this time. And we thank all of you for your participation.",23,"Thank you. This concludes today's teleconference. You may disconnect your lines at this time. And we thank all of you for your participation."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems teleconference. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Spencer Sias, VP, Investor Relations, for Varian Medical. Thank",44,"Greetings, and welcome to the Varian Medical Systems teleconference. [Operator Instructions] As a reminder, this conference is being recorded. 
It is now my pleasure to introduce your host, Spencer Sias, VP, Investor Relations, for Varian Medical. Thank you, Mr. Sias. You may now begin."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Good afternoon, and welcome to Varian Medical Systems Conference Call for the Third Quarter of Fiscal Year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will",269,"Thank you. Good afternoon, and welcome to Varian Medical Systems Conference Call for the Third Quarter of Fiscal Year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. 
To simplify our discussion, unless otherwise stated, all references to the quarter or year or fiscal quarters or fiscal years, quarterly comparisons are for the third quarter of fiscal 2016 versus the third quarter of fiscal 2015. References to financial results for orders are the gross orders unless otherwise indicated. 
This discussion includes some non-GAAP financial measures in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. 
A reconciliation to the most comparable GAAP measure is included in our earnings release, which can be accessed on our website. Please be advised that this discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, will, scheduled and similar expressions are intended to identify those statements which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks relating to our business are described in our third quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise.
And now, here's Dow."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Varian is reporting solid results for the third quarter of fiscal year 2016, with strong growth order and revenue growth in our Oncology Systems and Imaging Components businesses, together with substantial improvements in gros",1055,"Good afternoon, and welcome. Varian is reporting solid results for the third quarter of fiscal year 2016, with strong growth order and revenue growth in our Oncology Systems and Imaging Components businesses, together with substantial improvements in gross and operating margins for both. 
In summary, the company is reporting GAAP net earnings of $1.04 per diluted share and $1.22 per diluted share on a non-GAAP basis; revenues of $789 million, up 1% versus the year-ago quarter; a nearly 4-point improvement in the company's overall gross margin; and an order for new -- for a new multiroom proton installation in China, our first proton order there. 
Focusing on operational highlights. Our Oncology business generated third quarter gross orders of $676 million, up 6% in both dollars and constant currency. Gross orders in the Americas rose by 8% during the quarter with 15% growth in North America more than offsetting a greater than 40% decline in Latin America. 
Year-to-date gross order growth in North America is 8%, driven by a more stable reimbursement environment and, in this replacement market, a transition to more advanced clinically efficient systems. 
Gross orders in APAC increased 19% in dollars and 17% in constant currency during the quarter, driven by robust growth in China and Australia. 
In EMEA, gross orders declined 3% in dollars and 4% in constant currency, reflecting weakness in Western European markets. 
Looking at each of the regions in more detail. Our growth in North America was driven by demand for our TrueBeam platform, including EDGE radiosurgery systems and our software offerings. Among the highlights for North America were several large multi-system orders from consolidated networks as well as competitive takeouts. 
Order activity in Latin America continued to be weak due to macroeconomic factors. During the quarter, we shipped the first units for the large tender conducted by Brazil's Ministry of Health a couple of years ago. 
Turning to APAC. The Icon Group placed the largest Varian order ever in Australia for 10 TrueBeam systems, 7 of which are going to new sites along with the full complement of our information management and treatment planning software. We had wins for several new accelerator installations in China, where we saw good orders growth. We also saw strong demand for our EDGE radiosurgery system in this market, where we continue to be the share leader. 
Elsewhere in APAC, we made good progress in Thailand, Vietnam and Indonesia. Business was stable in Japan, where we saw good service growth. 
Turning to EMEA. Healthy gross order growth in emerging markets, including Iran, Russia, Ethiopia [indiscernible] and Libya was offset by weakness in Western Europe. Our third quarter business in Africa was outstanding with more than $25 million in gross orders. Among other wins, we saw Ethiopia order its first modern linear accelerators for cancer treatment. 
I'm pleased to report that overall unit order volumes was up in the quarter and year-to-date and that average pricing is stable. We're winning with clinically efficient advanced technology that makes quality cancer care affordable and accessible. This was reflected during the quarter, and strong orders to our RapidPlan and InSightive Analytics software. We booked our 500th order for RapidPlan, which is a game changer that enables clinics to improve the speed and quality of care for their patients. As of this quarter, treatment plans are now being shared among clinics through our ongoing OncoPeer web portal. 
As you all know, CMS has announced modest adjustments to reimbursement for 2017 for both hospitals and free-standing clinics. We don't expect for reimbursement to have a material impact on the radiation oncology markets in the U.S. next year. 
Following the topic of reimbursement, CMS did move forward with policies that will incentivize the adoption of digital X-ray imaging systems in place of film and computed radiography systems, and this should help to support growth in our Imaging Components business. 
Speaking of Imaging Components, the business returned to growth during the quarter. Orders grew by 13% to $138 million, and revenues rose by 9% to $147 million. Improvements in margins were driven by productivity gains and a favorable product mix. Our 2 business saw good growth in the quarter. We recently celebrated the 40th year of our relationship with Toshiba Medical Systems and look forward to continuing this relationship when they become part of Canon. 
Our recently acquired software and X-ray accessories businesses also helped to drive growth. 
Touching on the Industrial Imaging business, orders for security products were up in the quarter but we continue to have a cautious outlook in the face of ongoing customer consolidation. We continue to focus on generating growth in nondestructive testing and inspection. 
Let me update you on our progress towards the separation of the Imaging Components business into a new, independent publicly traded company via tax-free distribution to Varian stockholders. 
As you probably saw in the press release issued last week, the name of the new company will be Varex Imaging Corporation. We are now making good progress in the development of detailed plans and activities needed to execute the separation. We're on track to file an initial Form 10 with the SEC in the next several weeks, and we are currently on schedule to complete the separation at the end of the calendar year. We continue to be excited about the prospects of creating 2 great companies. 
Turning now to our Particle Therapy business. We booked an order during the quarter for a multiroom probing installation at the new Hefei medical center in China. This is China's first government-funded proton facility. Installation is waiting to take place in late 2017 with patient treatments scheduled to begin in late 2018. 
Our installation at Cincinnati Children's Hospital is on track with the first patient treatments scheduled to commence later this summer. 
We have now successfully commissioned the third room at the Maryland Proton Therapy (sic) [Treatment] Center, and installations are underway in Holland, Russia and Saudi Arabia. In total, we have 13 proton projects generating revenue. 
As you probably saw from our 8-K filing with the SEC at the end of June, we sold our $73 million senior loan for the New York Proton Therapy Center to Deutsche Bank, freeing up capital to help finance other proton projects. The proton sales funnel continues to look good. 
And now I'll turn it over to Elisha."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Great. Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 5% from the year-ago period. Backlog adjustments during the quarter totaled $51 million, bringing net or",589,"Great. Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 5% from the year-ago period. Backlog adjustments during the quarter totaled $51 million, bringing net orders for the company to $814 million. 
Third quarter revenues for the total company were $789 million, up 1% in dollars and even with the year-ago period in constant currency. Year-to-date, total company revenues were $2.3 billion, up 1% in dollars and up 3% in constant currency. Oncology posted a revenue gain of 8%, both in dollars and in constant currency, driven by strength in our high-end equipment as well as our software and service businesses. 
Imaging Components posted a third-quarter revenue gain of 9%, driven by our newly acquired X-ray accessories business as well as higher tube sales. 
Our Particle Therapy business posted third-quarter revenue of $37 million, down from the year-ago period, when we booked $91 million of revenues, including a substantial amount for the ProBeam installation at the University of Maryland. 
Total company gross margin for the quarter was 43.9%, up by nearly 4 points with significant contributions from both Oncology and Imaging Components. Oncology System's third quarter gross margin improved by more than 4 points to 46% with the help of a larger mix of TrueBeams and software as well as productivity gains. 
Imaging Components' third-quarter gross margin also rose by more than 4 points to 42.9% due largely to factory productivity gains and favorable product mix.  R&D expenses were $65 million, or 8% of revenue, equal as a percentage of revenue to the year-ago quarter. 
On a GAAP basis, third quarter SG&A expenses, the $151 million or 19% of revenue, we had about $22 million of unusual expenses in SG&A for items, including ongoing patent litigation and the recently announced initiative to separate the Imaging Components business into a new publicly traded company. Excluding these items, SG&A expenses on a non-GAAP basis for the quarter were $129 million or 16% of revenue. 
GAAP operating earnings for the quarter were 16.5% of revenues and 19.5% of revenues on a non-GAAP basis, reflecting our solid gross margin performance in the quarter. 
Depreciation and amortization totaled $18 million for the quarter. The effective tax rate was 25.1%, up 3 points from the year-ago quarter, when we benefited from the favorable geographic mix of profits and tax loss carryforwards associated with the proton business. We continue to expect that the tax rate will be about 26% to 27% for the year. 
Fully diluted shares outstanding were $95.4 million, more than $5 million lower than the year-ago quarter due to our ongoing share repurchase program. Diluted EPS was $1.04 for the quarter on a GAAP basis and was $1.22 on a non-GAAP basis.
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $836 million, debt of $701 million and stockholder's equity of $1.7 billion. 
DSO at 101 days was up significantly from the year-ago quarter but improved sequentially from the second quarter. 
Third quarter cash flow from operations was $95 million, bringing the total cash flow from operations year-to-date to $204 million. Primary uses of cash were $126 million for the repurchase of 1.5 million shares of stock, $95 million to reduce debt and $15 million for capital expenditure. At the end of the quarter, we had 4.8 million shares remaining under the existing repurchase authorization that extends to calendar year 2016. 
Now I'll turn it back to Dow for the outlook."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. Including the results of the third quarter, we believe that total company non-GAAP earnings will be in the range of $4.62 to $4.66 per diluted share for fiscal year 2016. We continue to believe revenues for fiscal year 2016 will increase b",56,"Thanks, Elisha. Including the results of the third quarter, we believe that total company non-GAAP earnings will be in the range of $4.62 to $4.66 per diluted share for fiscal year 2016. We continue to believe revenues for fiscal year 2016 will increase by about 3% over fiscal year 2015. 
We're now ready for your questions."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] And our first question will come from the line of Anthony Petrone with Jefferies.",16,"[Operator Instructions] And our first question will come from the line of Anthony Petrone with Jefferies."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Congratulations on a good quarter. Maybe to start a little bit with just the North American order growth in Oncology there, which sort of reached a multi-quarter high here. Maybe a little bit more in terms of the underlying drivers there, how much is mark",81,"Congratulations on a good quarter. Maybe to start a little bit with just the North American order growth in Oncology there, which sort of reached a multi-quarter high here. Maybe a little bit more in terms of the underlying drivers there, how much is market-related, maybe even replacement cycle-related? And how much was it from share gains? And then a follow-up there would be, on the product side, how much was driven by VitalBeam? What flows to that driver last quarter?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Good questions. I would start by saying our rolling 4-quarter growth in the Americas has been 7%. So we feel very good about kind of where that is. North America has certainly been the driver. And you're right, North America did get a high this quart",312,"Yes. Good questions. I would start by saying our rolling 4-quarter growth in the Americas has been 7%. So we feel very good about kind of where that is. North America has certainly been the driver. And you're right, North America did get a high this quarter, but it is kind of a sustained trend that we're seeing, which is good. We did have a couple of multi-system orders, including one with HCA. We also had very strong demand, as I mentioned in the call, for software products. 
And VitalBeam, I think a little more than half of our VitalBeams have been sold in the Americas. So that's -- VitalBeam has been part of the story, but I think the overall story, though, is TrueBeam. 
When you clearly look at what's going on, TrueBeam is what's driving both the Americas growth and the global growth, both in orders and revenues. I mean, some of the -- on revenue side, Elisha will talk about this later, but on the revenue side, we had very good TrueBeam mix on the quarter as some of the margin uptick, but it's -- from a kind of a market perspective, the U.S., it is a replacement market. That's true. As I said in the call, we are seeing people trade out aggressively to try to get new capability, especially for advanced radiosurgery and body radiosurgery. 
I think reimbursement may have been a small factor, certainly not over last year, but having that be calm in the quarter, kind of short of have short up -- short things up a little bit. I think from a high level, that's kind of the story. And I think -- the other thing I was going to mention is from the market share point of view, we think we've gained a little bit of share, but most of this is market."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","No, very, very helpful. And maybe to shift gears just to Imaging, and then one for Elisha. One of the headwinds for that business over the past couple of quarters was destocking from several key customers, including Toshiba. I'm just wondering if that has",62,"No, very, very helpful. And maybe to shift gears just to Imaging, and then one for Elisha. One of the headwinds for that business over the past couple of quarters was destocking from several key customers, including Toshiba. I'm just wondering if that has reversed at this point. And specifically with regards to Toshiba, are they back ordering anything at this point?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say Toshiba is back a little bit. I wouldn't say they're fully back yet. I mean, we had an okay quarter from Toshiba. The 2 business was actually quite strong in the quarter, and some of that was Toshiba, but we also had very good tube performance fro",91,"I'd say Toshiba is back a little bit. I wouldn't say they're fully back yet. I mean, we had an okay quarter from Toshiba. The 2 business was actually quite strong in the quarter, and some of that was Toshiba, but we also had very good tube performance from our other tube customers on the quarter, and it was as much on their backs that we drove this. So I'd say the best the Toshiba days, frankly, are still ahead of us. We're not totally out of that headwind yet."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And the oppositions helped us out, Anthony.",7,"And the oppositions helped us out, Anthony."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, yes, yes.",3,"Yes, yes, yes."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Sure. Sure, and then last, just quick, I'll hop in queue. And Elisha, Oncology gross margin, 46% you called out, that's beyond the normalized 44% level. I mean, is this sort of a new normal? Or do you expect it to sort of moderate back down to that 44% le",52,"Sure. Sure, and then last, just quick, I'll hop in queue. And Elisha, Oncology gross margin, 46% you called out, that's beyond the normalized 44% level. I mean, is this sort of a new normal? Or do you expect it to sort of moderate back down to that 44% level over time?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I would love to say yes, Anthony, but I'm -- we just had a really favorable product mix in the quarter and I just can't count on that every single quarter going forward. What I would say is Oncology has done a fantastic job on pricing, holding stabl",116,"Well, I would love to say yes, Anthony, but I'm -- we just had a really favorable product mix in the quarter and I just can't count on that every single quarter going forward. What I would say is Oncology has done a fantastic job on pricing, holding stable pricing and on product cost reduction and on productivity gains. And so the hope is, yes, that will last as we move forward. But again, product mix drives our margin much more than any other factor. 
I do think for this fiscal year, they should be at the high end of that 43% to 44% range that we've talked about and really helped by this last quarter."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And our next question comes from the line of Amit Hazan of Citibank.",13,"And our next question comes from the line of Amit Hazan of Citibank."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","It's Lee [ph] Preston, on for Amit. A couple of questions here. I'll start with margin. On the back of the gross margin question, is there anything stronger in gross margin this quarter that you would call out as more sustainable in nature as opposed to g",59,"It's Lee [ph] Preston, on for Amit. A couple of questions here. I'll start with margin. On the back of the gross margin question, is there anything stronger in gross margin this quarter that you would call out as more sustainable in nature as opposed to good mix and some of the other items you've already called out."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, mix -- product mix drives the margin, first and foremost, in Oncology. Geographic mix, secondly. The geographic mix was identical this quarter versus the year-ago quarter so that has no impact. I would say the cost -- the product cost reduction is r",85,"Well, mix -- product mix drives the margin, first and foremost, in Oncology. Geographic mix, secondly. The geographic mix was identical this quarter versus the year-ago quarter so that has no impact. I would say the cost -- the product cost reduction is real, and we should continue to have the benefit of that going forward as there's many, many -- much fewer C-series, our old legacy equipment and many more TrueBeams at a higher margin. And so we're starting to see that flow through."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then just on the operating margin for this year. It looks like there have been 2 good quarters at or around the 19%. The implications for fourth quarter looks above that, too. So is this kind of the range we should be thinking about going forwar",86,"Okay. And then just on the operating margin for this year. It looks like there have been 2 good quarters at or around the 19%. The implications for fourth quarter looks above that, too. So is this kind of the range we should be thinking about going forward here? It's a bit above the original guidance. Is this FX-related to some extent? Or are you seeing some sustainability that makes you comfortable, lift them off the bottom and maybe see some further gains heading into 2017?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, so I don't want to guide it all into 2017, particularly right at the moment with the spin-off going on. There is a lot of work that we're going to have to do in terms of looking into FY '17. You are correct. Once you run this model through, it's goi",116,"Well, so I don't want to guide it all into 2017, particularly right at the moment with the spin-off going on. There is a lot of work that we're going to have to do in terms of looking into FY '17. You are correct. Once you run this model through, it's going to put it to the close to 19% operating margin for this year, which would be up about 0.5 points versus the year-ago period. So again, all businesses have been very focused on headcount and on travel and on discretionary spending, and I think you're starting to see this flow through. But most of that improvement this year is coming through the gross margins."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Can I just point out, these are -- that it's consistent with our goal over the next 3, 4 years to get back to that higher return on sales. So it's kind of delivering on the track 50 basis points-ish a year that we were kind of set as an over;arching goal.",52,"Can I just point out, these are -- that it's consistent with our goal over the next 3, 4 years to get back to that higher return on sales. So it's kind of delivering on the track 50 basis points-ish a year that we were kind of set as an over;arching goal."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, great. And if I could sneak in one more, if I could. Can you talk about maybe the adjustments to backlog this quarter? They're a little bit higher than trends. Maybe you can give us some context as to what's going on there.",44,"Okay, great. And if I could sneak in one more, if I could. Can you talk about maybe the adjustments to backlog this quarter? They're a little bit higher than trends. Maybe you can give us some context as to what's going on there."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Actually, the backlog adjustments were lower, I believe, in the prior quarter and were pretty consistent with our average. So the $51 million is really what we would refer to -- some cancellations in that number, maybe $20 million of it. The rest is what",98,"Actually, the backlog adjustments were lower, I believe, in the prior quarter and were pretty consistent with our average. So the $51 million is really what we would refer to -- some cancellations in that number, maybe $20 million of it. The rest is what we call dormancies. When we reviewed the backlog and we feel like there's no longer a good probability of the machine delivering within 2 years, we just take it out of our backlog until it fits that criteria. So -- but the $51 million level is very consistent with historically how it's been."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then sorry, one last quick one. If you could maybe give us a hint of why the CS [ph] there was up during the quarter?",27,"Okay. And then sorry, one last quick one. If you could maybe give us a hint of why the CS [ph] there was up during the quarter?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. So we have done -- we've seen this the last couple of quarters. The good news is, Q3, if you look at our cash flow from operations, returned back to a very strong level and was almost equal to net income. So I'm feeling very good that we're back on t",120,"Yes. So we have done -- we've seen this the last couple of quarters. The good news is, Q3, if you look at our cash flow from operations, returned back to a very strong level and was almost equal to net income. So I'm feeling very good that we're back on track in terms of cash flow. 
What happened is we move that collection staff earlier in the fiscal year. We did a CRM implementation. I think those things just slowed down collections a little bit in the first half of the year. We've got some catching up to do. But in June and July, our collections have actually been very strong. So I think we're getting back on track."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. And Q2 to Q3, we had 10 days of shipment improvements going in the right direction.",17,"Yes. And Q2 to Q3, we had 10 days of shipment improvements going in the right direction."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes.",1,"Yes."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Brandon Henry with RBC Capital Markets.",15,"And the next question comes from the line of Brandon Henry with RBC Capital Markets."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","First, just on the North American strengthening gross orders, can you just help provide some more details on how much of that performance was running better systems order versus software and services?",32,"First, just on the North American strengthening gross orders, can you just help provide some more details on how much of that performance was running better systems order versus software and services?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I -- one of the things that we liked about it is that it was broad-based. It was both -- it was hardware, it was software and it was service. So we saw in all 3 categories, there wasn't one -- as I mentioned from a product mix point of view, that market h",130,"I -- one of the things that we liked about it is that it was broad-based. It was both -- it was hardware, it was software and it was service. So we saw in all 3 categories, there wasn't one -- as I mentioned from a product mix point of view, that market has largely -- it's probably been a 90% TrueBeam market for the last 18 months, 2 years, and it was at the high end of that. So maybe a little bit of product mix from an orders' point of view, but we -- as I said in the call, we had a couple of nice, large strategic deals, and we had a number of competitive takeouts in both the hardware and software area, but it was rocky."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And did you guys give any growth rates in terms of software servicing this quarter? I might have missed that.",21,"Okay. And did you guys give any growth rates in terms of software servicing this quarter? I might have missed that."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No. We haven't broken it out.",6,"No. We haven't broken it out."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then separate question. Could you provide an update on what portion of Siemens went active and traded out at this point? I mean, how much of the acceleration in the North American Oncology Systems business can be attributed to an acceleration in",47,"Okay. And then separate question. Could you provide an update on what portion of Siemens went active and traded out at this point? I mean, how much of the acceleration in the North American Oncology Systems business can be attributed to an acceleration in any Siemens trade-outs?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think it's a small and maybe even very small factor. It's not coming off the trend line. I think when we first did the relationship with them 3, 4 years ago, there was probably a 2,000-ish unit installed base. And I'd say that's coming out 150-ish a yea",93,"I think it's a small and maybe even very small factor. It's not coming off the trend line. I think when we first did the relationship with them 3, 4 years ago, there was probably a 2,000-ish unit installed base. And I'd say that's coming out 150-ish a year or probably coming out. We haven't seen a -- an acceleration or deceleration of that trend has been kind of steady as it goes. I mean, it is a replacement market, whether it's Siemens or everybody else, and that is what we're seeing."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then last question for me, just on China. It looks like from first the half '16 results from GE and Philips, it does look like Chinese tender activity in orders are picking up, at least in the volumes of [indiscernible] Imaging part of the marke",75,"Okay. And then last question for me, just on China. It looks like from first the half '16 results from GE and Philips, it does look like Chinese tender activity in orders are picking up, at least in the volumes of [indiscernible] Imaging part of the market. So can you speak to what trends here are seen in China and if you're seeing a similar pickup in activity in the radiation Oncology market in China?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, yes. I think that's very consistent. We had an okay first half, but we had a very good third quarter. Our third quarter was -- China was up 13%. We had very strong demand, especially for high-end products, which, our EDGE products, as I mentioned on",253,"Yes, yes. I think that's very consistent. We had an okay first half, but we had a very good third quarter. Our third quarter was -- China was up 13%. We had very strong demand, especially for high-end products, which, our EDGE products, as I mentioned on the call on the script, was very good. 
One of the things that we really like about the demand we're seeing is it is almost 90% new valves. It's -- so obviously, that's going to drive our long-term service business and software upgrade opportunities, et cetera, et cetera, et cetera. So these are new valves going in. They're happening on schedule. We are seeing significant tender activity. We do continue to see some protests of that activity. It doesn't change that much who wins. It just kind of lengthens the process. And they're also -- I mean, coming back to our previous question. In China, there is a large Siemens installed base opportunity. That's one of the geographies where they did the best, frankly because of their price position as much as anything else. And so I think over the next couple of years, we'll see maybe that installed base change out a little more aggressively. So that's going to be one to watch. 
The other thing to watch in China, we've got this -- the Hefei proton order, as I mentioned. We've -- we see a reasonable funnel of proton activity in China. So maybe this Hefei order will stimulate some proton growth in China."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Jeff Johnson with Robert W. Baird.",15,"And the next question comes from the line of Jeff Johnson with Robert W. Baird."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Great. Dow, so one question for you. I don't think anybody's asked on your Western European comments at this point. It sounds like you mentioned that being soft this quarter. Last quarter, you guys put up a very strong EMEA number. This quarter, the comp",108,"Great. Dow, so one question for you. I don't think anybody's asked on your Western European comments at this point. It sounds like you mentioned that being soft this quarter. Last quarter, you guys put up a very strong EMEA number. This quarter, the comp was a lot tougher. So have you really seen anything change? Or is it just kind of comp-driven? I know you had some big orders last year in this quarter in the EMEA. So just trying to figure out if you're really seeing anything sequentially changed in that market, or kind of how you describe market trends over in Western Europe right now."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We're watching Western Europe and Latin America. Those are the 2 light spots. Americas, we've talked about that a lot. It continues very strong. China looks good. Japan, flat, which has been down. So flat it -- flat is the new in Japan for us, so that's o",142,"We're watching Western Europe and Latin America. Those are the 2 light spots. Americas, we've talked about that a lot. It continues very strong. China looks good. Japan, flat, which has been down. So flat it -- flat is the new in Japan for us, so that's okay. The 2 watch areas for us are, frankly, Western Europe and Latin America. 
I mean, Latin America, was down more than 40% this quarter. That's macro economically driven. We do have it in Europe. There is a tough comp on the quarter. We had a large order in the U.K. last year. So we've got a little bit of a comp issue going into Q4 as well. But I'd say, we're watching Western Europe. It's -- it maybe hasn't been as strong as it has been over the last 18 months or so."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes. All right. That's very helpful. And then Elisha, maybe a few clarifying questions for you. One, I think somebody asked on the software and service side. You said you haven't given that. But could you give that? I think in the past quarters, you have",65,"Yes. All right. That's very helpful. And then Elisha, maybe a few clarifying questions for you. One, I think somebody asked on the software and service side. You said you haven't given that. But could you give that? I think in the past quarters, you have given those trends. If you could just give us, at least qualitatively, where software and service was this quarter?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Highest corporate and software than equipment and service.",9,"Yes. Highest corporate and software than equipment and service."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Can we be any more specific there? Double-digits, upper single digits? I mean, I think  I -- let me phrase it this way. I think you had been double-digits for a long while. Kind of flipped over the last couple of quarters, upper single digits. Are w",50,"Okay. Can we be any more specific there? Double-digits, upper single digits? I mean, I think  I -- let me phrase it this way. I think you had been double-digits for a long while. Kind of flipped over the last couple of quarters, upper single digits. Are we seeing any..."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","[indiscernible]",1,"[indiscernible]"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes. Any continuation of that trend there? Sorry.",8,"Yes. Any continuation of that trend there? Sorry."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So for year-to-date, let me just -- in constant currency, service is up in the high single digits, so 7% to 8%. So a little off the double-digit, but not terribly so. So again, we still feel good. The unit volume was up this quarter and orders, which bode",73,"So for year-to-date, let me just -- in constant currency, service is up in the high single digits, so 7% to 8%. So a little off the double-digit, but not terribly so. So again, we still feel good. The unit volume was up this quarter and orders, which bodes well for the service business going forward. So long-term, really not coming off of our expectations for the service business at this point."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","All right. That's helpful. And then last 2 clarifying. Just on the EPS guide, you took the low end up by a little over a $0.05. Is there anything in there rather than just operational at this point? Or a couple of companies have been adopting ASU 2016. An",68,"All right. That's helpful. And then last 2 clarifying. Just on the EPS guide, you took the low end up by a little over a $0.05. Is there anything in there rather than just operational at this point? Or a couple of companies have been adopting ASU 2016. Anything like that? Or anything else we should think about that's impacting your guidance other than just pure operational factors?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","It's purely operational. And we just took the midpoint and took it out by the $0.04 beat from the midpoint in Q3. So -- and there is the range a little bit, given that we're down to the last quarter. But no, we are not adopting the new tax provision becau",71,"It's purely operational. And we just took the midpoint and took it out by the $0.04 beat from the midpoint in Q3. So -- and there is the range a little bit, given that we're down to the last quarter. But no, we are not adopting the new tax provision because of the disband. We're going to wait until we get through that. So nothing in there other than operational."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Makes sense. And then last question, just on ICB. The order is up 13%, and revenue is up 13% -- or 9%, I'm sorry. How much of that was organic and how much was acquisition-driven?",35,"Makes sense. And then last question, just on ICB. The order is up 13%, and revenue is up 13% -- or 9%, I'm sorry. How much of that was organic and how much was acquisition-driven?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That -- we're year-over-year with MeVis, so that's in the base now. So Claymount is what's different, and it would've been 8% revenue growth.",24,"That -- we're year-over-year with MeVis, so that's in the base now. So Claymount is what's different, and it would've been 8% revenue growth."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. So you're only 1 point on those acquisitions?",9,"Okay. So you're only 1 point on those acquisitions?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Is that right? Did I get that number right?",9,"Is that right? Did I get that number right?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Certainly not.",2,"Certainly not."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Double check that then, but a little more than 1%.",10,"Double check that then, but a little more than 1%."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Steve Beuchaw with Morgan Stanley.",14,"And the next question comes from the line of Steve Beuchaw with Morgan Stanley."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Dow, when you look at the [indiscernible] business and you look at some of the trends in commodity or oil-sensitive countries and you look at the mid-stage funnel, what does it tell you about how things play out? I know we've had a couple of tough quarter",78,"Dow, when you look at the [indiscernible] business and you look at some of the trends in commodity or oil-sensitive countries and you look at the mid-stage funnel, what does it tell you about how things play out? I know we've had a couple of tough quarters here and there for obvious reasons in places like Latin America, but we've seen commodity prices in a number of spots pick up. Is that a cause for optimism about 2017?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say -- I wish I could look you in the eye and say that about Latin America. I think it's a little broader-based in Latin America. In the Middle East, maybe so. I think it's a good -- I don't know that we -- it's kind of interesting on this quarter a l",161,"I'd say -- I wish I could look you in the eye and say that about Latin America. I think it's a little broader-based in Latin America. In the Middle East, maybe so. I think it's a good -- I don't know that we -- it's kind of interesting on this quarter a lot of our Africa volume, and it's actually one of the thing you'll really like. Yes, a lot of the Africa volume was in non oil-based countries. So it's great to -- Ethiopia, I mentioned in the call, that's the first time we've had an [indiscernible] order from Ethiopia. And that's the kind of activity we're seeing in those of markets. I would say the Middle East has been a little quieter this year, looking back 12 months because of oil prices. And what are we today? $40, $45 a barrel? I think that might be enough to see some of that market come back next year."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Got it. And then on the imaging spin. I wonder how the strategic conversations outside the company have been evolving since the imaging spin. I mean, has that opened any new doors for you in terms of collaborations, partnerships or other strategic activit",43,"Got it. And then on the imaging spin. I wonder how the strategic conversations outside the company have been evolving since the imaging spin. I mean, has that opened any new doors for you in terms of collaborations, partnerships or other strategic activity?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","On that, we're continuing to look at how we reinforce the strategy of each company as we spin. As we're looking at a broader Oncology front for our -- for the remaining company and looking for a broader components [indiscernible] Head for our X-ray busine",133,"On that, we're continuing to look at how we reinforce the strategy of each company as we spin. As we're looking at a broader Oncology front for our -- for the remaining company and looking for a broader components [indiscernible] Head for our X-ray business. So now the good news is it has been pretty active. I think it's accomplishing both strategically and, we think, long-term from a value point of view what we want to do, and kind of unleashing a lot of energy around those initiatives. And frankly, we're a little bit in head-down mode to get the spin done. So that's consuming us pretty hard here for between now and the end of the year. But we're pushing very aggressive as well on kind of strategy front in both businesses."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Tycho Peterson with JPMorgan.",13,"And the next question comes from the line of Tycho Peterson with JPMorgan."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","First question, cancellations this quarter was about $42 million. And yes, that's a big step-down from you had the last quarter. So Elisha, I'm just wondering if you could kind of talk us through what you think is the underlying trend here.",42,"First question, cancellations this quarter was about $42 million. And yes, that's a big step-down from you had the last quarter. So Elisha, I'm just wondering if you could kind of talk us through what you think is the underlying trend here."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So yes. One of the big differences, Tyco. So it was $51 million in total on backlog adjustments. I believe the actual cancellation was closer to $20 million, and the rest was dormancy, where it just -- it's not probable at this point that this machine wil",120,"So yes. One of the big differences, Tyco. So it was $51 million in total on backlog adjustments. I believe the actual cancellation was closer to $20 million, and the rest was dormancy, where it just -- it's not probable at this point that this machine will ship within the 2-year period of time so we take it out of our backlog. The big difference is we did not have a big FX impact this quarter, and we had a large one on -- in some of the prior quarters because, as you know, our backlog is held at historical rates. And so it gets trued-up every quarter based on the FX. And so that was very minimal this quarter."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And then maybe for Dow on Services. You've been outgrowing the market here for quite some time. Can you maybe just talk about the sustainability of that trend? How long do you think you can kind of outgrow the market from a service p",62,"Okay. That's helpful. And then maybe for Dow on Services. You've been outgrowing the market here for quite some time. Can you maybe just talk about the sustainability of that trend? How long do you think you can kind of outgrow the market from a service perspective? And do the attach rates vary meaningfully by geography for you guys in that front?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, we're very bullish about our service business still. It's a little bit a lot of large numbers because it's now $1 billion business. I think on the quarter in Oncology, it was 41%, 42% of the total, and it continues to be a juggernaut for us. I w",207,"I mean, we're very bullish about our service business still. It's a little bit a lot of large numbers because it's now $1 billion business. I think on the quarter in Oncology, it was 41%, 42% of the total, and it continues to be a juggernaut for us. 
I would say that it's one of the things that we really like about the new socket growth that we're seeing in Latin America and Asia, in particular. That's going to help drive the growth. The software model going to more of a kind of a SaaS-based model, strengthens that business. And we are seeing lots of positives on the upside. On the -- we are seeing in some markets, some of these emerging markets, we're seeing a little bit of wackiness from third-party competition. I wouldn't say that's the reason for the slowdown. I think the slowdown probably has more to do with large numbers and just kind of where we are. But in some of these emerging markets, we are seeing some growing presence, especially in the older installed base, some third-party competition. 
But I'd say, we're still in that high single-digit range. It's kind of what we're feeling about the long-term capability of our service business."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then does having stability on the reimbursement front, I mean, we've got to the Physician Fee Schedule relatively unscathed. The first 2 years of macro would be kind of everybody gets a little bit of a bump. Does that free up the U.S. market a little",57,"And then does having stability on the reimbursement front, I mean, we've got to the Physician Fee Schedule relatively unscathed. The first 2 years of macro would be kind of everybody gets a little bit of a bump. Does that free up the U.S. market a little bit over the next couple of years, do you think?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, I think it's too early to tell. But that would be our -- our guess would be consistent with that, Tycho. I think the macro field is a little bit like some of the reimbursement incentives that there were on some of this early IT adoption 3, 4 years",63,"I mean, I think it's too early to tell. But that would be our -- our guess would be consistent with that, Tycho. I think the macro field is a little bit like some of the reimbursement incentives that there were on some of this early IT adoption 3, 4 years ago. So I think it's probably a little bit of an upside."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then -- and last one. You made a comment earlier on the kind of the proton funnel. Just -- I mean, any sense as to what -- how big you think that market could be? Because it doesn't seem [indiscernible]",41,"And then -- and last one. You made a comment earlier on the kind of the proton funnel. Just -- I mean, any sense as to what -- how big you think that market could be? Because it doesn't seem [indiscernible]"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Every time I forecasted this, I've been wrong. So I'm not going to take the bait. I mean, it's just -- the good news is, these are government customers. And so I think we had our first discussion with SA [ph] 15 months ago. So we went from first conversat",140,"Every time I forecasted this, I've been wrong. So I'm not going to take the bait. I mean, it's just -- the good news is, these are government customers. And so I think we had our first discussion with SA [ph] 15 months ago. So we went from first conversation to order in 15 months, and for that, for us, that's a record in proton therapy. 
When you get in the private market, and we're financing instruments, it's frankly the most difficult part of the transaction, these deals can take a really, really long time. And so we're at sovereign-financed. It can move pretty fast. And we are having -- I'd say there are 3 or 4 live conversations going on. Will they happen in the next 15, 18 months? Maybe. There's a -- at least we have one now."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Vijay Kumar with Evercore ISI.",14,"And the next question comes from the line of Vijay Kumar with Evercore ISI."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So maybe, Dow, a big-picture question on -- because I guess, now we'll have green numbers, right, in a few months on standalone Oncology. I was just wondering, can you just comment big picture, what's been the installed base over the last 3 years, right?",89,"So maybe, Dow, a big-picture question on -- because I guess, now we'll have green numbers, right, in a few months on standalone Oncology. I was just wondering, can you just comment big picture, what's been the installed base over the last 3 years, right? Has it been flattish? Has it been growing in North America? Because that -- I just feel like that's an important question, just given your really, really strong insurance here in North America. And obviously, that has a lot of implications to margin progression."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say, starting at a very high level, we have about a 7,500-unit installed base. We have had positive unit growth, 1% or 2% of the installed days. One of the things that we like about the whole U.S. growth is, as I mentioned, about China is those are al",114,"I'd say, starting at a very high level, we have about a 7,500-unit installed base. We have had positive unit growth, 1% or 2% of the installed days. One of the things that we like about the whole U.S. growth is, as I mentioned, about China is those are all new sockets, and we're -- we get some new installed base growth out of it. 
We did have very -- in Q3, we had very good unit growth. So one of the best unit growth quarters we've had in a while. So that can help our service business. So I don't know if I'm answering all your questions, Vijay. Elisha, anything to add?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Just that the U.S., as we said, Vijay, is largely a replacement market. So the installed base is not necessarily going up, but it is getting higher in equipment that does carry a higher level of service contracts.",39,"Just that the U.S., as we said, Vijay, is largely a replacement market. So the installed base is not necessarily going up, but it is getting higher in equipment that does carry a higher level of service contracts."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And when we made that trade out, I'd say our contract capture rate of TrueBeams is 10 to 15 points higher than our -- than the historical product.",28,"And when we made that trade out, I'd say our contract capture rate of TrueBeams is 10 to 15 points higher than our -- than the historical product."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And that was very helpful a lot, guys. And maybe just one on software. Because I -- this is the other question we've got to lock on.  In what kind of visibility do we have, right, on software option? Because I know at the Analyst Day, I knew you guys put",150,"And that was very helpful a lot, guys. And maybe just one on software. Because I -- this is the other question we've got to lock on.  In what kind of visibility do we have, right, on software option? Because I know at the Analyst Day, I knew you guys put out that $0.5 billion opportunity, right? Because, I guess, the reason -- when I look at your comments of the installed base, right, sort of 1% to 2%, obviously, you guys have done better on the share front. That's showing up in the North America region from an orders perspective, right? But how much more software can you keep selling into that installed base, right? Or am I thinking about this the right way? Or -- because I feel like having some clarity on that, I mean, has a lot of implications on how people look at the company."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Right here. I mean, there's some really simple math here. We've got an installed base of 7,500 units. We've sold, and we feel really good about it, 500 RapidPlans. We have got 7,000 to go. We've got, inside of analytics, what have we sold? 250? 200-ish?",253,"Right here. I mean, there's some really simple math here. We've got an installed base of 7,500 units. We've sold, and we feel really good about it, 500 RapidPlans. We have got 7,000 to go. 
We've got, inside of analytics, what have we sold? 250? 200-ish? We've got 7,300 to go. So we're in the top half of the first inning. Sorry, baseball analogy to my global friends. But we're -- the software is still -- has very significant upside for us. And what I'm liking is we're getting very good customer response on the software products. I -- a decade ago, ship me [ph] software and it works but I don't love it. Now we're getting, hey, if it does what I like it to do. It's making me for productive in the workplace. I can do better care and take care of patients better. And we've had some external validation out of this with our class, the wind that's kind of the gardener of radiation oncology class rate. It is #1 in treatment planning and in oncology information system. So we like that. 
So those were RapidPlan and InSightive Analytics are 2 examples. We do have -- in the 7,500 units linac installed base. In that installed base, we also have 3,400, 3,500 software installations. So those are opportunities for us to take rapid -- that's the low-hanging fruit of the RapidPlan and InSightive Analytics opportunity. So I think, Vijay, we still got a lot of opportunity on the software side."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","That was really helpful, Dow. And if I just may sort of retort with a baseball analogy, I think in the [indiscernible] be hitting a 6. So congrats.",28,"That was really helpful, Dow. And if I just may sort of retort with a baseball analogy, I think in the [indiscernible] be hitting a 6. So congrats."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think I know what that means, which is a little scary.",12,"I think I know what that means, which is a little scary."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Jason Wittes with Brean Capital.",14,"And the next question comes from the line of Jason Wittes with Brean Capital."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","I just want to get an update. I know that things are still moving, but in terms of the numbers you put out when you first announced the spin-out, you noticed -- you mentioned, I think, I believe $37 million in overhead, dis-synergies. Is that still the nu",66,"I just want to get an update. I know that things are still moving, but in terms of the numbers you put out when you first announced the spin-out, you noticed -- you mentioned, I think, I believe $37 million in overhead, dis-synergies. Is that still the number that we should be thinking about? And in terms of who absorbs what, is there any update there?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Jason, at this point, it was $20 million of dis-synergies at -- that would be -- remain co-Varian, and that number has not changed dramatically at this point. So I think it's still a good number to use. And again, with the goal of having that offset withi",64,"Jason, at this point, it was $20 million of dis-synergies at -- that would be -- remain co-Varian, and that number has not changed dramatically at this point. So I think it's still a good number to use. And again, with the goal of having that offset within 2 years so that we can get back to the same margin point, operating margin point."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And I believe that you're going to give the -- SpinCo will have cash on hand. I believe that was $50 million. But will that be cash taken from overseas? Or will that be cash that's been patriated in the U.S.?",42,"And I believe that you're going to give the -- SpinCo will have cash on hand. I believe that was $50 million. But will that be cash taken from overseas? Or will that be cash that's been patriated in the U.S.?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So there -- no number has been determined. And all we have said is they will not have debt at this -- at the time of the spin. And we are working with our advisors on the capital structure at this point. And so stay tuned, and we'll be talking about how m",69,"So there -- no number has been determined. And all we have said is they will not have debt at this -- at the time of the spin. And we are working with our advisors on the capital structure at this point. And so stay tuned, and we'll be talking about how much cash ends up going with SpinCo and how much of that is U.S. versus old U.S."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And when do you anticipate giving us that update? Will that be on your -- for the fourth quarter? Or will that be more towards December?",27,"Okay. And when do you anticipate giving us that update? Will that be on your -- for the fourth quarter? Or will that be more towards December?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","It's going to be more to words when we're going on the roadshow, closer to the spin date.",19,"It's going to be more to words when we're going on the roadshow, closer to the spin date."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Fair enough. And just on the Proton business. In terms of -- you've also put out sort of anticipation of reaching profitability. I assume that still goes. And what kind of revenue run rate do you need for that business to really sort of break even a",49,"Okay. Fair enough. And just on the Proton business. In terms of -- you've also put out sort of anticipation of reaching profitability. I assume that still goes. And what kind of revenue run rate do you need for that business to really sort of break even and [indiscernible]?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. It's a little hard to say, Jason. What we really need is the installs to be completed and the service business to become material to get a significant pop in the margins. But this year, it's going to be around $150 million. It's $200 million -- somew",60,"Yes. It's a little hard to say, Jason. What we really need is the installs to be completed and the service business to become material to get a significant pop in the margins. But this year, it's going to be around $150 million. It's $200 million -- somewhere between $200 million and $225 million, it's starts looking very different. So..."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And now as you know, it'll will -- I mean, this is going to change with time because the margin rates on the equipment, now today, they're high-teens, mid high-teens. We hope to get back to the 20 to 30 range with time. But the margin rates on service are",76,"And now as you know, it'll will -- I mean, this is going to change with time because the margin rates on the equipment, now today, they're high-teens, mid high-teens. We hope to get back to the 20 to 30 range with time. But the margin rates on service are pretty good. So as the service contracts start to land, the geography of that profitability becomes a little easier with time. That's probably not next year."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And then the reimbursement was pretty benign, or actually, it's a positive, not benign, more optimism in that. But in terms of -- you did mention that they're going to try to start coaxing the market into being more efficient. I beli",102,"Okay. That's helpful. And then the reimbursement was pretty benign, or actually, it's a positive, not benign, more optimism in that. But in terms of -- you did mention that they're going to try to start coaxing the market into being more efficient. I believe that's with macro MIPS. There are centers out there who have adopted it. Have you noticed a change in their behavior in terms of what their -- equipment they want? How they're doing their procedures, things like that? Is there a shift towards more concentrated dosing in those centers? Or is it just too early to say?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say, if anything, it might be an incentive for people to take our ARIA inside of analytics and other ARIA features into the market. ARIA is macro-compliant. One of the things that get that is a lot of metrics, a lot of portability. These are some of t",108,"I'd say, if anything, it might be an incentive for people to take our ARIA inside of analytics and other ARIA features into the market. ARIA is macro-compliant. One of the things that get that is a lot of metrics, a lot of portability. These are some of the things they're looking for, and that's part of that product. So short-term-ish, as we were talking about in one of the other questions, it could be a little bit of upside maybe next year. I would say we haven't really seen a behavior change in terms of peoples purchasing pattern, one way or the other, at this point."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So -- and also related to that, do you have a sense of how much of the marketplace is actually ready to fully implement macro here, that has all the software in place, et cetera?",35,"So -- and also related to that, do you have a sense of how much of the marketplace is actually ready to fully implement macro here, that has all the software in place, et cetera?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I think the short version is people just got the standard, so 0. So I mean, we look -- take a hard look at it. We know that we've got a few product things to do, but then our product is pretty compliant. We're -- the -- we're pretty comfortable with",291,"Well, I think the short version is people just got the standard, so 0. So I mean, we look -- take a hard look at it. We know that we've got a few product things to do, but then our product is pretty compliant. We're -- the -- we're pretty comfortable with where our product is. It's not going to be like a major rewrite or something that we're going to have to do, but we do have to add a few features, and we're very well positioned for macro implementation. So we like that. But I would say, to kind of come back to the main thrust of the question, I would say we have not seen a purchasing difference with those customers. 
With history, if anything, a lot of them tend to be -- they want to be clinically advanced and they want to be very productive, cost-efficient. And sometimes, it takes a little bit longer to convince them. But once they're convinced, they tend to move faster because they've got the clinical data or the productivity data to make their business case. And they may take a little bit longer to convince them, but once they're convinced, they -- I -- one of the examples I've used historically on this is RapidArc with Kaiser. 
It took us a while to convince them that RapidArc was really clinically advantageous and was going to give them a productivity pop. Once they were convinced, Kaiser nor its outfit, every hospital within a year. It was just, bang. They really moved. And I think that's typical from what we see from these kind of customers. It might take a little bit longer to convince them, but when they're convinced, they go fast."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And just sort of a follow-on, on that. When that happens, which it's going to take some time, I mean, I think macro itself doesn't really have teeth until the next couple of years, but it does seem like there could be some upgrade --",89,"Okay. That's helpful. And just sort of a follow-on, on that. When that happens, which it's going to take some time, I mean, I think macro itself doesn't really have teeth until the next couple of years, but it does seem like there could be some upgrade -- required upgrades for software that could help you or help, I guess, your customers as well. But there is an upgrade cycle to be had when this really starts to take over. Was that a fair way to think about it?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Absolutely. And that's the outside opportunity I've been referring to, yes.",12,"Yes. Absolutely. And that's the outside opportunity I've been referring to, yes."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Anthony Petrone with Jefferies.",13,"And the next question comes from the line of Anthony Petrone with Jefferies."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Just a couple of follow-ups, actually, on guidance and Imaging, in particular, and then one on the spin. So for guidance, I guess, the 3% reiteration here. You are baking quite an acceleration in the fourth quarter. And I'm just wondering how much of th",82,"Just a couple of follow-ups, actually, on guidance and Imaging, in particular, and then one on the spin. 
So for guidance, I guess, the 3% reiteration here. You are baking quite an acceleration in the fourth quarter. And I'm just wondering how much of that is Oncology-related versus maybe a rebound in imaging? And then you also spoke quite a bit on proton. So just trying to get a little bit more color on guidance. And then I'll have the follow-ups."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. So Anthony, the guidance in Oncology, and I'm assuming you're talking revenue here, should be in the mid single-digit growth. The Imaging Components business will be in the low single-digit growth versus the year-ago quarter. And we're going to get",72,"Sure. So Anthony, the guidance in Oncology, and I'm assuming you're talking revenue here, should be in the mid single-digit growth. The Imaging Components business will be in the low single-digit growth versus the year-ago quarter. And we're going to get $20 million to $25 million-or-so in additional proton revenue versus the year-ago period. So a big bump in protons is going to get you to around just 7% range on Q4."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","That's helpful. And then just Imaging Components again for the quarter. I know you mentioned in bookings the contribution from -- or gross orders rather from acquisitions. But I'm just wondering what the revenue contribution was in the quarter from Claymo",44,"That's helpful. And then just Imaging Components again for the quarter. I know you mentioned in bookings the contribution from -- or gross orders rather from acquisitions. But I'm just wondering what the revenue contribution was in the quarter from Claymount and MeVis?"
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","About $11 million, I believe, in total.",7,"About $11 million, I believe, in total."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Helpful. And then last, just on spin. Have you announce if it's a 1 for 1 share distribution? Or we're still...",21,"Helpful. And then last, just on spin. Have you announce if it's a 1 for 1 share distribution? Or we're still..."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No, we have not. We have not. We're working with JPMorgan on that.",13,"No, we have not. We have not. We're working with JPMorgan on that."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","There are no other questions on the queue at this time. I would now like to turn the call back over to management for any closing comments.",27,"There are no other questions on the queue at this time. I would now like to turn the call back over to management for any closing comments."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Thank you all for participating. The replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1(877) 660-6853 from inside the U.S.",70,"Thank you. Thank you all for participating. The replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1(877) 660-6853 from inside the U.S. or (201) 612-7415 from outside the U.S., and confirmation code 13640722. A telephone replay will be available through 5:00 p.m. this Friday July 29. Thank you all."
311907,370528018,1014658,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. This concludes today's teleconference. You may disconnect your lines at this time, and we thank all of you for your participation.",23,"Thank you. This concludes today's teleconference. You may disconnect your lines at this time, and we thank all of you for your participation."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems teleconference. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Spencer Sias, VP, Investor Relations, for Varian Medical. Thank",44,"Greetings, and welcome to the Varian Medical Systems teleconference. [Operator Instructions] As a reminder, this conference is being recorded. 
It is now my pleasure to introduce your host, Spencer Sias, VP, Investor Relations, for Varian Medical. Thank you, Mr. Sias. You may now begin."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Good afternoon, and welcome to Varian Medical Systems Conference Call for the Third Quarter of Fiscal Year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will",270,"Thank you. Good afternoon, and welcome to Varian Medical Systems Conference Call for the Third Quarter of Fiscal Year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. 
To simplify our discussion, unless otherwise stated, all references to the quarter or year or fiscal quarters or fiscal years -- quarterly comparisons are for the third quarter of fiscal 2016 versus the third quarter of fiscal 2015. References to financial results for orders are the gross orders unless otherwise indicated. 
This discussion includes some non-GAAP financial measures in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. 
A reconciliation to the most comparable GAAP measures is included in our earnings release, which can be accessed on our website. Please be advised that this discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, will, scheduled and similar expressions are intended to identify those statements which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks relating to our business are described in our third quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise.
And now, here's Dow."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Varian is reporting solid results for the third quarter of fiscal year 2016, with strong gross order and revenue growth in our Oncology Systems and Imaging Components businesses, together with substantial improvements in gross",1057,"Good afternoon, and welcome. Varian is reporting solid results for the third quarter of fiscal year 2016, with strong gross order and revenue growth in our Oncology Systems and Imaging Components businesses, together with substantial improvements in gross and operating margins for both. 
In summary, the company is reporting GAAP net earnings of $1.04 per diluted share and $1.22 per diluted share on a non-GAAP basis; revenues of $789 million, up 1% versus the year-ago quarter; a nearly 4-point improvement in the company's overall gross margin; and an order for new -- for a new multiroom proton installation in China, our first proton order there. 
Focusing on operational highlights. Our Oncology business generated third quarter gross orders of $676 million, up 6% in both dollars and constant currency. Gross orders in the Americas rose by 8% during the quarter with 15% growth in North America more than offsetting a greater than 40% decline in Latin America. 
Year-to-date gross order growth in North America is 8%, driven by a more stable reimbursement environment and, in this replacement market, a transition to more advanced clinically efficient systems. 
Gross orders in APAC increased 19% in dollars and 17% in constant currency during the quarter, driven by robust growth in China and Australia. 
In EMEA, gross orders declined 3% in dollars and 4% in constant currency, reflecting weakness in Western European markets. 
Looking at each of the regions in more detail. Our growth in North America was driven by demand for our TrueBeam platform, including EDGE radiosurgery systems and our software offerings. Among the highlights for North America were several large multi-system orders from consolidated networks as well as competitive takeouts. 
Order activity in Latin America continued to be weak due to macroeconomic factors. During the quarter, we shipped the first units for the large tender conducted by Brazil's Ministry of Health a couple of years ago. 
Turning to APAC. The Icon Group placed the largest Varian order ever in Australia for 10 TrueBeam systems, 7 of which are going to new sites along with the full complement of our information management and treatment planning software. We had wins for several new accelerator installations in China, where we saw good orders growth. We also saw strong demand for our EDGE radiosurgery system in this market, where we continue to be the share leader. 
Elsewhere in APAC, we made good progress in Thailand, Vietnam and Indonesia. Business was stable in Japan, where we saw good service growth. 
Turning to EMEA. Healthy gross order growth in emerging markets, including Iran, Russia, Ethiopia Burkina Faso and Libya was offset by weakness in Western Europe. Our third quarter business in Africa was outstanding, with more than $25 million in gross orders. Among other wins, we saw Ethiopia order its first modern linear accelerators for cancer treatment. 
I'm pleased to report that overall unit order volumes were up in the quarter and year-to-date and that average pricing is stable. We're winning with clinically efficient advanced technology that makes quality cancer care affordable and accessible. This was reflected during the quarter, in strong orders for our RapidPlan and InSightive Analytics software. We booked our 500th order for RapidPlan, which is a game changer that enables clinics to improve the speed and quality of care for their patients. As of this quarter, treatment plans are now being shared among clinics through our ongoing OncoPeer web portal. 
As you all know, CMS has announced modest adjustments to reimbursement for 2017 for both hospitals and free-standing clinics. We don't expect for reimbursement to have a material impact on the radiation oncology markets in the U.S. next year. 
Following the topic of reimbursement, CMS did move forward with policies that will incentivize the adoption of digital X-ray imaging systems in place of film and computed radiography systems, and this should help to support growth in our Imaging Components business. 
Speaking of Imaging Components, the business returned to growth during the quarter. Orders grew by 13% to $138 million, and revenues rose by 9% to $147 million. Improvements in margins were driven by productivity gains and a favorable product mix. Our tube business saw good growth in the quarter. We recently celebrated the 40th year of our relationship with Toshiba Medical Systems and look forward to continuing this relationship when they become part of Canon. 
Our recently acquired software and X-ray accessories businesses also helped to drive growth. 
Touching on the Industrial Imaging business, orders for security products were up in the quarter but we continue to have a cautious outlook in the face of ongoing customer consolidation. We continue to focus on generating growth in nondestructive testing and inspection. 
Let me update you on our progress towards the separation of the Imaging Components business into a new, independent publicly traded company via tax-free distribution to Varian stockholders. 
As you probably saw in the press release issued last week, the name of the new company will be Varex Imaging Corporation. We are now making good progress in the development of detailed plans and activities needed to execute the separation. We're on track to file an initial Form 10 with the SEC in the next several weeks, and we are currently on schedule to complete the separation at the end of the calendar year. We continue to be excited about the prospects of creating 2 great companies. 
Turning now to our Particle Therapy business. We booked an order during the quarter for a multiroom probing installation at the new Hefei medical center in China. This is China's first government-funded proton facility. Installation is slated to take place in late 2017 with patient treatments scheduled to begin in late 2018. 
Our installation at Cincinnati Children's Hospital is on track with the first patient treatments scheduled to commence later this summer. 
We have now successfully commissioned the third room at the Maryland Proton Therapy (sic -- Treatment) Center, and installations are underway in Holland, Russia and Saudi Arabia. In total, we have 13 proton projects generating revenue. 
As you probably saw from our 8-K filing with the SEC at the end of June, we sold our $73 million senior loan for the New York Proton Therapy Center to Deutsche Bank, freeing up capital to help finance other proton projects. The proton sales funnel continues to look good. 
And now I'll turn it over to Elisha."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Great. Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 5% from the year-ago period. Backlog adjustments during the quarter totaled $51 million, bringing net or",589,"Great. Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 5% from the year-ago period. Backlog adjustments during the quarter totaled $51 million, bringing net orders for the company to $814 million. 
Third quarter revenues for the total company were $789 million, up 1% in dollars and even with the year-ago period in constant currency. Year-to-date, total company revenues were $2.3 billion, up 1% in dollars and up 3% in constant currency. Oncology posted a revenue gain of 8%, both in dollars and in constant currency, driven by strength in our high-end equipment as well as our software and service businesses. 
Imaging Components posted a third-quarter revenue gain of 9%, driven by our newly acquired X-ray accessories business as well as higher tube sales. 
Our Particle Therapy business posted third-quarter revenue of $37 million, down from the year-ago period, when we booked $91 million of revenues, including a substantial amount for the ProBeam installation at the University of Maryland. 
Total company gross margin for the quarter was 43.9%, up by nearly 4 points with significant contributions from both Oncology and Imaging Components. Oncology Systems' third quarter gross margin improved by more than 4 points to 46% with the help of a larger mix of TrueBeams and software as well as productivity gains. 
Imaging Components' third-quarter gross margin also rose by more than 4 points to 42.9% due largely to factory productivity gains and favorable product mix. R&D expenses were $65 million, or 8% of revenue, equal as a percentage of revenue to the year-ago quarter. 
On a GAAP basis, third quarter SG&A expenses were $151 million or 19% of revenue, we had about $22 million of unusual expenses in SG&A for items, including ongoing patent litigation and the recently announced initiative to separate the Imaging Components business into a new publicly traded company. Excluding these items, SG&A expenses on a non-GAAP basis for the quarter were $129 million or 16% of revenue. 
GAAP operating earnings for the quarter were 16.5% of revenues and 19.5% of revenues on a non-GAAP basis, reflecting our solid gross margin performance in the quarter. 
Depreciation and amortization totaled $18 million for the quarter. The effective tax rate was 25.1%, up 3 points from the year-ago quarter, when we benefited from a favorable geographic mix of profits and tax loss carryforwards associated with the proton business. We continue to expect that the tax rate will be about 26% to 27% for the year. 
Fully diluted shares outstanding were $95.4 million, more than $5 million lower than the year-ago quarter due to our ongoing share repurchase program. Diluted EPS was $1.04 for the quarter on a GAAP basis and was $1.22 on a non-GAAP basis.
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $836 million, debt of $701 million and stockholder's equity of $1.7 billion. 
DSO at 101 days was up significantly from the year-ago quarter but improved sequentially from the second quarter. 
Third quarter cash flow from operations was $95 million, bringing the total cash flow from operations year-to-date to $204 million. Primary uses of cash were $126 million for the repurchase of 1.5 million shares of stock, $95 million to reduce debt and $15 million for capital expenditure. At the end of the quarter, we had 4.8 million shares remaining under the existing repurchase authorization that extends to calendar year 2016. 
Now I'll turn it back to Dow for the outlook."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. Including the results of the third quarter, we believe that total company non-GAAP earnings will be in the range of $4.62 to $4.66 per diluted share for fiscal year 2016. We continue to believe revenues for fiscal year 2016 will increase b",56,"Thanks, Elisha. Including the results of the third quarter, we believe that total company non-GAAP earnings will be in the range of $4.62 to $4.66 per diluted share for fiscal year 2016. We continue to believe revenues for fiscal year 2016 will increase by about 3% over fiscal year 2015. 
We're now ready for your questions."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] And our first question will come from the line of Anthony Petrone with Jefferies.",16,"[Operator Instructions] And our first question will come from the line of Anthony Petrone with Jefferies."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Congratulations on a good quarter. Maybe just start a little bit with just the North American order growth in Oncology there, which sort of reached a multi-quarter high here. Maybe a little bit more in terms of the underlying drivers there, how much is ma",80,"Congratulations on a good quarter. Maybe just start a little bit with just the North American order growth in Oncology there, which sort of reached a multi-quarter high here. Maybe a little bit more in terms of the underlying drivers there, how much is market-related, maybe even replacement cycle-related? And how much was it from share gains? And then a follow-up there would be, on the product side, how much was driven by VitalBeam, which was a driver last quarter?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Good questions. I would start by saying our rolling 4-quarter growth in the Americas has been 7%. So we feel very good about kind of where that is. North America has certainly been the driver. And you're right, North America did hit a high this quart",310,"Yes. Good questions. I would start by saying our rolling 4-quarter growth in the Americas has been 7%. So we feel very good about kind of where that is. North America has certainly been the driver. And you're right, North America did hit a high this quarter, but it is kind of a sustained trend that we're seeing, which is good. We did have a couple of multi-system orders, including one with HCA. We also had very strong demand, as I mentioned in the call, for software products. 
And VitalBeam, I think a little more than half of our VitalBeams have been sold in the Americas. So that's -- VitalBeam has been part of the story, but I think the overall story, though, is TrueBeam. 
When you clearly look at what's going on, TrueBeam is what's driving both the Americas growth and the global growth, both in orders and revenues. I mean, some of the -- on the revenue side, Elisha will talk about this later, but on the revenue side, we had very good TrueBeam mix on the quarter, that's some of the margin uptick, but it's -- from a kind of a market perspective, the U.S. is a replacement market. That's true. As I said in the call, we are seeing people trade out aggressively to try to get new capability, especially for advanced radiosurgery and body radiosurgery. 
I think reimbursement may have been a small factor -- certainly not over last year, but having that be calm in the quarter, kind of shored up -- shored things up a little bit. I think from a high level, that's kind of the story. And I think -- the other thing I was going to mention is from the market share point of view, we think we've gained a little bit of share, but most of this is market."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","No, very, very helpful. And maybe to shift gears just to Imaging, and then one for Elisha. One of the headwinds for that business over the past couple of quarters was destocking from several key customers, including Toshiba. I'm just wondering if that has",62,"No, very, very helpful. And maybe to shift gears just to Imaging, and then one for Elisha. One of the headwinds for that business over the past couple of quarters was destocking from several key customers, including Toshiba. I'm just wondering if that has reversed at this point. And specifically with regards to Toshiba, are they back ordering anything at this point?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say Toshiba is back a little bit. I wouldn't say they're fully back yet. I mean, we had an okay quarter from Toshiba. The tube business was actually quite strong in the quarter, and some of that was Toshiba, but we also had very good tube performance",90,"I'd say Toshiba is back a little bit. I wouldn't say they're fully back yet. I mean, we had an okay quarter from Toshiba. The tube business was actually quite strong in the quarter, and some of that was Toshiba, but we also had very good tube performance from our other tube customers on the quarter, and it was as much on their backs that we drove this. So I'd say the best Toshiba days, frankly, are still ahead of us. We're not totally out of that headwind yet."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And the oppositions helped us out, Anthony.",7,"And the oppositions helped us out, Anthony."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, yes, yes.",3,"Yes, yes, yes."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Sure. Sure, and then last, just quick and I'll hop in queue. Elisha, Oncology gross margin, 46% you called out, that's beyond the normalized 44% level. I mean, is this sort of a new normal? Or do you expect it to sort of moderate back down to that 44% lev",52,"Sure. Sure, and then last, just quick and I'll hop in queue. Elisha, Oncology gross margin, 46% you called out, that's beyond the normalized 44% level. I mean, is this sort of a new normal? Or do you expect it to sort of moderate back down to that 44% level over time?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I would love to say yes, Anthony, but I'm -- we just had a really favorable product mix in the quarter and I just can't count on that every single quarter going forward. What I would say is Oncology has done a fantastic job on pricing, holding stabl",116,"Well, I would love to say yes, Anthony, but I'm -- we just had a really favorable product mix in the quarter and I just can't count on that every single quarter going forward. What I would say is Oncology has done a fantastic job on pricing, holding stable pricing and on product cost reduction and on productivity gains. And so the hope is, yes, that will last as we move forward. But again, product mix drives our margin much more than any other factor. 
I do think for this fiscal year, they should be at the high end of that 43% to 44% range that we've talked about and really helped by this last quarter."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And our next question comes from the line of Amit Hazan of Citibank.",13,"And our next question comes from the line of Amit Hazan of Citibank."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","It's Lee [ph] Preston, on for Amit. A couple of questions here. I'll start with margin. On the back of the gross margin question, is there anything stronger in gross margin this quarter that you would call out as more sustainable in nature as opposed to g",59,"It's Lee [ph] Preston, on for Amit. A couple of questions here. I'll start with margin. On the back of the gross margin question, is there anything stronger in gross margin this quarter that you would call out as more sustainable in nature as opposed to good mix and some of the other items you've already called out?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, mix -- the product mix drives the margin first and foremost, in Oncology. Geographic mix, secondly. The geographic mix was identical this quarter versus the year-ago quarter so that has no impact. I would say the cost -- the product cost reduction i",86,"Well, mix -- the product mix drives the margin first and foremost, in Oncology. Geographic mix, secondly. The geographic mix was identical this quarter versus the year-ago quarter so that has no impact. I would say the cost -- the product cost reduction is real, and we should continue to have the benefit of that going forward as there's many, many -- much fewer C-series, our old legacy equipment and many more TrueBeams at a higher margin. And so we're starting to see that flow through."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then just on the operating margin for this year. It looks like there have been 2 good quarters at or around the 19%. The implications for fourth quarter looks above that, too. So is this kind of the range we should be thinking about going forwar",86,"Okay. And then just on the operating margin for this year. It looks like there have been 2 good quarters at or around the 19%. The implications for fourth quarter looks above that, too. So is this kind of the range we should be thinking about going forward here? It's a bit above the original guidance. Is this FX-related to some extent? Or are you seeing some sustainability that makes you comfortable you've come off the bottom and maybe see some further gains heading into 2017?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, so I don't want to guide it all into 2017, particularly right at the moment with the spin-off going on. There is a lot of work that we're going to have to do in terms of looking into FY '17. You are correct. Once you run this model through, it's goi",116,"Well, so I don't want to guide it all into 2017, particularly right at the moment with the spin-off going on. There is a lot of work that we're going to have to do in terms of looking into FY '17. You are correct. Once you run this model through, it's going to put it to a close to 19% operating margin for this year, which would be up about 0.5 points versus the year-ago period. So again, all businesses have been very focused on headcount and on travel and on discretionary spending, and I think you're starting to see this flow through. But most of that improvement this year is coming through the gross margins."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And I'd just point out, these are -- it's consistent with our goal over the next 3, 4 years to get back to that higher return on sales. So it's kind of delivering on the track 50 basis points-ish a year that we were -- that kind of set as an overarching g",54,"And I'd just point out, these are -- it's consistent with our goal over the next 3, 4 years to get back to that higher return on sales. So it's kind of delivering on the track 50 basis points-ish a year that we were -- that kind of set as an overarching goal."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, great. And if I could sneak in one more, if I could. Can you talk about maybe the adjustments to backlog this quarter? They're a little bit higher than trends. Maybe you can give us some context as to what's going on there.",44,"Okay, great. And if I could sneak in one more, if I could. Can you talk about maybe the adjustments to backlog this quarter? They're a little bit higher than trends. Maybe you can give us some context as to what's going on there."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Actually, the backlog adjustments were lower, I believe, in the prior quarter and were pretty consistent with our average. So the $51 million is really what we would refer to -- some cancellations in that number, maybe $20 million of it. The rest is what",98,"Actually, the backlog adjustments were lower, I believe, in the prior quarter and were pretty consistent with our average. So the $51 million is really what we would refer to -- some cancellations in that number, maybe $20 million of it. The rest is what we call dormancies. When we review the backlog and we feel like there's no longer a good probability of the machine delivering within 2 years, we just take it out of our backlog until it fits that criteria. So -- but a $51 million level is very consistent with historically how it's been."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then sorry, one last quick one. If you could maybe give us a hint of why the CFO was up during the quarter?",25,"Okay. And then sorry, one last quick one. If you could maybe give us a hint of why the CFO was up during the quarter?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. So we have done -- we've seen this the last couple of quarters. The good news is, Q3, if you look at our cash flow from operations, returned back to a very strong level and was almost equal to net income. So I'm feeling very good that we're back on t",120,"Yes. So we have done -- we've seen this the last couple of quarters. The good news is, Q3, if you look at our cash flow from operations, returned back to a very strong level and was almost equal to net income. So I'm feeling very good that we're back on track in terms of cash flow. 
What happened is we moved our collection staff earlier in the fiscal year. We did a CRM implementation. I think those things just slowed down collections a little bit in the first half of the year. We've got some catching up to do. But in June and July, our collections have actually been very strong. So I think we're getting back on track."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. And Q2 to Q3, we had 10 days of shipment improvements; going in the right direction.",17,"Yes. And Q2 to Q3, we had 10 days of shipment improvements; going in the right direction."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes.",1,"Yes."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Brandon Henry with RBC Capital Markets.",15,"And the next question comes from the line of Brandon Henry with RBC Capital Markets."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","First, just on the North American strengthening gross orders, can you just help provide some more details on how much of that performance was from better systems order versus software and services?",32,"First, just on the North American strengthening gross orders, can you just help provide some more details on how much of that performance was from better systems order versus software and services?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I -- one of the things that we liked about it is that it was broad-based. It was both -- it was hardware, it was software and it was service. So we saw it in all 3 categories, there wasn't one -- As I mentioned from a product mix point of view, that marke",131,"I -- one of the things that we liked about it is that it was broad-based. It was both -- it was hardware, it was software and it was service. So we saw it in all 3 categories, there wasn't one -- As I mentioned from a product mix point of view, that market has largely -- it's probably been a 90% TrueBeam market for the last 18 months, 2 years, and it was at the high end of that. So maybe a little bit of product mix from an orders' point of view, but we -- as I said in the call, we had a couple of nice, large strategic deals, and we had a number of competitive takeouts in both the hardware and software area, but it was broad-based."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And did you guys give any growth rates in terms of software servicing this quarter? I might have missed that.",21,"Okay. And did you guys give any growth rates in terms of software servicing this quarter? I might have missed that."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No. We haven't broken it out.",6,"No. We haven't broken it out."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then separate question. Could you provide an update on what portion of Siemens went active and traded out at this point? I mean, how much of the acceleration in the North American Oncology Systems business can be attributed to an acceleration in",46,"Okay. And then separate question. Could you provide an update on what portion of Siemens went active and traded out at this point? I mean, how much of the acceleration in the North American Oncology Systems business can be attributed to an acceleration in Siemens trade-outs?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think it's a small and maybe even very small factor. It's not coming off the trend line. I think when we first did the relationship with them 3, 4 years ago, there was probably a 2,000-ish unit installed base. And I'd say that's coming out -- 150-ish a",92,"I think it's a small and maybe even very small factor. It's not coming off the trend line. I think when we first did the relationship with them 3, 4 years ago, there was probably a 2,000-ish unit installed base. And I'd say that's coming out -- 150-ish a year or probably coming out. We haven't seen an acceleration or deceleration of that trend; it's been kind of steady as it goes. I mean, it is a replacement market, whether it's Siemens or everybody else, and that is what we're seeing."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then last question for me, just on China. It looks like from first half '16 results from GE and Philips, it does look like Chinese tender activity and orders are picking up, at least in the design if not the Imaging part of the market. So can yo",75,"Okay. And then last question for me, just on China. It looks like from first half '16 results from GE and Philips, it does look like Chinese tender activity and orders are picking up, at least in the design if not the Imaging part of the market. So can you speak to what trends you are seeing in China and if you're seeing a similar pickup in activity in the radiation Oncology market in China?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, yes. I think that's very consistent. We had an okay first half, but we had a very good third quarter. Our third quarter was -- China was up 13%. We had very strong demand, especially for high-end products, which, our EDGE products, as I mentioned on",251,"Yes, yes. I think that's very consistent. We had an okay first half, but we had a very good third quarter. Our third quarter was -- China was up 13%. We had very strong demand, especially for high-end products, which, our EDGE products, as I mentioned on the call on the script, was very good. 
One of the things that we really like about the demand we're seeing is it is almost 90% new socket. It's -- so obviously, that's going to drive our long-term service business and software upgrade opportunities, et cetera, et cetera, et cetera. So these are new socket going in. They're happening on schedule. We are seeing significant tender activity. We do continue to see some protests of that activity. It doesn't change that much who wins. It just kind of lengthens the process. And they're also -- I mean, coming back to our previous question. In China, there is a large Siemens installed base opportunity. That's one of the geographies where they did the best, frankly because of their price position as much as anything else. And so I think over the next couple of years, we'll see maybe that installed base change out a little more aggressively. So that's going to be one to watch. 
The other thing to watch in China, we've got this  Hefei proton order, as I mentioned. We've -- we see a reasonable funnel of proton activity in China. So maybe this Hefei order will stimulate some proton growth in China."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Jeff Johnson with Robert W. Baird.",15,"And the next question comes from the line of Jeff Johnson with Robert W. Baird."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Great. Dow, so one question for you I don't think anybody's asked, on your Western European comments at this point. It sounds like you mentioned that being soft this quarter. Last quarter, you guys put up a very strong EMEA number. This quarter, the comp",107,"Great. Dow, so one question for you I don't think anybody's asked, on your Western European comments at this point. It sounds like you mentioned that being soft this quarter. Last quarter, you guys put up a very strong EMEA number. This quarter, the comp was a lot tougher. So have you really seen anything change? Or is it just kind of comp-driven? I know you had some big orders last year in this quarter in EMEA. So just trying to figure out if you're really seeing anything sequentially changed in that market, or kind of how you describe market trends over in Western Europe right now."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We're watching Western Europe and Latin America. Those are the 2 light spots. Americas, we've talked about that a lot. It continues very strong. China looks good. Japan, flat, which has been down. So flat is -- flat is the new in Japan for us, so that's o",141,"We're watching Western Europe and Latin America. Those are the 2 light spots. Americas, we've talked about that a lot. It continues very strong. China looks good. Japan, flat, which has been down. So flat is -- flat is the new in Japan for us, so that's okay. The 2 watch areas for us are, frankly, Western Europe and Latin America. 
I mean, Latin America was down more than 40% this quarter. That's macro-economically driven. We do have it in Europe. There is a tough comp on the quarter. We had a large order in the U.K. last year. So we've got a little bit of a comp issue going into Q4 as well. But I'd say, we're watching Western Europe. It's -- it maybe hasn't been as strong as it has been over the last 18 months or so."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes. All right. That's very helpful. And then Elisha, maybe a few clarifying questions for you. One, I think somebody asked on the software and service side. You said you haven't given that. But could you give that? I think in the past quarters, you have",65,"Yes. All right. That's very helpful. And then Elisha, maybe a few clarifying questions for you. One, I think somebody asked on the software and service side. You said you haven't given that. But could you give that? I think in the past quarters, you have given those trends. If you could just give us, at least qualitatively, where software and service was this quarter?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Highest corporate and software, then equipment and service.",9,"Yes. Highest corporate and software, then equipment and service."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Can we be any more specific there? Double-digits, upper single digits? I mean, I think  I -- let me phrase it this way. I think you had been double-digits for a long while. It kind of flipped over the last couple of quarters, upper single digits. Ar",51,"Okay. Can we be any more specific there? Double-digits, upper single digits? I mean, I think  I -- let me phrase it this way. I think you had been double-digits for a long while. It kind of flipped over the last couple of quarters, upper single digits. Are we seeing any..."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","[indiscernible]",1,"[indiscernible]"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes. Any continuation of that trend there? Sorry.",8,"Yes. Any continuation of that trend there? Sorry."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So for year-to-date, let me just say, in constant currency, service is up in the high single digits, so 7% to 8%. So a little off the double-digit but not terribly so. So again, we still feel good. The unit volume was up this quarter and orders, which bod",73,"So for year-to-date, let me just say, in constant currency, service is up in the high single digits, so 7% to 8%. So a little off the double-digit but not terribly so. So again, we still feel good. The unit volume was up this quarter and orders, which bodes well for the service business going forward. So long-term, really not coming off of our expectations for the service business at this point."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","All right. That's helpful. And then last 2 clarifying. Just on the EPS guide, you took the low end up by a little over a $0.05. Is there anything in there rather than just operational at this point? As you know, a couple of companies have been adopting AS",70,"All right. That's helpful. And then last 2 clarifying. Just on the EPS guide, you took the low end up by a little over a $0.05. Is there anything in there rather than just operational at this point? As you know, a couple of companies have been adopting ASU 2016. Anything like that? Or anything else we should think about that's impacting your guidance other than just pure operational factors?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","It's purely operational. And we just took the midpoint and took it out by the $0.04 beat from the midpoint in Q3. So -- and there is a range a little bit, given that we're down to the last quarter. But no, we are not adopting the new tax provision because",71,"It's purely operational. And we just took the midpoint and took it out by the $0.04 beat from the midpoint in Q3. So -- and there is a range a little bit, given that we're down to the last quarter. But no, we are not adopting the new tax provision because of the disband. We're going to wait until we get through that. So nothing in there other than operational."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Makes sense. And then last question, just on ICB. Orders up 13%, and revs up 13% -- or 9%, I'm sorry. How much of that was organic and how much was acquisition-driven?",32,"Makes sense. And then last question, just on ICB. Orders up 13%, and revs up 13% -- or 9%, I'm sorry. How much of that was organic and how much was acquisition-driven?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That -- we're year-over-year with MeVis, so that's in the base now. So Claymount is what's different, and it would've been 8% revenue growth.",24,"That -- we're year-over-year with MeVis, so that's in the base now. So Claymount is what's different, and it would've been 8% revenue growth."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. So you're only 1 point on those acquisitions?",9,"Okay. So you're only 1 point on those acquisitions?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Is that right? Did I get that number right?",9,"Is that right? Did I get that number right?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That's -- yeah.",4,"That's -- yeah."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yeah, might want to check that, but a little more than 1%.",12,"Yeah, might want to check that, but a little more than 1%."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Steve Beuchaw with Morgan Stanley.",14,"And the next question comes from the line of Steve Beuchaw with Morgan Stanley."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Dow, when you look at the [indiscernible] business and you look at some of the trends in commodity or oil-sensitive countries and you look at the mid-stage funnel, what does it tell you about how things play out? I know we've had a couple of tough quarter",78,"Dow, when you look at the [indiscernible] business and you look at some of the trends in commodity or oil-sensitive countries and you look at the mid-stage funnel, what does it tell you about how things play out? I know we've had a couple of tough quarters here and there for obvious reasons in places like Latin America, but we've seen commodity prices in a number of spots pick up. Is that a cause for optimism about 2017?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say -- I wish I could look you in the eye and say that about Latin America. I think it's a little broader-based in Latin America. In the Middle East, maybe so. I think it's a good -- I don't know that we -- it's kind of interesting on this quarter a l",161,"I'd say -- I wish I could look you in the eye and say that about Latin America. I think it's a little broader-based in Latin America. In the Middle East, maybe so. I think it's a good -- I don't know that we -- it's kind of interesting on this quarter a lot of our Africa volume -- and it's actually one of the things we really liked; a lot of the Africa volume was in non oil-based countries. So it's great to -- Ethiopia, I mentioned in the call, that's the first time we've had a linac (sic) order from Ethiopia. And that's the kind of activity we're seeing in those markets. I would say the Middle East has been a little quieter this year, looking back 12 months, because of oil prices. And what are we today? $40, $45 a barrel? I think that might be enough to see some of that market come back next year."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Got it. And then on the imaging spin. I wonder how the strategic conversations outside the company have been evolving since the imaging spin. I mean, has that opened any new doors for you in terms of collaborations, partnerships or other strategic activit",43,"Got it. And then on the imaging spin. I wonder how the strategic conversations outside the company have been evolving since the imaging spin. I mean, has that opened any new doors for you in terms of collaborations, partnerships or other strategic activity?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","On that, we're continuing to look at how we reinforce the strategy of each company as we spin. So we're looking at a broader Oncology front for our -- for the remaining company and looking for a broader components beachhead for our X-ray business. So now",133,"On that, we're continuing to look at how we reinforce the strategy of each company as we spin. So we're looking at a broader Oncology front for our -- for the remaining company and looking for a broader components beachhead for our X-ray business. So now the good news is it has been pretty active. I think it's accomplishing both strategically and, we think, long-term from a value point of view what we want to do, and kind of unleashing a lot of energy around those initiatives. Now frankly, we're a little bit in head-down mode to get the spin done. So that's consuming us pretty hard here for between now and the end of the year. But we're pushing very aggressive as well on kind of the strategy front in both businesses."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Tycho Peterson with JPMorgan.",13,"And the next question comes from the line of Tycho Peterson with JPMorgan."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","First question, cancellations this quarter was about $42 million. And that's a big step-down from what you had the last quarter. So Elisha, I'm just wondering if you could kind of talk us through what you think is the underlying trend here.",42,"First question, cancellations this quarter was about $42 million. And that's a big step-down from what you had the last quarter. So Elisha, I'm just wondering if you could kind of talk us through what you think is the underlying trend here."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So yes. One of the big differences, Tyco. So it was $51 million in total on backlog adjustments. I believe the actual cancellation was closer to $20 million, and the rest was dormancy, where it just -- it's not probable at this point that some machine wil",120,"So yes. One of the big differences, Tyco. So it was $51 million in total on backlog adjustments. I believe the actual cancellation was closer to $20 million, and the rest was dormancy, where it just -- it's not probable at this point that some machine will ship within the 2-year period of time so we take it out of our backlog. The big difference is we did not have a big FX impact this quarter, and we had a large one on -- in some of the prior quarters because, as you know, our backlog is held at historical rates. And so it gets trued-up every quarter based on the FX. And so that was very minimal this quarter."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And then maybe for Dow on Services. You've been outgrowing the market here for quite some time. Can you maybe just talk about just the sustainability of that trend? How long do you think you can kind of outgrow the market from a serv",63,"Okay. That's helpful. And then maybe for Dow on Services. You've been outgrowing the market here for quite some time. Can you maybe just talk about just the sustainability of that trend? How long do you think you can kind of outgrow the market from a service perspective? And do the attach rates vary meaningfully by geography for you guys in that front?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, we're very bullish about our service business still. It's a little bit a lot of large numbers because it's now a $1 billion business. I think on the quarter in Oncology, it was 41%, 42% of the total, and it continues to be a juggernaut for us. I",210,"I mean, we're very bullish about our service business still. It's a little bit a lot of large numbers because it's now a $1 billion business. I think on the quarter in Oncology, it was 41%, 42% of the total, and it continues to be a juggernaut for us. 
I would say that it's one of the things that we really like about the new socket growth that we're seeing in Latin America and Asia, in particular. That's going to help drive the growth. The software model is going to more of a kind of a SaaS-based model, which strengthens that business. And we are seeing lots of positives on the upside. On the -- we are seeing in some markets, some of these emerging markets, we're seeing a little bit of wackiness from third-party competition. I wouldn't say that's the reason for the slowdown. I think the slowdown probably has more to do with large numbers and just kind of where we are. But in some of these emerging markets, we are seeing some growing presence, especially in the older installed base, some third-party competition. 
But I'd say, we're still in that high single-digit range. It's kind of what we're feeling about the long-term capability of our service business."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then does having stability on the reimbursement front, I mean, we got through this Physician Fee Schedule relatively unscathed. The first 2 years of macro would be kind of everybody gets a little bit of a bump. Does that free up the U.S. market a litt",57,"And then does having stability on the reimbursement front, I mean, we got through this Physician Fee Schedule relatively unscathed. The first 2 years of macro would be kind of everybody gets a little bit of a bump. Does that free up the U.S. market a little bit over the next couple of years, do you think?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, I think it's too early to tell. But that would be our -- our guess would be consistent with that, Tycho. I think the macro field is a little bit like some of the reimbursement incentives that there were on some of this early IT adoption 3, 4 years",63,"I mean, I think it's too early to tell. But that would be our -- our guess would be consistent with that, Tycho. I think the macro field is a little bit like some of the reimbursement incentives that there were on some of this early IT adoption 3, 4 years ago. So I think it's probably a little bit of an upside."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then -- and last one. You made a comment earlier on the kind of proton funnel. Just -- I mean, any sense as to what -- how big you think that market could be? [indiscernible]",36,"And then -- and last one. You made a comment earlier on the kind of proton funnel. Just -- I mean, any sense as to what -- how big you think that market could be? [indiscernible]"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Every time I've forecasted this, I've been wrong. So I'm not going to take the bait. I mean, it's just -- the good news is, these are government customers. And so I think we had our first discussion with SA 15 months ago. So we went from first conversatio",139,"Every time I've forecasted this, I've been wrong. So I'm not going to take the bait. I mean, it's just -- the good news is, these are government customers. And so I think we had our first discussion with SA 15 months ago. So we went from first conversation to order in 15 months, and for that, for us, that's a record in proton therapy. 
When you get in the private markets, and where financing instruments is frankly the most difficult part of the transaction, these deals can take a really, really long time. And so whereas sovereign-financed, it can move pretty fast. And we are having -- I'd say there are 3 or 4 live conversations going on. Will they happen in the next 15, 18 months? Maybe. There's a -- at least we have one now."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Vijay Kumar with Evercore ISI.",14,"And the next question comes from the line of Vijay Kumar with Evercore ISI."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So maybe, Dow, a big-picture question on -- because I guess, now we'll have green numbers, right, in a few months on standalone Oncology. I was just wondering, can you just comment big picture, what's been the installed base over the last 3 years, right?",89,"So maybe, Dow, a big-picture question on -- because I guess, now we'll have green numbers, right, in a few months on standalone Oncology. I was just wondering, can you just comment big picture, what's been the installed base over the last 3 years, right? Has it been flattish? Has it been growing in North America? Because that -- I just feel like that's an important question, just given your really, really strong showing here in North America. And obviously, that has a lot of implications to margin progression."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say, starting at a very high level, we have about a 7,500-unit installed base. We have had positive unit growth, 1% or 2% of the installed days. One of the things that we like about the whole U.S. growth is, as I mentioned, about China is those are al",115,"I'd say, starting at a very high level, we have about a 7,500-unit installed base. We have had positive unit growth, 1% or 2% of the installed days. One of the things that we like about the whole U.S. growth is, as I mentioned, about China is those are all new sockets, and we're -- we get some new installed base growth out of it. 
We did have very -- in Q3, we had very good unit growth. So one of the best unit growth quarters we've had in a while. So that's going to help our service business. So I don't know if I'm answering all your questions, Vijay. Elisha, anything to add?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Just that the U.S., as we said, Vijay, is largely a replacement market. So the installed base is not necessarily going up, but it is getting higher in equipment that does carry a higher level of service contract.",39,"Just that the U.S., as we said, Vijay, is largely a replacement market. So the installed base is not necessarily going up, but it is getting higher in equipment that does carry a higher level of service contract."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And when we made that trade out, I'd say our contract capture rate of TrueBeams is 10 to 15 points higher than our -- than the historical product.",28,"And when we made that trade out, I'd say our contract capture rate of TrueBeams is 10 to 15 points higher than our -- than the historical product."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And that was very helpful -- a lot, guys. And maybe just one on software. Because I -- this is the other question we get a lot on -- in what kind of visibility do we have, right, on the software option? Because I know at the Analyst Day, I knew you guys p",154,"And that was very helpful -- a lot, guys. And maybe just one on software. Because I -- this is the other question we get a lot on -- in what kind of visibility do we have, right, on the software option? Because I know at the Analyst Day, I knew you guys put out that $0.5 billion opportunity, right? Because, I guess, the reason -- when I look at your comments of the installed base, right, sort of 1% to 2%, obviously, you guys have done better on the share front. That's showing up in the North America region from an orders perspective, right? But how much more software can you keep selling into that installed base, right? Or am I thinking about this the right way? Or -- because I feel like having some clarity on that, I mean, that has a lot of implications on how people look at the company."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So here -- I mean, there's some really simple math here. We've got an installed base of 7,500 units. We've sold -- and we feel really good about it -- 500 RapidPlans. We have got 7,000 to go. We've got -- inside of analytics, what have we sold? 250? 200",262,"So here -- I mean, there's some really simple math here. We've got an installed base of 7,500 units. We've sold -- and we feel really good about it -- 500 RapidPlans. We have got 7,000 to go. 
We've got -- inside of analytics, what have we sold? 250? 200-ish? We've got 7,300 to go. So we're in the top half of the first inning. Sorry, baseball analogy for my global friends. But we're -- the software is still -- has very significant upside for us. And what I'm liking is we're getting very good customer response on the software products. I -- a decade ago, ""Oh, you ship me software and it works but I don't love it."" Now we're getting, ""Hey, if it does what I like it to do. It's making me for productive in the workplace. I can do better care and take care of patients better."" And we've had some external validation out of this with our class -- the Wynn [ph], which is kind of the Gartner of radiation oncology -- Class rate is #1 in treatment planning and in oncology information systems, so we like that. 
So those were -- RapidPlan and InSightive Analytics are 2 examples. We do have -- in the 7,500 units linac installed base. In that installed base, we also have 3,400, 3,500 software installations. So those are opportunities for us to take rapid -- that's the low-hanging fruit of the RapidPlan and InSightive Analytics opportunity. So I think, Vijay, we've still got a lot of opportunity on the software side."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","That was really helpful, Dow. And if I just may just sort of resort to a baseball analogy, I think in Cricket parlance that would be hitting a 6. So congrats.",31,"That was really helpful, Dow. And if I just may just sort of resort to a baseball analogy, I think in Cricket parlance that would be hitting a 6. So congrats."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think I know what that means, which is a little scary.",12,"I think I know what that means, which is a little scary."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Jason Wittes with Brean Capital.",14,"And the next question comes from the line of Jason Wittes with Brean Capital."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","I just want to get an update. I know that things are still moving, but in terms of the numbers you put out when you first announced the spin-out, you noticed -- you mentioned, I think, I believe $37 million in overhead, dis-synergies. Is that still the nu",66,"I just want to get an update. I know that things are still moving, but in terms of the numbers you put out when you first announced the spin-out, you noticed -- you mentioned, I think, I believe $37 million in overhead, dis-synergies. Is that still the number that we should be thinking about? And in terms of who absorbs what, is there any update there?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Jason, at this point, it was $20 million of dis-synergies at -- that would be -- remain co-Varian, and that number has not changed dramatically at this point. So I think it's still a good number to use. And again, with the goal of having that offset withi",64,"Jason, at this point, it was $20 million of dis-synergies at -- that would be -- remain co-Varian, and that number has not changed dramatically at this point. So I think it's still a good number to use. And again, with the goal of having that offset within 2 years so that we can get back to the same margin point, operating margin point."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And I believe that you're going to give the -- SpinCo will have cash on hand. I believe that was $50 million. But will that be cash taken from overseas? Or will that be cash that's been patriated in the U.S.?",42,"And I believe that you're going to give the -- SpinCo will have cash on hand. I believe that was $50 million. But will that be cash taken from overseas? Or will that be cash that's been patriated in the U.S.?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So there -- no number has been determined. And all we have said is they will not have debt at this -- at the time of the spin. And we are working with our advisors on the capital structure at this point. And so stay tuned, and we'll be talking about how m",68,"So there -- no number has been determined. And all we have said is they will not have debt at this -- at the time of the spin. And we are working with our advisors on the capital structure at this point. And so stay tuned, and we'll be talking about how much cash ends up going with SpinCo and how much of that is U.S. versus O-U.S."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And when do you anticipate giving us that update? Will that be on your -- for the fourth quarter? Or will that be more towards December?",27,"Okay. And when do you anticipate giving us that update? Will that be on your -- for the fourth quarter? Or will that be more towards December?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","It's going to be more to words when we're going on the roadshow, closer to the spin date.",19,"It's going to be more to words when we're going on the roadshow, closer to the spin date."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Fair enough. And just on the Proton business. In terms of -- you've also put out sort of anticipation of reaching profitability. I assume that still goes. And what kind of revenue run rate do you need for that business to really sort of break even a",53,"Okay. Fair enough. And just on the Proton business. In terms of -- you've also put out sort of anticipation of reaching profitability. I assume that still goes. And what kind of revenue run rate do you need for that business to really sort of break even and so thinking about the --"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. It's a little hard to say, Jason. What we really need is the installs to be completed and the service business to become material to get a significant pop in the margins. But this year, it's going to be around $150 million. It's $200 million -- somew",60,"Yes. It's a little hard to say, Jason. What we really need is the installs to be completed and the service business to become material to get a significant pop in the margins. But this year, it's going to be around $150 million. It's $200 million -- somewhere between $200 million and $225 million, it's starts looking very different. So..."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And now as you know, it will -- I mean, this is going to change with time because the margin rates on the equipment, now today, they're high-teens, mid high-teens. We hope to get back to the 20 to 30 range with time. But the margin rates on service are pr",76,"And now as you know, it will -- I mean, this is going to change with time because the margin rates on the equipment, now today, they're high-teens, mid high-teens. We hope to get back to the 20 to 30 range with time. But the margin rates on service are pretty good. So as the service contracts start to land, the geography of that profitability becomes a little easier with time. That's probably not next year."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And then the reimbursement was pretty benign, or actually, it's a positive, not benign, more optimism in that. But in terms of -- you did mention that they're going to try to start coaxing the market into being more efficient. I beli",103,"Okay. That's helpful. And then the reimbursement was pretty benign, or actually, it's a positive, not benign, more optimism in that. But in terms of -- you did mention that they're going to try to start coaxing the market into being more efficient. I believe that's with macro and MIPS. There are centers out there who have adopted it. Have you noticed a change in their behavior in terms of what their -- equipment they want? How they're doing their procedures, things like that? Is there a shift towards more concentrated dosing in those centers? Or is it just too early to say?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say, if anything, it might be an incentive for people to take our ARIA insight of analytics and other ARIA features into the market. ARIA is MACRA compliant. One of the things that gets that is a lot of metrics, a lot of portability. These are some of",109,"I'd say, if anything, it might be an incentive for people to take our ARIA insight of analytics and other ARIA features into the market. ARIA is MACRA compliant. One of the things that gets that is a lot of metrics, a lot of portability. These are some of the things they're looking for, and that's part of that product. So short-term-ish, as we were talking about in one of the other questions, it could be a little bit of upside maybe next year. I would say we haven't really seen a behavior change in terms of peoples' purchasing pattern, one way or the other, at this point."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So -- and also related to that, do you have a sense of how much of the marketplace is actually ready to fully implement MACRA here, that has all the software in place, et cetera?",35,"So -- and also related to that, do you have a sense of how much of the marketplace is actually ready to fully implement MACRA here, that has all the software in place, et cetera?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I think the short version is people just got the standard, so 0. So I mean, we look -- take a hard look at it. We know that we've got a few product things to do, but then our product is pretty compliant. We're -- the -- we're pretty comfortable with",290,"Well, I think the short version is people just got the standard, so 0. So I mean, we look -- take a hard look at it. We know that we've got a few product things to do, but then our product is pretty compliant. We're -- the -- we're pretty comfortable with where our product is. It's not going to be like a major rewrite or something that we're going to have to do, but we do have to add a few features, and we're very well positioned for MACRA implementation. So we like that. But I would say, to kind of come back to the main thrust of the question, I would say we have not seen a purchasing difference with those customers. 
With history, if anything, a lot of them tend to be -- they want to be clinically advanced and they want to be very productive, cost-efficient. And sometimes, it takes a little bit longer to convince them. But once they're convinced, they tend to move faster because they've got the clinical data or the productivity data to make their business case. And they may take a little bit longer to convince them, but once they're convinced, they -- I -- one of the examples I've used historically on this is RapidArc with Kaiser. 
It took us a while to convince them that RapidArc was really clinically advantageous and was going to give them a productivity pop. Once they were convinced, Kaiser and Orrick outfit every hospital one year. It was just, bang. They really moved. And I think that's typical from what we see from these kind of customers. It might take a little bit longer to convince them, but when they're convinced, they go fast."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And just sort of a follow-on, on that. When that happens, which it's going to take some time, I mean, I think MACRA itself doesn't really have teeth until the next couple of years, but it does seem like there could be some upgrade --",89,"Okay. That's helpful. And just sort of a follow-on, on that. When that happens, which it's going to take some time, I mean, I think MACRA itself doesn't really have teeth until the next couple of years, but it does seem like there could be some upgrade -- required upgrades for software that could help you or help, I guess, your customers as well. But there is an upgrade cycle to be had when this really starts to take over. Was that a fair way to think about it?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Absolutely. And that's the outside opportunity I've been referring to, yes.",12,"Yes. Absolutely. And that's the outside opportunity I've been referring to, yes."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Anthony Petrone with Jefferies.",13,"And the next question comes from the line of Anthony Petrone with Jefferies."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Just a couple of follow-ups, actually, on guidance and Imaging, in particular, and then one on the spin. So for guidance, I guess, the 3% reiteration here. You are baking quite an acceleration in the fourth quarter. And I'm just wondering how much of th",83,"Just a couple of follow-ups, actually, on guidance and Imaging, in particular, and then one on the spin. 
So for guidance, I guess, the 3% reiteration here. You are baking quite an acceleration in the fourth quarter. And I'm just wondering how much of that is Oncology-related versus maybe a rebound in imaging? And then you also spoke quite a bit on proton. So just trying to get a little bit more color on guidance. And then I follow on the follow-ups."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. So Anthony, the guidance in Oncology, and I'm assuming you're talking revenue here, should be in the mid single-digit growth. The Imaging Components business will be in the low single-digit growth versus the year-ago quarter. And we're going to get",69,"Sure. So Anthony, the guidance in Oncology, and I'm assuming you're talking revenue here, should be in the mid single-digit growth. The Imaging Components business will be in the low single-digit growth versus the year-ago quarter. And we're going to get $20 million to $25 million-or-so in additional proton revenue versus the year-ago period. So a big bump in protons gets you to around just 7% range on Q4."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","That's helpful. And then just Imaging Components again for the quarter. I know you mentioned in bookings the contribution from -- or gross orders rather from acquisitions. But I'm just wondering what the revenue contribution was in the quarter from Claymo",44,"That's helpful. And then just Imaging Components again for the quarter. I know you mentioned in bookings the contribution from -- or gross orders rather from acquisitions. But I'm just wondering what the revenue contribution was in the quarter from Claymount and MeVis?"
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","About $11 million, I believe, in total.",7,"About $11 million, I believe, in total."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Helpful. And then last, just on spin. Have you announced if it's a 1 for 1 share distribution? Or we're still...",21,"Helpful. And then last, just on spin. Have you announced if it's a 1 for 1 share distribution? Or we're still..."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No, we have not. We have not. We're working with JPMorgan on that.",13,"No, we have not. We have not. We're working with JPMorgan on that."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","There are no other questions on the queue at this time. I would now like to turn the call back over to management for any closing comments.",27,"There are no other questions on the queue at this time. I would now like to turn the call back over to management for any closing comments."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Thank you all for participating. The replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1(877) 660-6853 from inside the U.S.",70,"Thank you. Thank you all for participating. The replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1(877) 660-6853 from inside the U.S. or (201) 612-7415 from outside the U.S., and confirmation code 13640722. A telephone replay will be available through 5:00 p.m. this Friday July 29. Thank you all."
311907,370528018,1014723,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. This concludes today's teleconference. You may disconnect your lines at this time, and we thank all of you for your participation.",23,"Thank you. This concludes today's teleconference. You may disconnect your lines at this time, and we thank all of you for your participation."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems teleconference. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Spencer Sias, VP, Investor Relations, for Varian Medical. Thank",44,"Greetings, and welcome to the Varian Medical Systems teleconference. [Operator Instructions] As a reminder, this conference is being recorded. 
It is now my pleasure to introduce your host, Spencer Sias, VP, Investor Relations, for Varian Medical. Thank you, Mr. Sias. You may now begin."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Good afternoon, and welcome to Varian Medical Systems Conference Call for the Third Quarter of Fiscal Year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will",270,"Thank you. Good afternoon, and welcome to Varian Medical Systems Conference Call for the Third Quarter of Fiscal Year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. 
To simplify our discussion, unless otherwise stated, all references to the quarter or year or fiscal quarters or fiscal years -- quarterly comparisons are for the third quarter of fiscal 2016 versus the third quarter of fiscal 2015. References to financial results for orders are the gross orders unless otherwise indicated. 
This discussion includes some non-GAAP financial measures in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. 
A reconciliation to the most comparable GAAP measures is included in our earnings release, which can be accessed on our website. Please be advised that this discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, will, scheduled and similar expressions are intended to identify those statements which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks relating to our business are described in our third quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise.
And now, here's Dow."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Varian is reporting solid results for the third quarter of fiscal year 2016, with strong gross order and revenue growth in our Oncology Systems and Imaging Components businesses, together with substantial improvements in gross",1057,"Good afternoon, and welcome. Varian is reporting solid results for the third quarter of fiscal year 2016, with strong gross order and revenue growth in our Oncology Systems and Imaging Components businesses, together with substantial improvements in gross and operating margins for both. 
In summary, the company is reporting GAAP net earnings of $1.04 per diluted share and $1.22 per diluted share on a non-GAAP basis; revenues of $789 million, up 1% versus the year-ago quarter; a nearly 4-point improvement in the company's overall gross margin; and an order for new -- for a new multiroom proton installation in China, our first proton order there. 
Focusing on operational highlights. Our Oncology business generated third quarter gross orders of $676 million, up 6% in both dollars and constant currency. Gross orders in the Americas rose by 8% during the quarter with 15% growth in North America more than offsetting a greater than 40% decline in Latin America. 
Year-to-date gross order growth in North America is 8%, driven by a more stable reimbursement environment and, in this replacement market, a transition to more advanced clinically efficient systems. 
Gross orders in APAC increased 19% in dollars and 17% in constant currency during the quarter, driven by robust growth in China and Australia. 
In EMEA, gross orders declined 3% in dollars and 4% in constant currency, reflecting weakness in Western European markets. 
Looking at each of the regions in more detail. Our growth in North America was driven by demand for our TrueBeam platform, including EDGE radiosurgery systems and our software offerings. Among the highlights for North America were several large multi-system orders from consolidated networks as well as competitive takeouts. 
Order activity in Latin America continued to be weak due to macroeconomic factors. During the quarter, we shipped the first units for the large tender conducted by Brazil's Ministry of Health a couple of years ago. 
Turning to APAC. The Icon Group placed the largest Varian order ever in Australia for 10 TrueBeam systems, 7 of which are going to new sites along with the full complement of our information management and treatment planning software. We had wins for several new accelerator installations in China, where we saw good orders growth. We also saw strong demand for our EDGE radiosurgery system in this market, where we continue to be the share leader. 
Elsewhere in APAC, we made good progress in Thailand, Vietnam and Indonesia. Business was stable in Japan, where we saw good service growth. 
Turning to EMEA. Healthy gross order growth in emerging markets, including Iran, Russia, Ethiopia Burkina Faso and Libya was offset by weakness in Western Europe. Our third quarter business in Africa was outstanding, with more than $25 million in gross orders. Among other wins, we saw Ethiopia order its first modern linear accelerators for cancer treatment. 
I'm pleased to report that overall unit order volumes were up in the quarter and year-to-date and that average pricing is stable. We're winning with clinically efficient advanced technology that makes quality cancer care affordable and accessible. This was reflected during the quarter, in strong orders for our RapidPlan and InSightive Analytics software. We booked our 500th order for RapidPlan, which is a game changer that enables clinics to improve the speed and quality of care for their patients. As of this quarter, treatment plans are now being shared among clinics through our ongoing OncoPeer web portal. 
As you all know, CMS has announced modest adjustments to reimbursement for 2017 for both hospitals and free-standing clinics. We don't expect for reimbursement to have a material impact on the radiation oncology markets in the U.S. next year. 
Following the topic of reimbursement, CMS did move forward with policies that will incentivize the adoption of digital X-ray imaging systems in place of film and computed radiography systems, and this should help to support growth in our Imaging Components business. 
Speaking of Imaging Components, the business returned to growth during the quarter. Orders grew by 13% to $138 million, and revenues rose by 9% to $147 million. Improvements in margins were driven by productivity gains and a favorable product mix. Our tube business saw good growth in the quarter. We recently celebrated the 40th year of our relationship with Toshiba Medical Systems and look forward to continuing this relationship when they become part of Canon. 
Our recently acquired software and X-ray accessories businesses also helped to drive growth. 
Touching on the Industrial Imaging business, orders for security products were up in the quarter but we continue to have a cautious outlook in the face of ongoing customer consolidation. We continue to focus on generating growth in nondestructive testing and inspection. 
Let me update you on our progress towards the separation of the Imaging Components business into a new, independent publicly traded company via tax-free distribution to Varian stockholders. 
As you probably saw in the press release issued last week, the name of the new company will be Varex Imaging Corporation. We are now making good progress in the development of detailed plans and activities needed to execute the separation. We're on track to file an initial Form 10 with the SEC in the next several weeks, and we are currently on schedule to complete the separation at the end of the calendar year. We continue to be excited about the prospects of creating 2 great companies. 
Turning now to our Particle Therapy business. We booked an order during the quarter for a multiroom probing installation at the new Hefei medical center in China. This is China's first government-funded proton facility. Installation is slated to take place in late 2017 with patient treatments scheduled to begin in late 2018. 
Our installation at Cincinnati Children's Hospital is on track with the first patient treatments scheduled to commence later this summer. 
We have now successfully commissioned the third room at the Maryland Proton Therapy (sic -- Treatment) Center, and installations are underway in Holland, Russia and Saudi Arabia. In total, we have 13 proton projects generating revenue. 
As you probably saw from our 8-K filing with the SEC at the end of June, we sold our $73 million senior loan for the New York Proton Therapy Center to Deutsche Bank, freeing up capital to help finance other proton projects. The proton sales funnel continues to look good. 
And now I'll turn it over to Elisha."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Great. Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 5% from the year-ago period. Backlog adjustments during the quarter totaled $51 million, bringing net or",589,"Great. Thanks, Dow, and hello, everyone. Dow has already covered growth orders, so let me start with backlog. We ended the quarter at $3.3 billion, up 5% from the year-ago period. Backlog adjustments during the quarter totaled $51 million, bringing net orders for the company to $814 million. 
Third quarter revenues for the total company were $789 million, up 1% in dollars and even with the year-ago period in constant currency. Year-to-date, total company revenues were $2.3 billion, up 1% in dollars and up 3% in constant currency. Oncology posted a revenue gain of 8%, both in dollars and in constant currency, driven by strength in our high-end equipment as well as our software and service businesses. 
Imaging Components posted a third-quarter revenue gain of 9%, driven by our newly acquired X-ray accessories business as well as higher tube sales. 
Our Particle Therapy business posted third-quarter revenue of $37 million, down from the year-ago period, when we booked $91 million of revenues, including a substantial amount for the ProBeam installation at the University of Maryland. 
Total company gross margin for the quarter was 43.9%, up by nearly 4 points with significant contributions from both Oncology and Imaging Components. Oncology Systems' third quarter gross margin improved by more than 4 points to 46% with the help of a larger mix of TrueBeams and software as well as productivity gains. 
Imaging Components' third-quarter gross margin also rose by more than 4 points to 42.9% due largely to factory productivity gains and favorable product mix. R&D expenses were $65 million, or 8% of revenue, equal as a percentage of revenue to the year-ago quarter. 
On a GAAP basis, third quarter SG&A expenses were $151 million or 19% of revenue, we had about $22 million of unusual expenses in SG&A for items, including ongoing patent litigation and the recently announced initiative to separate the Imaging Components business into a new publicly traded company. Excluding these items, SG&A expenses on a non-GAAP basis for the quarter were $129 million or 16% of revenue. 
GAAP operating earnings for the quarter were 16.5% of revenues and 19.5% of revenues on a non-GAAP basis, reflecting our solid gross margin performance in the quarter. 
Depreciation and amortization totaled $18 million for the quarter. The effective tax rate was 25.1%, up 3 points from the year-ago quarter, when we benefited from a favorable geographic mix of profits and tax loss carryforwards associated with the proton business. We continue to expect that the tax rate will be about 26% to 27% for the year. 
Fully diluted shares outstanding were $95.4 million, more than $5 million lower than the year-ago quarter due to our ongoing share repurchase program. Diluted EPS was $1.04 for the quarter on a GAAP basis and was $1.22 on a non-GAAP basis.
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $836 million, debt of $701 million and stockholder's equity of $1.7 billion. 
DSO at 101 days was up significantly from the year-ago quarter but improved sequentially from the second quarter. 
Third quarter cash flow from operations was $95 million, bringing the total cash flow from operations year-to-date to $204 million. Primary uses of cash were $126 million for the repurchase of 1.5 million shares of stock, $95 million to reduce debt and $15 million for capital expenditure. At the end of the quarter, we had 4.8 million shares remaining under the existing repurchase authorization that extends to calendar year 2016. 
Now I'll turn it back to Dow for the outlook."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. Including the results of the third quarter, we believe that total company non-GAAP earnings will be in the range of $4.62 to $4.66 per diluted share for fiscal year 2016. We continue to believe revenues for fiscal year 2016 will increase b",56,"Thanks, Elisha. Including the results of the third quarter, we believe that total company non-GAAP earnings will be in the range of $4.62 to $4.66 per diluted share for fiscal year 2016. We continue to believe revenues for fiscal year 2016 will increase by about 3% over fiscal year 2015. 
We're now ready for your questions."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] And our first question will come from the line of Anthony Petrone with Jefferies.",16,"[Operator Instructions] And our first question will come from the line of Anthony Petrone with Jefferies."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Congratulations on a good quarter. Maybe just start a little bit with just the North American order growth in Oncology there, which sort of reached a multi-quarter high here. Maybe a little bit more in terms of the underlying drivers there, how much is ma",80,"Congratulations on a good quarter. Maybe just start a little bit with just the North American order growth in Oncology there, which sort of reached a multi-quarter high here. Maybe a little bit more in terms of the underlying drivers there, how much is market-related, maybe even replacement cycle-related? And how much was it from share gains? And then a follow-up there would be, on the product side, how much was driven by VitalBeam, which was a driver last quarter?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Good questions. I would start by saying our rolling 4-quarter growth in the Americas has been 7%. So we feel very good about kind of where that is. North America has certainly been the driver. And you're right, North America did hit a high this quart",310,"Yes. Good questions. I would start by saying our rolling 4-quarter growth in the Americas has been 7%. So we feel very good about kind of where that is. North America has certainly been the driver. And you're right, North America did hit a high this quarter, but it is kind of a sustained trend that we're seeing, which is good. We did have a couple of multi-system orders, including one with HCA. We also had very strong demand, as I mentioned in the call, for software products. 
And VitalBeam, I think a little more than half of our VitalBeams have been sold in the Americas. So that's -- VitalBeam has been part of the story, but I think the overall story, though, is TrueBeam. 
When you clearly look at what's going on, TrueBeam is what's driving both the Americas growth and the global growth, both in orders and revenues. I mean, some of the -- on the revenue side, Elisha will talk about this later, but on the revenue side, we had very good TrueBeam mix on the quarter, that's some of the margin uptick, but it's -- from a kind of a market perspective, the U.S. is a replacement market. That's true. As I said in the call, we are seeing people trade out aggressively to try to get new capability, especially for advanced radiosurgery and body radiosurgery. 
I think reimbursement may have been a small factor -- certainly not over last year, but having that be calm in the quarter, kind of shored up -- shored things up a little bit. I think from a high level, that's kind of the story. And I think -- the other thing I was going to mention is from the market share point of view, we think we've gained a little bit of share, but most of this is market."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","No, very, very helpful. And maybe to shift gears just to Imaging, and then one for Elisha. One of the headwinds for that business over the past couple of quarters was destocking from several key customers, including Toshiba. I'm just wondering if that has",62,"No, very, very helpful. And maybe to shift gears just to Imaging, and then one for Elisha. One of the headwinds for that business over the past couple of quarters was destocking from several key customers, including Toshiba. I'm just wondering if that has reversed at this point. And specifically with regards to Toshiba, are they back ordering anything at this point?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say Toshiba is back a little bit. I wouldn't say they're fully back yet. I mean, we had an okay quarter from Toshiba. The tube business was actually quite strong in the quarter, and some of that was Toshiba, but we also had very good tube performance",90,"I'd say Toshiba is back a little bit. I wouldn't say they're fully back yet. I mean, we had an okay quarter from Toshiba. The tube business was actually quite strong in the quarter, and some of that was Toshiba, but we also had very good tube performance from our other tube customers on the quarter, and it was as much on their backs that we drove this. So I'd say the best Toshiba days, frankly, are still ahead of us. We're not totally out of that headwind yet."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And the oppositions helped us out, Anthony.",7,"And the oppositions helped us out, Anthony."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, yes, yes.",3,"Yes, yes, yes."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Sure. Sure, and then last, just quick and I'll hop in queue. Elisha, Oncology gross margin, 46% you called out, that's beyond the normalized 44% level. I mean, is this sort of a new normal? Or do you expect it to sort of moderate back down to that 44% lev",52,"Sure. Sure, and then last, just quick and I'll hop in queue. Elisha, Oncology gross margin, 46% you called out, that's beyond the normalized 44% level. I mean, is this sort of a new normal? Or do you expect it to sort of moderate back down to that 44% level over time?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I would love to say yes, Anthony, but I'm -- we just had a really favorable product mix in the quarter and I just can't count on that every single quarter going forward. What I would say is Oncology has done a fantastic job on pricing, holding stabl",116,"Well, I would love to say yes, Anthony, but I'm -- we just had a really favorable product mix in the quarter and I just can't count on that every single quarter going forward. What I would say is Oncology has done a fantastic job on pricing, holding stable pricing and on product cost reduction and on productivity gains. And so the hope is, yes, that will last as we move forward. But again, product mix drives our margin much more than any other factor. 
I do think for this fiscal year, they should be at the high end of that 43% to 44% range that we've talked about and really helped by this last quarter."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And our next question comes from the line of Amit Hazan of Citibank.",13,"And our next question comes from the line of Amit Hazan of Citibank."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","It's Lee [ph] Preston, on for Amit. A couple of questions here. I'll start with margin. On the back of the gross margin question, is there anything stronger in gross margin this quarter that you would call out as more sustainable in nature as opposed to g",59,"It's Lee [ph] Preston, on for Amit. A couple of questions here. I'll start with margin. On the back of the gross margin question, is there anything stronger in gross margin this quarter that you would call out as more sustainable in nature as opposed to good mix and some of the other items you've already called out?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, mix -- the product mix drives the margin first and foremost, in Oncology. Geographic mix, secondly. The geographic mix was identical this quarter versus the year-ago quarter so that has no impact. I would say the cost -- the product cost reduction i",86,"Well, mix -- the product mix drives the margin first and foremost, in Oncology. Geographic mix, secondly. The geographic mix was identical this quarter versus the year-ago quarter so that has no impact. I would say the cost -- the product cost reduction is real, and we should continue to have the benefit of that going forward as there's many, many -- much fewer C-series, our old legacy equipment and many more TrueBeams at a higher margin. And so we're starting to see that flow through."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then just on the operating margin for this year. It looks like there have been 2 good quarters at or around the 19%. The implications for fourth quarter looks above that, too. So is this kind of the range we should be thinking about going forwar",86,"Okay. And then just on the operating margin for this year. It looks like there have been 2 good quarters at or around the 19%. The implications for fourth quarter looks above that, too. So is this kind of the range we should be thinking about going forward here? It's a bit above the original guidance. Is this FX-related to some extent? Or are you seeing some sustainability that makes you comfortable you've come off the bottom and maybe see some further gains heading into 2017?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, so I don't want to guide it all into 2017, particularly right at the moment with the spin-off going on. There is a lot of work that we're going to have to do in terms of looking into FY '17. You are correct. Once you run this model through, it's goi",116,"Well, so I don't want to guide it all into 2017, particularly right at the moment with the spin-off going on. There is a lot of work that we're going to have to do in terms of looking into FY '17. You are correct. Once you run this model through, it's going to put it to a close to 19% operating margin for this year, which would be up about 0.5 points versus the year-ago period. So again, all businesses have been very focused on headcount and on travel and on discretionary spending, and I think you're starting to see this flow through. But most of that improvement this year is coming through the gross margins."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And I'd just point out, these are -- it's consistent with our goal over the next 3, 4 years to get back to that higher return on sales. So it's kind of delivering on the track 50 basis points-ish a year that we were -- that kind of set as an overarching g",54,"And I'd just point out, these are -- it's consistent with our goal over the next 3, 4 years to get back to that higher return on sales. So it's kind of delivering on the track 50 basis points-ish a year that we were -- that kind of set as an overarching goal."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay, great. And if I could sneak in one more, if I could. Can you talk about maybe the adjustments to backlog this quarter? They're a little bit higher than trends. Maybe you can give us some context as to what's going on there.",44,"Okay, great. And if I could sneak in one more, if I could. Can you talk about maybe the adjustments to backlog this quarter? They're a little bit higher than trends. Maybe you can give us some context as to what's going on there."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Actually, the backlog adjustments were lower, I believe, in the prior quarter and were pretty consistent with our average. So the $51 million is really what we would refer to -- some cancellations in that number, maybe $20 million of it. The rest is what",98,"Actually, the backlog adjustments were lower, I believe, in the prior quarter and were pretty consistent with our average. So the $51 million is really what we would refer to -- some cancellations in that number, maybe $20 million of it. The rest is what we call dormancies. When we review the backlog and we feel like there's no longer a good probability of the machine delivering within 2 years, we just take it out of our backlog until it fits that criteria. So -- but a $51 million level is very consistent with historically how it's been."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then sorry, one last quick one. If you could maybe give us a hint of why the CFO was up during the quarter?",25,"Okay. And then sorry, one last quick one. If you could maybe give us a hint of why the CFO was up during the quarter?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. So we have done -- we've seen this the last couple of quarters. The good news is, Q3, if you look at our cash flow from operations, returned back to a very strong level and was almost equal to net income. So I'm feeling very good that we're back on t",120,"Yes. So we have done -- we've seen this the last couple of quarters. The good news is, Q3, if you look at our cash flow from operations, returned back to a very strong level and was almost equal to net income. So I'm feeling very good that we're back on track in terms of cash flow. 
What happened is we moved our collection staff earlier in the fiscal year. We did a CRM implementation. I think those things just slowed down collections a little bit in the first half of the year. We've got some catching up to do. But in June and July, our collections have actually been very strong. So I think we're getting back on track."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. And Q2 to Q3, we had 10 days of shipment improvements; going in the right direction.",17,"Yes. And Q2 to Q3, we had 10 days of shipment improvements; going in the right direction."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes.",1,"Yes."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Brandon Henry with RBC Capital Markets.",15,"And the next question comes from the line of Brandon Henry with RBC Capital Markets."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","First, just on the North American strengthening gross orders, can you just help provide some more details on how much of that performance was from better systems order versus software and services?",32,"First, just on the North American strengthening gross orders, can you just help provide some more details on how much of that performance was from better systems order versus software and services?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I -- one of the things that we liked about it is that it was broad-based. It was both -- it was hardware, it was software and it was service. So we saw it in all 3 categories, there wasn't one -- As I mentioned from a product mix point of view, that marke",131,"I -- one of the things that we liked about it is that it was broad-based. It was both -- it was hardware, it was software and it was service. So we saw it in all 3 categories, there wasn't one -- As I mentioned from a product mix point of view, that market has largely -- it's probably been a 90% TrueBeam market for the last 18 months, 2 years, and it was at the high end of that. So maybe a little bit of product mix from an orders' point of view, but we -- as I said in the call, we had a couple of nice, large strategic deals, and we had a number of competitive takeouts in both the hardware and software area, but it was broad-based."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And did you guys give any growth rates in terms of software servicing this quarter? I might have missed that.",21,"Okay. And did you guys give any growth rates in terms of software servicing this quarter? I might have missed that."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No. We haven't broken it out.",6,"No. We haven't broken it out."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then separate question. Could you provide an update on what portion of Siemens went active and traded out at this point? I mean, how much of the acceleration in the North American Oncology Systems business can be attributed to an acceleration in",46,"Okay. And then separate question. Could you provide an update on what portion of Siemens went active and traded out at this point? I mean, how much of the acceleration in the North American Oncology Systems business can be attributed to an acceleration in Siemens trade-outs?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think it's a small and maybe even very small factor. It's not coming off the trend line. I think when we first did the relationship with them 3, 4 years ago, there was probably a 2,000-ish unit installed base. And I'd say that's coming out -- 150-ish a",92,"I think it's a small and maybe even very small factor. It's not coming off the trend line. I think when we first did the relationship with them 3, 4 years ago, there was probably a 2,000-ish unit installed base. And I'd say that's coming out -- 150-ish a year or probably coming out. We haven't seen an acceleration or deceleration of that trend; it's been kind of steady as it goes. I mean, it is a replacement market, whether it's Siemens or everybody else, and that is what we're seeing."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then last question for me, just on China. It looks like from first half '16 results from GE and Philips, it does look like Chinese tender activity and orders are picking up, at least in the design if not the Imaging part of the market. So can yo",75,"Okay. And then last question for me, just on China. It looks like from first half '16 results from GE and Philips, it does look like Chinese tender activity and orders are picking up, at least in the design if not the Imaging part of the market. So can you speak to what trends you are seeing in China and if you're seeing a similar pickup in activity in the radiation Oncology market in China?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, yes. I think that's very consistent. We had an okay first half, but we had a very good third quarter. Our third quarter was -- China was up 13%. We had very strong demand, especially for high-end products, which, our EDGE products, as I mentioned on",251,"Yes, yes. I think that's very consistent. We had an okay first half, but we had a very good third quarter. Our third quarter was -- China was up 13%. We had very strong demand, especially for high-end products, which, our EDGE products, as I mentioned on the call on the script, was very good. 
One of the things that we really like about the demand we're seeing is it is almost 90% new socket. It's -- so obviously, that's going to drive our long-term service business and software upgrade opportunities, et cetera, et cetera, et cetera. So these are new socket going in. They're happening on schedule. We are seeing significant tender activity. We do continue to see some protests of that activity. It doesn't change that much who wins. It just kind of lengthens the process. And they're also -- I mean, coming back to our previous question. In China, there is a large Siemens installed base opportunity. That's one of the geographies where they did the best, frankly because of their price position as much as anything else. And so I think over the next couple of years, we'll see maybe that installed base change out a little more aggressively. So that's going to be one to watch. 
The other thing to watch in China, we've got this  Hefei proton order, as I mentioned. We've -- we see a reasonable funnel of proton activity in China. So maybe this Hefei order will stimulate some proton growth in China."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Jeff Johnson with Robert W. Baird.",15,"And the next question comes from the line of Jeff Johnson with Robert W. Baird."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Great. Dow, so one question for you I don't think anybody's asked, on your Western European comments at this point. It sounds like you mentioned that being soft this quarter. Last quarter, you guys put up a very strong EMEA number. This quarter, the comp",107,"Great. Dow, so one question for you I don't think anybody's asked, on your Western European comments at this point. It sounds like you mentioned that being soft this quarter. Last quarter, you guys put up a very strong EMEA number. This quarter, the comp was a lot tougher. So have you really seen anything change? Or is it just kind of comp-driven? I know you had some big orders last year in this quarter in EMEA. So just trying to figure out if you're really seeing anything sequentially changed in that market, or kind of how you describe market trends over in Western Europe right now."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","We're watching Western Europe and Latin America. Those are the 2 light spots. Americas, we've talked about that a lot. It continues very strong. China looks good. Japan, flat, which has been down. So flat is -- flat is the new in Japan for us, so that's o",141,"We're watching Western Europe and Latin America. Those are the 2 light spots. Americas, we've talked about that a lot. It continues very strong. China looks good. Japan, flat, which has been down. So flat is -- flat is the new in Japan for us, so that's okay. The 2 watch areas for us are, frankly, Western Europe and Latin America. 
I mean, Latin America was down more than 40% this quarter. That's macro-economically driven. We do have it in Europe. There is a tough comp on the quarter. We had a large order in the U.K. last year. So we've got a little bit of a comp issue going into Q4 as well. But I'd say, we're watching Western Europe. It's -- it maybe hasn't been as strong as it has been over the last 18 months or so."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes. All right. That's very helpful. And then Elisha, maybe a few clarifying questions for you. One, I think somebody asked on the software and service side. You said you haven't given that. But could you give that? I think in the past quarters, you have",65,"Yes. All right. That's very helpful. And then Elisha, maybe a few clarifying questions for you. One, I think somebody asked on the software and service side. You said you haven't given that. But could you give that? I think in the past quarters, you have given those trends. If you could just give us, at least qualitatively, where software and service was this quarter?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Highest corporate and software, then equipment and service.",9,"Yes. Highest corporate and software, then equipment and service."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Can we be any more specific there? Double-digits, upper single digits? I mean, I think  I -- let me phrase it this way. I think you had been double-digits for a long while. It kind of flipped over the last couple of quarters, upper single digits. Ar",51,"Okay. Can we be any more specific there? Double-digits, upper single digits? I mean, I think  I -- let me phrase it this way. I think you had been double-digits for a long while. It kind of flipped over the last couple of quarters, upper single digits. Are we seeing any..."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","[indiscernible]",1,"[indiscernible]"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes. Any continuation of that trend there? Sorry.",8,"Yes. Any continuation of that trend there? Sorry."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So for year-to-date, let me just say, in constant currency, service is up in the high single digits, so 7% to 8%. So a little off the double-digit but not terribly so. So again, we still feel good. The unit volume was up this quarter and orders, which bod",73,"So for year-to-date, let me just say, in constant currency, service is up in the high single digits, so 7% to 8%. So a little off the double-digit but not terribly so. So again, we still feel good. The unit volume was up this quarter and orders, which bodes well for the service business going forward. So long-term, really not coming off of our expectations for the service business at this point."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","All right. That's helpful. And then last 2 clarifying. Just on the EPS guide, you took the low end up by a little over a $0.05. Is there anything in there rather than just operational at this point? As you know, a couple of companies have been adopting AS",70,"All right. That's helpful. And then last 2 clarifying. Just on the EPS guide, you took the low end up by a little over a $0.05. Is there anything in there rather than just operational at this point? As you know, a couple of companies have been adopting ASU 2016. Anything like that? Or anything else we should think about that's impacting your guidance other than just pure operational factors?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","It's purely operational. And we just took the midpoint and took it out by the $0.04 beat from the midpoint in Q3. So -- and there is a range a little bit, given that we're down to the last quarter. But no, we are not adopting the new tax provision because",71,"It's purely operational. And we just took the midpoint and took it out by the $0.04 beat from the midpoint in Q3. So -- and there is a range a little bit, given that we're down to the last quarter. But no, we are not adopting the new tax provision because of the disband. We're going to wait until we get through that. So nothing in there other than operational."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Makes sense. And then last question, just on ICB. Orders up 13%, and revs up 13% -- or 9%, I'm sorry. How much of that was organic and how much was acquisition-driven?",32,"Makes sense. And then last question, just on ICB. Orders up 13%, and revs up 13% -- or 9%, I'm sorry. How much of that was organic and how much was acquisition-driven?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That -- we're year-over-year with MeVis, so that's in the base now. So Claymount is what's different, and it would've been 8% revenue growth.",24,"That -- we're year-over-year with MeVis, so that's in the base now. So Claymount is what's different, and it would've been 8% revenue growth."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. So you're only 1 point on those acquisitions?",9,"Okay. So you're only 1 point on those acquisitions?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Is that right? Did I get that number right?",9,"Is that right? Did I get that number right?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That's -- yeah.",4,"That's -- yeah."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yeah, might want to check that, but a little more than 1%.",12,"Yeah, might want to check that, but a little more than 1%."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Steve Beuchaw with Morgan Stanley.",14,"And the next question comes from the line of Steve Beuchaw with Morgan Stanley."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Dow, when you look at the [indiscernible] business and you look at some of the trends in commodity or oil-sensitive countries and you look at the mid-stage funnel, what does it tell you about how things play out? I know we've had a couple of tough quarter",78,"Dow, when you look at the [indiscernible] business and you look at some of the trends in commodity or oil-sensitive countries and you look at the mid-stage funnel, what does it tell you about how things play out? I know we've had a couple of tough quarters here and there for obvious reasons in places like Latin America, but we've seen commodity prices in a number of spots pick up. Is that a cause for optimism about 2017?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say -- I wish I could look you in the eye and say that about Latin America. I think it's a little broader-based in Latin America. In the Middle East, maybe so. I think it's a good -- I don't know that we -- it's kind of interesting on this quarter a l",161,"I'd say -- I wish I could look you in the eye and say that about Latin America. I think it's a little broader-based in Latin America. In the Middle East, maybe so. I think it's a good -- I don't know that we -- it's kind of interesting on this quarter a lot of our Africa volume -- and it's actually one of the things we really liked; a lot of the Africa volume was in non oil-based countries. So it's great to -- Ethiopia, I mentioned in the call, that's the first time we've had a linac [ph] order from Ethiopia. And that's the kind of activity we're seeing in those markets. I would say the Middle East has been a little quieter this year, looking back 12 months, because of oil prices. And what are we today? $40, $45 a barrel? I think that might be enough to see some of that market come back next year."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Got it. And then on the imaging spin. I wonder how the strategic conversations outside the company have been evolving since the imaging spin. I mean, has that opened any new doors for you in terms of collaborations, partnerships or other strategic activit",43,"Got it. And then on the imaging spin. I wonder how the strategic conversations outside the company have been evolving since the imaging spin. I mean, has that opened any new doors for you in terms of collaborations, partnerships or other strategic activity?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","On that, we're continuing to look at how we reinforce the strategy of each company as we spin. So we're looking at a broader Oncology front for our -- for the remaining company and looking for a broader components beachhead for our X-ray business. So now",133,"On that, we're continuing to look at how we reinforce the strategy of each company as we spin. So we're looking at a broader Oncology front for our -- for the remaining company and looking for a broader components beachhead for our X-ray business. So now the good news is it has been pretty active. I think it's accomplishing both strategically and, we think, long-term from a value point of view what we want to do, and kind of unleashing a lot of energy around those initiatives. Now frankly, we're a little bit in head-down mode to get the spin done. So that's consuming us pretty hard here for between now and the end of the year. But we're pushing very aggressive as well on kind of the strategy front in both businesses."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Tycho Peterson with JPMorgan.",13,"And the next question comes from the line of Tycho Peterson with JPMorgan."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","First question, cancellations this quarter was about $42 million. And that's a big step-down from what you had the last quarter. So Elisha, I'm just wondering if you could kind of talk us through what you think is the underlying trend here.",42,"First question, cancellations this quarter was about $42 million. And that's a big step-down from what you had the last quarter. So Elisha, I'm just wondering if you could kind of talk us through what you think is the underlying trend here."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So yes. One of the big differences, Tyco. So it was $51 million in total on backlog adjustments. I believe the actual cancellation was closer to $20 million, and the rest was dormancy, where it just -- it's not probable at this point that some machine wil",120,"So yes. One of the big differences, Tyco. So it was $51 million in total on backlog adjustments. I believe the actual cancellation was closer to $20 million, and the rest was dormancy, where it just -- it's not probable at this point that some machine will ship within the 2-year period of time so we take it out of our backlog. The big difference is we did not have a big FX impact this quarter, and we had a large one on -- in some of the prior quarters because, as you know, our backlog is held at historical rates. And so it gets trued-up every quarter based on the FX. And so that was very minimal this quarter."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And then maybe for Dow on Services. You've been outgrowing the market here for quite some time. Can you maybe just talk about just the sustainability of that trend? How long do you think you can kind of outgrow the market from a serv",63,"Okay. That's helpful. And then maybe for Dow on Services. You've been outgrowing the market here for quite some time. Can you maybe just talk about just the sustainability of that trend? How long do you think you can kind of outgrow the market from a service perspective? And do the attach rates vary meaningfully by geography for you guys in that front?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, we're very bullish about our service business still. It's a little bit a lot of large numbers because it's now a $1 billion business. I think on the quarter in Oncology, it was 41%, 42% of the total, and it continues to be a juggernaut for us. I",210,"I mean, we're very bullish about our service business still. It's a little bit a lot of large numbers because it's now a $1 billion business. I think on the quarter in Oncology, it was 41%, 42% of the total, and it continues to be a juggernaut for us. 
I would say that it's one of the things that we really like about the new socket growth that we're seeing in Latin America and Asia, in particular. That's going to help drive the growth. The software model is going to more of a kind of a SaaS-based model, which strengthens that business. And we are seeing lots of positives on the upside. On the -- we are seeing in some markets, some of these emerging markets, we're seeing a little bit of wackiness from third-party competition. I wouldn't say that's the reason for the slowdown. I think the slowdown probably has more to do with large numbers and just kind of where we are. But in some of these emerging markets, we are seeing some growing presence, especially in the older installed base, some third-party competition. 
But I'd say, we're still in that high single-digit range. It's kind of what we're feeling about the long-term capability of our service business."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then does having stability on the reimbursement front, I mean, we got through this Physician Fee Schedule relatively unscathed. The first 2 years of macro would be kind of everybody gets a little bit of a bump. Does that free up the U.S. market a litt",57,"And then does having stability on the reimbursement front, I mean, we got through this Physician Fee Schedule relatively unscathed. The first 2 years of macro would be kind of everybody gets a little bit of a bump. Does that free up the U.S. market a little bit over the next couple of years, do you think?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, I think it's too early to tell. But that would be our -- our guess would be consistent with that, Tycho. I think the macro field is a little bit like some of the reimbursement incentives that there were on some of this early IT adoption 3, 4 years",63,"I mean, I think it's too early to tell. But that would be our -- our guess would be consistent with that, Tycho. I think the macro field is a little bit like some of the reimbursement incentives that there were on some of this early IT adoption 3, 4 years ago. So I think it's probably a little bit of an upside."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then -- and last one. You made a comment earlier on the kind of proton funnel. Just -- I mean, any sense as to what -- how big you think that market could be? [indiscernible]",36,"And then -- and last one. You made a comment earlier on the kind of proton funnel. Just -- I mean, any sense as to what -- how big you think that market could be? [indiscernible]"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Every time I've forecasted this, I've been wrong. So I'm not going to take the bait. I mean, it's just -- the good news is, these are government customers. And so I think we had our first discussion with SA 15 months ago. So we went from first conversatio",139,"Every time I've forecasted this, I've been wrong. So I'm not going to take the bait. I mean, it's just -- the good news is, these are government customers. And so I think we had our first discussion with SA 15 months ago. So we went from first conversation to order in 15 months, and for that, for us, that's a record in proton therapy. 
When you get in the private markets, and where financing instruments is frankly the most difficult part of the transaction, these deals can take a really, really long time. And so whereas sovereign-financed, it can move pretty fast. And we are having -- I'd say there are 3 or 4 live conversations going on. Will they happen in the next 15, 18 months? Maybe. There's a -- at least we have one now."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Vijay Kumar with Evercore ISI.",14,"And the next question comes from the line of Vijay Kumar with Evercore ISI."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So maybe, Dow, a big-picture question on -- because I guess, now we'll have green numbers, right, in a few months on standalone Oncology. I was just wondering, can you just comment big picture, what's been the installed base over the last 3 years, right?",89,"So maybe, Dow, a big-picture question on -- because I guess, now we'll have green numbers, right, in a few months on standalone Oncology. I was just wondering, can you just comment big picture, what's been the installed base over the last 3 years, right? Has it been flattish? Has it been growing in North America? Because that -- I just feel like that's an important question, just given your really, really strong showing here in North America. And obviously, that has a lot of implications to margin progression."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say, starting at a very high level, we have about a 7,500-unit installed base. We have had positive unit growth, 1% or 2% of the installed days. One of the things that we like about the whole U.S. growth is, as I mentioned, about China is those are al",115,"I'd say, starting at a very high level, we have about a 7,500-unit installed base. We have had positive unit growth, 1% or 2% of the installed days. One of the things that we like about the whole U.S. growth is, as I mentioned, about China is those are all new sockets, and we're -- we get some new installed base growth out of it. 
We did have very -- in Q3, we had very good unit growth. So one of the best unit growth quarters we've had in a while. So that's going to help our service business. So I don't know if I'm answering all your questions, Vijay. Elisha, anything to add?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Just that the U.S., as we said, Vijay, is largely a replacement market. So the installed base is not necessarily going up, but it is getting higher in equipment that does carry a higher level of service contract.",39,"Just that the U.S., as we said, Vijay, is largely a replacement market. So the installed base is not necessarily going up, but it is getting higher in equipment that does carry a higher level of service contract."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And when we made that trade out, I'd say our contract capture rate of TrueBeams is 10 to 15 points higher than our -- than the historical product.",28,"And when we made that trade out, I'd say our contract capture rate of TrueBeams is 10 to 15 points higher than our -- than the historical product."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And that was very helpful -- a lot, guys. And maybe just one on software. Because I -- this is the other question we get a lot on -- in what kind of visibility do we have, right, on the software option? Because I know at the Analyst Day, I knew you guys p",154,"And that was very helpful -- a lot, guys. And maybe just one on software. Because I -- this is the other question we get a lot on -- in what kind of visibility do we have, right, on the software option? Because I know at the Analyst Day, I knew you guys put out that $0.5 billion opportunity, right? Because, I guess, the reason -- when I look at your comments of the installed base, right, sort of 1% to 2%, obviously, you guys have done better on the share front. That's showing up in the North America region from an orders perspective, right? But how much more software can you keep selling into that installed base, right? Or am I thinking about this the right way? Or -- because I feel like having some clarity on that, I mean, that has a lot of implications on how people look at the company."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So here -- I mean, there's some really simple math here. We've got an installed base of 7,500 units. We've sold -- and we feel really good about it -- 500 RapidPlans. We have got 7,000 to go. We've got -- inside of analytics, what have we sold? 250? 200",263,"So here -- I mean, there's some really simple math here. We've got an installed base of 7,500 units. We've sold -- and we feel really good about it -- 500 RapidPlans. We have got 7,000 to go. 
We've got -- inside of analytics, what have we sold? 250? 200-ish? We've got 7,300 to go. So we're in the top half of the first inning. Sorry, baseball analogy for my global friends. But we're -- the software is still -- has very significant upside for us. And what I'm liking is we're getting very good customer response on the software products. I -- a decade ago, ""Oh, you ship me software and it works but I don't love it."" Now we're getting, ""Hey, if it does what I like it to do. It's making me for productive in the workplace. I can do better care and take care of patients better."" And we've had some external validation out of this with our class -- the Wynn [ph], which is kind of the Gartner of radiation oncology -- Class rate is #1 in treatment planning and in oncology information systems, so we like that. 
So those were -- RapidPlan and InSightive Analytics are 2 examples. We do have -- in the 7,500 units linac [ph] installed base. In that installed base, we also have 3,400, 3,500 software installations. So those are opportunities for us to take rapid -- that's the low-hanging fruit of the RapidPlan and InSightive Analytics opportunity. So I think, Vijay, we've still got a lot of opportunity on the software side."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","That was really helpful, Dow. And if I just may just sort of resort to a baseball analogy, I think in Cricket parlance that would be hitting a 6. So congrats.",31,"That was really helpful, Dow. And if I just may just sort of resort to a baseball analogy, I think in Cricket parlance that would be hitting a 6. So congrats."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think I know what that means, which is a little scary.",12,"I think I know what that means, which is a little scary."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Jason Wittes with Brean Capital.",14,"And the next question comes from the line of Jason Wittes with Brean Capital."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","I just want to get an update. I know that things are still moving, but in terms of the numbers you put out when you first announced the spin-out, you noticed -- you mentioned, I think, I believe $37 million in overhead, dis-synergies. Is that still the nu",66,"I just want to get an update. I know that things are still moving, but in terms of the numbers you put out when you first announced the spin-out, you noticed -- you mentioned, I think, I believe $37 million in overhead, dis-synergies. Is that still the number that we should be thinking about? And in terms of who absorbs what, is there any update there?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Jason, at this point, it was $20 million of dis-synergies at -- that would be -- remain co-Varian, and that number has not changed dramatically at this point. So I think it's still a good number to use. And again, with the goal of having that offset withi",64,"Jason, at this point, it was $20 million of dis-synergies at -- that would be -- remain co-Varian, and that number has not changed dramatically at this point. So I think it's still a good number to use. And again, with the goal of having that offset within 2 years so that we can get back to the same margin point, operating margin point."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And I believe that you're going to give the -- SpinCo will have cash on hand. I believe that was $50 million. But will that be cash taken from overseas? Or will that be cash that's been patriated in the U.S.?",42,"And I believe that you're going to give the -- SpinCo will have cash on hand. I believe that was $50 million. But will that be cash taken from overseas? Or will that be cash that's been patriated in the U.S.?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So there -- no number has been determined. And all we have said is they will not have debt at this -- at the time of the spin. And we are working with our advisors on the capital structure at this point. And so stay tuned, and we'll be talking about how m",68,"So there -- no number has been determined. And all we have said is they will not have debt at this -- at the time of the spin. And we are working with our advisors on the capital structure at this point. And so stay tuned, and we'll be talking about how much cash ends up going with SpinCo and how much of that is U.S. versus O-U.S."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And when do you anticipate giving us that update? Will that be on your -- for the fourth quarter? Or will that be more towards December?",27,"Okay. And when do you anticipate giving us that update? Will that be on your -- for the fourth quarter? Or will that be more towards December?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","It's going to be more to words when we're going on the roadshow, closer to the spin date.",19,"It's going to be more to words when we're going on the roadshow, closer to the spin date."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. Fair enough. And just on the Proton business. In terms of -- you've also put out sort of anticipation of reaching profitability. I assume that still goes. And what kind of revenue run rate do you need for that business to really sort of break even a",53,"Okay. Fair enough. And just on the Proton business. In terms of -- you've also put out sort of anticipation of reaching profitability. I assume that still goes. And what kind of revenue run rate do you need for that business to really sort of break even and so thinking about the --"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. It's a little hard to say, Jason. What we really need is the installs to be completed and the service business to become material to get a significant pop in the margins. But this year, it's going to be around $150 million. It's $200 million -- somew",60,"Yes. It's a little hard to say, Jason. What we really need is the installs to be completed and the service business to become material to get a significant pop in the margins. But this year, it's going to be around $150 million. It's $200 million -- somewhere between $200 million and $225 million, it starts looking very different. So..."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And now as you know, it will -- I mean, this is going to change with time because the margin rates on the equipment, now today, they're high-teens, mid high-teens. We hope to get back to the 20 to 30 range with time. But the margin rates on service are pr",76,"And now as you know, it will -- I mean, this is going to change with time because the margin rates on the equipment, now today, they're high-teens, mid high-teens. We hope to get back to the 20 to 30 range with time. But the margin rates on service are pretty good. So as the service contracts start to land, the geography of that profitability becomes a little easier with time. That's probably not next year."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And then the reimbursement was pretty benign, or actually, it's a positive, not benign, more optimism in that. But in terms of -- you did mention that they're going to try to start coaxing the market into being more efficient. I beli",103,"Okay. That's helpful. And then the reimbursement was pretty benign, or actually, it's a positive, not benign, more optimism in that. But in terms of -- you did mention that they're going to try to start coaxing the market into being more efficient. I believe that's with macro and MIPS. There are centers out there who have adopted it. Have you noticed a change in their behavior in terms of what their -- equipment they want? How they're doing their procedures, things like that? Is there a shift towards more concentrated dosing in those centers? Or is it just too early to say?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I'd say, if anything, it might be an incentive for people to take our ARIA insight of analytics and other ARIA features into the market. ARIA is MACRA compliant. One of the things that gets that is a lot of metrics, a lot of portability. These are some of",109,"I'd say, if anything, it might be an incentive for people to take our ARIA insight of analytics and other ARIA features into the market. ARIA is MACRA compliant. One of the things that gets that is a lot of metrics, a lot of portability. These are some of the things they're looking for, and that's part of that product. So short-term-ish, as we were talking about in one of the other questions, it could be a little bit of upside maybe next year. I would say we haven't really seen a behavior change in terms of peoples' purchasing pattern, one way or the other, at this point."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So -- and also related to that, do you have a sense of how much of the marketplace is actually ready to fully implement MACRA here, that has all the software in place, et cetera?",35,"So -- and also related to that, do you have a sense of how much of the marketplace is actually ready to fully implement MACRA here, that has all the software in place, et cetera?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Well, I think the short version is people just got the standard, so 0. So I mean, we look -- take a hard look at it. We know that we've got a few product things to do, but then our product is pretty compliant. We're -- the -- we're pretty comfortable with",290,"Well, I think the short version is people just got the standard, so 0. So I mean, we look -- take a hard look at it. We know that we've got a few product things to do, but then our product is pretty compliant. We're -- the -- we're pretty comfortable with where our product is. It's not going to be like a major rewrite or something that we're going to have to do, but we do have to add a few features, and we're very well positioned for MACRA implementation. So we like that. But I would say, to kind of come back to the main thrust of the question, I would say we have not seen a purchasing difference with those customers. 
With history, if anything, a lot of them tend to be -- they want to be clinically advanced and they want to be very productive, cost-efficient. And sometimes, it takes a little bit longer to convince them. But once they're convinced, they tend to move faster because they've got the clinical data or the productivity data to make their business case. And they may take a little bit longer to convince them, but once they're convinced, they -- I -- one of the examples I've used historically on this is RapidArc with Kaiser. 
It took us a while to convince them that RapidArc was really clinically advantageous and was going to give them a productivity pop. Once they were convinced, Kaiser and Orrick outfit every hospital one year. It was just, bang. They really moved. And I think that's typical from what we see from these kind of customers. It might take a little bit longer to convince them, but when they're convinced, they go fast."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's helpful. And just sort of a follow-on, on that. When that happens, which it's going to take some time, I mean, I think MACRA itself doesn't really have teeth until the next couple of years, but it does seem like there could be some upgrade --",89,"Okay. That's helpful. And just sort of a follow-on, on that. When that happens, which it's going to take some time, I mean, I think MACRA itself doesn't really have teeth until the next couple of years, but it does seem like there could be some upgrade -- required upgrades for software that could help you or help, I guess, your customers as well. But there is an upgrade cycle to be had when this really starts to take over. Was that a fair way to think about it?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Absolutely. And that's the outside opportunity I've been referring to, yes.",12,"Yes. Absolutely. And that's the outside opportunity I've been referring to, yes."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","And the next question comes from the line of Anthony Petrone with Jefferies.",13,"And the next question comes from the line of Anthony Petrone with Jefferies."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Just a couple of follow-ups, actually, on guidance and Imaging, in particular, and then one on the spin. So for guidance, I guess, the 3% reiteration here. You are baking quite an acceleration in the fourth quarter. And I'm just wondering how much of th",83,"Just a couple of follow-ups, actually, on guidance and Imaging, in particular, and then one on the spin. 
So for guidance, I guess, the 3% reiteration here. You are baking quite an acceleration in the fourth quarter. And I'm just wondering how much of that is Oncology-related versus maybe a rebound in imaging? And then you also spoke quite a bit on proton. So just trying to get a little bit more color on guidance. And then I follow on the follow-ups."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. So Anthony, the guidance in Oncology, and I'm assuming you're talking revenue here, should be in the mid-single-digit growth. The Imaging Components business will be in the low single-digit growth versus the year-ago quarter. And we're going to get",68,"Sure. So Anthony, the guidance in Oncology, and I'm assuming you're talking revenue here, should be in the mid-single-digit growth. The Imaging Components business will be in the low single-digit growth versus the year-ago quarter. And we're going to get $20 million to $25 million-or-so in additional proton revenue versus the year-ago period. So a big bump in protons gets you to around just 7% range on Q4."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","That's helpful. And then just Imaging Components again for the quarter. I know you mentioned in bookings the contribution from -- or gross orders rather from acquisitions. But I'm just wondering what the revenue contribution was in the quarter from Claymo",44,"That's helpful. And then just Imaging Components again for the quarter. I know you mentioned in bookings the contribution from -- or gross orders rather from acquisitions. But I'm just wondering what the revenue contribution was in the quarter from Claymount and MeVis?"
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","About $11 million, I believe, in total.",7,"About $11 million, I believe, in total."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Helpful. And then last, just on spin. Have you announced if it's a 1 for 1 share distribution? Or we're still...",21,"Helpful. And then last, just on spin. Have you announced if it's a 1 for 1 share distribution? Or we're still..."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","No, we have not. We have not. We're working with JPMorgan on that.",13,"No, we have not. We have not. We're working with JPMorgan on that."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","There are no other questions on the queue at this time. I would now like to turn the call back over to management for any closing comments.",27,"There are no other questions on the queue at this time. I would now like to turn the call back over to management for any closing comments."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Thank you all for participating. The replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1(877) 660-6853 from inside the U.S.",70,"Thank you. Thank you all for participating. The replay of this call can be heard on the Varian Investor website at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1(877) 660-6853 from inside the U.S. or (201) 612-7415 from outside the U.S., and confirmation code 13640722. A telephone replay will be available through 5:00 p.m. this Friday July 29. Thank you all."
311907,370528018,1015207,"Varian Medical Systems, Inc., Q3 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. This concludes today's teleconference. You may disconnect your lines at this time, and we thank all of you for your participation.",23,"Thank you. This concludes today's teleconference. You may disconnect your lines at this time, and we thank all of you for your participation."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems Fourth Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.It is now my pleasure to introduce your host, Spencer Sias, Vice Presiden",42,"Greetings, and welcome to the Varian Medical Systems Fourth Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Spencer Sias, Vice President. Please go ahead, sir."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Good afternoon, and welcome to Varian Medical Systems' conference call for the fourth quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha wil",271,"Thank you. Good afternoon, and welcome to Varian Medical Systems' conference call for the fourth quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. 
To simplify our discussion, unless otherwise stated, all references to the quarter or year or fiscal quarters or fiscal years, quarterly comparisons are for the fourth quarter of fiscal 2016 versus the fourth quarter of fiscal 2015. References to financial results for orders are to gross orders unless otherwise indicated. 
The company is reporting non-GAAP results in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. A reconciliation to the most comparable GAAP measure is included in our earnings release, which can be accessed on our website. 
Please be advised that this presentation and discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, should, will, promising and similar expressions are intended to identify those statements which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks related to our business are described in our fourth quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise. 
And now here's Dow."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Our company finished fiscal year 2016 on a positive note, with healthy fourth quarter growth in revenues and significant margin improvement in both our Oncology and Imaging Components businesses. Orders in the Oncology and pro",1519,"Good afternoon, and welcome. Our company finished fiscal year 2016 on a positive note, with healthy fourth quarter growth in revenues and significant margin improvement in both our Oncology and Imaging Components businesses. Orders in the Oncology and proton businesses, on the other hand, were down during the quarter versus tough year-ago comparisons in which we had record-setting Oncology growth in Western Europe and in our proton business. 
To summarize, our fourth quarter results for fiscal 2016 we are reporting GAAP net earnings of $1.24 per diluted share, up from $0.99 in the year-ago quarter; non-GAAP net earnings of $1.38 per diluted share, up more than 30% from $1.04 in year-ago quarter; a decline in Oncology orders due to weakness in Western Europe; revenues of $912 million, up 12% in dollars and up 11% in constant currency; and gains of about 4 percentage points in our gross margin, with significant improvements in both our major businesses. 
Focusing on Oncology operations. Orders totaled $897 million for the fourth quarter, down 2% in dollars and down 4% in constant currency versus a strong year-ago quarter. Orders for the year totaled $2.7 billion, up 1% from the prior year and up 2% in constant currency. 
Fourth quarter orders in the Americas grew by 4% in dollars, an increase by 3% in constant currency for the year. Orders in the Americas were up 4% in both dollars and constant currency. 
In North America, orders fell by 2% in the fourth quarter but grew by 5% for the year, ahead of our expectations for this market. 
Fourth quarter Oncology orders in APAC rose by 8% in dollars and fell by 1% in constant currency. For the full year, APAC orders rose by 5% in dollars and by 3% in constant currency. 
In EMEA, Oncology orders declined by 17% in dollars and in constant currency, principally because of weakness in Western Europe, where we had exceptionally strong growth in the year-ago quarter when we set a record by booking orders for more than 100 accelerators. 
For the year, orders in EMEA were down 6% in dollars and down 4% in constant currency, driven by weakness in Western Europe. 
Comparing revenues on a trailing 12-month basis, we believe we gained market share versus our primary competition. Our average selling price rose with the help of a higher mix of TrueBeam and VitalBeam orders. We generated solid order growth during the quarter in emerging markets, including Brazil, Africa and in the Middle East. 
In Brazil, we booked nearly $30 million of new business, including a big win at Grupo Oncoclnicas, where we will be installing 13 TrueBeam and VitalBeam accelerators as well as software to support clinical operations. These will be the first VitalBeam accelerators installed in Latin America. 
Colombia was also a strong contributor to robust order growth in the quarter. Total orders in Latin America exceeded $60 million during the quarter, up more than 70% from the prior year period. 
Other emerging markets contributing to Oncology orders during the quarter included Africa, with about $20 million; and the Middle East, where we booked more than $40 million. As an example of progress, we received a $14 million order for 8 accelerators at the Shifa International Hospital in Islamabad. 
In APAC emerging markets, we generated healthy order growth in Indonesia, Korea and the Philippines. Developed markets, particularly Japan, also contributed to the order growth in this region. Meanwhile, orders in Greater China were down from the year-ago period in part because of continuing tender protest. While we are anniversary-ing the effects of these multiple orders, and while we are retaining the book of the business that we've won, we estimate that orders in China in the fiscal year could have been more than $15 million higher without this protest activity. 
Turning to North America. We established a significant new 3-year strategic agreement with McKesson Specialty Health to supply its U.S. oncology and vantage cancer treatment networks with equipment, software and services. In the first phase, we will be equipping centers with 7 TrueBeam and 5 VitalBeam accelerators. We also will be working to establish interoperability with Varian's information management and McKesson's iKnowMed G2 clinical oncology software. We see an opportunity here to support these networks with more of our Eclipse, ARIA, Velocity and new 360 Oncology software. 
Overall, we had a very good year in North America, where we had in excess of $130 million in takeouts of more than 40 accelerators and nearly 100 software installations from competitors. 
As you know, we've just returned from ASTRO in Boston. It was a great show for us, with some 900 attendees at our users meeting, numerous customers from emerging markets and very positive response to several major new products that we'll be bringing to market this year. 
We introduced 360 Oncology, a first-of-its-kind software tool that enables clinicians on tumor boards to more effectively coordinate patient care among the numerous specialists involved in cancer treatment. This software also provides patients with a clearer picture of how the many elements involving -- involved in treating their cancer fit together. Customer response is enthusiastic, and we believe we have a winning product on our hands. 
We also showed our progress in the development of our HyperArc technology for automating and simplifying the delivery of stereotactic radiosurgery, with more compact dose distribution and better protection of surrounding healthy tissue. We're aiming to introduce this important upgrade to our TrueBeam and EDGE platforms this year, beginning with a module for treating head and neck cancers. 
Oncology administrators are also very interested in our initiative, in which we will be enhancing the security embedded within Varian software systems. We believe we have a leading position in the development of this important new capability, and we expect it could generate an additional $80 million in revenues by the end of fiscal year 2018. 
We have continued to see a very positive market response to our RapidPlan and InSightive Analytics software products that help to improve the speed, quality and cost efficiency of treatments. We've taken more than 650 orders for RapidPlan since its launch and more than 135 orders for our InSightive software. 
Touching on the service business. Global revenues rose by 7% during the quarter, with gains in all geographies. 
Turning now to our Particle Therapy business. We generated $38 million in orders during the fourth quarter, bringing total orders for the year to $104 million. Orders were down significantly from fiscal 2015 when we had a total of 6 system orders, including an $87 million order for our probing system at the University of Maryland. 
Revenues from 14 ongoing projects grew nicely, reaching $68 million in the fourth quarter and bringing total revenues for the year to $163 million, including about $10 million in annual service revenues. 
During the fourth quarter, we booked our first single-room ProBeam Compact order, marking an important milestone for the business. This new system will be installed at the Advanced Medicine Training Centre in Singapore, where Varian will also provide its Eclipse treatment planning system. We also have a 10-year agreement to service this system. 
Also during the quarter, the U.K.'s University College London Hospital placed an order for a fourth treatment gantry at the proton therapy center that is currently under construction. 
Earlier this month, treatments commenced using our ProBeam system at Cincinnati Children's Hospital, making it the fifth Varian-equipped proton center to treat clinically. At this point, the proton sales funnel looks healthy, and I'm pleased by the progress we are making. 
  
Let me turn now to Imaging Components. Recovery in this business continued in the fourth quarter. Orders grew by 2% to $168 million in the fourth quarter, resulting in 7% orders growth for the last 6 months. Orders for the year totaled $571 million, down 6% from the prior year because of first half headwinds, including significant purchasing slowdowns at 2 major customers. Revenues were up 7% for the fourth quarter and down 2% for the year. 
Our MeVis and Claymount acquisitions as well as successful efforts to develop business with new customers contributed to Imaging Components' order and revenue growth during the quarter. Great cost control as well as a favorable product mix in tubes and flat panel imaging detectors and higher volumes in our security and inspection line enabled the Imaging business to achieve the significant gain in its gross margin for the quarter. 
Looking at operational highlights for the whole year. The Imaging Components business introduced 20 new products, completed 140,000 square foot expansion of its manufacturing facility in Salt Lake City, opened a new facility in China to service growing customer base there, successfully integrated and mobilized its MeVis and Claymount acquisitions, added 12 new customers to offset slower purchasing from established customers and exceeded its profit targets. We're proud of this performance, and we expect Imaging Components to be a great company that delivers solid returns when it separates from Varian and has established as Varex Imaging, an independent publicly traded company. Work on the separation continues to go smoothly. 
Now I'll turn it over to Elisha."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog. We ended the quarter at $3.5 billion, down 1% from the year-ago period, with a gain in Oncology offset by declines in our Particle Therapy and Imaging Co",832,"Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog. We ended the quarter at $3.5 billion, down 1% from the year-ago period, with a gain in Oncology offset by declines in our Particle Therapy and Imaging Components backlogs. Backlog adjustments during the quarter totaled $47 million, bringing net orders for the company to $1.1 million. 
Fourth quarter revenues for the total company were $912 million, up 12% in dollars and up 11% in constant currency. For the year, total company revenues were $3.2 billion, up 4% in dollars and up 5% in constant currency. 
Oncology posted a fourth quarter revenue gain, up 7% in dollars and 6% in constant currency. For the year, Oncology revenues increased 5% in dollars and 6% in constant currency. 
Imaging Components posted a fourth quarter revenue gain of 7%, driven by our recently acquired X-ray accessories businesses as well as security and inspection products. Including the challenges in the first half, Imaging Components revenues declined 2% for the full year. 
Our Particle Therapy business posted fourth quarter revenues of $68 million, bringing total revenues for the year to $163 million, a 13% increase from the prior year. 
The total company gross margin for the quarter was 42.7%, up by nearly 4 points, with significant contributions from both Oncology and Imaging Components. 
Oncology Systems fourth quarter gross margin improved by about 5 points to 45.3%, with the help of favorable product and geographic mix shifts as well as product cost reductions. For the year, Oncology Systems gross margin improved by almost 2 points to 44.5%. 
Imaging Components fourth quarter gross margin rose by about 3 points to 42.1% due largely to favorable product mix, high volumes in tube and security products and lower warranty cost. For the year, Imaging Components gross margin improved by about 1 point to 41.9%. 
R&D expenses were $66 million or 7% of revenue, down 1 point as a percentage of revenue from the year-ago quarter. For the year, R&D expenses were $254 million or equal with the prior year as a percentage of revenue at 8%.
On a GAAP basis, fourth quarter SG&A expenses were $152 million or 17% of revenue. On a non-GAAP basis, fourth quarter SG&A expenses were $134 million or 15% of revenue. 
The $19 million in non-GAAP adjustments, primarily related to the planned separation of the Imaging Components business, ongoing patent litigation and amortization of intangibles. 
Operating earnings for the quarter were 18.6% of revenues on a GAAP basis and 20.7% of revenues on a non-GAAP basis, reflecting our solid gross margin performance in the quarter. 
For the year, our operating earnings were 17.1% of revenues on a GAAP basis and up 50 basis points from the prior year to 19.1% of revenues on a non-GAAP basis. 
Depreciation and amortization totaled $24 million for the fourth quarter and $80 million for the year. The fourth quarter effective tax rate is 31.1%, up from the year-ago quarter due to an unfavorable geographic mix of profits. For the year, the effective tax rate was 27.6%. 
Fully diluted shares outstanding for the fourth quarter were 94.5 million, down almost 5 million shares from the year-ago period due to our ongoing share repurchase program. Fourth quarter diluted EPS was $1.24 for the quarter on a GAAP basis and $1.38 on a non-GAAP basis. For the year, diluted EPS was $4.19 on a GAAP basis. On a non-GAAP basis, diluted EPS rose 9% to $4.68. 
 
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $844 million, debt of $667 million and stockholders' equity of $1.7 billion. 
DSO at 93 days was up from the year-ago quarter, but improved sequentially from the third quarter. 
Fourth quarter cash flow from operations was $152 million, bringing the total cash flow from operations for the year to $356 million. Primary uses of cash were $87 million for the repurchase of about 1 million shares of stock, $43 million to reduce debt and $20 million for capital expenditures. At the end of the quarter, we had 3.8 million shares remaining under the existing repurchase authorization. 
Before I turn it over to Dow, as you may have seen in the release issued before this call, I intend to retire from Varian in fiscal year 2017. I will remain in my current role as CFO until a replacement is found and a smooth transition has been completed. I will also continue leading the separation of our Imaging Components business. We have a tremendous finance team that will perform to this transition to a new CFO without missing a beat. It has been an honor to serve all of Varian's investors and analysts over the past 17.5 years, and it's been a privilege to be part of a tremendous growth story that has seen Varian become a global power in the fight against cancer. 
Thank you for being part of the story with me. And now here's Dow."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. For our company and for our investors, Elisha has been an intelligent, trusted and energetic leader that all of us count on to help deliver winning results. We're just counting it up. We think it's 71 quarters. So bravo, Elisha. With her h",204,"Thanks, Elisha. For our company and for our investors, Elisha has been an intelligent, trusted and energetic leader that all of us count on to help deliver winning results. We're just counting it up. We think it's 71 quarters. So bravo, Elisha. With her help and guidance, we've achieved this sustained decades-long record of growth in revenues and profitability. I've been fortunate to have Elisha on our management team. I'm confident that we'll make a smooth transition. 
Turning now to guidance. We believe that for the first quarter of fiscal year 2017, non-GAAP earnings for the total company, including the Imaging Components business and ramp-up costs for its separation, will be in the range of $1.03 to $1.07 per diluted share, and revenues will increase by about 1% to 2%. 
As we announced earlier, we will not give earnings guidance for the full fiscal year until after we have completed the separation of the Imaging Components business. 
For the full fiscal year 2017, we expect that Varian revenues, excluding the Imaging Components business, will rise by 3% to 4%. We expect that Imaging Components revenues for the full fiscal year 2017 will also rise by 3% to 4%. 
We're now ready for your questions."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] Our first question today is coming from Jeff Johnson from Robert W. Baird.",15,"[Operator Instructions] Our first question today is coming from Jeff Johnson from Robert W. Baird."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Elisha, I'm not going to touch the 71 quarter comment. I'll just leave that one alone, I guess. But it's been great working for you -- or working with you. I say that every time. It's been great working with you for the last 7 or 8 years that I've covered",62,"Elisha, I'm not going to touch the 71 quarter comment. I'll just leave that one alone, I guess. But it's been great working for you -- or working with you. I say that every time. It's been great working with you for the last 7 or 8 years that I've covered the stock, and I wish you the best in the future."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you, Jeff.",3,"Thank you, Jeff."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So 2 questions here. One, I guess, just on cash flow. So cash flow was down, I think, on the year, down about 25%. It looks like it's kind of the lowest level we've seen since fiscal 2009, in fact, as I was going back. And if I add back some of the non-GA",114,"So 2 questions here. One, I guess, just on cash flow. So cash flow was down, I think, on the year, down about 25%. It looks like it's kind of the lowest level we've seen since fiscal 2009, in fact, as I was going back. And if I add back some of the non-GAAP cash charges, even if I add those back, it's still down below $400 million. And it looks like receivables were up, I think about $120 million year-on-year, and even $50 million up sequentially. So just trying to figure out if it's a receivables issue, what's going on there? Or what's going on basically with your cash flow at this point?"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. So Jeff, the Oncology AR increased about 8%, and that compares to their year-to-date sales up 5%. And as we've been talking all through this fiscal year, early in the year, we moved our collections staff. We had a sales force IT implementation. And",198,"Sure. So Jeff, the Oncology AR increased about 8%, and that compares to their year-to-date sales up 5%. And as we've been talking all through this fiscal year, early in the year, we moved our collections staff. We had a sales force IT implementation. And I think that slowed down collections in the first half, and we are continuing to feel that effect. Although we're making good progress, collections in Q3 and Q4 were very strong, but as we move into FY '17, absolutely, AR collections is going to be a big focus for the entire team. Little bit of it has to do with more extended terms. In a 0 interest-rate environment, we can continue to win high-margin business by offering terms. And then some of it also, both inventory and AR, up in the proton business as we continue to grow that business. And with percentage of completion accounting, it gets a little funky in proton because a lot of times we're taking revenue and creating an AR under the percentage of completion long before the builds are actually due by the customer. But it will be a big focus as we move into this year."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And I know you don't guide -- you guided to cash flow, but I mean, on a consolidated basis, can we expect to get back above $400 million? We were almost touching $500 million a couple years ago, and it seems like $350 million. Can we at least get ba",63,"Okay. And I know you don't guide -- you guided to cash flow, but I mean, on a consolidated basis, can we expect to get back above $400 million? We were almost touching $500 million a couple years ago, and it seems like $350 million. Can we at least get back above $400 million, do you think, over the next year or 2?"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, that is absolutely my goal this year. And also, contract advances were down in the proton business as orders being lower. That drove about, I think, $40 million of it. So -- but yes, our goal is we would get back on a consolidated basis to the $400 m",51,"Yes, that is absolutely my goal this year. And also, contract advances were down in the proton business as orders being lower. That drove about, I think, $40 million of it. So -- but yes, our goal is we would get back on a consolidated basis to the $400 million level."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes. All right. And Dow, from a guidance standpoint, I think we all knew you weren't going to issue full year guidance from an EPS perspective, and we understand the reasons why. But if I look at first quarter guidance from an EPS perspective, you're guid",128,"Yes. All right. And Dow, from a guidance standpoint, I think we all knew you weren't going to issue full year guidance from an EPS perspective, and we understand the reasons why. But if I look at first quarter guidance from an EPS perspective, you're guiding to about 5% to 6% EPS growth on a year-over-year basis. Is it fair to think about that on kind of a core basis over the following few quarters? Obviously, we have to take into account that extra $20 million of revenue to synergies that will start to hit the back 3 quarters. But outside of that issue, is kind of your first quarter guidance a reasonable way to think about kind of the core outlook for the rest of the year?"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me talk to the market side of it, and I'll let Elisha talk to the nuts and bolts on the guidance side. I think from a market perspective, we had big comp in Europe here in the fourth quarter. But fundamentally, we had a very sound year in the U.S. We",189,"Let me talk to the market side of it, and I'll let Elisha talk to the nuts and bolts on the guidance side. I think from a market perspective, we had big comp in Europe here in the fourth quarter. But fundamentally, we had a very sound year in the U.S. We see that continuing next year. Our funnel remains very good in the U.S. In Asia, China was a little bit off due to some of the structural issues we've seen there. But we think that, that market remains robust and should kind of bounce back to double-digit levels. And then the question for us all this year has been kind of Western Europe, and where's it going to land. We've talked about that on this call, about it being soft all this year. As we closed the year, I'd say we feel pretty good about Europe for next year. So just kind of rounding out the market and top line side of it, I think we feel pretty good about where the market's going to be globally next year with the -- especially Western Europe bouncing back."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So for -- specifically for Q1 of FY '17, Jeff, that 1% to 2% on the revenue side, Varian Oncology and proton is going to be flattish on revenue, but that's really because in the year-ago Q1, we had something like 9% constant currency revenue growth. And t",220,"So for -- specifically for Q1 of FY '17, Jeff, that 1% to 2% on the revenue side, Varian Oncology and proton is going to be flattish on revenue, but that's really because in the year-ago Q1, we had something like 9% constant currency revenue growth. And then when we looked at Q2, it was actually down 1%. So this is just a matter of timing, and I think the revenue will be split more evenly between Q1 and Q2. So again, 3% to 4% for the full year for Oncology. Q1 for Varex, the Imaging Components business, should be up in the, call it, low double-digit range. And that's versus a very easy year-ago comp as their recovery continues. On EPS, we're -- if you look at our range, it would be 4% to 8% EPS growth versus the year-ago quarter. But I need to stress, that also includes $0.01 to $0.02 of cost that we're building in the Imaging Components business today to prepare them for the spin. So for an example, they've hired a CIO. They've hired a manager of tax. As they're building out their corporate function, those costs are duplicated in this quarter. And so really, you need to tack on an additional $0.01 to $0.02 to account for that to get to an apples-to-apples."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And I guess I'll just repeat the last part of my question, which was can I -- is it fair to think of that 4% to 8% EPS growth as kind of a core range we could think of for the rest of the year before we then tack on that $20 million of dis-synergies",56,"Okay. And I guess I'll just repeat the last part of my question, which was can I -- is it fair to think of that 4% to 8% EPS growth as kind of a core range we could think of for the rest of the year before we then tack on that $20 million of dis-synergies?"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Okay. So let me answer it this way, and this is a completely non-relevant number, but I'll give it to you anyway because we are going forward with the spin. But if we weren't spinning, I believe fiscal year '17, on a consolidated basis, we could grow EPS",53,"Okay. So let me answer it this way, and this is a completely non-relevant number, but I'll give it to you anyway because we are going forward with the spin. But if we weren't spinning, I believe fiscal year '17, on a consolidated basis, we could grow EPS in the high single-digit range."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Amit Hazan from Citi.",11,"Our next question today is coming from Amit Hazan from Citi."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Let me just add, Elisha, it's been a great run and we'll definitely miss you.",15,"Let me just add, Elisha, it's been a great run and we'll definitely miss you."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you, Amit.",3,"Thank you, Amit."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Let me start with the guidance on the top line and that you guys talked about. So the 3% to 4% top line growth, I just want to make sure we understand it that the reported number are constant currency number first. And then either way, really, if I kind l",103,"Let me start with the guidance on the top line and that you guys talked about. So the 3% to 4% top line growth, I just want to make sure we understand it that the reported number are constant currency number first. And then either way, really, if I kind look at orders from Oncology, [indiscernible] now pretty much flat for the last couple of years on a reported basis. Backlog is kind of flattish. So maybe just help us, Elisha, to kind of get to that 3% to 4% growth range versus the order in the backlog growth rates we've been seeing.[ph]"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, well that's assuming at today's exchange rates, which fortunately have stabilized over the last several quarters. The euro has stabilized. The yen is obviously helping us. If the yen weakens significantly, that could be an impact. But if I look at wh",86,"Yes, well that's assuming at today's exchange rates, which fortunately have stabilized over the last several quarters. The euro has stabilized. The yen is obviously helping us. If the yen weakens significantly, that could be an impact. But if I look at where currency rates are today, that 3% to 4% for Oncology and proton combined feels about right. That does compare to an Oncology backlog that's up 3% at the end of the fiscal year '16. So that looks pretty achievable going into FY '17."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And let me just follow up on the orders side on Europe. I mean, if I look at EMEA for the year, down 4%, you talked about -- I think there's obviously some tough comps in there. But are you actually seeing some issues that have been persistent in Eu",97,"Okay. And let me just follow up on the orders side on Europe. I mean, if I look at EMEA for the year, down 4%, you talked about -- I think there's obviously some tough comps in there. But are you actually seeing some issues that have been persistent in Europe that you would call out that you don't have great visibility to other than easy comps? Or maybe just a little more color on what's going on Europe and if the issues that you've seen have been or continue to be persistent and what those are."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. Through the course of 2016, Amit, I think we had weakness, especially in U.K., France and Germany. And as I mentioned in my response to Jeff's question, we're seeing our funnels in those markets and the rest of Western Europe and the rest of our Eur",119,"Sure. Through the course of 2016, Amit, I think we had weakness, especially in U.K., France and Germany. And as I mentioned in my response to Jeff's question, we're seeing our funnels in those markets and the rest of Western Europe and the rest of our European map look pretty good as we look forward. So I think we're a little more encouraged about what we see forward than what we see backwards. So we also see some opportunity in Italy and Spain going forward. So -- and then of course, our map of Europe includes Africa, Middle East, India and those markets were good to us in Q4, and we see those as continued strength from those markets."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then last one for me. Just on the word. Maybe just give us a sense of when those units would actually be booked as orders, if they haven't been booked already. And then you kind of talked about it as Phase 1. To the extent that you can, maybe just tal",95,"And then last one for me. Just on the word. Maybe just give us a sense of when those units would actually be booked as orders, if they haven't been booked already. And then you kind of talked about it as Phase 1. To the extent that you can, maybe just talk about they're obviously a big organization center perspective. Just the installed base, how much of it is yours? And the extent to kind of a phase potential for a Phase 2 here [ph] how you see this developing beyond this first or so?"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, all that we've booked so far is this first 14 units. So that's just this first phase. We feel very good about our relationship with McKesson U.S. Oncology, Vantage. There's -- what we've booked so far is pretty much the hardware piece of the relation",137,"Yes, all that we've booked so far is this first 14 units. So that's just this first phase. We feel very good about our relationship with McKesson U.S. Oncology, Vantage. There's -- what we've booked so far is pretty much the hardware piece of the relationship. The contracts does include software and service, and that'll be booked, some of it next year and beyond. So we feel very good about where that is headed. I think the -- very much in sync for kind of what the software products have to do in terms of managing the clinic, providing the analytic tools, the MACRA reimbursement tools. It will include some interoperability with the McKesson IknowMed product, which is important for McKesson. And very excited about that whole relationship, but most of it is yet to be booked."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Tycho Peterson with JPMorgan.",11,"Our next question today is coming from Tycho Peterson with JPMorgan."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Apologies. I'm going to ask another guidance question, but if we think about kind of the end markets, Dow, you used to talk about kind of 6% to 8% market growth and then it was kind mid-single digits. You're talking about 3% to 4% revenue growth with some",89,"Apologies. I'm going to ask another guidance question, but if we think about kind of the end markets, Dow, you used to talk about kind of 6% to 8% market growth and then it was kind mid-single digits. You're talking about 3% to 4% revenue growth with some share gains, I guess, embedded in. So can you maybe just talk about what you see as underlying market growth? And in your 3% to 4% revenue guidance, how much of that is software and service versus underlying growth in linac."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","To the last. I don't know if I can break that out for you at this point from a guidance point of view. But as to the overall markets, I mean, if anything, we might have been a little bit conservative here. I think as we look at our funnels here at the beg",206,"To the last. I don't know if I can break that out for you at this point from a guidance point of view. But as to the overall markets, I mean, if anything, we might have been a little bit conservative here. I think as we look at our funnels here at the beginning of the year, I think the market looks pretty good. We had a ton of activity in -- especially in the fourth quarter in Europe last year. And as we look forward, we see pretty good strength. So I'd say it's -- there's some uncertainty around the course, but it's probably 3%, 3.5% to 6% market growth scenario. China's going to continue to do well. India is going to do well. We're growing in Africa. We had pretty good year this past year in Brazil, but we see continued strength in the Brazilian market, and that's good news. And then in the U.S. market, it's been, as I mentioned in the script, it was 5% growth on the year. And if anything, that was a little bit ahead kind of where we thought it would be coming into the year. As we look at 2017, funnels remain very strong in the U.S."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","If I could just add to that, Tycho, in terms of the top line growth for Oncology, the good news is pricing is holding globally, and we have seen significant product cost reductions. We basically obsoleted the C series and moved everyone onto the TrueBeam",112,"If I could just add to that, Tycho, in terms of the top line growth for Oncology, the good news is pricing is holding globally, and we have seen significant product cost reductions. We basically obsoleted the C series and moved everyone onto the TrueBeam platform. And I think this is the margin improvement you've seen the last couple of quarters in Oncology is sustainable going forward. So we're kind of moving them up to a 44% to 45% gross margin level. And so obviously, even if the top line is off a point or so, we make up a lot of that difference in the margin improvement that we're seeing there."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's good to hear. And then Dow, maybe on MACRA the final rule. What are your thoughts on as we think about getting implemented, how do we think about that may be driving more of a bias toward software and some...",42,"Okay. That's good to hear. And then Dow, maybe on MACRA the final rule. What are your thoughts on as we think about getting implemented, how do we think about that may be driving more of a bias toward software and some..."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I think the overall, it's a good opportunity for our product line with our InSightive Analytics tools, our RapidPlan and treatment planning and our 360 Oncology. It's going to create an opportunity for us to provide our customers with required reports tha",224,"I think the overall, it's a good opportunity for our product line with our InSightive Analytics tools, our RapidPlan and treatment planning and our 360 Oncology. It's going to create an opportunity for us to provide our customers with required reports that they're going to need to comply. They've got to demonstrate a certified EHR, electronic health record. They've got to demonstrate improvement in care management and practices, and they've got to report on their quality metrics. So these tools all do that. So I think it's going to be pretty good news for us. The product line is about where we need it to be. They comply. We've got a few things to button down, but we'll be way ahead of the compliance requirements. And we've got just our own installed base. It's about 1,800 units -- sorry, 1,800 sites that got to go. And we're very excited about that. Maybe just on top of that, this isn't the MACRA, but the other piece from a market point of view that is at least as important as MACRA is the cybersecurity. And this -- at ASTRO, we launched very significant upgrade to our software products for cybersecurity. And that product would be ready here in the early spring. And that should drive some upside for us, too. So we're excited about that one."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then one last one. North American Oncology orders last quarter up 15%. They were up only 3% this quarter. Were there some pull-forward dynamic CMS to kind of come out ahead of time schedule would be too disrupted around?",40,"And then one last one. North American Oncology orders last quarter up 15%. They were up only 3% this quarter. Were there some pull-forward dynamic CMS to kind of come out ahead of time schedule would be too disrupted around?"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","There's always some lumpiness quarter to quarter. I would say in the second half that CMS had very little to do with it. It's just timing of some of the orders.",32,"There's always some lumpiness quarter to quarter. I would say in the second half that CMS had very little to do with it. It's just timing of some of the orders."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Vijay Kumar from Evercore ISI.",12,"Our next question today is coming from Vijay Kumar from Evercore ISI."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So Elisha, maybe I'll start one with a question for you. Just sort of on the timing here. Just on the decision to step aside, so if you could just walk us through some of the timing I think that would be helpful context dropping heading into the spin.",49,"So Elisha, maybe I'll start one with a question for you. Just sort of on the timing here. Just on the decision to step aside, so if you could just walk us through some of the timing I think that would be helpful context dropping heading into the spin."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. Well, I started my CFO career with a spin. I figured why not end it with a spin. So back in 1999 and as Dow said about 71 quarters, it just feels like the right timing, Vijay. In terms of the exact timing, that's to be determined. I'm completely ded",115,"Sure. Well, I started my CFO career with a spin. I figured why not end it with a spin. So back in 1999 and as Dow said about 71 quarters, it just feels like the right timing, Vijay. In terms of the exact timing, that's to be determined. I'm completely dedicated to getting us through the spend of the Imaging Components business, getting -- we can now go out and conduct a search and want to find a world-class finance leader who can come into this great organization and have time to transition. And so it will be at some point in this fiscal year, but the exact date is not determined at this point."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Got you. And maybe just a couple of quick ones on the, I guess, the guidance question. So did I hear you correctly when you said that the EPS was a high singles off of the current year base? And then just what -- does that number include the $20 million d",76,"Got you. And maybe just a couple of quick ones on the, I guess, the guidance question. So did I hear you correctly when you said that the EPS was a high singles off of the current year base? And then just what -- does that number include the $20 million dis-synergies and do you have the accounting rule change sort of baked in? Just can you walk us through some of the moving parts there?"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, so we did -- that was a hypothetical number that said if we weren't spinning, we believe EPS would grow on a consolidated basis in the high single digits. The $20 million of dis-synergies, I have to say we are well under way of looking for cost-reduc",159,"Yes, so we did -- that was a hypothetical number that said if we weren't spinning, we believe EPS would grow on a consolidated basis in the high single digits. The $20 million of dis-synergies, I have to say we are well under way of looking for cost-reduction opportunities, and we are absolutely committed to having $10 million of that out at a run rate by the end of fiscal year '17 and the additional $10 million out by FY '18. So lots of work already going on, on that. I will tell you that most of those dis-synergies for Varian are offset because we will have a lower tax rate because Varex has a 35%, 36% tax rate. And so unfortunately, for my colleague Clarence here, his tax rate is going up versus the Varian average. But Varian's tax rate will come down a point or 2. And that largely offsets that dis-synergies in year 1 and 2."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","That was helpful. And maybe just a quick one on Q1. I mean, when I look at the guidance commentary at the midpoint EPS. It looks like maybe margins would be somewhere in 17.5, maybe a few basis points above 17.5. So that's a step down just from the Q4 lev",76,"That was helpful. And maybe just a quick one on Q1. I mean, when I look at the guidance commentary at the midpoint EPS. It looks like maybe margins would be somewhere in 17.5, maybe a few basis points above 17.5. So that's a step down just from the Q4 levels. In commentary on, which is gross margins for Oncology, can you just walk us through why the margins would step down from Q4 to Q1?"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Well, yes, you always every year or when you go back to see seasonality. I mean, Q4 is always our largest quarter with the highest operating margin typically. So it's not uncommon for the operating margin to step down from Q4 to Q1. When you run your",154,"Yes. Well, yes, you always every year or when you go back to see seasonality. I mean, Q4 is always our largest quarter with the highest operating margin typically. So it's not uncommon for the operating margin to step down from Q4 to Q1. When you run your model through, I mean, what I am showing at the midpoint is it that we will increase our operating margin by about a point to 18% on a non-GAAP basis. Again, Oncology's gross margin will be between 44%, 45%. Imaging Components in the low 40s, so it looks closer to an 18% operating margin. And again, Vijay, that does include -- I want to make sure everyone understands it includes some duplicative costs in Varex as we're hiring people to gear up for the spin. We cannot take those costs out to be non-GAAP, and it's between $0.01 and $0.02 in Q1 for those duplicative costs."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Anthony Petrone from Jefferies.",11,"Our next question today is coming from Anthony Petrone from Jefferies."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And congratulations, Elisha. It was great working over the years, and good luck on the next phase.",17,"And congratulations, Elisha. It was great working over the years, and good luck on the next phase."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you.",2,"Thank you."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Couple of questions, just I guess higher level. maybe exiting fiscal '16 here would be helpful to get an update on the percentage of the installed base, the linac installed base that really is TrueBeam and VitalBeam and really what I'm getting at is what",117,"Couple of questions, just I guess higher level. maybe exiting fiscal '16 here would be helpful to get an update on the percentage of the installed base, the linac installed base that really is TrueBeam and VitalBeam and really what I'm getting at is what percentage of the installed base has stereotactic capabilities? And what percent does not? And it's really in relation to sort of presentation at ASTRO, the opportunity for SRS SBRT going forward over the next 10 to 15 years. I'm just trying to get a sense of what percentage of the base can migrate to having stereotactic capabilities in the next few years? And then I have a follow-up on software and margins."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That's a good question. I'd say from a very high level, we've got about 1,500 TrueBeams in the installed base of call it 7,500 machines. Now when you look at some of the capabilities, the interesting thing when you talk about HyperArc, it's HyperArc's ava",340,"That's a good question. I'd say from a very high level, we've got about 1,500 TrueBeams in the installed base of call it 7,500 machines. Now when you look at some of the capabilities, the interesting thing when you talk about HyperArc, it's HyperArc's available on every one of those TrueBeams. So this is kind of our first real -- we've had some other smaller upgrades to that we've offered on TrueBeam, like some imaging improvements and some other things over the last few years. But the HyperArc for some of the stereotactic radiosurgery applications that Dr. talked about at ASTRO will be available on the EDGE and TrueBeam only. So very excited about that. I think that the probably drive some of the other installed base to trade out to TrueBeam as well. So very encouraged about that. We're, I'd say, when you look at the past quarter, Americas was almost virtually 100% TrueBeam, VitalBeam, might have been 1 or 2 that weren't, but pretty much everything in the Americas -- North America for sure was TrueBeam VitalBeam. In rest of the -- and I'd say of those in terms of the capabilities that they had in the fourth quarter, maybe half-ish had SRS SBRT capability. When you look at the installed base, big opportunity there. Most of them do not have that capability. And so I think this bodes well for us next year in 2 ways. One, it's an upgrade opportunity; and two, it's going to help us on pricing on TrueBeam. It's going to -- we're going to be able to maintain or grow price on TrueBeam, and I think that's a little bit of the -- we're doing very well on the cost side. We're just margin rate improvement coming from. We're doing very well on the cost side, the operational team's done a fabulous job getting cost down on TrueBeam. But then as well, we're seeing a really nice mix of these advanced capabilities giving us some price support on the pricing side."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And just a quick follow-up on that, Dow, how do you see that transitioning just when you think of the 2019 reimbursement changes in Oncology he may go bundled. I mean, and then more focused on efficiencies and outcomes. I mean, does it accelerate the dema",69,"And just a quick follow-up on that, Dow, how do you see that transitioning just when you think of the 2019 reimbursement changes in Oncology he may go bundled. I mean, and then more focused on efficiencies and outcomes. I mean, does it accelerate the demand for stereotactic within the installed base? Or do you think this sort of plays out pretty ratably over 12 to 15 years?"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, I think, if anything, it'll be a little faster because some of the reimbursement pressure. Having said that, clinicians are going to want to make sure there's a really responsible clinical comparison done. So our customers are sensitive about that",191,"I mean, I think, if anything, it'll be a little faster because some of the reimbursement pressure. Having said that, clinicians are going to want to make sure there's a really responsible clinical comparison done. So our customers are sensitive about that. I think one of the exciting things to us is in some applications, hypofractionation -- the hypofractionation trend is going to bring more patients back to us. So for example, in prostate cancer, over the last half dozen years, we've lost little bit of shared robotic surgery. But I think now I still start to go hypofractionation, we get a lot of those patients back. The results are as good or better than surgery, and that's well documented. And then as well, I think the other big opportunity from a clinical growth perspective here is metastatic disease, this capability really enables a very precise dose deposition. And we think that there are, in the U.S. alone, 300,000 patients that we could have opportunity to go after with this capability and bring some new folks into the radiation therapy paradigm. So we're excited about the capability that this opens up."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then just quickly on software margins. May be just another high level. Where do we sit exiting fiscal '16 when you look at software/services as a percent of the total for the RemainCo? And do you see a point where there is a higher mix of software, sa",74,"And then just quickly on software margins. May be just another high level. Where do we sit exiting fiscal '16 when you look at software/services as a percent of the total for the RemainCo? And do you see a point where there is a higher mix of software, say over the next 3 to 5 years? And if we do have that scenario, what do you think overall margins look like under that scenario?"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me just say for year-to-date, '16 service was just low 40s. So it was about 42% of the total revenue for Oncology. So call it 60-40. And clearly, as both service and software grow faster than the hardware, it does have an upward bias in gross margin.",70,"Let me just say for year-to-date, '16 service was just low 40s. So it was about 42% of the total revenue for Oncology. So call it 60-40. And clearly, as both service and software grow faster than the hardware, it does have an upward bias in gross margin. In fact, that has been helping us in the last couple of quarters. Software is roughly 10% of total Oncology revenue."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Brandon Henry with RBC Capital Markets.",13,"Our next question today is coming from Brandon Henry with RBC Capital Markets."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","First of all, can you just discuss how software and services performed in the quarter? Did these businesses continue growing combined kind of high single digits? And were there any change in growth rates this quarter versus last quarter?",39,"First of all, can you just discuss how software and services performed in the quarter? Did these businesses continue growing combined kind of high single digits? And were there any change in growth rates this quarter versus last quarter?"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Our revenues in service were up 7%. Revenues in software were...",12,"Our revenues in service were up 7%. Revenues in software were..."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Probably about the same.",4,"Probably about the same."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Around the same. I think the -- as we look forward in the service funnel, I'd say it looks very good. We had a little bit of currency last year. We had a little bit of timing. I think on the year, we'd like to see that number be a little bit north of 7%,",252,"Around the same. I think the -- as we look forward in the service funnel, I'd say it looks very good. We had a little bit of currency last year. We had a little bit of timing. I think on the year, we'd like to see that number be a little bit north of 7%, and that's kind of what we're stretching the team for. But service business continues to be solid growth for us. Software, we had very good year in treatment planning. We talked about that in the script with all the RapidPlan orders. I think this next year, with the improvements that we have in our InSightive Analytics and with our 360 Oncology product, that can be very exciting. We're curious little bit to see how that goes because the 360 Oncology is going to be cloud-based, so the financial impact is going to be a little more back-end loaded as we accumulate sites due to billing and click the orders on that basis. I think it's going to be a little -- it is a little bit of a transition as we go kind of from a annual license model to a software-as-a-service model. So having said that, one of the really cool things about the 360 Oncology product is it can play not just in ARIA Varian sites, it can play in every radiation oncology site in the world. And just really a great opportunity for us to get some penetration insights that we don't have today."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then separately, can you talk about your expectation for free cash flow for fiscal year '17 versus fiscal year '16? And how should we think about the balance of M&A versus share repurchases in the near term? And then what size of deals and debt",55,"Okay. And then separately, can you talk about your expectation for free cash flow for fiscal year '17 versus fiscal year '16? And how should we think about the balance of M&A versus share repurchases in the near term? And then what size of deals and debt levels do you feel comfortable company going forward?"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So I'll answer the first part of that question, Branden. As it came up earlier on the call, our cash flow from operations was down year-over-year. We ended both Q3 and Q4 on a strong note, but we were kind of in a hole in the first half of the fiscal year",170,"So I'll answer the first part of that question, Branden. As it came up earlier on the call, our cash flow from operations was down year-over-year. We ended both Q3 and Q4 on a strong note, but we were kind of in a hole in the first half of the fiscal year on collections they are for a couple of reasons moved to collection staff. We had IT implementation, et cetera. So we're very focused on cash flow, particularly AR as we move into FY '17. And on a consolidated basis, our expectation would be that we could get back to around the $400 million level and cash flow from operations. CapEx has always been relatively stable. And then in terms of share repurchase versus M&A, I think we would always love to prioritize M&A if the right targets come along. And that's the duty of our share repurchase program. We can turn it on and off and at various levels, depending on what activity and M&A that's there."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","And just as a comment, it's going to be strategically driven. How can we strengthen our Oncology franchise. I don't see us going on the EDGE and doing something, for example, may be in chemotherapy, to pick one. But other image guidance technologies? Are",70,"And just as a comment, it's going to be strategically driven. How can we strengthen our Oncology franchise. I don't see us going on the EDGE and doing something, for example, may be in chemotherapy, to pick one. But other image guidance technologies? Are there radiation technologies? Are their software technologies that can reinforce our core and give us some higher-growth segments to participate in, that's what we look at."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question's coming from Anthony Petrone from Jefferies.",10,"Our next question's coming from Anthony Petrone from Jefferies."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Just a quick housekeeping one. Just kind of going through some on the Candela acquisition in Poland. Maybe what's baked in there for fiscal '17. And if any of that hit in the fiscal fourth quarter as well.",38,"Just a quick housekeeping one. Just kind of going through some on the Candela acquisition in Poland. Maybe what's baked in there for fiscal '17. And if any of that hit in the fiscal fourth quarter as well."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","In terms of revenue?",4,"In terms of revenue?"
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes, revenue contribution in the quarter and then...",8,"Yes, revenue contribution in the quarter and then..."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","It would just be service revenue, so about $1 million or so. It was small.",15,"It would just be service revenue, so about $1 million or so. It was small."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","In 4Q. And I guess, can we just annualized that in '17 to get the contribution or...",17,"In 4Q. And I guess, can we just annualized that in '17 to get the contribution or..."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, you can -- it's somewhere between an annualized $14 million to $16 million market for us. And it's a growing market, so we feel very good about Poland over the next several years. And one of the reasons that the timing was right to make the acquisiti",51,"Yes, you can -- it's somewhere between an annualized $14 million to $16 million market for us. And it's a growing market, so we feel very good about Poland over the next several years. And one of the reasons that the timing was right to make the acquisition and go direct."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","We reached the end of our question-and-answer session. I'd like to turn the floor back over to management for any further closing comments.",24,"We reached the end of our question-and-answer session. I'd like to turn the floor back over to management for any further closing comments."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Thank you for participating. The replay of the call can be heard on Varian's investor site at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or (201)",70,"Thank you. Thank you for participating. The replay of the call can be heard on Varian's investor site at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or (201) 612-7415 from outside the U.S., and entering confirmation code 13647671. A telephone replay will be available through 5 p.m. this Friday, October 28. Thanks very much."
311907,404405398,1062230,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. That does conclude today's teleconference. You may disconnect your lines at this time., and have a wonderful day. We thank you for your participation today.",27,"Thank you. That does conclude today's teleconference. You may disconnect your lines at this time., and have a wonderful day. We thank you for your participation today."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems Fourth Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.It is now my pleasure to introduce your host, Spencer Sias, Vice Presiden",42,"Greetings, and welcome to the Varian Medical Systems Fourth Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Spencer Sias, Vice President. Please go ahead, sir."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Good afternoon, and welcome to Varian Medical Systems' conference call for the fourth quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha wil",271,"Thank you. Good afternoon, and welcome to Varian Medical Systems' conference call for the fourth quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. 
To simplify our discussion, unless otherwise stated, all references to the quarter or year or fiscal quarters or fiscal years, quarterly comparisons are for the fourth quarter of fiscal 2016 versus the fourth quarter of fiscal 2015. References to financial results for orders are to gross orders unless otherwise indicated. 
The company is reporting non-GAAP results in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. A reconciliation to the most comparable GAAP measure is included in our earnings release, which can be accessed on our website. 
Please be advised that this presentation and discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, should, will, promising and similar expressions are intended to identify those statements which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks related to our business are described in our fourth quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise. 
And now here's Dow."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Our company finished fiscal year 2016 on a positive note, with healthy fourth quarter growth in revenues and significant margin improvement in both our Oncology and Imaging Components businesses. Orders in the Oncology and pro",1519,"Good afternoon, and welcome. Our company finished fiscal year 2016 on a positive note, with healthy fourth quarter growth in revenues and significant margin improvement in both our Oncology and Imaging Components businesses. Orders in the Oncology and proton businesses, on the other hand, were down during the quarter versus tough year-ago comparisons in which we had record-setting Oncology growth in Western Europe and in our proton business. 
To summarize, our fourth quarter results for fiscal 2016 we are reporting GAAP net earnings of $1.24 per diluted share, up from $0.99 in the year-ago quarter; non-GAAP net earnings of $1.38 per diluted share, up more than 30% from $1.04 in year-ago quarter; a decline in Oncology orders due to weakness in Western Europe; revenues of $912 million, up 12% in dollars and up 11% in constant currency; and gains of about 4 percentage points in our gross margin, with significant improvements in both our major businesses. 
Focusing on Oncology operations. Orders totaled $897 million for the fourth quarter, down 2% in dollars and down 4% in constant currency versus a strong year-ago quarter. Orders for the year totaled $2.7 billion, up 1% from the prior year and up 2% in constant currency. 
Fourth quarter orders in the Americas grew by 4% in dollars, an increase by 3% in constant currency for the year. Orders in the Americas were up 4% in both dollars and constant currency. 
In North America, orders fell by 2% in the fourth quarter but grew by 5% for the year, ahead of our expectations for this market. 
Fourth quarter Oncology orders in APAC rose by 8% in dollars and fell by 1% in constant currency. For the full year, APAC orders rose by 5% in dollars and by 3% in constant currency. 
In EMEA, Oncology orders declined by 17% in dollars and in constant currency, principally because of weakness in Western Europe, where we had exceptionally strong growth in the year-ago quarter when we set a record by booking orders for more than 100 accelerators. 
For the year, orders in EMEA were down 6% in dollars and down 4% in constant currency, driven by weakness in Western Europe. 
Comparing revenues on a trailing 12-month basis, we believe we gained market share versus our primary competition. Our average selling price rose with the help of a higher mix of TrueBeam and VitalBeam orders. We generated solid order growth during the quarter in emerging markets, including Brazil, Africa and in the Middle East. 
In Brazil, we booked nearly $30 million of new business, including a big win at Grupo Oncoclnicas, where we will be installing 13 TrueBeam and VitalBeam accelerators as well as software to support clinical operations. These will be the first VitalBeam accelerators installed in Latin America. 
Colombia was also a strong contributor to robust order growth in the quarter. Total orders in Latin America exceeded $60 million during the quarter, up more than 70% from the prior year period. 
Other emerging markets contributing to Oncology orders during the quarter included Africa, with about $20 million; and the Middle East, where we booked more than $40 million. As an example of progress, we received a $14 million order for 8 accelerators at the Shifa International Hospital in Islamabad. 
In APAC emerging markets, we generated healthy order growth in Indonesia, Korea and the Philippines. Developed markets, particularly Japan, also contributed to the order growth in this region. Meanwhile, orders in Greater China were down from the year-ago period in part because of continuing tender protest. While we are anniversary-ing the effects of these multiple orders, and while we are retaining the book of the business that we've won, we estimate that orders in China in the fiscal year could have been more than $15 million higher without this protest activity. 
Turning to North America. We established a significant new 3-year strategic agreement with McKesson Specialty Health to supply its U.S. oncology and vantage cancer treatment networks with equipment, software and services. In the first phase, we will be equipping centers with 7 TrueBeam and 5 VitalBeam accelerators. We also will be working to establish interoperability with Varian's information management and McKesson's iKnowMed G2 clinical oncology software. We see an opportunity here to support these networks with more of our Eclipse, ARIA, Velocity and new 360 Oncology software. 
Overall, we had a very good year in North America, where we had in excess of $130 million in takeouts of more than 40 accelerators and nearly 100 software installations from competitors. 
As you know, we've just returned from ASTRO in Boston. It was a great show for us, with some 900 attendees at our users meeting, numerous customers from emerging markets and very positive response to several major new products that we'll be bringing to market this year. 
We introduced 360 Oncology, a first-of-its-kind software tool that enables clinicians on tumor boards to more effectively coordinate patient care among the numerous specialists involved in cancer treatment. This software also provides patients with a clearer picture of how the many elements involving -- involved in treating their cancer fit together. Customer response is enthusiastic, and we believe we have a winning product on our hands. 
We also showed our progress in the development of our HyperArc technology for automating and simplifying the delivery of stereotactic radiosurgery, with more compact dose distribution and better protection of surrounding healthy tissue. We're aiming to introduce this important upgrade to our TrueBeam and EDGE platforms this year, beginning with a module for treating head and neck cancers. 
Oncology administrators are also very interested in our initiative, in which we will be enhancing the security embedded within Varian software systems. We believe we have a leading position in the development of this important new capability, and we expect it could generate an additional $80 million in revenues by the end of fiscal year 2018. 
We have continued to see a very positive market response to our RapidPlan and InSightive Analytics software products that help to improve the speed, quality and cost efficiency of treatments. We've taken more than 650 orders for RapidPlan since its launch and more than 135 orders for our InSightive software. 
Touching on the service business. Global revenues rose by 7% during the quarter, with gains in all geographies. 
Turning now to our Particle Therapy business. We generated $38 million in orders during the fourth quarter, bringing total orders for the year to $104 million. Orders were down significantly from fiscal 2015 when we had a total of 6 system orders, including an $87 million order for our ProBeam system at the University of Maryland. 
Revenues from 14 ongoing projects grew nicely, reaching $68 million in the fourth quarter and bringing total revenues for the year to $163 million, including about $10 million in annual service revenues. 
During the fourth quarter, we booked our first single-room ProBeam Compact order, marking an important milestone for the business. This new system will be installed at the Advanced Medicine Training Centre in Singapore, where Varian will also provide its Eclipse treatment planning system. We also have a 10-year agreement to service this system. 
Also during the quarter, the U.K.'s University College London Hospital placed an order for a fourth treatment gantry at the proton therapy center that is currently under construction. 
Earlier this month, treatments commenced using our ProBeam system at Cincinnati Children's Hospital, making it the fifth Varian-equipped proton center to treat clinically. At this point, the proton sales funnel looks healthy, and I'm pleased by the progress we are making. 
  
Let me turn now to Imaging Components. Recovery in this business continued in the fourth quarter. Orders grew by 2% to $168 million in the fourth quarter, resulting in 7% orders growth for the last 6 months. Orders for the year totaled $571 million, down 6% from the prior year because of first half headwinds, including significant purchasing slowdowns at 2 major customers. Revenues were up 7% for the fourth quarter and down 2% for the year. 
Our MeVis and Claymount acquisitions as well as successful efforts to develop business with new customers contributed to Imaging Components' order and revenue growth during the quarter. Great cost control as well as a favorable product mix in tubes and flat panel imaging detectors and higher volumes in our security and inspection line enabled the Imaging business to achieve the significant gain in its gross margin for the quarter. 
Looking at operational highlights for the whole year. The Imaging Components business introduced 20 new products, completed 140,000 square foot expansion of its manufacturing facility in Salt Lake City, opened a new facility in China to service growing customer base there, successfully integrated and mobilized its MeVis and Claymount acquisitions, added 12 new customers to offset slower purchasing from established customers and exceeded its profit targets. We're proud of this performance, and we expect Imaging Components to be a great company that delivers solid returns when it separates from Varian and has established as Varex Imaging, an independent publicly traded company. Work on the separation continues to go smoothly. 
Now I'll turn it over to Elisha."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog. We ended the quarter at $3.5 billion, down 1% from the year-ago period, with a gain in Oncology offset by declines in our Particle Therapy and Imaging Co",832,"Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog. We ended the quarter at $3.5 billion, down 1% from the year-ago period, with a gain in Oncology offset by declines in our Particle Therapy and Imaging Components backlogs. Backlog adjustments during the quarter totaled $47 million, bringing net orders for the company to $1.1 million. 
Fourth quarter revenues for the total company were $912 million, up 12% in dollars and up 11% in constant currency. For the year, total company revenues were $3.2 billion, up 4% in dollars and up 5% in constant currency. 
Oncology posted a fourth quarter revenue gain, up 7% in dollars and 6% in constant currency. For the year, Oncology revenues increased 5% in dollars and 6% in constant currency. 
Imaging Components posted a fourth quarter revenue gain of 7%, driven by our recently acquired X-ray accessories businesses as well as security and inspection products. Including the challenges in the first half, Imaging Components revenues declined 2% for the full year. 
Our Particle Therapy business posted fourth quarter revenues of $68 million, bringing total revenues for the year to $163 million, a 13% increase from the prior year. 
The total company gross margin for the quarter was 42.7%, up by nearly 4 points, with significant contributions from both Oncology and Imaging Components. 
Oncology Systems fourth quarter gross margin improved by about 5 points to 45.3%, with the help of favorable product and geographic mix shifts as well as product cost reductions. For the year, Oncology Systems gross margin improved by almost 2 points to 44.5%. 
Imaging Components fourth quarter gross margin rose by about 3 points to 42.1% due largely to favorable product mix, high volumes in tube and security products and lower warranty cost. For the year, Imaging Components gross margin improved by about 1 point to 41.9%. 
R&D expenses were $66 million or 7% of revenue, down 1 point as a percentage of revenue from the year-ago quarter. For the year, R&D expenses were $254 million or equal with the prior year as a percentage of revenue at 8%.
On a GAAP basis, fourth quarter SG&A expenses were $152 million or 17% of revenue. On a non-GAAP basis, fourth quarter SG&A expenses were $134 million or 15% of revenue. 
The $19 million in non-GAAP adjustments, primarily related to the planned separation of the Imaging Components business, ongoing patent litigation and amortization of intangibles. 
Operating earnings for the quarter were 18.6% of revenues on a GAAP basis and 20.7% of revenues on a non-GAAP basis, reflecting our solid gross margin performance in the quarter. 
For the year, our operating earnings were 17.1% of revenues on a GAAP basis and up 50 basis points from the prior year to 19.1% of revenues on a non-GAAP basis. 
Depreciation and amortization totaled $24 million for the fourth quarter and $80 million for the year. The fourth quarter effective tax rate is 31.1%, up from the year-ago quarter due to an unfavorable geographic mix of profits. For the year, the effective tax rate was 27.6%. 
Fully diluted shares outstanding for the fourth quarter were 94.5 million, down almost 5 million shares from the year-ago period due to our ongoing share repurchase program. Fourth quarter diluted EPS was $1.24 for the quarter on a GAAP basis and $1.38 on a non-GAAP basis. For the year, diluted EPS was $4.19 on a GAAP basis. On a non-GAAP basis, diluted EPS rose 9% to $4.68. 
 
Turning to the balance sheet. We ended the quarter with cash and cash equivalents of $844 million, debt of $667 million and stockholders' equity of $1.7 billion. 
DSO at 93 days was up from the year-ago quarter, but improved sequentially from the third quarter. 
Fourth quarter cash flow from operations was $152 million, bringing the total cash flow from operations for the year to $356 million. Primary uses of cash were $87 million for the repurchase of about 1 million shares of stock, $43 million to reduce debt and $20 million for capital expenditures. At the end of the quarter, we had 3.8 million shares remaining under the existing repurchase authorization. 
Before I turn it over to Dow, as you may have seen in the release issued before this call, I intend to retire from Varian in fiscal year 2017. I will remain in my current role as CFO until a replacement is found and a smooth transition has been completed. I will also continue leading the separation of our Imaging Components business. We have a tremendous finance team that will perform to this transition to a new CFO without missing a beat. It has been an honor to serve all of Varian's investors and analysts over the past 17.5 years, and it's been a privilege to be part of a tremendous growth story that has seen Varian become a global power in the fight against cancer. 
Thank you for being part of the story with me. And now here's Dow."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. For our company and for our investors, Elisha has been an intelligent, trusted and energetic leader that all of us count on to help deliver winning results. We're just counting it up. We think it's 71 quarters. So bravo, Elisha. With her h",204,"Thanks, Elisha. For our company and for our investors, Elisha has been an intelligent, trusted and energetic leader that all of us count on to help deliver winning results. We're just counting it up. We think it's 71 quarters. So bravo, Elisha. With her help and guidance, we've achieved this sustained decades-long record of growth in revenues and profitability. I've been fortunate to have Elisha on our management team. I'm confident that we'll make a smooth transition. 
Turning now to guidance. We believe that for the first quarter of fiscal year 2017, non-GAAP earnings for the total company, including the Imaging Components business and ramp-up costs for its separation, will be in the range of $1.03 to $1.07 per diluted share, and revenues will increase by about 1% to 2%. 
As we announced earlier, we will not give earnings guidance for the full fiscal year until after we have completed the separation of the Imaging Components business. 
For the full fiscal year 2017, we expect that Varian revenues, excluding the Imaging Components business, will rise by 3% to 4%. We expect that Imaging Components revenues for the full fiscal year 2017 will also rise by 3% to 4%. 
We're now ready for your questions."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] Our first question today is coming from Jeff Johnson from Robert W. Baird.",15,"[Operator Instructions] Our first question today is coming from Jeff Johnson from Robert W. Baird."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Elisha, I'm not going to touch the 71 quarter comment. I'll just leave that one alone, I guess. But it's been great working for you -- or working with you. I say that every time. It's been great working with you for the last 7 or 8 years that I've covered",62,"Elisha, I'm not going to touch the 71 quarter comment. I'll just leave that one alone, I guess. But it's been great working for you -- or working with you. I say that every time. It's been great working with you for the last 7 or 8 years that I've covered the stock, and I wish you the best in the future."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you, Jeff.",3,"Thank you, Jeff."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So 2 questions here. One, I guess, just on cash flow. So cash flow was down, I think, on the year, down about 25%. It looks like it's kind of the lowest level we've seen since fiscal 2009, in fact, as I was going back. And if I add back some of the non-GA",114,"So 2 questions here. One, I guess, just on cash flow. So cash flow was down, I think, on the year, down about 25%. It looks like it's kind of the lowest level we've seen since fiscal 2009, in fact, as I was going back. And if I add back some of the non-GAAP cash charges, even if I add those back, it's still down below $400 million. And it looks like receivables were up, I think about $120 million year-on-year, and even $50 million up sequentially. So just trying to figure out if it's a receivables issue, what's going on there? Or what's going on basically with your cash flow at this point?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. So Jeff, the Oncology AR increased about 8%, and that compares to their year-to-date sales up 5%. And as we've been talking all through this fiscal year, early in the year, we moved our collections staff. We had a sales force IT implementation. And",198,"Sure. So Jeff, the Oncology AR increased about 8%, and that compares to their year-to-date sales up 5%. And as we've been talking all through this fiscal year, early in the year, we moved our collections staff. We had a sales force IT implementation. And I think that slowed down collections in the first half, and we are continuing to feel that effect. Although we're making good progress, collections in Q3 and Q4 were very strong, but as we move into FY '17, absolutely, AR collections is going to be a big focus for the entire team. Little bit of it has to do with more extended terms. In a 0 interest-rate environment, we can continue to win high-margin business by offering terms. And then some of it also, both inventory and AR, up in the proton business as we continue to grow that business. And with percentage of completion accounting, it gets a little funky in proton because a lot of times we're taking revenue and creating an AR under the percentage of completion long before the builds are actually due by the customer. But it will be a big focus as we move into this year."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And I know you don't guide -- you guided to cash flow, but I mean, on a consolidated basis, can we expect to get back above $400 million? We're almost touching $500 million a couple of years ago, and it seems like $350 million. Can we at least get b",63,"Okay. And I know you don't guide -- you guided to cash flow, but I mean, on a consolidated basis, can we expect to get back above $400 million? We're almost touching $500 million a couple of years ago, and it seems like $350 million. Can we at least get back above $400 million, do you think, over the next year or 2?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, that is absolutely my goal this year. And also, contract advances were down in the proton business as orders being lower. That drove about, I think, $40 million of it. So -- but yes, our goal is we would get back on a consolidated basis to the $400 m",51,"Yes, that is absolutely my goal this year. And also, contract advances were down in the proton business as orders being lower. That drove about, I think, $40 million of it. So -- but yes, our goal is we would get back on a consolidated basis to the $400 million level."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes. All right. And Dow, from a guidance standpoint, I think we all knew you weren't going to issue full year guidance from an EPS perspective, and we understand the reasons why. But if I look at first quarter guidance from an EPS perspective, you're guid",127,"Yes. All right. And Dow, from a guidance standpoint, I think we all knew you weren't going to issue full year guidance from an EPS perspective, and we understand the reasons why. But if I look at first quarter guidance from an EPS perspective, you're guiding to about 5% to 6% EPS growth on a year-over-year basis. Is it fair to think about that on kind of a core basis over the following few quarters? Obviously, we have to take into account that extra $20 million of revenue dis-synergies that will start to hit the back 3 quarters. But outside of that issue, is kind of your first quarter guidance a reasonable way to think about kind of the core outlook for the rest of the year?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me talk to the market side of it, and I'll let Elisha talk to the nuts and bolts on the guidance side. I think from a market perspective, we had a big comp in Europe here in the fourth quarter. But fundamentally, we had a very sound year in the U.S. W",189,"Let me talk to the market side of it, and I'll let Elisha talk to the nuts and bolts on the guidance side. I think from a market perspective, we had a big comp in Europe here in the fourth quarter. But fundamentally, we had a very sound year in the U.S. We see that continuing next year. Our funnel remains very good in the U.S. In Asia, China was a little bit off due to some of the structural issues we've seen there. But we think that, that market remains robust and should kind of bounce back to double-digit levels. And then the question for us all this year has been kind of Western Europe and where's it going to land. We've talked about that on this call, about it being soft all this year. As we closed the year, I'd say we feel pretty good about Europe for next year. So just kind of rounding out the market and top line side of it, I think we feel pretty good about where the market's going to be globally next year with -- especially Western Europe bouncing back."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. so for -- specifically for Q1 of FY '17, Jeff, that 1% to 2% on the revenue side, Varian Oncology and proton is going to be flattish on revenue, but that's really because in the year-ago Q1, we had something like 9% constant currency revenue growth.",221,"Yes. so for -- specifically for Q1 of FY '17, Jeff, that 1% to 2% on the revenue side, Varian Oncology and proton is going to be flattish on revenue, but that's really because in the year-ago Q1, we had something like 9% constant currency revenue growth. And then when we look at Q2, it was actually down 1%. So this is just a matter of timing, and I think the revenue will be split more evenly between Q1 and Q2. So again, 3% to 4% for the full year for Oncology. Q1 for Varex, the Imaging Components business, should be up in the, call it, low double-digit range. And that's versus a very easy year-ago comp as their recovery continues. On EPS, we're -- if you look at our range, it would be 4% to 8% EPS growth versus the year-ago quarter. But I need to stress, that also includes $0.01 to $0.02 of costs that we're building in the Imaging Components business today to prepare them for the spin. So for an example, they've hired a CIO. They've hired a manager of tax. As they're building out their corporate function, those costs are duplicated in this quarter. And so really, you need to tack on an additional $0.01 to $0.02 to account for that to get to an apples-to-apples."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And I guess I'll just repeat the last part of my question, which was, can I -- is it fair to think of that 4% to 8% EPS growth as kind of a core range we could think of for the rest of the year before we then tack on that $20 million of dis-synergie",56,"Okay. And I guess I'll just repeat the last part of my question, which was, can I -- is it fair to think of that 4% to 8% EPS growth as kind of a core range we could think of for the rest of the year before we then tack on that $20 million of dis-synergies?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Okay. So let me answer it this way, and this is a completely non-relevant number, but I'll give it to you anyway because we are going forward with the spin. But if we weren't spinning, I believe fiscal year '17, on a consolidated basis, we could grow EPS",53,"Okay. So let me answer it this way, and this is a completely non-relevant number, but I'll give it to you anyway because we are going forward with the spin. But if we weren't spinning, I believe fiscal year '17, on a consolidated basis, we could grow EPS in the high single-digit range."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Amit Hazan from Citi.",11,"Our next question today is coming from Amit Hazan from Citi."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Let me just add, Elisha, it's been a great run and we'll definitely miss you.",15,"Let me just add, Elisha, it's been a great run and we'll definitely miss you."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you, Amit.",3,"Thank you, Amit."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Let me start with the guidance on the top line and that you guys talked about. So the 3% to 4% top line growth, I just want to make sure we understand it that the reported number are constant currency number, first. And then either way, really, if I kind",105,"Let me start with the guidance on the top line and that you guys talked about. So the 3% to 4% top line growth, I just want to make sure we understand it that the reported number are constant currency number, first. And then either way, really, if I kind look at orders for Oncology, they've been obviously now pretty much flat for the last couple of years on a reported basis. Backlog is kind of flattish. So maybe just help us, Elisha, to kind of get to that 3% to 4% growth range versus the order and the backlog growth rates we've been seeing."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, well that's assuming at today's exchange rates, which fortunately have stabilized over the last several quarters. The euro has stabilized. The yen is obviously helping us. If the yen weakens significantly, that could be an impact. But if I look at wh",86,"Yes, well that's assuming at today's exchange rates, which fortunately have stabilized over the last several quarters. The euro has stabilized. The yen is obviously helping us. If the yen weakens significantly, that could be an impact. But if I look at where currency rates are today, that 3% to 4% for Oncology and proton combined feels about right. That does compare to an Oncology backlog that's up 3% at the end of the fiscal year '16. So that looks pretty achievable going into FY '17."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And let me just follow up on the order side on Europe. I mean, if I look at EMEA for the year, down 4%, you talked about -- I think there's obviously some tough comps in there. But are you actually seeing some issues that have been persistent in Eur",99,"Okay. And let me just follow up on the order side on Europe. I mean, if I look at EMEA for the year, down 4%, you talked about -- I think there's obviously some tough comps in there. But are you actually seeing some issues that have been persistent in Europe that you would call out that you don't have great visibility to them ending other than easy comps? Or maybe just a little more color on what's going on Europe and if the issues that you've seen have been or continue to be persistent and what those are?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. Through the course of 2016, Amit, I think we had weakness especially in U.K., France and Germany. And as I mentioned in my response to Jeff's question, we're seeing our funnels in those markets and the rest of Western Europe and the rest of our Euro",119,"Sure. Through the course of 2016, Amit, I think we had weakness especially in U.K., France and Germany. And as I mentioned in my response to Jeff's question, we're seeing our funnels in those markets and the rest of Western Europe and the rest of our European map look pretty good as we look forward. So I think we're a little more encouraged about what we see forward than what we see backwards. So we also see some opportunity in Italy and Spain going forward. So -- and then of course, our map of Europe includes Africa, Middle East, India, and those markets were good to us in Q4, and we see those as continued strength from those markets."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then last one for me. Just on the [indiscernible]. Maybe just give us a sense of when those units would actually be booked as orders, if they haven't been booked already. And then you kind of talked about it as Phase 1. To the extent that you can, may",102,"And then last one for me. Just on the [indiscernible]. Maybe just give us a sense of when those units would actually be booked as orders, if they haven't been booked already. And then you kind of talked about it as Phase 1. To the extent that you can, maybe just talk about there, there's obviously a big organization from a [indiscernible] center perspective. Just the installed base, how much of it is yours? And the extent, the kind of the phase, the potential for maybe a Phase 2 here, how you see this developing beyond these first 14 units or so?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, all that we've booked so far is these first 14 units. So that's just this first phase. We feel very good about our relationship with McKesson U.S. Oncology, Vantage. There's -- what we've booked so far is pretty much the hardware piece of the relatio",138,"Yes, all that we've booked so far is these first 14 units. So that's just this first phase. We feel very good about our relationship with McKesson U.S. Oncology, Vantage. There's -- what we've booked so far is pretty much the hardware piece of the relationship. The contract does include software and service, and that'll be booked, some of it next year and beyond. So we feel very good about where that is headed. I think the -- very much in sync for kind of what the software products have to do in terms of managing the clinic, providing the analytic tools, the MACRA reimbursement tools. It will include some interoperability with the McKesson IknowMed product, which was important for McKesson. And I'm very excited about that whole relationship, but most of it is yet to be booked."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Tycho Peterson from JPMorgan.",11,"Our next question today is coming from Tycho Peterson from JPMorgan."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Apologies. I'm going to ask another guidance question, but if we think about kind of the end markets, Dow, you used to talk about kind of 6% to 8% market growth and then it was kind mid-single digits. You're talking about 3% to 4% market growth -- revenue",92,"Apologies. I'm going to ask another guidance question, but if we think about kind of the end markets, Dow, you used to talk about kind of 6% to 8% market growth and then it was kind mid-single digits. You're talking about 3% to 4% market growth -- revenue growth with some share gains, I guess, embedded in. So can you maybe just talk about what you see as underlying market growth? And in your 3% to 4% revenue guidance, how much of that is software and service versus underlying growth in linac?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","[indiscernible] to the last. I don't know if I can break that out for you at this point from a guidance point of view. But as to the overall markets, I mean, if anything, we might have been a little bit conservative here. I think as we look at our funnels",210,"[indiscernible] to the last. I don't know if I can break that out for you at this point from a guidance point of view. But as to the overall markets, I mean, if anything, we might have been a little bit conservative here. I think as we look at our funnels here at the beginning of the year, I think the market looks pretty good. We had a ton of activity in -- especially in the fourth quarter in Europe last year. And as we look forward, we see pretty good strength. So I'd say it's -- there's some uncertainty around it, of course, but it's probably 3%, 3.5% to 6% market growth scenario. China is going to continue to do well. India is going to do well. We're growing in Africa. We had pretty good year this past year in Brazil, but we see continued strength in the Brazilian market, and that's good news. And then in the U.S. market, it's been, as I mentioned in the script, it was 5% growth on the year. And if anything, that was a little bit ahead of kind of where we thought it would be coming into the year. As we look at 2017, funnels remain very strong in the U.S."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","If I could just add to that, Tycho, in terms of the top line growth for Oncology, the good news is pricing is holding globally, and we have seen significant product cost reductions. We basically obsoleted the C-series and moved everyone onto the TrueBeam",112,"If I could just add to that, Tycho, in terms of the top line growth for Oncology, the good news is pricing is holding globally, and we have seen significant product cost reductions. We basically obsoleted the C-series and moved everyone onto the TrueBeam platform. And I think this -- the margin improvement you've seen in the last couple of quarters in Oncology is sustainable going forward. So we're kind of moving them up to a 44% to 45% gross margin level. And so obviously, even if the top line is off a point or so, we make up a lot of that difference in the margin improvement that we're seeing there."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's good to hear. And then Dow, maybe can you talk on MACRA, the final rule? What are your thoughts on -- as we think about getting implemented, how do we think about that maybe driving more of a bias toward software and some of this?",47,"Okay. That's good to hear. And then Dow, maybe can you talk on MACRA, the final rule? What are your thoughts on -- as we think about getting implemented, how do we think about that maybe driving more of a bias toward software and some of this?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, I think that overall, it's a good opportunity for our product line with our InSightive Analytics tools, our RapidPlan and treatment planning and our 360 Oncology. It's going to create an opportunity for us to provide our customers with the required r",226,"Yes, I think that overall, it's a good opportunity for our product line with our InSightive Analytics tools, our RapidPlan and treatment planning and our 360 Oncology. It's going to create an opportunity for us to provide our customers with the required reports that they're going to need to comply. They've got to demonstrate a certified EHR, electronic health record. They've got to demonstrate improvement in care management and practices, and they've got to report on their quality metrics. So these tools all do that. So I think it's going to be pretty good news for us. The product line is about where we need it to be. They comply. We've got a few things to button down, but we'll be way ahead of the compliance requirements. And we've got just our own installed base. It's about 1,800 units -- sorry, 1,800 sites that got to go. And we're very excited about that. Maybe just on top of that, this isn't MACRA, but the other piece from a market point of view that is at least as important as MACRA is the cybersecurity. And this -- at ASTRO, we launched a very significant upgrade to our software products for cybersecurity. And that product will be ready here in the early spring. And that should drive some upside for us, too. So we're excited about that one."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then one last one. North American Oncology orders last quarter, up 15%. They were up only 3% this quarter. Was there some pull-forward dynamic? Because CMS had kind of come out ahead of time and said the schedule wouldn't be too disrupted [indiscernib",45,"And then one last one. North American Oncology orders last quarter, up 15%. They were up only 3% this quarter. Was there some pull-forward dynamic? Because CMS had kind of come out ahead of time and said the schedule wouldn't be too disrupted [indiscernible] around."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","There's always some lumpiness quarter to quarter. I would say in the second half that CMS had very little to do with it. It's just timing of some of the orders.",32,"There's always some lumpiness quarter to quarter. I would say in the second half that CMS had very little to do with it. It's just timing of some of the orders."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Vijay Kumar from Evercore ISI.",12,"Our next question today is coming from Vijay Kumar from Evercore ISI."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So Elisha, maybe I'll start one with a question for you. Just sort of on the timing here just on the decision to step aside. So if you could just walk us through some of the timing decision. I think that would be a helpful context heading into the spin.",50,"So Elisha, maybe I'll start one with a question for you. Just sort of on the timing here just on the decision to step aside. So if you could just walk us through some of the timing decision. I think that would be a helpful context heading into the spin."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. Well, I started my CFO career with a spin. I figured why not end it with a spin? So back in 1999, and as Dow said, about 71 quarters, it just feels like the right timing, Vijay. In terms of the exact timing, that's to be determined. I am completely",116,"Sure. Well, I started my CFO career with a spin. I figured why not end it with a spin? So back in 1999, and as Dow said, about 71 quarters, it just feels like the right timing, Vijay. In terms of the exact timing, that's to be determined. I am completely dedicated to getting us through the spin of the Imaging Components business, getting -- we can now go out and conduct a search and want to find a world-class finance leader who can come into this great organization and have time to transition. And so it will be at some point in this fiscal year, but the exact date is not determined at this point."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Got you. And maybe just a couple of quick ones on the, I guess, the guidance question. So did I hear you correctly when you said that the EPS growth was a high singles off of the current year base? And just what -- and then does that number include the $2",78,"Got you. And maybe just a couple of quick ones on the, I guess, the guidance question. So did I hear you correctly when you said that the EPS growth was a high singles off of the current year base? And just what -- and then does that number include the $20 million dis-synergies? And do you have the accounting rule change sort of baked in? Just can you walk us through some of the moving parts there?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, so it did -- that was a hypothetical number that said if we weren't spinning, we believe EPS would grow on a consolidated basis in the high single digits. The $20 million of dis-synergies, I have to say we are well under way of looking for cost-reduc",159,"Yes, so it did -- that was a hypothetical number that said if we weren't spinning, we believe EPS would grow on a consolidated basis in the high single digits. The $20 million of dis-synergies, I have to say we are well under way of looking for cost-reduction opportunities, and we are absolutely committed to having $10 million of that out at a run rate by the end of fiscal year '17 and the additional $10 million out by FY '18. So lots of work already going on, on that. I will tell you that most of those dis-synergies for Varian are offset because we will have a lower tax rate because Varex has a 35%, 36% tax rate. And so unfortunately, for my colleague, Clarence, here, his tax rate is going up versus the Varian average. But Varian's tax rate will come down a point or 2, and that largely offsets the dis-synergies in year 1 and 2."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","That was helpful. And maybe just a quick one on Q1. I mean, if I look at the guidance commentary at the midpoint EPS, it looks like maybe margins would be somewhere around 17.5, maybe a few basis points above the 17.5. So that's a step-down just from the",77,"That was helpful. And maybe just a quick one on Q1. I mean, if I look at the guidance commentary at the midpoint EPS, it looks like maybe margins would be somewhere around 17.5, maybe a few basis points above the 17.5. So that's a step-down just from the Q4 levels. Any commentary on what your gross margin is for Oncology? Can you just walk us through why the margins will step down from Q4 to Q1?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Well, yes, you always -- every year, if you go back, you see seasonality. I mean, Q4 is always our largest quarter with the highest operating margin typically. So it's not uncommon for the operating margin to step down from Q4 to Q1. When you run you",153,"Yes. Well, yes, you always -- every year, if you go back, you see seasonality. I mean, Q4 is always our largest quarter with the highest operating margin typically. So it's not uncommon for the operating margin to step down from Q4 to Q1. When you run your model through, I mean, what I am showing at the midpoint is that we will increase our operating margin by about a point to 18% on a non-GAAP basis. Again, Oncology's gross margin will be between 44%, 45%. Imaging Components in the low 40s, so it looks closer to an 18% operating margin. And again, Vijay, that does include -- I want to make sure everyone understands. It includes some duplicative costs in Varex as we're hiring people to gear up for this spin. We cannot take those costs out to be non-GAAP, and it's between $0.01 and $0.02 in Q1 for those duplicative costs."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Anthony Petrone from Jefferies.",11,"Our next question today is coming from Anthony Petrone from Jefferies."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Congratulations, Elisha. It was great working with you over the years, and good luck on the next phase.",18,"Congratulations, Elisha. It was great working with you over the years, and good luck on the next phase."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you.",2,"Thank you."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","A couple of questions, just I guess higher level. maybe exiting fiscal '16 here would be helpful to get an update on the percentage of the installed base, the linac installed base that really is now TrueBeam and VitalBeam. And really what I'm getting at i",120,"A couple of questions, just I guess higher level. maybe exiting fiscal '16 here would be helpful to get an update on the percentage of the installed base, the linac installed base that really is now TrueBeam and VitalBeam. And really what I'm getting at is what percentage of the installed base has stereotactic capabilities? And what percent does not? And it's really in relation to Dr. Khuntia's sort of presentation at ASTRO, the opportunity for SRS/SBRT going forward over the next 10 to 15 years. I'm just trying to get a sense of what percentage of the base can migrate to having stereotactic capabilities in the next few years? And then I have a follow-up on software and margins."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That's a good question. I'd say from a very high level, we've got about 1,500 TrueBeams in the installed base of, call it, 7,500 machines. Now when you look at some of the capabilities, the interesting thing when you talk about HyperArc, HyperArc's availa",347,"That's a good question. I'd say from a very high level, we've got about 1,500 TrueBeams in the installed base of, call it, 7,500 machines. Now when you look at some of the capabilities, the interesting thing when you talk about HyperArc, HyperArc's available on every one of those TrueBeams. So this is the kind of our first real -- we've had some other smaller upgrades that we've offered on TrueBeam, like some imaging improvements and just some other things over the last few years. But the HyperArc for some of the stereotactic radiosurgery applications that Dr. Khuntia talked about at ASTRO will be available on the EDGE and TrueBeam only. So we're very excited about that. I think that will probably drive some of the other installed base to trade out to TrueBeam as well. So we're very encouraged about that. We're, I'd say, when you look at the past quarter, Americas was almost virtually 100% TrueBeam/VitalBeam. There might have been 1 or 2 that weren't, but pretty much everything in the Americas -- well, North America for sure, was TrueBeam/VitalBeam. In rest of the -- and I'd say of those, in terms of the capabilities that they had in the fourth quarter, maybe half-ish had SRS/SBRT capability. When you look at the installed base, a big opportunity there. Most of them do not have that capability. And so I think this bodes well for us next year in 2 ways. One, it's an upgrade opportunity; and two, it's going to help us on pricing on TrueBeam. It's going to  -- we're going to be able to maintain or grow price on TrueBeam, and I think that's a little bit of the -- we're doing very well on the cost side, where is this margin rate improvement coming from? We're doing very well on the cost side. The operational team has done a fabulous job getting cost down on TrueBeam. But then as well, we're seeing a really nice mix of these advanced capabilities that are giving us some price support on the pricing side."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And just a quick follow-up on that, Dow, would be, just how do you see that transitioning just when you think of the 2019 reimbursement changes, where Oncology may go bundled. I mean, and then more focused on efficiencies and outcomes. I mean, does it acc",71,"And just a quick follow-up on that, Dow, would be, just how do you see that transitioning just when you think of the 2019 reimbursement changes, where Oncology may go bundled. I mean, and then more focused on efficiencies and outcomes. I mean, does it accelerate the demand for stereotactic within the installed base? Or do you think this sort of plays out pretty ratably over 12 to 15 years?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, I think, if anything, it'll be a little faster because of some of the reimbursement pressure. Having said that, clinicians are going to want to make sure there's a really responsible clinical comparison done. So our customers are sensitive about t",197,"I mean, I think, if anything, it'll be a little faster because of some of the reimbursement pressure. Having said that, clinicians are going to want to make sure there's a really responsible clinical comparison done. So our customers are sensitive about that. I think one of the exciting things to us is in some applications, hypofractionation -- the hypofractionation trend is going to bring more patients back to us. So for example, in prostate cancer, over the last half dozen years, we've lost a little bit of share in [ph] robotic surgery. But I think now as those start to go hypofractionation, we get those -- a lot of those patients back. The results are as good or better than surgery, and that's well documented. And then as well, I think the other big opportunity from a clinical growth perspective here is metastatic disease. This capability really enables a very precise dose deposition. And we think that there are, in the U.S. alone, 300,000 patients that we could have opportunity to go after with this capability and bring some new folks into the radiation therapy paradigm. So we're excited about the capability that this opens up."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then just quickly on software margins. Maybe just another high level. Where do we sit exiting fiscal '16 when you look at software/services as a percent of the total for the RemainCo? And do you see a point where there is a higher mix of software, say",73,"And then just quickly on software margins. Maybe just another high level. Where do we sit exiting fiscal '16 when you look at software/services as a percent of the total for the RemainCo? And do you see a point where there is a higher mix of software, say, over the next 3 to 5 years? And if we do have that scenario, what do you think overall margins look like under that scenario?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me just say for year-to-date, '16 service was just low 40s. So it's about 42% of the total revenue for Oncology. So call it 60-40. And clearly, as both service and software grow faster than the hardware, it does have an upward bias on gross margin. In",68,"Let me just say for year-to-date, '16 service was just low 40s. So it's about 42% of the total revenue for Oncology. So call it 60-40. And clearly, as both service and software grow faster than the hardware, it does have an upward bias on gross margin. In fact, that has been helping us the last couple of quarters. Software is roughly 10% of total Oncology revenue."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Brandon Henry with RBC Capital Markets.",13,"Our next question today is coming from Brandon Henry with RBC Capital Markets."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","First of all, can you just discuss how software and services performed in the quarter? As these businesses continue growing, combined kind of high single digits? And were there any change in growth rates this quarter versus last quarter?",39,"First of all, can you just discuss how software and services performed in the quarter? As these businesses continue growing, combined kind of high single digits? And were there any change in growth rates this quarter versus last quarter?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Our revenues in service were up 7%. Revenues in software were...",12,"Our revenues in service were up 7%. Revenues in software were..."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Probably about the same.",4,"Probably about the same."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Around the same. I think the -- as we look forward in the service funnel, I'd say it looks very good. We had a little bit of currency last year. We had a little bit of timing. I think on the year, we'd like to see that number be a little bit north of 7%,",254,"Around the same. I think the -- as we look forward in the service funnel, I'd say it looks very good. We had a little bit of currency last year. We had a little bit of timing. I think on the year, we'd like to see that number be a little bit north of 7%, and that's kind of what we're stretching the team for. But service business continues to be solid growth for us. Software, we had very good year in treatment planning. We talked about that in the script with all the RapidPlan orders. I think this next year, with the improvement that we have in our InSightive Analytics and with our 360 Oncology product, it can be very exciting. We're curious a little bit to see how that goes because the 360 Oncology is going to be cloud-based, so the financial impact is going to be a little more back-end loaded as we accumulate sites, do to billing and click the orders on that basis. I think it's going to be a little -- it is a little bit of a transition as we go kind of from an annual license model to a software-as-a-service model. So having said that, one of the really cool things about the 360 Oncology product is it can play not just in ARIA Varian sites, it can play in every radiation oncology site in the world. And just really a great opportunity for us to get some penetration in Insightive that we don't have today."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then separately, can you kind of talk about your expectation for free cash flow for fiscal year '17 versus fiscal year '16? And how should we think about the balance of M&A versus share repurchases in the near term? And then what size of deals a",59,"Okay. And then separately, can you kind of talk about your expectation for free cash flow for fiscal year '17 versus fiscal year '16? And how should we think about the balance of M&A versus share repurchases in the near term? And then what size of deals and debt levels do you feel comfortable for each company going forward?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So I'll answer the first part of that question, Brandon. As it came up earlier on the call, our cash flow from operations was down year-over-year. We ended both Q3 and Q4 on a strong note, but we were kind of in a hole in the first half of the fiscal year",172,"So I'll answer the first part of that question, Brandon. As it came up earlier on the call, our cash flow from operations was down year-over-year. We ended both Q3 and Q4 on a strong note, but we were kind of in a hole in the first half of the fiscal year on collections of AR for a couple of reasons -- moved this collection staff, we had an IT implementation, et cetera. So we're very focused on cash flow, particularly AR, as we move into FY '17. And on a consolidated basis, our expectation would be that we could get back to around the $400 million level in cash flow from operations. CapEx has always been relatively stable. And then, in terms of share repurchase versus M&A, I think we would always love to prioritize M&A if the right targets come along. And that's the duty of our share repurchase program. We can turn it on and off and at various levels, depending on what activity and M&A that's there."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. And just as a comment, it's going to be strategically driven, how can we strengthen our Oncology franchise. I don't see us going way out on the EDGE and doing something, for example, maybe in chemotherapy, to pick one. But are there image guidance te",73,"Yes. And just as a comment, it's going to be strategically driven, how can we strengthen our Oncology franchise. I don't see us going way out on the EDGE and doing something, for example, maybe in chemotherapy, to pick one. But are there image guidance technologies? Are there radiation technologies? Are there software technologies that can reinforce our core and give us some higher-growth segments to participate in? That's what we look at."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question is coming from Anthony Petrone from Jefferies.",10,"Our next question is coming from Anthony Petrone from Jefferies."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Just a quick housekeeping one. Just kind of going through some Qs here on the Candela acquisition in Poland. Maybe what's baked in there for fiscal '17 and if any of that hit in the fiscal fourth quarter as well.",40,"Just a quick housekeeping one. Just kind of going through some Qs here on the Candela acquisition in Poland. Maybe what's baked in there for fiscal '17 and if any of that hit in the fiscal fourth quarter as well."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","In terms of revenue?",4,"In terms of revenue?"
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes, revenue contribution in the quarter and then...",8,"Yes, revenue contribution in the quarter and then..."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","It would just be service revenue, so about $1 million or so. It was small.",15,"It would just be service revenue, so about $1 million or so. It was small."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","In 4Q. And I guess, can we just annualized that in '17 to get their contribution or...",17,"In 4Q. And I guess, can we just annualized that in '17 to get their contribution or..."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, you can -- it's somewhere between an annualized $14 million to $16 million market for us, and it's a growing market. So we feel very good about Poland over the next several years, and one of the reasons that the timing was right to make the acquisiti",51,"Yes, you can -- it's somewhere between an annualized $14 million to $16 million market for us, and it's a growing market. So we feel very good about Poland over the next several years, and one of the reasons that the timing was right to make the acquisition and go direct."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","We reached the end of our question-and-answer session. I'd like to turn the floor back over to management for any further closing comments.",24,"We reached the end of our question-and-answer session. I'd like to turn the floor back over to management for any further closing comments."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Thank you for participating. The replay of the call can be heard on Varian's investor site at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or (201)",70,"Thank you. Thank you for participating. The replay of the call can be heard on Varian's investor site at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or (201) 612-7415 from outside the U.S., and entering confirmation code 13647671. The telephone replay will be available through 5 p.m. this Friday, October 28. Thanks very much."
311907,404405398,1062361,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. That does conclude today's teleconference. You may disconnect your lines at this time, and have a wonderful day. We thank you for your participation today.",27,"Thank you. That does conclude today's teleconference. You may disconnect your lines at this time, and have a wonderful day. We thank you for your participation today."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems Fourth Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.It is now my pleasure to introduce your host, Spencer Sias, Vice Presiden",42,"Greetings, and welcome to the Varian Medical Systems Fourth Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Spencer Sias, Vice President. Please go ahead, sir."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Good afternoon, and welcome to Varian Medical Systems' conference call for the fourth quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha wil",271,"Thank you. Good afternoon, and welcome to Varian Medical Systems' conference call for the fourth quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. 
To simplify our discussion, unless otherwise stated, all references to the quarter or year or fiscal quarters or fiscal years, quarterly comparisons are for the fourth quarter of fiscal 2016 versus the fourth quarter of fiscal 2015. References to financial results for orders are to gross orders unless otherwise indicated. 
The company is reporting non-GAAP results in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. A reconciliation to the most comparable GAAP measure is included in our earnings release, which can be accessed on our website. 
Please be advised that this presentation and discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, should, will, promising and similar expressions are intended to identify those statements which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks related to our business are described in our fourth quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise. 
And now here's Dow."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Our company finished fiscal year 2016 on a positive note, with healthy fourth quarter growth in revenues and significant margin improvement in both our Oncology and Imaging Components businesses. Orders in the Oncology and pro",1519,"Good afternoon, and welcome. Our company finished fiscal year 2016 on a positive note, with healthy fourth quarter growth in revenues and significant margin improvement in both our Oncology and Imaging Components businesses. Orders in the Oncology and proton businesses, on the other hand, were down during the quarter versus tough year-ago comparisons in which we had record-setting Oncology growth in Western Europe and in our proton business. 
To summarize, our fourth quarter results for fiscal 2016 we are reporting GAAP net earnings of $1.24 per diluted share, up from $0.99 in the year-ago quarter; non-GAAP net earnings of $1.38 per diluted share, up more than 30% from $1.04 in year-ago quarter; a decline in Oncology orders due to weakness in Western Europe; revenues of $912 million, up 12% in dollars and up 11% in constant currency; and gains of about 4 percentage points in our gross margin, with significant improvements in both our major businesses. 
Focusing on Oncology operations. Orders totaled $897 million for the fourth quarter, down 2% in dollars and down 4% in constant currency versus a strong year-ago quarter. Orders for the year totaled $2.7 billion, up 1% from the prior year and up 2% in constant currency. 
Fourth quarter orders in the Americas grew by 4% in dollars, an increase by 3% in constant currency for the year. Orders in the Americas were up 4% in both dollars and constant currency. 
In North America, orders fell by 2% in the fourth quarter but grew by 5% for the year, ahead of our expectations for this market. 
Fourth quarter Oncology orders in APAC rose by 8% in dollars and fell by 1% in constant currency. For the full year, APAC orders rose by 5% in dollars and by 3% in constant currency. 
In EMEA, Oncology orders declined by 17% in dollars and in constant currency, principally because of weakness in Western Europe, where we had exceptionally strong growth in the year-ago quarter when we set a record by booking orders for more than 100 accelerators. 
For the year, orders in EMEA were down 6% in dollars and down 4% in constant currency, driven by weakness in Western Europe. 
Comparing revenues on a trailing 12-month basis, we believe we gained market share versus our primary competition. Our average selling price rose with the help of a higher mix of TrueBeam and VitalBeam orders. We generated solid order growth during the quarter in emerging markets, including Brazil, Africa and in the Middle East. 
In Brazil, we booked nearly $30 million of new business, including a big win at Grupo Oncoclnicas, where we will be installing 13 TrueBeam and VitalBeam accelerators as well as software to support clinical operations. These will be the first VitalBeam accelerators installed in Latin America. 
Colombia was also a strong contributor to robust order growth in the quarter. Total orders in Latin America exceeded $60 million during the quarter, up more than 70% from the prior year period. 
Other emerging markets contributing to Oncology orders during the quarter included Africa, with about $20 million; and the Middle East, where we booked more than $40 million. As an example of progress, we received a $14 million order for 8 accelerators at the Shifa International Hospital in Islamabad. 
In APAC emerging markets, we generated healthy order growth in Indonesia, Korea and the Philippines. Developed markets, particularly Japan, also contributed to the order growth in this region. Meanwhile, orders in Greater China were down from the year-ago period in part because of continuing tender protest. While we are anniversarying the effects of these multiple orders, and while we are retaining the bulk of the business that we've won, we estimate that orders in China in the fiscal year could have been more than $15 million higher without this protest activity. 
Turning to North America. We established a significant new 3-year strategic agreement with McKesson Specialty Health to supply its U.S. oncology and vantage cancer treatment networks with equipment, software and services. In the first phase, we will be equipping centers with 7 TrueBeam and 5 VitalBeam accelerators. We also will be working to establish interoperability with Varian's information management and McKesson's iKnowMed G2 clinical oncology software. We see an opportunity here to support these networks with more of our Eclipse, ARIA, Velocity and new 360 Oncology software. 
Overall, we had a very good year in North America, where we had in excess of $130 million in takeouts of more than 40 accelerators and nearly 100 software installations from competitors. 
As you know, we've just returned from ASTRO in Boston. It was a great show for us, with some 900 attendees at our users meeting, numerous customers from emerging markets and very positive response to several major new products that we'll be bringing to market this year. 
We introduced 360 Oncology, a first-of-its-kind software tool that enables clinicians on tumor boards to more effectively coordinate patient care among the numerous specialists involved in cancer treatment. This software also provides patients with a clearer picture of how the many elements involving -- involved in treating their cancer fit together. Customer response is enthusiastic, and we believe we have a winning product on our hands. 
We also showed our progress in the development of our HyperArc technology for automating and simplifying the delivery of stereotactic radiosurgery, with more compact dose distribution and better protection of surrounding healthy tissue. We're aiming to introduce this important upgrade to our TrueBeam and EDGE platforms this year, beginning with a module for treating head and neck cancers. 
Oncology administrators are also very interested in our initiative, in which we will be enhancing the security embedded within Varian software systems. We believe we have a leading position in the development of this important new capability, and we expect it could generate an additional $80 million in revenues by the end of fiscal year 2018. 
We have continued to see a very positive market response to our RapidPlan and InSightive Analytics software products that help to improve the speed, quality and cost efficiency of treatments. We've taken more than 650 orders for RapidPlan since its launch and more than 135 orders for our InSightive software. 
Touching on the service business, global revenues rose by 7% during the quarter, with gains in all geographies. 
Turning now to our Particle Therapy business, we generated $38 million in orders during the fourth quarter, bringing total orders for the year to $104 million. Orders were down significantly from fiscal 2015 when we had a total of 6 system orders, including an $87 million order for our ProBeam system at the University of Maryland. 
Revenues from 14 ongoing projects grew nicely, reaching $68 million in the fourth quarter and bringing total revenues for the year to $163 million, including about $10 million in annual service revenues. 
During the fourth quarter, we booked our first single-room ProBeam Compact order, marking an important milestone for the business. This new system will be installed at the Advanced Medicine Training Centre in Singapore, where Varian will also provide its Eclipse treatment planning system. We also have a 10-year agreement to service this system. 
Also during the quarter, the U.K.'s University College London Hospital placed an order for a fourth treatment gantry at the proton therapy center that is currently under construction. 
Earlier this month, treatments commenced using our ProBeam system at Cincinnati Children's Hospital, making it the fifth Varian-equipped proton center to treat clinically. At this point, the proton sales funnel looks healthy, and I'm pleased by the progress we are making. 
  
Let me turn now to Imaging Components. Recovery in this business continued in the fourth quarter. Orders grew by 2% to $168 million in the fourth quarter, resulting in 7% orders growth for the last 6 months. Orders for the year totaled $571 million, down 6% from the prior year because of first half headwinds, including significant purchasing slowdowns at 2 major customers. Revenues were up 7% for the fourth quarter and down 2% for the year. 
Our MeVis and Claymount acquisitions as well as successful efforts to develop business with new customers contributed to Imaging Components' order and revenue growth during the quarter. Great cost control as well as a favorable product mix in tubes and flat panel imaging detectors and higher volumes in our security and inspection line enabled the Imaging business to achieve the significant gain in its gross margin for the quarter. 
Looking at operational highlights for the whole year. The Imaging Components business introduced 20 new products, completed 140,000 square foot expansion of its manufacturing facility in Salt Lake City, opened a new facility in China to service growing customer base there, successfully integrated and mobilized its MeVis and Claymount acquisitions, added 12 new customers to offset slower purchasing from established customers and exceeded its profit targets. We're proud of this performance, and we expect Imaging Components to be a great company that delivers solid returns when it separates from Varian and has established as Varex Imaging, an independent publicly traded company. Work on the separation continues to go smoothly. 
Now I'll turn it over to Elisha."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog. We ended the quarter at $3.5 billion, down 1% from the year-ago period, with a gain in Oncology offset by declines in our Particle Therapy and Imaging Co",832,"Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog. We ended the quarter at $3.5 billion, down 1% from the year-ago period, with a gain in Oncology offset by declines in our Particle Therapy and Imaging Components backlogs. Backlog adjustments during the quarter totaled $47 million, bringing net orders for the company to $1.1 million. 
Fourth quarter revenues for the total company were $912 million, up 12% in dollars and up 11% in constant currency. For the year, total company revenues were $3.2 billion, up 4% in dollars and up 5% in constant currency. 
Oncology posted a fourth quarter revenue gain, up 7% in dollars and 6% in constant currency. For the year, Oncology revenues increased 5% in dollars and 6% in constant currency. 
Imaging Components posted a fourth quarter revenue gain of 7%, driven by our recently acquired X-ray accessories businesses as well as security and inspection products. Including the challenges in the first half, Imaging Components revenues declined 2% for the full year. 
Our Particle Therapy business posted fourth quarter revenues of $68 million, bringing total revenues for the year to $163 million, a 13% increase from the prior year. 
The total company gross margin for the quarter was 42.7%, up by nearly 4 points, with significant contributions from both Oncology and Imaging Components. 
Oncology Systems fourth quarter gross margin improved by about 5 points to 45.3%, with the help of favorable product and geographic mix shifts as well as product cost reductions. For the year, Oncology Systems gross margin improved by almost 2 points to 44.5%. 
Imaging Components fourth quarter gross margin rose by about 3 points to 42.1% due largely to favorable product mix, high volumes in tube and security products and lower warranty cost. For the year, Imaging Components gross margin improved by about 1 point to 41.9%. 
R&D expenses were $66 million or 7% of revenue, down 1 point as a percentage of revenue from the year-ago quarter. For the year, R&D expenses were $254 million or equal with the prior year as a percentage of revenue at 8%.
On a GAAP basis, fourth quarter SG&A expenses were $152 million or 17% of revenue. On a non-GAAP basis, fourth quarter SG&A expenses were $134 million or 15% of revenue. 
The $19 million in non-GAAP adjustments, primarily related to the planned separation of the Imaging Components business, ongoing patent litigation and amortization of intangibles. 
Operating earnings for the quarter were 18.6% of revenues on a GAAP basis and 20.7% of revenues on a non-GAAP basis, reflecting our solid gross margin performance in the quarter. 
For the year, our operating earnings were 17.1% of revenues on a GAAP basis and up 50 basis points from the prior year to 19.1% of revenues on a non-GAAP basis. 
Depreciation and amortization totaled $24 million for the fourth quarter and $80 million for the year. The fourth quarter effective tax rate is 31.1%, up from the year-ago quarter due to an unfavorable geographic mix of profits. For the year, the effective tax rate was 27.6%. 
Fully diluted shares outstanding for the fourth quarter were 94.5 million, down almost 5 million shares from the year-ago period due to our ongoing share repurchase program. Fourth quarter diluted EPS was $1.24 for the quarter on a GAAP basis and $1.38 on a non-GAAP basis. For the year, diluted EPS was $4.19 on a GAAP basis. On a non-GAAP basis, diluted EPS rose 9% to $4.68. 
 
Turning to the balance sheet, we ended the quarter with cash and cash equivalents of $844 million, debt of $667 million and stockholders' equity of $1.7 billion. 
DSO at 93 days was up from the year-ago quarter, but improved sequentially from the third quarter. 
Fourth quarter cash flow from operations was $152 million, bringing the total cash flow from operations for the year to $356 million. Primary uses of cash were $87 million for the repurchase of about 1 million shares of stock, $43 million to reduce debt and $20 million for capital expenditures. At the end of the quarter, we had 3.8 million shares remaining under the existing repurchase authorization. 
Before I turn it over to Dow, as you may have seen in the release issued before this call, I intend to retire from Varian in fiscal year 2017. I will remain in my current role as CFO until a replacement is found and a smooth transition has been completed. I will also continue leading the separation of our Imaging Components business. We have a tremendous finance team that will perform to this transition to a new CFO without missing a beat. It has been an honor to serve all of Varian's investors and analysts over the past 17.5 years, and it's been a privilege to be part of a tremendous growth story that has seen Varian become a global power in the fight against cancer. 
Thank you for being part of the story with me. And now here's Dow."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. For our company and for our investors, Elisha has been an intelligent, trusted and energetic leader that all of us count on to help deliver winning results. We're just counting it up. We think it's 71 quarters. So bravo, Elisha. With her h",204,"Thanks, Elisha. For our company and for our investors, Elisha has been an intelligent, trusted and energetic leader that all of us count on to help deliver winning results. We're just counting it up. We think it's 71 quarters. So bravo, Elisha. With her help and guidance, we've achieved this sustained decades-long record of growth in revenues and profitability. I've been fortunate to have Elisha on our management team. I'm confident that we'll make a smooth transition. 
Turning now to guidance. We believe that for the first quarter of fiscal year 2017, non-GAAP earnings for the total company, including the Imaging Components business and ramp-up costs for its separation, will be in the range of $1.03 to $1.07 per diluted share, and revenues will increase by about 1% to 2%. 
As we announced earlier, we will not give earnings guidance for the full fiscal year until after we have completed the separation of the Imaging Components business. 
For the full fiscal year 2017, we expect that Varian revenues, excluding the Imaging Components business, will rise by 3% to 4%. We expect that Imaging Components revenues for the full fiscal year 2017 will also rise by 3% to 4%. 
We're now ready for your questions."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] Our first question today is coming from Jeff Johnson from Robert W. Baird.",15,"[Operator Instructions] Our first question today is coming from Jeff Johnson from Robert W. Baird."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So 2 questions here. One, I guess, just on cash flow. So cash flow was down, I think, on the year, down about 25%. It looks like it's kind of the lowest level we've seen since fiscal 2009, in fact, as I was going back. And if I add back some of the non-GA",114,"So 2 questions here. One, I guess, just on cash flow. So cash flow was down, I think, on the year, down about 25%. It looks like it's kind of the lowest level we've seen since fiscal 2009, in fact, as I was going back. And if I add back some of the non-GAAP cash charges, even if I add those back, it's still down below $400 million. And it looks like receivables were up, I think about $120 million year-on-year, and even $50 million up sequentially. So just trying to figure out if it's a receivables issue, what's going on there? Or what's going on basically with your cash flow at this point?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. So Jeff, the Oncology AR increased about 8%, and that compares to their year-to-date sales up 5%. And as we've been talking all through this fiscal year, early in the year, we moved our collections staff. We had a Salesforce IT implementation. And I",197,"Sure. So Jeff, the Oncology AR increased about 8%, and that compares to their year-to-date sales up 5%. And as we've been talking all through this fiscal year, early in the year, we moved our collections staff. We had a Salesforce IT implementation. And I think that slowed down collections in the first half, and we are continuing to feel that effect. Although we're making good progress, collections in Q3 and Q4 were very strong, but as we move into FY '17, absolutely, AR collections is going to be a big focus for the entire team. Little bit of it has to do with more extended terms. In a 0 interest-rate environment, we can continue to win high-margin business by offering terms. And then some of it also, both inventory and AR, up in the proton business as we continue to grow that business. And with percentage of completion accounting, it gets a little funky in proton because a lot of times we're taking revenue and creating an AR under the percentage of completion long before the bills are actually due by the customer. But it will be a big focus as we move into this year."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And I know you don't guide on -- you guide the cash flow, but I mean, on a consolidated basis, can we expect to get back above $400 million? We're almost touching $500 million a couple of years ago, and it seems like $350 million. Can we at least ge",64,"Okay. And I know you don't guide on -- you guide the cash flow, but I mean, on a consolidated basis, can we expect to get back above $400 million? We're almost touching $500 million a couple of years ago, and it seems like $350 million. Can we at least get back above $400 million, do you think, over the next year or 2?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, that is absolutely my goal this year. And also, contract advances were down in the proton business with orders being lower. That drove about, I think, $40 million of it. So -- but yes, our goal is we would get back on a consolidated basis to the $400",51,"Yes, that is absolutely my goal this year. And also, contract advances were down in the proton business with orders being lower. That drove about, I think, $40 million of it. So -- but yes, our goal is we would get back on a consolidated basis to the $400 million level."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes. All right. And Dow, from a guidance standpoint, I think we all knew you weren't going to issue full year guidance from an EPS perspective, and we understand the reasons why. But if I look at first quarter guidance from an EPS perspective, you're guid",127,"Yes. All right. And Dow, from a guidance standpoint, I think we all knew you weren't going to issue full year guidance from an EPS perspective, and we understand the reasons why. But if I look at first quarter guidance from an EPS perspective, you're guiding to about 5% to 6% EPS growth on a year-over-year basis. Is it fair to think about that on kind of a core basis over the following few quarters? Obviously, we have to take into account that extra $20 million of revenue dissynergies that will start to hit the back 3 quarters. But outside of that issue, is kind of your first quarter guidance a reasonable way to think about kind of the core outlook for the rest of the year?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me talk to the market side of it, and I'll let Elisha talk to the nuts and bolts on the guidance side. I think from a market perspective, we had a big comp in Europe here in the fourth quarter. But fundamentally, we had a very sound year in the U.S. W",189,"Let me talk to the market side of it, and I'll let Elisha talk to the nuts and bolts on the guidance side. I think from a market perspective, we had a big comp in Europe here in the fourth quarter. But fundamentally, we had a very sound year in the U.S. We see that continuing next year. Our funnel remains very good in the U.S. In Asia, China was a little bit off due to some of the structural issues we've seen there. But we think that, that market remains robust and should kind of bounce back to double-digit levels. And then the question for us all this year has been kind of Western Europe and where's it going to land. We've talked about that on this call, about it being soft all this year. As we closed the year, I'd say we feel pretty good about Europe for next year. So just kind of rounding out the market and top line side of it, I think we feel pretty good about where the market's going to be globally next year with -- especially Western Europe bouncing back."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. so for -- specifically for Q1 of FY '17, Jeff, that 1% to 2% on the revenue side, Varian Oncology and proton is going to be flattish on revenue, but that's really because in the year-ago Q1, we had something like 9% constant currency revenue growth.",221,"Yes. so for -- specifically for Q1 of FY '17, Jeff, that 1% to 2% on the revenue side, Varian Oncology and proton is going to be flattish on revenue, but that's really because in the year-ago Q1, we had something like 9% constant currency revenue growth. And then when we look at Q2, it was actually down 1%. So this is just a matter of timing, and I think the revenue will be split more evenly between Q1 and Q2. So again, 3% to 4% for the full year for Oncology. Q1 for Varex, the Imaging Components business, should be up in the, call it, low double-digit range. And that's versus a very easy year-ago comp as their recovery continues. On EPS, we're -- if you look at our range, it would be 4% to 8% EPS growth versus the year-ago quarter. But I need to stress, that also includes $0.01 to $0.02 of costs that we're building in the Imaging Components business today to prepare them for the spin. So for an example, they've hired a CIO. They've hired a manager of tax. As they're building out their corporate function, those costs are duplicated in this quarter. And so really, you need to tack on an additional $0.01 to $0.02 to account for that to get to an apples-to-apples."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And I guess I'll just repeat the last part of my question, which was, can I -- is it fair to think of that 4% to 8% EPS growth as kind of a core range we could think of for the rest of the year before we then tack on that $20 million of dissynergies",56,"Okay. And I guess I'll just repeat the last part of my question, which was, can I -- is it fair to think of that 4% to 8% EPS growth as kind of a core range we could think of for the rest of the year before we then tack on that $20 million of dissynergies?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Okay. So let me answer it this way, and this is a completely non-relevant number, but I'll give it to you anyway because we are going forward with the spin. But if we weren't spinning, I believe fiscal year '17, on a consolidated basis, we could grow EPS",53,"Okay. So let me answer it this way, and this is a completely non-relevant number, but I'll give it to you anyway because we are going forward with the spin. But if we weren't spinning, I believe fiscal year '17, on a consolidated basis, we could grow EPS in the high single-digit range."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Amit Hazan from Citi.",11,"Our next question today is coming from Amit Hazan from Citi."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Let me start with the guidance on the top line and that you guys talked about. So the 3% to 4% top line growth, I just want to make sure we understand it that the reported number are constant currency number, first. And then either way, really, if I kind",105,"Let me start with the guidance on the top line and that you guys talked about. So the 3% to 4% top line growth, I just want to make sure we understand it that the reported number are constant currency number, first. And then either way, really, if I kind look at orders for Oncology, they've been obviously now pretty much flat for the last couple of years on a reported basis. Backlog is kind of flattish. So maybe just help us, Elisha, to kind of get to that 3% to 4% growth range versus the order and the backlog growth rates we've been seeing."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, well that's assuming at today's exchange rates, which fortunately have stabilized over the last several quarters. The euro has stabilized. The yen is obviously helping us. If the yen weakens significantly, that could be an impact. But if I look at wh",86,"Yes, well that's assuming at today's exchange rates, which fortunately have stabilized over the last several quarters. The euro has stabilized. The yen is obviously helping us. If the yen weakens significantly, that could be an impact. But if I look at where currency rates are today, that 3% to 4% for Oncology and proton combined feels about right. That does compare to an Oncology backlog that's up 3% at the end of the fiscal year '16. So that looks pretty achievable going into FY '17."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And let me just follow up on the order side on Europe. I mean, if I look at EMEA for the year, down 4%, you talked about -- I think there's obviously some tough comps in there. But are you actually seeing some issues that have been persistent in Eur",99,"Okay. And let me just follow up on the order side on Europe. I mean, if I look at EMEA for the year, down 4%, you talked about -- I think there's obviously some tough comps in there. But are you actually seeing some issues that have been persistent in Europe that you would call out that you don't have great visibility to them. Anything other than easy comps? Or maybe just a little more color on what's going on Europe and if the issues that you've seen have been or continue to be persistent and what those are?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. Through the course of 2016, Amit, I think we had weakness especially in U.K., France and Germany. And as I mentioned in my response to Jeff's question, we're seeing our funnels in those markets and the rest of Western Europe and the rest of our Euro",119,"Sure. Through the course of 2016, Amit, I think we had weakness especially in U.K., France and Germany. And as I mentioned in my response to Jeff's question, we're seeing our funnels in those markets and the rest of Western Europe and the rest of our European map look pretty good as we look forward. So I think we're a little more encouraged about what we see forward than what we see backwards. So we also see some opportunity in Italy and Spain going forward. So -- and then of course, our map of Europe includes Africa, Middle East, India, and those markets were good to us in Q4, and we see those as continued strength from those markets."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then last one for me. Just on McKesson, maybe just give us a sense of when those units would actually be booked as orders, if they haven't been booked already. And then you kind of talked about it as Phase 1. To the extent that you can, maybe just tal",103,"And then last one for me. Just on McKesson, maybe just give us a sense of when those units would actually be booked as orders, if they haven't been booked already. And then you kind of talked about it as Phase 1. To the extent that you can, maybe just talk about their --  they're obviously a big organization from a rad onco center perspective. Just the installed base, how much of it is yours? And the extent, the kind of the phase, the potential for maybe a Phase 2 here, how you see this developing beyond these first 14 units or so?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, all that we've booked so far is these first 14 units. So that's just this first phase. We feel very good about our relationship with McKesson U.S. Oncology, Vantage. There's -- what we've booked so far is pretty much the hardware piece of the relatio",138,"Yes, all that we've booked so far is these first 14 units. So that's just this first phase. We feel very good about our relationship with McKesson U.S. Oncology, Vantage. There's -- what we've booked so far is pretty much the hardware piece of the relationship. The contract does include software and service, and that'll be booked, some of it next year and beyond. So we feel very good about where that is headed. I think the -- very much in sync for kind of what the software products have to do in terms of managing the clinic, providing the analytic tools, the MACRA reimbursement tools. It will include some interoperability with the McKesson IknowMed product, which was important for McKesson. And I'm very excited about that whole relationship, but most of it is yet to be booked."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Tycho Peterson from JPMorgan.",11,"Our next question today is coming from Tycho Peterson from JPMorgan."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Apologies. I'm going to ask another guidance question, but if we think about kind of the end markets, Dow, you used to talk about kind of 6% to 8% market growth and then it was kind mid-single digits. You're talking about 3% to 4% market growth -- revenue",92,"Apologies. I'm going to ask another guidance question, but if we think about kind of the end markets, Dow, you used to talk about kind of 6% to 8% market growth and then it was kind mid-single digits. You're talking about 3% to 4% market growth -- revenue growth with some share gains, I guess, embedded in. So can you maybe just talk about what you see as underlying market growth? And in your 3% to 4% revenue guidance, how much of that is software and service versus underlying growth in linac?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","[indiscernible] to the last. I don't know if I can break that out for you at this point from a guidance point of view. But as to the overall markets, I mean, if anything, we might have been a little bit conservative here. I think as we look at our funnels",210,"[indiscernible] to the last. I don't know if I can break that out for you at this point from a guidance point of view. But as to the overall markets, I mean, if anything, we might have been a little bit conservative here. I think as we look at our funnels here at the beginning of the year, I think the market looks pretty good. We had a ton of activity in -- especially in the fourth quarter in Europe last year. And as we look forward, we see pretty good strength. So I'd say it's -- there's some uncertainty around it, of course, but it's probably 3%, 3.5% to 6% market growth scenario. China is going to continue to do well. India is going to do well. We're growing in Africa. We had pretty good year this past year in Brazil, but we see continued strength in the Brazilian market, and that's good news. And then in the U.S. market, it's been, as I mentioned in the script, it was 5% growth on the year. And if anything, that was a little bit ahead of kind of where we thought it would be coming into the year. As we look at 2017, funnels remain very strong in the U.S."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","If I could just add to that, Tycho, in terms of the top line growth for Oncology, the good news is pricing is holding globally, and we have seen significant product cost reductions. We basically obsoleted the C-series and moved everyone onto the TrueBeam",112,"If I could just add to that, Tycho, in terms of the top line growth for Oncology, the good news is pricing is holding globally, and we have seen significant product cost reductions. We basically obsoleted the C-series and moved everyone onto the TrueBeam platform. And I think this -- the margin improvement you've seen in the last couple of quarters in Oncology is sustainable going forward. So we're kind of moving them up to a 44% to 45% gross margin level. And so obviously, even if the top line is off a point or so, we make up a lot of that difference in the margin improvement that we're seeing there."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's good to hear. And then Dow, maybe can you talk on MACRA, the final rule? What are your thoughts on -- as we think about that getting implemented, how do we think about that maybe driving more of a bias toward software and some of this?",48,"Okay. That's good to hear. And then Dow, maybe can you talk on MACRA, the final rule? What are your thoughts on -- as we think about that getting implemented, how do we think about that maybe driving more of a bias toward software and some of this?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, I think that overall, it's a good opportunity for our product line with our InSightive Analytics tools, our RapidPlan and treatment planning and our 360 Oncology. It's going to create an opportunity for us to provide our customers with the required r",226,"Yes, I think that overall, it's a good opportunity for our product line with our InSightive Analytics tools, our RapidPlan and treatment planning and our 360 Oncology. It's going to create an opportunity for us to provide our customers with the required reports that they're going to need to comply. They've got to demonstrate a certified EHR, electronic health record. They've got to demonstrate improvement in care management and practices, and they've got to report on their quality metrics. So these tools all do that. So I think it's going to be pretty good news for us. The product line is about where we need it to be. They comply. We've got a few things to button down, but we'll be way ahead of the compliance requirements. And we've got just our own installed base. It's about 1,800 units -- sorry, 1,800 sites that got to go. And we're very excited about that. Maybe just on top of that, this isn't MACRA, but the other piece from a market point of view that is at least as important as MACRA is the cybersecurity. And this -- at ASTRO, we launched a very significant upgrade to our software products for cybersecurity. And that product will be ready here in the early spring. And that should drive some upside for us, too. So we're excited about that one."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then one last one. North American Oncology orders last quarter, up 15%. They were up only 3% this quarter. Was there some pull-forward dynamic? Because CMS had kind of come out ahead of time and said the physician fee schedule wouldn't be too disrupte",47,"And then one last one. North American Oncology orders last quarter, up 15%. They were up only 3% this quarter. Was there some pull-forward dynamic? Because CMS had kind of come out ahead of time and said the physician fee schedule wouldn't be too disrupted [indiscernible] around."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","There's always some lumpiness quarter to quarter. I would say in the second half that CMS had very little to do with it. It's just timing of some of the orders.",32,"There's always some lumpiness quarter to quarter. I would say in the second half that CMS had very little to do with it. It's just timing of some of the orders."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Vijay Kumar from Evercore ISI.",12,"Our next question today is coming from Vijay Kumar from Evercore ISI."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So Elisha, maybe I'll start one with a question for you. Just sort of on the timing here just on the decision to step aside. So if you could just walk us through some of the timing decision. I think that would be a helpful context heading into the spin.",50,"So Elisha, maybe I'll start one with a question for you. Just sort of on the timing here just on the decision to step aside. So if you could just walk us through some of the timing decision. I think that would be a helpful context heading into the spin."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. Well, I started my CFO career with a spin. I figured why not end it with a spin? So back in 1999, and as Dow said, about 71 quarters, it just feels like the right timing, Vijay. In terms of the exact timing, that's to be determined. I am completely",116,"Sure. Well, I started my CFO career with a spin. I figured why not end it with a spin? So back in 1999, and as Dow said, about 71 quarters, it just feels like the right timing, Vijay. In terms of the exact timing, that's to be determined. I am completely dedicated to getting us through the spin of the Imaging Components business, getting -- we can now go out and conduct a search and want to find a world-class finance leader who can come into this great organization and have time to transition. And so it will be at some point in this fiscal year, but the exact date is not determined at this point."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Got you. And maybe just a couple of quick ones on the, I guess, the guidance question. So did I hear you correctly when you said that the EPS growth was a high singles off of the current year base? And just what -- and then does that number include the $2",78,"Got you. And maybe just a couple of quick ones on the, I guess, the guidance question. So did I hear you correctly when you said that the EPS growth was a high singles off of the current year base? And just what -- and then does that number include the $20 million dissynergies? And do you have the accounting rule change sort of baked in? Just can you walk us through some of the moving parts there?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, so it did -- that was a hypothetical number that said if we weren't spinning, we believe EPS would grow on a consolidated basis in the high single digits. The $20 million of dissynergies, I have to say we are well under way of looking for cost-reduct",159,"Yes, so it did -- that was a hypothetical number that said if we weren't spinning, we believe EPS would grow on a consolidated basis in the high single digits. The $20 million of dissynergies, I have to say we are well under way of looking for cost-reduction opportunities, and we are absolutely committed to having $10 million of that out at a run rate by the end of fiscal year '17 and the additional $10 million out by FY '18. So lots of work already going on, on that. I will tell you that most of those dissynergies for Varian are offset because we will have a lower tax rate because Varex has a 35%, 36% tax rate. And so unfortunately, for my colleague, Clarence, here, his tax rate is going up versus the Varian average. But Varian's tax rate will come down a point or 2, and that largely offsets the dissynergies in year 1 and 2."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","That was helpful. And maybe just a quick one on Q1. I mean, if I look at the guidance comments, we had the midpoint EPS, it looks like maybe margins would be somewhere around 17.5, maybe a few basis points above the 17.5. So that's a step-down just from t",78,"That was helpful. And maybe just a quick one on Q1. I mean, if I look at the guidance comments, we had the midpoint EPS, it looks like maybe margins would be somewhere around 17.5, maybe a few basis points above the 17.5. So that's a step-down just from the Q4 levels. Any commentary on what your gross margin is for Oncology? Can you just walk us through why the margins will step down from Q4 to Q1?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Well, yes, you always -- every year, if you go back, you see seasonality. I mean, Q4 is always our largest quarter with the highest operating margin typically. So it's not uncommon for the operating margin to step down from Q4 to Q1. When you run you",153,"Yes. Well, yes, you always -- every year, if you go back, you see seasonality. I mean, Q4 is always our largest quarter with the highest operating margin typically. So it's not uncommon for the operating margin to step down from Q4 to Q1. When you run your model through, I mean, what I am showing at the midpoint is that we will increase our operating margin by about a point to 18% on a non-GAAP basis. Again, Oncology's gross margin will be between 44%, 45%. Imaging Components in the low 40s, so it looks closer to an 18% operating margin. And again, Vijay, that does include -- I want to make sure everyone understands. It includes some duplicative costs in Varex as we're hiring people to gear up for this spin. We cannot take those costs out to be non-GAAP, and it's between $0.01 and $0.02 in Q1 for those duplicative costs."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Anthony Petrone from Jefferies.",11,"Our next question today is coming from Anthony Petrone from Jefferies."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","A couple of questions, just I guess higher level. maybe exiting fiscal '16 here would be helpful to get an update on the percentage of the installed base, the linac installed base that really is now TrueBeam and VitalBeam. And really what I'm getting at i",120,"A couple of questions, just I guess higher level. maybe exiting fiscal '16 here would be helpful to get an update on the percentage of the installed base, the linac installed base that really is now TrueBeam and VitalBeam. And really what I'm getting at is what percentage of the installed base has stereotactic capabilities? And what percent does not? And it's really in relation to Dr. Khuntia's sort of presentation at ASTRO, the opportunity for SRS/SPRT going forward over the next 10 to 15 years. I'm just trying to get a sense of what percentage of the base can migrate to having stereotactic capabilities in the next few years? And then I have a follow-up on software and margins."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That's a good question. I'd say from a very high level, we've got about 1,500 TrueBeams in the installed base of, call it, 7,500 machines. Now when you look at some of the capabilities, the interesting thing when you talk about HyperArc, HyperArc's availa",347,"That's a good question. I'd say from a very high level, we've got about 1,500 TrueBeams in the installed base of, call it, 7,500 machines. Now when you look at some of the capabilities, the interesting thing when you talk about HyperArc, HyperArc's available on every one of those TrueBeams. So this is the kind of our first real -- we've had some other smaller upgrades that we've offered on TrueBeam, like some imaging improvements and just some other things over the last few years. But the HyperArc for some of the stereotactic radiosurgery applications that Dr. Khuntia talked about at ASTRO will be available on the EDGE and TrueBeam only. So we're very excited about that. I think that will probably drive some of the other installed base to trade out to TrueBeam as well. So we're very encouraged about that. We're, I'd say, when you look at the past quarter, Americas was almost virtually 100% TrueBeam/VitalBeam. There might have been 1 or 2 that weren't, but pretty much everything in the Americas -- well, North America for sure, was TrueBeam/VitalBeam. In rest of the -- and I'd say of those, in terms of the capabilities that they had in the fourth quarter, maybe half-ish had SRS/SPRT capability. When you look at the installed base, a big opportunity there. Most of them do not have that capability. And so I think this bodes well for us next year in 2 ways. One, it's an upgrade opportunity; and two, it's going to help us on pricing on TrueBeam. It's going to  -- we're going to be able to maintain or grow price on TrueBeam, and I think that's a little bit of the -- we're doing very well on the cost side, where is this margin rate improvement coming from? We're doing very well on the cost side. The operational team has done a fabulous job getting cost down on TrueBeam. But then as well, we're seeing a really nice mix of these advanced capabilities that are giving us some price support on the pricing side."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And just a quick follow-up on that, Dow, would be, just how do you see that transitioning just when you think of the 2019 reimbursement changes, where Oncology may go bundled? I mean, and then more focused on efficiencies and outcomes. I mean, does it acc",71,"And just a quick follow-up on that, Dow, would be, just how do you see that transitioning just when you think of the 2019 reimbursement changes, where Oncology may go bundled? I mean, and then more focused on efficiencies and outcomes. I mean, does it accelerate the demand for stereotactic within the installed base? Or do you think this sort of plays out pretty ratably over 12 to 15 years?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, I think, if anything, it'll be a little faster because of some of the reimbursement pressure. Having said that, clinicians are going to want to make sure there's a really responsible clinical comparison done. So our customers are sensitive about t",197,"I mean, I think, if anything, it'll be a little faster because of some of the reimbursement pressure. Having said that, clinicians are going to want to make sure there's a really responsible clinical comparison done. So our customers are sensitive about that. I think one of the exciting things to us is in some applications, hypofractionation -- the hypofractionation trend is going to bring more patients back to us. So for example, in prostate cancer, over the last half dozen years, we've lost a little bit of share in [ph] robotic surgery. But I think now as those start to go hypofractionation, we get those -- a lot of those patients back. The results are as good or better than surgery, and that's well documented. And then as well, I think the other big opportunity from a clinical growth perspective here is metastatic disease. This capability really enables a very precise dose deposition. And we think that there are, in the U.S. alone, 300,000 patients that we could have opportunity to go after with this capability and bring some new folks into the radiation therapy paradigm. So we're excited about the capability that this opens up."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then just quickly on software margins. Maybe just another high level. Where do we sit exiting fiscal '16 when you look at software/services as a percent of the total for the RemainCo? And do you see a point where there is a higher mix of software, say",73,"And then just quickly on software margins. Maybe just another high level. Where do we sit exiting fiscal '16 when you look at software/services as a percent of the total for the RemainCo? And do you see a point where there is a higher mix of software, say, over the next 3 to 5 years? And if we do have that scenario, what do you think overall margins look like under that scenario?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me just say for year-to-date, '16 service was just low 40s. So it's about 42% of the total revenue for Oncology. So call it 60-40. And clearly, as both service and software grow faster than the hardware, it does have an upward bias on gross margin. In",68,"Let me just say for year-to-date, '16 service was just low 40s. So it's about 42% of the total revenue for Oncology. So call it 60-40. And clearly, as both service and software grow faster than the hardware, it does have an upward bias on gross margin. In fact, that has been helping us the last couple of quarters. Software is roughly 10% of total Oncology revenue."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Brandon Henry with RBC Capital Markets.",13,"Our next question today is coming from Brandon Henry with RBC Capital Markets."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","First of all, can you just discuss how software and services performed in the quarter? As these businesses continue growing, combined kind of high single digits? And were there any change in growth rates this quarter versus last quarter?",39,"First of all, can you just discuss how software and services performed in the quarter? As these businesses continue growing, combined kind of high single digits? And were there any change in growth rates this quarter versus last quarter?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Our revenues in service were up 7%. Revenues in software were...",12,"Our revenues in service were up 7%. Revenues in software were..."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Probably about the same.",4,"Probably about the same."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Around the same. I think the -- as we look forward in the service funnel, I'd say it looks very good. We had a little bit of currency last year. We had a little bit of timing. I think on the year, we'd like to see that number be a little bit north of 7%,",254,"Around the same. I think the -- as we look forward in the service funnel, I'd say it looks very good. We had a little bit of currency last year. We had a little bit of timing. I think on the year, we'd like to see that number be a little bit north of 7%, and that's kind of what we're stretching the team for. But service business continues to be solid growth for us. Software, we had very good year in treatment planning. We talked about that in the script with all the RapidPlan orders. I think this next year, with the improvement that we have in our InSightive Analytics and with our 360 Oncology product, it can be very exciting. We're curious a little bit to see how that goes because the 360 Oncology is going to be cloud-based, so the financial impact is going to be a little more back-end loaded as we accumulate sites, do the billing and click the orders on that basis. I think it's going to be a little -- it is a little bit of a transition as we go kind of from an annual license model to a software-as-a-service model. So having said that, one of the really cool things about the 360 Oncology product is it can play not just in ARIA Varian sites, it can play in every radiation oncology site in the world. And just really a great opportunity for us to get some penetration in InSightive that we don't have today."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then separately, can you kind of talk about your expectation for free cash flow for fiscal year '17 versus fiscal year '16? And how should we think about the balance of M&A versus share repurchases in the near term? And then what size of deals a",59,"Okay. And then separately, can you kind of talk about your expectation for free cash flow for fiscal year '17 versus fiscal year '16? And how should we think about the balance of M&A versus share repurchases in the near term? And then what size of deals and debt levels do you feel comfortable for each company going forward?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So I'll answer the first part of that question, Brandon. As it came up earlier on the call, our cash flow from operations was down year-over-year. We ended both Q3 and Q4 on a strong note, but we were kind of in a hole in the first half of the fiscal year",172,"So I'll answer the first part of that question, Brandon. As it came up earlier on the call, our cash flow from operations was down year-over-year. We ended both Q3 and Q4 on a strong note, but we were kind of in a hole in the first half of the fiscal year on collections of AR for a couple of reasons -- moved this collection staff, we had an IT implementation, et cetera. So we're very focused on cash flow, particularly AR, as we move into FY '17. And on a consolidated basis, our expectation would be that we could get back to around the $400 million level in cash flow from operations. CapEx has always been relatively stable. And then, in terms of share repurchase versus M&A, I think we would always love to prioritize M&A if the right targets come along. And that's the beauty of our share repurchase program. We can turn it on and off and at various levels, depending on what activity and M&A that's there."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. And just as a comment, it's going to be strategically driven, how can we strengthen our Oncology franchise. I don't see us going way out on the EDGE and doing something, for example, maybe in chemotherapy, to pick one. But are there image guidance te",73,"Yes. And just as a comment, it's going to be strategically driven, how can we strengthen our Oncology franchise. I don't see us going way out on the EDGE and doing something, for example, maybe in chemotherapy, to pick one. But are there image guidance technologies? Are there radiation technologies? Are there software technologies that can reinforce our core and give us some higher-growth segments to participate in? That's what we look at."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question is coming from Anthony Petrone from Jefferies.",10,"Our next question is coming from Anthony Petrone from Jefferies."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Just a quick housekeeping one. Just kind of going through some Qs here on the Candela acquisition in Poland. Maybe what's baked in there for fiscal '17 and if any of that hit in the fiscal fourth quarter as well.",40,"Just a quick housekeeping one. Just kind of going through some Qs here on the Candela acquisition in Poland. Maybe what's baked in there for fiscal '17 and if any of that hit in the fiscal fourth quarter as well."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","In terms of revenue?",4,"In terms of revenue?"
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes, revenue contribution in the quarter and then...",8,"Yes, revenue contribution in the quarter and then..."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","It would just be service revenue, so about $1 million or so. It was small.",15,"It would just be service revenue, so about $1 million or so. It was small."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","In 4Q. And I guess, can we just annualized that in '17 to get their contribution or...",17,"In 4Q. And I guess, can we just annualized that in '17 to get their contribution or..."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, you can -- it's somewhere between an annualized $14 million to $16 million market for us, and it's a growing market. So we feel very good about Poland over the next several years, and one of the reasons that the timing was right to make the acquisiti",51,"Yes, you can -- it's somewhere between an annualized $14 million to $16 million market for us, and it's a growing market. So we feel very good about Poland over the next several years, and one of the reasons that the timing was right to make the acquisition and go direct."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","We reached the end of our question-and-answer session. I'd like to turn the floor back over to management for any further closing comments.",24,"We reached the end of our question-and-answer session. I'd like to turn the floor back over to management for any further closing comments."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Thank you for participating. The replay of the call can be heard on Varian's investor site at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or (201)",70,"Thank you. Thank you for participating. The replay of the call can be heard on Varian's investor site at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or (201) 612-7415 from outside the U.S., and entering confirmation code 13647671. The telephone replay will be available through 5 p.m. this Friday, October 28. Thanks very much."
311907,404405398,1062512,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. That does conclude today's teleconference. You may disconnect your lines at this time, and have a wonderful day. We thank you for your participation today.",27,"Thank you. That does conclude today's teleconference. You may disconnect your lines at this time, and have a wonderful day. We thank you for your participation today."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Greetings, and welcome to the Varian Medical Systems Fourth Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.It is now my pleasure to introduce your host, Spencer Sias, Vice Presiden",42,"Greetings, and welcome to the Varian Medical Systems Fourth Quarter 2016 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Spencer Sias, Vice President. Please go ahead, sir."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Good afternoon, and welcome to Varian Medical Systems' conference call for the fourth quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha wil",271,"Thank you. Good afternoon, and welcome to Varian Medical Systems' conference call for the fourth quarter of fiscal year 2016. With me are Dow Wilson, President and CEO; Elisha Finney, CFO; and Clarence Verhoef, our Corporate Controller. Dow and Elisha will summarize our results, and we'll take your questions following the presentation. 
To simplify our discussion, unless otherwise stated, all references to the quarter or year or fiscal quarters or fiscal years, quarterly comparisons are for the fourth quarter of fiscal 2016 versus the fourth quarter of fiscal 2015. References to financial results for orders are to gross orders unless otherwise indicated. 
The company is reporting non-GAAP results in order to provide quarter-over-quarter comparisons of operational performance, excluding unusual items. A reconciliation to the most comparable GAAP measure is included in our earnings release, which can be accessed on our website. 
Please be advised that this presentation and discussion contains forward-looking statements. Our use of words and phrases such as outlook, believe, expect, anticipate, could, should, will, promising and similar expressions are intended to identify those statements which represent our current judgment on future performance or other future matters. While we believe them to be reasonable based on information currently available to us, these statements are subject to risks and uncertainties that could cause actual results to differ materially. Some of the important risks related to our business are described in our fourth quarter earnings release and in our filings with the SEC. We assume no obligation to update or revise the forward-looking statements in this presentation and discussion because of new information, future events or otherwise. 
And now here's Dow."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Good afternoon, and welcome. Our company finished fiscal year 2016 on a positive note, with healthy fourth quarter growth in revenues and significant margin improvement in both our Oncology and Imaging Components businesses. Orders in the Oncology and pro",1519,"Good afternoon, and welcome. Our company finished fiscal year 2016 on a positive note, with healthy fourth quarter growth in revenues and significant margin improvement in both our Oncology and Imaging Components businesses. Orders in the Oncology and proton businesses, on the other hand, were down during the quarter versus tough year-ago comparisons in which we had record-setting Oncology growth in Western Europe and in our proton business. 
To summarize, our fourth quarter results for fiscal 2016 we are reporting GAAP net earnings of $1.24 per diluted share, up from $0.99 in the year-ago quarter; non-GAAP net earnings of $1.38 per diluted share, up more than 30% from $1.04 in year-ago quarter; a decline in Oncology orders due to weakness in Western Europe; revenues of $912 million, up 12% in dollars and up 11% in constant currency; and gains of about 4 percentage points in our gross margin, with significant improvements in both our major businesses. 
Focusing on Oncology operations. Orders totaled $897 million for the fourth quarter, down 2% in dollars and down 4% in constant currency versus a strong year-ago quarter. Orders for the year totaled $2.7 billion, up 1% from the prior year and up 2% in constant currency. 
Fourth quarter orders in the Americas grew by 4% in dollars, an increase by 3% in constant currency for the year. Orders in the Americas were up 4% in both dollars and constant currency. 
In North America, orders fell by 2% in the fourth quarter but grew by 5% for the year, ahead of our expectations for this market. 
Fourth quarter Oncology orders in APAC rose by 8% in dollars and fell by 1% in constant currency. For the full year, APAC orders rose by 5% in dollars and by 3% in constant currency. 
In EMEA, Oncology orders declined by 17% in dollars and in constant currency, principally because of weakness in Western Europe, where we had exceptionally strong growth in the year-ago quarter when we set a record by booking orders for more than 100 accelerators. 
For the year, orders in EMEA were down 6% in dollars and down 4% in constant currency, driven by weakness in Western Europe. 
Comparing revenues on a trailing 12-month basis, we believe we gained market share versus our primary competition. Our average selling price rose with the help of a higher mix of TrueBeam and VitalBeam orders. We generated solid order growth during the quarter in emerging markets, including Brazil, Africa and in the Middle East. 
In Brazil, we booked nearly $30 million of new business, including a big win at Grupo Oncoclnicas, where we will be installing 13 TrueBeam and VitalBeam accelerators as well as software to support clinical operations. These will be the first VitalBeam accelerators installed in Latin America. 
Colombia was also a strong contributor to robust order growth in the quarter. Total orders in Latin America exceeded $60 million during the quarter, up more than 70% from the prior year period. 
Other emerging markets contributing to Oncology orders during the quarter included Africa, with about $20 million; and the Middle East, where we booked more than $40 million. As an example of progress, we received a $14 million order for 8 accelerators at the Shifa International Hospital in Islamabad. 
In APAC emerging markets, we generated healthy order growth in Indonesia, Korea and the Philippines. Developed markets, particularly Japan, also contributed to the order growth in this region. Meanwhile, orders in Greater China were down from the year-ago period in part because of continuing tender protest. While we are anniversarying the effects of these multiple orders, and while we are retaining the bulk of the business that we've won, we estimate that orders in China in the fiscal year could have been more than $15 million higher without this protest activity. 
Turning to North America. We established a significant new 3-year strategic agreement with McKesson Specialty Health to supply its U.S. oncology and vantage cancer treatment networks with equipment, software and services. In the first phase, we will be equipping centers with 7 TrueBeam and 5 VitalBeam accelerators. We also will be working to establish interoperability with Varian's information management and McKesson's iKnowMed G2 clinical oncology software. We see an opportunity here to support these networks with more of our Eclipse, ARIA, Velocity and new 360 Oncology software. 
Overall, we had a very good year in North America, where we had in excess of $130 million in takeouts of more than 40 accelerators and nearly 100 software installations from competitors. 
As you know, we've just returned from ASTRO in Boston. It was a great show for us, with some 900 attendees at our users meeting, numerous customers from emerging markets and very positive response to several major new products that we'll be bringing to market this year. 
We introduced 360 Oncology, a first-of-its-kind software tool that enables clinicians on tumor boards to more effectively coordinate patient care among the numerous specialists involved in cancer treatment. This software also provides patients with a clearer picture of how the many elements involving -- involved in treating their cancer fit together. Customer response is enthusiastic, and we believe we have a winning product on our hands. 
We also showed our progress in the development of our HyperArc technology for automating and simplifying the delivery of stereotactic radiosurgery, with more compact dose distribution and better protection of surrounding healthy tissue. We're aiming to introduce this important upgrade to our TrueBeam and EDGE platforms this year, beginning with a module for treating head and neck cancers. 
Oncology administrators are also very interested in our initiative, in which we will be enhancing the security embedded within Varian software systems. We believe we have a leading position in the development of this important new capability, and we expect it could generate an additional $80 million in revenues by the end of fiscal year 2018. 
We have continued to see a very positive market response to our RapidPlan and InSightive Analytics software products that help to improve the speed, quality and cost efficiency of treatments. We've taken more than 650 orders for RapidPlan since its launch and more than 135 orders for our InSightive software. 
Touching on the service business, global revenues rose by 7% during the quarter, with gains in all geographies. 
Turning now to our Particle Therapy business, we generated $38 million in orders during the fourth quarter, bringing total orders for the year to $104 million. Orders were down significantly from fiscal 2015 when we had a total of 6 system orders, including an $87 million order for our ProBeam system at the University of Maryland. 
Revenues from 14 ongoing projects grew nicely, reaching $68 million in the fourth quarter and bringing total revenues for the year to $163 million, including about $10 million in annual service revenues. 
During the fourth quarter, we booked our first single-room ProBeam Compact order, marking an important milestone for the business. This new system will be installed at the Advanced Medicine Training Centre in Singapore, where Varian will also provide its Eclipse treatment planning system. We also have a 10-year agreement to service this system. 
Also during the quarter, the U.K.'s University College London Hospital placed an order for a fourth treatment gantry at the proton therapy center that is currently under construction. 
Earlier this month, treatments commenced using our ProBeam system at Cincinnati Children's Hospital, making it the fifth Varian-equipped proton center to treat clinically. At this point, the proton sales funnel looks healthy, and I'm pleased by the progress we are making. 
  
Let me turn now to Imaging Components. Recovery in this business continued in the fourth quarter. Orders grew by 2% to $168 million in the fourth quarter, resulting in 7% orders growth for the last 6 months. Orders for the year totaled $571 million, down 6% from the prior year because of first half headwinds, including significant purchasing slowdowns at 2 major customers. Revenues were up 7% for the fourth quarter and down 2% for the year. 
Our MeVis and Claymount acquisitions as well as successful efforts to develop business with new customers contributed to Imaging Components' order and revenue growth during the quarter. Great cost control as well as a favorable product mix in tubes and flat panel imaging detectors and higher volumes in our security and inspection line enabled the Imaging business to achieve the significant gain in its gross margin for the quarter. 
Looking at operational highlights for the whole year. The Imaging Components business introduced 20 new products, completed 140,000 square foot expansion of its manufacturing facility in Salt Lake City, opened a new facility in China to service growing customer base there, successfully integrated and mobilized its MeVis and Claymount acquisitions, added 12 new customers to offset slower purchasing from established customers and exceeded its profit targets. We're proud of this performance, and we expect Imaging Components to be a great company that delivers solid returns when it separates from Varian and has established as Varex Imaging, an independent publicly traded company. Work on the separation continues to go smoothly. 
Now I'll turn it over to Elisha."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog. We ended the quarter at $3.5 billion, down 1% from the year-ago period, with a gain in Oncology offset by declines in our Particle Therapy and Imaging Co",832,"Thanks, Dow, and hello, everyone. Dow has already covered gross orders, so let me start with backlog. We ended the quarter at $3.5 billion, down 1% from the year-ago period, with a gain in Oncology offset by declines in our Particle Therapy and Imaging Components backlogs. Backlog adjustments during the quarter totaled $47 million, bringing net orders for the company to $1.1 million. 
Fourth quarter revenues for the total company were $912 million, up 12% in dollars and up 11% in constant currency. For the year, total company revenues were $3.2 billion, up 4% in dollars and up 5% in constant currency. 
Oncology posted a fourth quarter revenue gain, up 7% in dollars and 6% in constant currency. For the year, Oncology revenues increased 5% in dollars and 6% in constant currency. 
Imaging Components posted a fourth quarter revenue gain of 7%, driven by our recently acquired X-ray accessories businesses as well as security and inspection products. Including the challenges in the first half, Imaging Components revenues declined 2% for the full year. 
Our Particle Therapy business posted fourth quarter revenues of $68 million, bringing total revenues for the year to $163 million, a 13% increase from the prior year. 
The total company gross margin for the quarter was 42.7%, up by nearly 4 points, with significant contributions from both Oncology and Imaging Components. 
Oncology Systems fourth quarter gross margin improved by about 5 points to 45.3%, with the help of favorable product and geographic mix shifts as well as product cost reductions. For the year, Oncology Systems gross margin improved by almost 2 points to 44.5%. 
Imaging Components fourth quarter gross margin rose by about 3 points to 42.1% due largely to favorable product mix, high volumes in tube and security products and lower warranty cost. For the year, Imaging Components gross margin improved by about 1 point to 41.9%. 
R&D expenses were $66 million or 7% of revenue, down 1 point as a percentage of revenue from the year-ago quarter. For the year, R&D expenses were $254 million or equal with the prior year as a percentage of revenue at 8%.
On a GAAP basis, fourth quarter SG&A expenses were $152 million or 17% of revenue. On a non-GAAP basis, fourth quarter SG&A expenses were $134 million or 15% of revenue. 
The $19 million in non-GAAP adjustments, primarily related to the planned separation of the Imaging Components business, ongoing patent litigation and amortization of intangibles. 
Operating earnings for the quarter were 18.6% of revenues on a GAAP basis and 20.7% of revenues on a non-GAAP basis, reflecting our solid gross margin performance in the quarter. 
For the year, our operating earnings were 17.1% of revenues on a GAAP basis and up 50 basis points from the prior year to 19.1% of revenues on a non-GAAP basis. 
Depreciation and amortization totaled $24 million for the fourth quarter and $80 million for the year. The fourth quarter effective tax rate is 31.1%, up from the year-ago quarter due to an unfavorable geographic mix of profits. For the year, the effective tax rate was 27.6%. 
Fully diluted shares outstanding for the fourth quarter were 94.5 million, down almost 5 million shares from the year-ago period due to our ongoing share repurchase program. Fourth quarter diluted EPS was $1.24 for the quarter on a GAAP basis and $1.38 on a non-GAAP basis. For the year, diluted EPS was $4.19 on a GAAP basis. On a non-GAAP basis, diluted EPS rose 9% to $4.68. 
 
Turning to the balance sheet, we ended the quarter with cash and cash equivalents of $844 million, debt of $667 million and stockholders' equity of $1.7 billion. 
DSO at 93 days was up from the year-ago quarter, but improved sequentially from the third quarter. 
Fourth quarter cash flow from operations was $152 million, bringing the total cash flow from operations for the year to $356 million. Primary uses of cash were $87 million for the repurchase of about 1 million shares of stock, $43 million to reduce debt and $20 million for capital expenditures. At the end of the quarter, we had 3.8 million shares remaining under the existing repurchase authorization. 
Before I turn it over to Dow, as you may have seen in the release issued before this call, I intend to retire from Varian in fiscal year 2017. I will remain in my current role as CFO until a replacement is found and a smooth transition has been completed. I will also continue leading the separation of our Imaging Components business. We have a tremendous finance team that will perform to this transition to a new CFO without missing a beat. It has been an honor to serve all of Varian's investors and analysts over the past 17.5 years, and it's been a privilege to be part of a tremendous growth story that has seen Varian become a global power in the fight against cancer. 
Thank you for being part of the story with me. And now here's Dow."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thanks, Elisha. For our company and for our investors, Elisha has been an intelligent, trusted and energetic leader that all of us count on to help deliver winning results. We're just counting it up. We think it's 71 quarters. So bravo, Elisha. With her h",204,"Thanks, Elisha. For our company and for our investors, Elisha has been an intelligent, trusted and energetic leader that all of us count on to help deliver winning results. We're just counting it up. We think it's 71 quarters. So bravo, Elisha. With her help and guidance, we've achieved this sustained decades-long record of growth in revenues and profitability. I've been fortunate to have Elisha on our management team. I'm confident that we'll make a smooth transition. 
Turning now to guidance. We believe that for the first quarter of fiscal year 2017, non-GAAP earnings for the total company, including the Imaging Components business and ramp-up costs for its separation, will be in the range of $1.03 to $1.07 per diluted share, and revenues will increase by about 1% to 2%. 
As we announced earlier, we will not give earnings guidance for the full fiscal year until after we have completed the separation of the Imaging Components business. 
For the full fiscal year 2017, we expect that Varian revenues, excluding the Imaging Components business, will rise by 3% to 4%. We expect that Imaging Components revenues for the full fiscal year 2017 will also rise by 3% to 4%. 
We're now ready for your questions."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","[Operator Instructions] Our first question today is coming from Jeff Johnson from Robert W. Baird.",15,"[Operator Instructions] Our first question today is coming from Jeff Johnson from Robert W. Baird."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Elisha, I'm not going to touch the 71 quarter comment. I'll just leave that one alone, I guess. But it's been great working for you -- or working with you. I say that every time. It's been great working with you for the last 7 or 8 years that I've covered",62,"Elisha, I'm not going to touch the 71 quarter comment. I'll just leave that one alone, I guess. But it's been great working for you -- or working with you. I say that every time. It's been great working with you for the last 7 or 8 years that I've covered the stock, and I wish you the best in the future."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you, Jeff.",3,"Thank you, Jeff."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So 2 questions here. One, I guess, just on cash flow. So cash flow was down, I think, on the year, down about 25%. It looks like it's kind of the lowest level we've seen since fiscal 2009, in fact, as I was going back. And if I add back some of the non-GA",114,"So 2 questions here. One, I guess, just on cash flow. So cash flow was down, I think, on the year, down about 25%. It looks like it's kind of the lowest level we've seen since fiscal 2009, in fact, as I was going back. And if I add back some of the non-GAAP cash charges, even if I add those back, it's still down below $400 million. And it looks like receivables were up, I think about $120 million year-on-year, and even $50 million up sequentially. So just trying to figure out if it's a receivables issue, what's going on there? Or what's going on basically with your cash flow at this point?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. So Jeff, the Oncology AR increased about 8%, and that compares to their year-to-date sales up 5%. And as we've been talking all through this fiscal year, early in the year, we moved our collections staff. We had a Salesforce IT implementation. And I",197,"Sure. So Jeff, the Oncology AR increased about 8%, and that compares to their year-to-date sales up 5%. And as we've been talking all through this fiscal year, early in the year, we moved our collections staff. We had a Salesforce IT implementation. And I think that slowed down collections in the first half, and we are continuing to feel that effect. Although we're making good progress, collections in Q3 and Q4 were very strong, but as we move into FY '17, absolutely, AR collections is going to be a big focus for the entire team. Little bit of it has to do with more extended terms. In a 0 interest-rate environment, we can continue to win high-margin business by offering terms. And then some of it also, both inventory and AR, up in the proton business as we continue to grow that business. And with percentage of completion accounting, it gets a little funky in proton because a lot of times we're taking revenue and creating an AR under the percentage of completion long before the bills are actually due by the customer. But it will be a big focus as we move into this year."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And I know you don't guide on -- you guide the cash flow, but I mean, on a consolidated basis, can we expect to get back above $400 million? We're almost touching $500 million a couple of years ago, and it seems like $350 million. Can we at least ge",64,"Okay. And I know you don't guide on -- you guide the cash flow, but I mean, on a consolidated basis, can we expect to get back above $400 million? We're almost touching $500 million a couple of years ago, and it seems like $350 million. Can we at least get back above $400 million, do you think, over the next year or 2?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, that is absolutely my goal this year. And also, contract advances were down in the proton business with orders being lower. That drove about, I think, $40 million of it. So -- but yes, our goal is we would get back on a consolidated basis to the $400",51,"Yes, that is absolutely my goal this year. And also, contract advances were down in the proton business with orders being lower. That drove about, I think, $40 million of it. So -- but yes, our goal is we would get back on a consolidated basis to the $400 million level."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes. All right. And Dow, from a guidance standpoint, I think we all knew you weren't going to issue full year guidance from an EPS perspective, and we understand the reasons why. But if I look at first quarter guidance from an EPS perspective, you're guid",127,"Yes. All right. And Dow, from a guidance standpoint, I think we all knew you weren't going to issue full year guidance from an EPS perspective, and we understand the reasons why. But if I look at first quarter guidance from an EPS perspective, you're guiding to about 5% to 6% EPS growth on a year-over-year basis. Is it fair to think about that on kind of a core basis over the following few quarters? Obviously, we have to take into account that extra $20 million of revenue dissynergies that will start to hit the back 3 quarters. But outside of that issue, is kind of your first quarter guidance a reasonable way to think about kind of the core outlook for the rest of the year?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me talk to the market side of it, and I'll let Elisha talk to the nuts and bolts on the guidance side. I think from a market perspective, we had a big comp in Europe here in the fourth quarter. But fundamentally, we had a very sound year in the U.S. W",189,"Let me talk to the market side of it, and I'll let Elisha talk to the nuts and bolts on the guidance side. I think from a market perspective, we had a big comp in Europe here in the fourth quarter. But fundamentally, we had a very sound year in the U.S. We see that continuing next year. Our funnel remains very good in the U.S. In Asia, China was a little bit off due to some of the structural issues we've seen there. But we think that, that market remains robust and should kind of bounce back to double-digit levels. And then the question for us all this year has been kind of Western Europe and where's it going to land. We've talked about that on this call, about it being soft all this year. As we closed the year, I'd say we feel pretty good about Europe for next year. So just kind of rounding out the market and top line side of it, I think we feel pretty good about where the market's going to be globally next year with -- especially Western Europe bouncing back."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. so for -- specifically for Q1 of FY '17, Jeff, that 1% to 2% on the revenue side, Varian Oncology and proton is going to be flattish on revenue, but that's really because in the year-ago Q1, we had something like 9% constant currency revenue growth.",221,"Yes. so for -- specifically for Q1 of FY '17, Jeff, that 1% to 2% on the revenue side, Varian Oncology and proton is going to be flattish on revenue, but that's really because in the year-ago Q1, we had something like 9% constant currency revenue growth. And then when we look at Q2, it was actually down 1%. So this is just a matter of timing, and I think the revenue will be split more evenly between Q1 and Q2. So again, 3% to 4% for the full year for Oncology. Q1 for Varex, the Imaging Components business, should be up in the, call it, low double-digit range. And that's versus a very easy year-ago comp as their recovery continues. On EPS, we're -- if you look at our range, it would be 4% to 8% EPS growth versus the year-ago quarter. But I need to stress, that also includes $0.01 to $0.02 of costs that we're building in the Imaging Components business today to prepare them for the spin. So for an example, they've hired a CIO. They've hired a manager of tax. As they're building out their corporate function, those costs are duplicated in this quarter. And so really, you need to tack on an additional $0.01 to $0.02 to account for that to get to an apples-to-apples."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And I guess I'll just repeat the last part of my question, which was, can I -- is it fair to think of that 4% to 8% EPS growth as kind of a core range we could think of for the rest of the year before we then tack on that $20 million of dissynergies",56,"Okay. And I guess I'll just repeat the last part of my question, which was, can I -- is it fair to think of that 4% to 8% EPS growth as kind of a core range we could think of for the rest of the year before we then tack on that $20 million of dissynergies?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Okay. So let me answer it this way, and this is a completely non-relevant number, but I'll give it to you anyway because we are going forward with the spin. But if we weren't spinning, I believe fiscal year '17, on a consolidated basis, we could grow EPS",53,"Okay. So let me answer it this way, and this is a completely non-relevant number, but I'll give it to you anyway because we are going forward with the spin. But if we weren't spinning, I believe fiscal year '17, on a consolidated basis, we could grow EPS in the high single-digit range."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Amit Hazan from Citi.",11,"Our next question today is coming from Amit Hazan from Citi."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Let me just add, Elisha, it's been a great run and we'll definitely miss you.",15,"Let me just add, Elisha, it's been a great run and we'll definitely miss you."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you, Amit.",3,"Thank you, Amit."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Let me start with the guidance on the top line and that you guys talked about. So the 3% to 4% top line growth, I just want to make sure we understand it that the reported number are constant currency number, first. And then either way, really, if I kind",105,"Let me start with the guidance on the top line and that you guys talked about. So the 3% to 4% top line growth, I just want to make sure we understand it that the reported number are constant currency number, first. And then either way, really, if I kind look at orders for Oncology, they've been obviously now pretty much flat for the last couple of years on a reported basis. Backlog is kind of flattish. So maybe just help us, Elisha, to kind of get to that 3% to 4% growth range versus the order and the backlog growth rates we've been seeing."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, well that's assuming at today's exchange rates, which fortunately have stabilized over the last several quarters. The euro has stabilized. The yen is obviously helping us. If the yen weakens significantly, that could be an impact. But if I look at wh",86,"Yes, well that's assuming at today's exchange rates, which fortunately have stabilized over the last several quarters. The euro has stabilized. The yen is obviously helping us. If the yen weakens significantly, that could be an impact. But if I look at where currency rates are today, that 3% to 4% for Oncology and proton combined feels about right. That does compare to an Oncology backlog that's up 3% at the end of the fiscal year '16. So that looks pretty achievable going into FY '17."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And let me just follow up on the order side on Europe. I mean, if I look at EMEA for the year, down 4%, you talked about -- I think there's obviously some tough comps in there. But are you actually seeing some issues that have been persistent in Eur",99,"Okay. And let me just follow up on the order side on Europe. I mean, if I look at EMEA for the year, down 4%, you talked about -- I think there's obviously some tough comps in there. But are you actually seeing some issues that have been persistent in Europe that you would call out that you don't have great visibility to them. Anything other than easy comps? Or maybe just a little more color on what's going on Europe and if the issues that you've seen have been or continue to be persistent and what those are?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. Through the course of 2016, Amit, I think we had weakness especially in U.K., France and Germany. And as I mentioned in my response to Jeff's question, we're seeing our funnels in those markets and the rest of Western Europe and the rest of our Euro",119,"Sure. Through the course of 2016, Amit, I think we had weakness especially in U.K., France and Germany. And as I mentioned in my response to Jeff's question, we're seeing our funnels in those markets and the rest of Western Europe and the rest of our European map look pretty good as we look forward. So I think we're a little more encouraged about what we see forward than what we see backwards. So we also see some opportunity in Italy and Spain going forward. So -- and then of course, our map of Europe includes Africa, Middle East, India, and those markets were good to us in Q4, and we see those as continued strength from those markets."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then last one for me. Just on McKesson, maybe just give us a sense of when those units would actually be booked as orders, if they haven't been booked already. And then you kind of talked about it as Phase 1. To the extent that you can, maybe just tal",103,"And then last one for me. Just on McKesson, maybe just give us a sense of when those units would actually be booked as orders, if they haven't been booked already. And then you kind of talked about it as Phase 1. To the extent that you can, maybe just talk about their --  they're obviously a big organization from a rad onco center perspective. Just the installed base, how much of it is yours? And the extent, the kind of the phase, the potential for maybe a Phase 2 here, how you see this developing beyond these first 14 units or so?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, all that we've booked so far is these first 14 units. So that's just this first phase. We feel very good about our relationship with McKesson U.S. Oncology, Vantage. There's -- what we've booked so far is pretty much the hardware piece of the relatio",138,"Yes, all that we've booked so far is these first 14 units. So that's just this first phase. We feel very good about our relationship with McKesson U.S. Oncology, Vantage. There's -- what we've booked so far is pretty much the hardware piece of the relationship. The contract does include software and service, and that'll be booked, some of it next year and beyond. So we feel very good about where that is headed. I think the -- very much in sync for kind of what the software products have to do in terms of managing the clinic, providing the analytic tools, the MACRA reimbursement tools. It will include some interoperability with the McKesson IknowMed product, which was important for McKesson. And I'm very excited about that whole relationship, but most of it is yet to be booked."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Tycho Peterson from JPMorgan.",11,"Our next question today is coming from Tycho Peterson from JPMorgan."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Apologies. I'm going to ask another guidance question, but if we think about kind of the end markets, Dow, you used to talk about kind of 6% to 8% market growth and then it was kind mid-single digits. You're talking about 3% to 4% market growth -- revenue",92,"Apologies. I'm going to ask another guidance question, but if we think about kind of the end markets, Dow, you used to talk about kind of 6% to 8% market growth and then it was kind mid-single digits. You're talking about 3% to 4% market growth -- revenue growth with some share gains, I guess, embedded in. So can you maybe just talk about what you see as underlying market growth? And in your 3% to 4% revenue guidance, how much of that is software and service versus underlying growth in linac?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","[indiscernible] to the last. I don't know if I can break that out for you at this point from a guidance point of view. But as to the overall markets, I mean, if anything, we might have been a little bit conservative here. I think as we look at our funnels",210,"[indiscernible] to the last. I don't know if I can break that out for you at this point from a guidance point of view. But as to the overall markets, I mean, if anything, we might have been a little bit conservative here. I think as we look at our funnels here at the beginning of the year, I think the market looks pretty good. We had a ton of activity in -- especially in the fourth quarter in Europe last year. And as we look forward, we see pretty good strength. So I'd say it's -- there's some uncertainty around it, of course, but it's probably 3%, 3.5% to 6% market growth scenario. China is going to continue to do well. India is going to do well. We're growing in Africa. We had pretty good year this past year in Brazil, but we see continued strength in the Brazilian market, and that's good news. And then in the U.S. market, it's been, as I mentioned in the script, it was 5% growth on the year. And if anything, that was a little bit ahead of kind of where we thought it would be coming into the year. As we look at 2017, funnels remain very strong in the U.S."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","If I could just add to that, Tycho, in terms of the top line growth for Oncology, the good news is pricing is holding globally, and we have seen significant product cost reductions. We basically obsoleted the C-series and moved everyone onto the TrueBeam",112,"If I could just add to that, Tycho, in terms of the top line growth for Oncology, the good news is pricing is holding globally, and we have seen significant product cost reductions. We basically obsoleted the C-series and moved everyone onto the TrueBeam platform. And I think this -- the margin improvement you've seen in the last couple of quarters in Oncology is sustainable going forward. So we're kind of moving them up to a 44% to 45% gross margin level. And so obviously, even if the top line is off a point or so, we make up a lot of that difference in the margin improvement that we're seeing there."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. That's good to hear. And then Dow, maybe can you talk on MACRA, the final rule? What are your thoughts on -- as we think about that getting implemented, how do we think about that maybe driving more of a bias toward software and some of this?",48,"Okay. That's good to hear. And then Dow, maybe can you talk on MACRA, the final rule? What are your thoughts on -- as we think about that getting implemented, how do we think about that maybe driving more of a bias toward software and some of this?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, I think that overall, it's a good opportunity for our product line with our InSightive Analytics tools, our RapidPlan and treatment planning and our 360 Oncology. It's going to create an opportunity for us to provide our customers with the required r",226,"Yes, I think that overall, it's a good opportunity for our product line with our InSightive Analytics tools, our RapidPlan and treatment planning and our 360 Oncology. It's going to create an opportunity for us to provide our customers with the required reports that they're going to need to comply. They've got to demonstrate a certified EHR, electronic health record. They've got to demonstrate improvement in care management and practices, and they've got to report on their quality metrics. So these tools all do that. So I think it's going to be pretty good news for us. The product line is about where we need it to be. They comply. We've got a few things to button down, but we'll be way ahead of the compliance requirements. And we've got just our own installed base. It's about 1,800 units -- sorry, 1,800 sites that got to go. And we're very excited about that. Maybe just on top of that, this isn't MACRA, but the other piece from a market point of view that is at least as important as MACRA is the cybersecurity. And this -- at ASTRO, we launched a very significant upgrade to our software products for cybersecurity. And that product will be ready here in the early spring. And that should drive some upside for us, too. So we're excited about that one."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then one last one. North American Oncology orders last quarter, up 15%. They were up only 3% this quarter. Was there some pull-forward dynamic? Because CMS had kind of come out ahead of time and said the physician fee schedule wouldn't be too disrupte",47,"And then one last one. North American Oncology orders last quarter, up 15%. They were up only 3% this quarter. Was there some pull-forward dynamic? Because CMS had kind of come out ahead of time and said the physician fee schedule wouldn't be too disrupted [indiscernible] around."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","There's always some lumpiness quarter to quarter. I would say in the second half that CMS had very little to do with it. It's just timing of some of the orders.",32,"There's always some lumpiness quarter to quarter. I would say in the second half that CMS had very little to do with it. It's just timing of some of the orders."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Vijay Kumar from Evercore ISI.",12,"Our next question today is coming from Vijay Kumar from Evercore ISI."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","So Elisha, maybe I'll start one with a question for you. Just sort of on the timing here just on the decision to step aside. So if you could just walk us through some of the timing decision. I think that would be a helpful context heading into the spin.",50,"So Elisha, maybe I'll start one with a question for you. Just sort of on the timing here just on the decision to step aside. So if you could just walk us through some of the timing decision. I think that would be a helpful context heading into the spin."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Sure. Well, I started my CFO career with a spin. I figured why not end it with a spin? So back in 1999, and as Dow said, about 71 quarters, it just feels like the right timing, Vijay. In terms of the exact timing, that's to be determined. I am completely",116,"Sure. Well, I started my CFO career with a spin. I figured why not end it with a spin? So back in 1999, and as Dow said, about 71 quarters, it just feels like the right timing, Vijay. In terms of the exact timing, that's to be determined. I am completely dedicated to getting us through the spin of the Imaging Components business, getting -- we can now go out and conduct a search and want to find a world-class finance leader who can come into this great organization and have time to transition. And so it will be at some point in this fiscal year, but the exact date is not determined at this point."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Got you. And maybe just a couple of quick ones on the, I guess, the guidance question. So did I hear you correctly when you said that the EPS growth was a high singles off of the current year base? And just what -- and then does that number include the $2",78,"Got you. And maybe just a couple of quick ones on the, I guess, the guidance question. So did I hear you correctly when you said that the EPS growth was a high singles off of the current year base? And just what -- and then does that number include the $20 million dissynergies? And do you have the accounting rule change sort of baked in? Just can you walk us through some of the moving parts there?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, so it did -- that was a hypothetical number that said if we weren't spinning, we believe EPS would grow on a consolidated basis in the high single digits. The $20 million of dissynergies, I have to say we are well under way of looking for cost-reduct",159,"Yes, so it did -- that was a hypothetical number that said if we weren't spinning, we believe EPS would grow on a consolidated basis in the high single digits. The $20 million of dissynergies, I have to say we are well under way of looking for cost-reduction opportunities, and we are absolutely committed to having $10 million of that out at a run rate by the end of fiscal year '17 and the additional $10 million out by FY '18. So lots of work already going on, on that. I will tell you that most of those dissynergies for Varian are offset because we will have a lower tax rate because Varex has a 35%, 36% tax rate. And so unfortunately, for my colleague, Clarence, here, his tax rate is going up versus the Varian average. But Varian's tax rate will come down a point or 2, and that largely offsets the dissynergies in year 1 and 2."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","That was helpful. And maybe just a quick one on Q1. I mean, if I look at the guidance comments, we had the midpoint EPS, it looks like maybe margins would be somewhere around 17.5, maybe a few basis points above the 17.5. So that's a step-down just from t",78,"That was helpful. And maybe just a quick one on Q1. I mean, if I look at the guidance comments, we had the midpoint EPS, it looks like maybe margins would be somewhere around 17.5, maybe a few basis points above the 17.5. So that's a step-down just from the Q4 levels. Any commentary on what your gross margin is for Oncology? Can you just walk us through why the margins will step down from Q4 to Q1?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. Well, yes, you always -- every year, if you go back, you see seasonality. I mean, Q4 is always our largest quarter with the highest operating margin typically. So it's not uncommon for the operating margin to step down from Q4 to Q1. When you run you",153,"Yes. Well, yes, you always -- every year, if you go back, you see seasonality. I mean, Q4 is always our largest quarter with the highest operating margin typically. So it's not uncommon for the operating margin to step down from Q4 to Q1. When you run your model through, I mean, what I am showing at the midpoint is that we will increase our operating margin by about a point to 18% on a non-GAAP basis. Again, Oncology's gross margin will be between 44%, 45%. Imaging Components in the low 40s, so it looks closer to an 18% operating margin. And again, Vijay, that does include -- I want to make sure everyone understands. It includes some duplicative costs in Varex as we're hiring people to gear up for this spin. We cannot take those costs out to be non-GAAP, and it's between $0.01 and $0.02 in Q1 for those duplicative costs."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Anthony Petrone from Jefferies.",11,"Our next question today is coming from Anthony Petrone from Jefferies."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Congratulations, Elisha. It was great working with you over the years, and good luck on the next phase.",18,"Congratulations, Elisha. It was great working with you over the years, and good luck on the next phase."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you",2,"Thank you"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","A couple of questions, just I guess higher level. maybe exiting fiscal '16 here would be helpful to get an update on the percentage of the installed base, the linac installed base that really is now TrueBeam and VitalBeam. And really what I'm getting at i",120,"A couple of questions, just I guess higher level. maybe exiting fiscal '16 here would be helpful to get an update on the percentage of the installed base, the linac installed base that really is now TrueBeam and VitalBeam. And really what I'm getting at is what percentage of the installed base has stereotactic capabilities? And what percent does not? And it's really in relation to Dr. Khuntia's sort of presentation at ASTRO, the opportunity for SRS/SPRT going forward over the next 10 to 15 years. I'm just trying to get a sense of what percentage of the base can migrate to having stereotactic capabilities in the next few years? And then I have a follow-up on software and margins."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","That's a good question. I'd say from a very high level, we've got about 1,500 TrueBeams in the installed base of, call it, 7,500 machines. Now when you look at some of the capabilities, the interesting thing when you talk about HyperArc, HyperArc's availa",347,"That's a good question. I'd say from a very high level, we've got about 1,500 TrueBeams in the installed base of, call it, 7,500 machines. Now when you look at some of the capabilities, the interesting thing when you talk about HyperArc, HyperArc's available on every one of those TrueBeams. So this is the kind of our first real -- we've had some other smaller upgrades that we've offered on TrueBeam, like some imaging improvements and just some other things over the last few years. But the HyperArc for some of the stereotactic radiosurgery applications that Dr. Khuntia talked about at ASTRO will be available on the EDGE and TrueBeam only. So we're very excited about that. I think that will probably drive some of the other installed base to trade out to TrueBeam as well. So we're very encouraged about that. We're, I'd say, when you look at the past quarter, Americas was almost virtually 100% TrueBeam/VitalBeam. There might have been 1 or 2 that weren't, but pretty much everything in the Americas -- well, North America for sure, was TrueBeam/VitalBeam. In rest of the -- and I'd say of those, in terms of the capabilities that they had in the fourth quarter, maybe half-ish had SRS/SPRT capability. When you look at the installed base, a big opportunity there. Most of them do not have that capability. And so I think this bodes well for us next year in 2 ways. One, it's an upgrade opportunity; and two, it's going to help us on pricing on TrueBeam. It's going to  -- we're going to be able to maintain or grow price on TrueBeam, and I think that's a little bit of the -- we're doing very well on the cost side, where is this margin rate improvement coming from? We're doing very well on the cost side. The operational team has done a fabulous job getting cost down on TrueBeam. But then as well, we're seeing a really nice mix of these advanced capabilities that are giving us some price support on the pricing side."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And just a quick follow-up on that, Dow, would be, just how do you see that transitioning just when you think of the 2019 reimbursement changes, where Oncology may go bundled? I mean, and then more focused on efficiencies and outcomes. I mean, does it acc",71,"And just a quick follow-up on that, Dow, would be, just how do you see that transitioning just when you think of the 2019 reimbursement changes, where Oncology may go bundled? I mean, and then more focused on efficiencies and outcomes. I mean, does it accelerate the demand for stereotactic within the installed base? Or do you think this sort of plays out pretty ratably over 12 to 15 years?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","I mean, I think, if anything, it'll be a little faster because of some of the reimbursement pressure. Having said that, clinicians are going to want to make sure there's a really responsible clinical comparison done. So our customers are sensitive about t",197,"I mean, I think, if anything, it'll be a little faster because of some of the reimbursement pressure. Having said that, clinicians are going to want to make sure there's a really responsible clinical comparison done. So our customers are sensitive about that. I think one of the exciting things to us is in some applications, hypofractionation -- the hypofractionation trend is going to bring more patients back to us. So for example, in prostate cancer, over the last half dozen years, we've lost a little bit of share in [ph] robotic surgery. But I think now as those start to go hypofractionation, we get those -- a lot of those patients back. The results are as good or better than surgery, and that's well documented. And then as well, I think the other big opportunity from a clinical growth perspective here is metastatic disease. This capability really enables a very precise dose deposition. And we think that there are, in the U.S. alone, 300,000 patients that we could have opportunity to go after with this capability and bring some new folks into the radiation therapy paradigm. So we're excited about the capability that this opens up."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","And then just quickly on software margins. Maybe just another high level. Where do we sit exiting fiscal '16 when you look at software/services as a percent of the total for the RemainCo? And do you see a point where there is a higher mix of software, say",73,"And then just quickly on software margins. Maybe just another high level. Where do we sit exiting fiscal '16 when you look at software/services as a percent of the total for the RemainCo? And do you see a point where there is a higher mix of software, say, over the next 3 to 5 years? And if we do have that scenario, what do you think overall margins look like under that scenario?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Let me just say for year-to-date, '16 service was just low 40s. So it's about 42% of the total revenue for Oncology. So call it 60-40. And clearly, as both service and software grow faster than the hardware, it does have an upward bias on gross margin. In",68,"Let me just say for year-to-date, '16 service was just low 40s. So it's about 42% of the total revenue for Oncology. So call it 60-40. And clearly, as both service and software grow faster than the hardware, it does have an upward bias on gross margin. In fact, that has been helping us the last couple of quarters. Software is roughly 10% of total Oncology revenue."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question today is coming from Brandon Henry with RBC Capital Markets.",13,"Our next question today is coming from Brandon Henry with RBC Capital Markets."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","First of all, can you just discuss how software and services performed in the quarter? As these businesses continue growing, combined kind of high single digits? And were there any change in growth rates this quarter versus last quarter?",39,"First of all, can you just discuss how software and services performed in the quarter? As these businesses continue growing, combined kind of high single digits? And were there any change in growth rates this quarter versus last quarter?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Our revenues in service were up 7%. Revenues in software were...",12,"Our revenues in service were up 7%. Revenues in software were..."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Probably about the same.",4,"Probably about the same."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Around the same. I think the -- as we look forward in the service funnel, I'd say it looks very good. We had a little bit of currency last year. We had a little bit of timing. I think on the year, we'd like to see that number be a little bit north of 7%,",254,"Around the same. I think the -- as we look forward in the service funnel, I'd say it looks very good. We had a little bit of currency last year. We had a little bit of timing. I think on the year, we'd like to see that number be a little bit north of 7%, and that's kind of what we're stretching the team for. But service business continues to be solid growth for us. Software, we had very good year in treatment planning. We talked about that in the script with all the RapidPlan orders. I think this next year, with the improvement that we have in our InSightive Analytics and with our 360 Oncology product, it can be very exciting. We're curious a little bit to see how that goes because the 360 Oncology is going to be cloud-based, so the financial impact is going to be a little more back-end loaded as we accumulate sites, do the billing and click the orders on that basis. I think it's going to be a little -- it is a little bit of a transition as we go kind of from an annual license model to a software-as-a-service model. So having said that, one of the really cool things about the 360 Oncology product is it can play not just in ARIA Varian sites, it can play in every radiation oncology site in the world. And just really a great opportunity for us to get some penetration in InSightive that we don't have today."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Okay. And then separately, can you kind of talk about your expectation for free cash flow for fiscal year '17 versus fiscal year '16? And how should we think about the balance of M&A versus share repurchases in the near term? And then what size of deals a",59,"Okay. And then separately, can you kind of talk about your expectation for free cash flow for fiscal year '17 versus fiscal year '16? And how should we think about the balance of M&A versus share repurchases in the near term? And then what size of deals and debt levels do you feel comfortable for each company going forward?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","So I'll answer the first part of that question, Brandon. As it came up earlier on the call, our cash flow from operations was down year-over-year. We ended both Q3 and Q4 on a strong note, but we were kind of in a hole in the first half of the fiscal year",172,"So I'll answer the first part of that question, Brandon. As it came up earlier on the call, our cash flow from operations was down year-over-year. We ended both Q3 and Q4 on a strong note, but we were kind of in a hole in the first half of the fiscal year on collections of AR for a couple of reasons -- moved this collection staff, we had an IT implementation, et cetera. So we're very focused on cash flow, particularly AR, as we move into FY '17. And on a consolidated basis, our expectation would be that we could get back to around the $400 million level in cash flow from operations. CapEx has always been relatively stable. And then, in terms of share repurchase versus M&A, I think we would always love to prioritize M&A if the right targets come along. And that's the beauty of our share repurchase program. We can turn it on and off and at various levels, depending on what activity and M&A that's there."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes. And just as a comment, it's going to be strategically driven, how can we strengthen our Oncology franchise. I don't see us going way out on the EDGE and doing something, for example, maybe in chemotherapy, to pick one. But are there image guidance te",73,"Yes. And just as a comment, it's going to be strategically driven, how can we strengthen our Oncology franchise. I don't see us going way out on the EDGE and doing something, for example, maybe in chemotherapy, to pick one. But are there image guidance technologies? Are there radiation technologies? Are there software technologies that can reinforce our core and give us some higher-growth segments to participate in? That's what we look at."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Our next question is coming from Anthony Petrone from Jefferies.",10,"Our next question is coming from Anthony Petrone from Jefferies."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Just a quick housekeeping one. Just kind of going through some Qs here on the Candela acquisition in Poland. Maybe what's baked in there for fiscal '17 and if any of that hit in the fiscal fourth quarter as well.",40,"Just a quick housekeeping one. Just kind of going through some Qs here on the Candela acquisition in Poland. Maybe what's baked in there for fiscal '17 and if any of that hit in the fiscal fourth quarter as well."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","In terms of revenue?",4,"In terms of revenue?"
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","Yes, revenue contribution in the quarter and then...",8,"Yes, revenue contribution in the quarter and then..."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","It would just be service revenue, so about $1 million or so. It was small.",15,"It would just be service revenue, so about $1 million or so. It was small."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Analysts","In 4Q. And I guess, can we just annualized that in '17 to get their contribution or...",17,"In 4Q. And I guess, can we just annualized that in '17 to get their contribution or..."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Yes, you can -- it's somewhere between an annualized $14 million to $16 million market for us, and it's a growing market. So we feel very good about Poland over the next several years, and one of the reasons that the timing was right to make the acquisiti",51,"Yes, you can -- it's somewhere between an annualized $14 million to $16 million market for us, and it's a growing market. So we feel very good about Poland over the next several years, and one of the reasons that the timing was right to make the acquisition and go direct."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","We reached the end of our question-and-answer session. I'd like to turn the floor back over to management for any further closing comments.",24,"We reached the end of our question-and-answer session. I'd like to turn the floor back over to management for any further closing comments."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Executives","Thank you. Thank you for participating. The replay of the call can be heard on Varian's investor site at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or (201)",70,"Thank you. Thank you for participating. The replay of the call can be heard on Varian's investor site at www.varian.com/investor, where it will be archived for a year. To hear a telephone replay, please dial 1 (877) 660-6853 from inside the U.S. or (201) 612-7415 from outside the U.S., and entering confirmation code 13647671. The telephone replay will be available through 5 p.m. this Friday, October 28. Thanks very much."
311907,404405398,1063118,"Varian Medical Systems, Inc., Q4 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Varian Medical Systems, Inc.","Operator","Thank you. That does conclude today's teleconference. You may disconnect your lines at this time, and have a wonderful day. We thank you for your participation today.",27,"Thank you. That does conclude today's teleconference. You may disconnect your lines at this time, and have a wonderful day. We thank you for your participation today."
